{"PMC7113862": [["IntroductionMiddle East respiratory syndrome (MERS) is a severe emerging zoonotic disease.", [["Middle East respiratory syndrome", "DISEASE", 12, 44], ["MERS", "DISEASE", 46, 50], ["zoonotic disease", "DISEASE", 73, 89], ["Middle East respiratory syndrome (MERS)", "SPECIES", 12, 51], ["Middle East respiratory syndrome", "PROBLEM", 12, 44], ["a severe emerging zoonotic disease", "PROBLEM", 55, 89], ["Middle", "ANATOMY_MODIFIER", 12, 18], ["respiratory syndrome", "OBSERVATION", 24, 44], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["zoonotic disease", "OBSERVATION", 73, 89]]], ["Since its initial identification in June 2012 in Saudi Arabia, MERS has caused 2090 infections and 730 deaths (case fatality rate: \u223c35%) in 27 countries as of November 2017 (WHO, 2017).", [["infections", "DISEASE", 84, 94], ["deaths", "DISEASE", 103, 109], ["fatality rate", "TEST", 116, 129]]], ["MERS is caused by the MERS coronavirus (MERS-CoV), and belongs to the family of Coronaviridae, the genus \u00df-coronavirus.", [["MERS", "DISEASE", 0, 4], ["MERS coronavirus", "ORGANISM", 22, 38], ["MERS-CoV", "ORGANISM", 40, 48], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 80, 93], ["\u00df-coronavirus", "CANCER", 105, 118], ["MERS coronavirus", "SPECIES", 22, 38], ["MERS-CoV", "SPECIES", 40, 48], ["the MERS coronavirus", "PROBLEM", 18, 38], ["Coronaviridae", "TREATMENT", 80, 93], ["genus \u00df-coronavirus", "OBSERVATION", 99, 118]]], ["Like SARS-CoV that belongs in the same genus, MERS-CoV is a zoonotic disease that originates from bats, suggesting that bats are the most likely natural reservoir of MERS-CoV(Annan et al., 2013, Memish et al., 2013, Wang et al., 2014, Yang et al., 2014).", [["zoonotic disease", "DISEASE", 60, 76], ["SARS-CoV", "ORGANISM", 5, 13], ["MERS-CoV", "ORGANISM", 46, 54], ["MERS-CoV", "ORGANISM", 166, 174], ["SARS-CoV", "SPECIES", 5, 13], ["MERS-CoV", "SPECIES", 46, 54], ["MERS-CoV", "SPECIES", 166, 174], ["SARS", "PROBLEM", 5, 9], ["a zoonotic disease", "PROBLEM", 58, 76], ["zoonotic disease", "OBSERVATION", 60, 76]]], ["Studies have confirmed the presence of MERS-CoV in dromedaries in the Arabian Peninsula and North Africa (Hemida et al., 2017, Kayali and Peiris, 2015, Reusken et al., 2013).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["MERS-CoV", "SPECIES", 39, 47], ["Studies", "TEST", 0, 7], ["MERS", "PROBLEM", 39, 43], ["MERS", "OBSERVATION", 39, 43], ["CoV", "OBSERVATION", 44, 47], ["Arabian Peninsula", "ANATOMY", 70, 87]]], ["Dromedaries are thought to be the main reservoir of MERS-CoV.", [["MERS-CoV", "ORGANISM", 52, 60], ["MERS-CoV", "SPECIES", 52, 60], ["Dromedaries", "TREATMENT", 0, 11], ["thought to be", "UNCERTAINTY", 16, 29], ["main", "OBSERVATION_MODIFIER", 34, 38], ["reservoir", "OBSERVATION", 39, 48]]], ["Although transmission of MERS-CoV from camels to humans has not been reported to date, it has been postulated that primary human infection could result from close contact with camels, which shed the virus (Azhar et al., 2014).", [["primary human infection", "DISEASE", 115, 138], ["MERS-CoV", "ORGANISM", 25, 33], ["camels", "ORGANISM", 39, 45], ["humans", "ORGANISM", 49, 55], ["human", "ORGANISM", 123, 128], ["humans", "SPECIES", 49, 55], ["human", "SPECIES", 123, 128], ["MERS-CoV", "SPECIES", 25, 33], ["humans", "SPECIES", 49, 55], ["human", "SPECIES", 123, 128], ["primary human infection", "PROBLEM", 115, 138], ["infection", "OBSERVATION", 129, 138]]], ["Of note, a major MERS outbreak in South Korea resulted in 186 cases, including 36 deaths in 2015.", [["deaths", "DISEASE", 82, 88]]], ["The majority of these cases were health care workers who were in close contact with infected patients (Korea Ministry of Health and Welfare, 2015).", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["Thus developing a MERS vaccine that can provide rapid immune response for high-risk populations (such as health care workers) is of significant importance to public health.IntroductionThe coronavirus Spike protein (S) is immunogenic and is capable of inducing protective immunity against coronavirus infections including MERS-CoV and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) (Yang et al., 2004, Ying et al., 2014).", [["coronavirus infections", "DISEASE", 288, 310], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 341, 379], ["SARS", "DISEASE", 381, 385], ["coronavirus", "ORGANISM", 188, 199], ["Spike protein (S)", "GENE_OR_GENE_PRODUCT", 200, 217], ["coronavirus", "ORGANISM", 288, 299], ["MERS-CoV", "ORGANISM", 321, 329], ["coronavirus Spike protein", "PROTEIN", 188, 213], ["S", "PROTEIN", 215, 216], ["coronavirus", "SPECIES", 288, 299], ["MERS-CoV", "SPECIES", 321, 329], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 334, 389], ["a MERS vaccine", "TREATMENT", 16, 30], ["The coronavirus Spike protein", "TEST", 184, 213], ["immunogenic", "PROBLEM", 221, 232], ["coronavirus infections", "PROBLEM", 288, 310], ["MERS", "PROBLEM", 321, 325], ["CoV", "PROBLEM", 326, 329], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 334, 379], ["coronavirus Spike", "OBSERVATION", 188, 205], ["Severe", "OBSERVATION_MODIFIER", 334, 340], ["Acute", "OBSERVATION_MODIFIER", 341, 346], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 347, 379]]], ["Indeed, MVA-based and DNA-based MERS-CoV vaccines designed with S protein as the target immunogen have proven effective in animal models (Haagmans et al., 2016, Muthumani et al., 2015, Song et al., 2013, Volz et al., 2015, Wang et al., 2015).", [["DNA", "CELLULAR_COMPONENT", 22, 25], ["MERS-CoV", "ORGANISM", 32, 40], ["S protein", "GENE_OR_GENE_PRODUCT", 64, 73], ["S protein", "PROTEIN", 64, 73], ["MVA", "TEST", 8, 11], ["DNA", "TEST", 22, 25], ["CoV vaccines", "TREATMENT", 37, 49], ["S protein", "TREATMENT", 64, 73], ["the target immunogen", "TREATMENT", 77, 97]]], ["However, these vaccine strategies require multiple dosing to elicit desired immune responses, thus may not be ideal for emergency vaccinations when facing the emerging infectious disease pandemics.IntroductionStudies have demonstrated that single-dose recombinant vesicular stomatitis virus (VSV)-based Ebola, Marburg and Lassa fever vaccines can induce rapid immune protection in animal models (Geisbert et al., 2009, Marzi et al., 2015a, Marzi et al., 2015b); for example, a large scale clinical trial of VSV-vectored Ebola vaccine (rVSV-ZEBOV) conducted in west Africa in 2015 demonstrated that a single dose rVSV-ZEBOV immunization was highly safe and effective for humans (Henao-Restrepo et al., 2015).", [["infectious disease pandemics", "DISEASE", 168, 196], ["vesicular stomatitis", "DISEASE", 264, 284], ["Ebola", "DISEASE", 303, 308], ["Lassa fever", "DISEASE", 322, 333], ["Ebola", "DISEASE", 520, 525], ["rVSV", "CHEMICAL", 612, 616], ["recombinant", "ORGANISM", 252, 263], ["vesicular stomatitis virus", "ORGANISM", 264, 290], ["VSV", "ORGANISM", 292, 295], ["Ebola", "ORGANISM", 303, 308], ["Marburg", "ORGANISM", 310, 317], ["Lassa fever", "ORGANISM", 322, 333], ["VSV-vectored", "ORGANISM", 507, 519], ["Ebola vaccine", "ORGANISM", 520, 533], ["rVSV-ZEBOV", "ORGANISM", 535, 545], ["rVSV-ZEBOV", "ORGANISM", 612, 622], ["humans", "ORGANISM", 670, 676], ["Lassa fever", "SPECIES", 322, 333], ["Ebola vaccine", "SPECIES", 520, 533], ["humans", "SPECIES", 670, 676], ["stomatitis virus", "SPECIES", 274, 290], ["VSV", "SPECIES", 292, 295], ["VSV", "SPECIES", 507, 510], ["rVSV", "SPECIES", 535, 539], ["ZEBOV", "SPECIES", 540, 545], ["rVSV", "SPECIES", 612, 616], ["ZEBOV", "SPECIES", 617, 622], ["humans", "SPECIES", 670, 676], ["these vaccine strategies", "TREATMENT", 9, 33], ["multiple dosing", "TREATMENT", 42, 57], ["emergency vaccinations", "TREATMENT", 120, 142], ["the emerging infectious disease pandemics", "PROBLEM", 155, 196], ["single-dose recombinant vesicular stomatitis virus (VSV)", "TREATMENT", 240, 296], ["Marburg and Lassa fever vaccines", "TREATMENT", 310, 342], ["rapid immune protection", "TREATMENT", 354, 377], ["VSV", "TREATMENT", 507, 510], ["vectored Ebola vaccine", "TREATMENT", 511, 533], ["a single dose rVSV", "TREATMENT", 598, 616], ["ZEBOV immunization", "TREATMENT", 617, 635], ["vesicular stomatitis", "ANATOMY", 264, 284]]], ["Here, we report a VSV-based chimeric recombinant virus, VSV\u0394G-MERS, in which VSV glycoprotein (G) gene was replaced by the MERS-CoV S gene.", [["VSV", "ORGANISM", 18, 21], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 56, 66], ["VSV", "ORGANISM", 77, 80], ["G", "GENE_OR_GENE_PRODUCT", 95, 96], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 123, 133], ["VSV\u0394G-MERS", "DNA", 56, 66], ["VSV glycoprotein (G) gene", "DNA", 77, 102], ["MERS-CoV S gene", "DNA", 123, 138], ["VSV", "SPECIES", 18, 21], ["VSV", "SPECIES", 77, 80], ["MERS-CoV", "SPECIES", 123, 131], ["a VSV-based chimeric recombinant virus", "PROBLEM", 16, 54], ["VSV\u0394G", "TEST", 56, 61], ["VSV glycoprotein (G) gene", "TREATMENT", 77, 102]]], ["Single-dose immunization, either by the intramuscular or intranasal route, induced high-level and lasting MERS-CoV-specific neutralizing antibodies and T-cell responses in rhesus monkeys.", [["intramuscular", "ANATOMY", 40, 53], ["T-cell", "ANATOMY", 152, 158], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 106, 114], ["T-cell", "CELL", 152, 158], ["rhesus", "ORGANISM", 172, 178], ["monkeys", "ORGANISM", 179, 186], ["MERS-CoV", "PROTEIN", 106, 114], ["neutralizing antibodies", "PROTEIN", 124, 147], ["rhesus monkeys", "SPECIES", 172, 186], ["rhesus monkeys", "SPECIES", 172, 186], ["Single-dose immunization", "TREATMENT", 0, 24], ["CoV", "TEST", 111, 114], ["specific neutralizing antibodies", "TEST", 115, 147]]], ["Our results demonstrate, therefore, the potential of VSV\u0394G-MERS as a candidate vaccine against MERS-CoV.Recombinant virus construction and rescue ::: Materials and methodsA previously described VSV\u0394G-eGFP pseudovirus system (Wang et al., 2006) was adapted and modified to construct VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS.", [["VSV\u0394G-MERS", "CHEMICAL", 53, 63], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 53, 63], ["MERS-CoV", "ORGANISM", 95, 103], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 194, 199], ["eGFP", "ORGANISM", 200, 204], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 282, 292], ["eGFP", "GENE_OR_GENE_PRODUCT", 303, 307], ["VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS", "DNA", 282, 312], ["MERS-CoV", "SPECIES", 95, 103], ["a candidate vaccine", "TREATMENT", 67, 86], ["MERS", "PROBLEM", 95, 99], ["CoV", "PROBLEM", 100, 103], ["VSV\u0394G", "TEST", 297, 302], ["virus", "OBSERVATION", 116, 121]]], ["Chemically synthesized MERS-CoV S gene (GenBank accession No.", [["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 23, 33], ["MERS-CoV S gene", "DNA", 23, 38], ["MERS-CoV", "OBSERVATION", 23, 31]]], ["KF186567.1) was amplified by PCR and flanked by NheI restriction site., VSV gene-start and gene-end sequences were introduced.", [["NheI", "GENE_OR_GENE_PRODUCT", 48, 52], ["VSV", "ORGANISM", 72, 75], ["KF186567.1", "DNA", 0, 10], ["NheI restriction site", "DNA", 48, 69], ["VSV gene-start and gene-end sequences", "DNA", 72, 109], ["VSV", "SPECIES", 72, 75], ["VSV gene", "TREATMENT", 72, 80], ["gene-end sequences", "TREATMENT", 91, 109]]], ["The PCR product was sequenced and cloned into the NheI site after the eGFP gene of pVSV\u0394G-eGFP (plasmid containing VSV genomic cDNA without G gene).", [["NheI", "GENE_OR_GENE_PRODUCT", 50, 54], ["eGFP", "GENE_OR_GENE_PRODUCT", 70, 74], ["pVSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 83, 94], ["VSV", "ORGANISM", 115, 118], ["G", "GENE_OR_GENE_PRODUCT", 140, 141], ["NheI site", "DNA", 50, 59], ["eGFP gene", "DNA", 70, 79], ["pVSV\u0394G", "DNA", 83, 89], ["eGFP", "DNA", 90, 94], ["plasmid", "DNA", 96, 103], ["VSV genomic cDNA", "DNA", 115, 131], ["G gene", "DNA", 140, 146], ["VSV", "SPECIES", 115, 118], ["The PCR product", "TREATMENT", 0, 15], ["pVSV\u0394G", "TEST", 83, 89], ["plasmid containing VSV genomic cDNA", "TREATMENT", 96, 131]]], ["The resultant plasmid was named pVSV\u0394G-eGFP-MERS.", [["plasmid", "ANATOMY", 14, 21], ["eGFP", "GENE_OR_GENE_PRODUCT", 39, 43], ["pVSV\u0394G", "DNA", 32, 38], ["eGFP", "DNA", 39, 43], ["MERS", "DNA", 44, 48], ["The resultant plasmid", "TREATMENT", 0, 21], ["pVSV\u0394G", "TEST", 32, 38], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["plasmid", "OBSERVATION", 14, 21]]], ["There were two MluI sites flanking the eGFP gene so construction of the pVSV\u0394G-MERS plasmid was achieved by MluI digestion and self-ligation. pVSV\u0394G-eGFP-MERS or pVSV\u0394G-MERS was co-transfected with a eukaryotic plasmid expressing VSV N, P and L protein, respectively, in BSR-T7/5 cells to rescue the recombinant virus.", [["plasmid", "ANATOMY", 211, 218], ["BSR-T7/5 cells", "ANATOMY", 271, 285], ["MluI", "GENE_OR_GENE_PRODUCT", 15, 19], ["eGFP", "GENE_OR_GENE_PRODUCT", 39, 43], ["pVSV\u0394G", "GENE_OR_GENE_PRODUCT", 72, 78], ["MluI", "GENE_OR_GENE_PRODUCT", 108, 112], ["pVSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 142, 158], ["pVSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 162, 173], ["VSV", "ORGANISM", 230, 233], ["BSR-T7/5 cells", "CELL", 271, 285], ["MluI sites", "DNA", 15, 25], ["eGFP gene", "DNA", 39, 48], ["pVSV\u0394G", "DNA", 72, 78], ["MERS plasmid", "DNA", 79, 91], ["pVSV\u0394G", "DNA", 142, 148], ["eGFP", "DNA", 149, 153], ["MERS", "DNA", 154, 158], ["pVSV\u0394G", "DNA", 162, 168], ["MERS", "DNA", 169, 173], ["eukaryotic plasmid", "DNA", 200, 218], ["VSV N, P and L protein", "PROTEIN", 230, 252], ["BSR-T7/5 cells", "CELL_LINE", 271, 285], ["VSV", "SPECIES", 230, 233], ["the pVSV\u0394G", "TREATMENT", 68, 78], ["MERS plasmid", "TREATMENT", 79, 91], ["self-ligation", "TREATMENT", 127, 140], ["pVSV\u0394G", "TEST", 142, 148], ["MERS", "PROBLEM", 154, 158], ["pVSV\u0394G", "PROBLEM", 162, 168], ["MERS", "PROBLEM", 169, 173], ["P and L protein", "TEST", 237, 252], ["BSR", "TEST", 271, 274], ["T7/5 cells", "TREATMENT", 275, 285], ["the recombinant virus", "PROBLEM", 296, 317], ["ligation", "OBSERVATION", 132, 140], ["T7", "ANATOMY", 275, 277], ["virus", "OBSERVATION", 312, 317]]], ["At 96 h post-transfection, the supernatant was harvested and clarified by low speed centrifugation, and serially passaged on Vero E6 cells for at least 3 passages until obvious green fluorescence or cytopathic effect (CPE) was observed.", [["supernatant", "ANATOMY", 31, 42], ["cells", "ANATOMY", 133, 138], ["Vero E6 cells", "CELL", 125, 138], ["Vero E6 cells", "CELL_LINE", 125, 138], ["Vero E6", "SPECIES", 125, 132], ["Vero E6 cells", "TREATMENT", 125, 138], ["green fluorescence", "PROBLEM", 177, 195], ["cytopathic effect (CPE", "PROBLEM", 199, 221], ["cytopathic", "OBSERVATION_MODIFIER", 199, 209]]], ["The rescued viruses were named VSV\u0394G-eGFP-MERS and VSV\u0394G-MERS respectively.", [["eGFP", "GENE_OR_GENE_PRODUCT", 37, 41], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 51, 61], ["VSV\u0394G", "DNA", 31, 36], ["eGFP", "DNA", 37, 41], ["MERS", "DNA", 42, 46], ["VSV\u0394G", "DNA", 51, 56], ["MERS", "DNA", 57, 61], ["The rescued viruses", "PROBLEM", 0, 19], ["VSV\u0394G", "TEST", 31, 36], ["viruses", "OBSERVATION", 12, 19]]], ["The growth kinetics of the recombinant viruses was determined.", [["the recombinant viruses", "PROBLEM", 23, 46], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["kinetics", "OBSERVATION_MODIFIER", 11, 19], ["recombinant", "OBSERVATION_MODIFIER", 27, 38], ["viruses", "OBSERVATION", 39, 46]]], ["VSV\u0394G-eGFP-MERS and VSV\u0394G-MERS were, respectively, inoculated at an MOI = 0.01 onto Vero E6 cells growing in a 6-well plate and the supernatant was removed at 12-h intervals from 12 h to 96 h.", [["cells", "ANATOMY", 92, 97], ["supernatant", "ANATOMY", 132, 143], ["VSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 0, 15], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 20, 30], ["E6", "ORGANISM", 89, 91], ["cells", "CELL", 92, 97], ["VSV\u0394G-eGFP-MERS and VSV\u0394G-MERS", "DNA", 0, 30], ["Vero E6 cells", "CELL_LINE", 84, 97], ["Vero E6", "SPECIES", 84, 91], ["VSV\u0394G", "TEST", 0, 5], ["eGFP", "TEST", 6, 10], ["MERS", "PROBLEM", 11, 15], ["VSV\u0394G", "TEST", 20, 25], ["an MOI", "TEST", 65, 71], ["Vero E6 cells", "TREATMENT", 84, 97], ["the supernatant", "TREATMENT", 128, 143]]], ["The samples of each time-point were titrated on Vero E6 cells using indirect immunofluorescence by staining with mouse anti-S serum and TRITC-labeled goat anti-mouse IgG as primary and secondary antibodies.", [["samples", "ANATOMY", 4, 11], ["Vero E6 cells", "ANATOMY", 48, 61], ["serum", "ANATOMY", 126, 131], ["Vero E6 cells", "CELL", 48, 61], ["mouse", "ORGANISM", 113, 118], ["anti-S", "ORGANISM_SUBSTANCE", 119, 125], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["TRITC", "SIMPLE_CHEMICAL", 136, 141], ["goat", "ORGANISM", 150, 154], ["Vero E6 cells", "CELL_LINE", 48, 61], ["mouse anti-S serum and TRITC-labeled goat anti-mouse IgG", "PROTEIN", 113, 169], ["primary and secondary antibodies", "PROTEIN", 173, 205], ["mouse", "SPECIES", 113, 118], ["goat", "SPECIES", 150, 154], ["anti-mouse", "SPECIES", 155, 165], ["Vero E6", "SPECIES", 48, 55], ["mouse", "SPECIES", 113, 118], ["goat", "SPECIES", 150, 154], ["The samples", "TEST", 0, 11], ["Vero E6 cells", "TREATMENT", 48, 61], ["indirect immunofluorescence", "TEST", 68, 95], ["mouse anti-S serum", "TEST", 113, 131], ["TRITC", "TEST", 136, 141], ["anti-mouse IgG", "TEST", 155, 169], ["secondary antibodies", "PROBLEM", 185, 205], ["secondary antibodies", "OBSERVATION", 185, 205]]], ["The titer was expressed as the reciprocal of the highest dilution titer (fluorescence forming unit, FFU).Indirect immunofluorescence and Western blot assay ::: Materials and methodsFor Indirect immunofluorescence assay, Vero E6 cells were infected with either VSV\u0394G-eGFP-MERS or VSV\u0394G-MERS at an MOI = 1.", [["Vero E6 cells", "ANATOMY", 220, 233], ["Vero E6 cells", "CELL", 220, 233], ["Vero E6 cells", "CELL_LINE", 220, 233], ["VSV\u0394G-eGFP-MERS or VSV\u0394G-MERS", "DNA", 260, 289], ["Vero E6", "SPECIES", 220, 227], ["Indirect immunofluorescence", "TEST", 105, 132], ["methods", "TEST", 174, 181], ["Indirect immunofluorescence assay", "TEST", 185, 218], ["Vero E6 cells", "PROBLEM", 220, 233], ["VSV\u0394G", "TEST", 260, 265], ["MERS", "PROBLEM", 271, 275], ["VSV\u0394G", "PROBLEM", 279, 284]]], ["At 24 h post-infection, cells were fixed with 3% paraformaldehyde, and cells were stained with mouse anti-S serum (pCAGGS-MERS-S immunized mouse serum) as primary antibody and TRITC-conjugated goat anti-mouse IgG as secondary antibody.", [["cells", "ANATOMY", 24, 29], ["cells", "ANATOMY", 71, 76], ["serum", "ANATOMY", 108, 113], ["serum", "ANATOMY", 145, 150], ["paraformaldehyde", "CHEMICAL", 49, 65], ["cells", "CELL", 24, 29], ["paraformaldehyde", "SIMPLE_CHEMICAL", 49, 65], ["cells", "CELL", 71, 76], ["mouse", "ORGANISM", 95, 100], ["anti-S serum", "ORGANISM_SUBSTANCE", 101, 113], ["pCAGGS", "SIMPLE_CHEMICAL", 115, 121], ["mouse", "ORGANISM", 139, 144], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["TRITC", "SIMPLE_CHEMICAL", 176, 181], ["goat", "ORGANISM", 193, 197], ["pCAGGS", "PROTEIN", 115, 121], ["MERS", "PROTEIN", 122, 126], ["primary antibody", "PROTEIN", 155, 171], ["TRITC-conjugated goat anti-mouse IgG", "PROTEIN", 176, 212], ["secondary antibody", "PROTEIN", 216, 234], ["mouse", "SPECIES", 95, 100], ["mouse", "SPECIES", 139, 144], ["goat", "SPECIES", 193, 197], ["anti-mouse", "SPECIES", 198, 208], ["mouse", "SPECIES", 95, 100], ["mouse", "SPECIES", 139, 144], ["goat", "SPECIES", 193, 197], ["infection", "PROBLEM", 13, 22], ["cells", "PROBLEM", 24, 29], ["3% paraformaldehyde", "TREATMENT", 46, 65], ["cells", "TEST", 71, 76], ["mouse anti-S serum", "TEST", 95, 113], ["pCAGGS", "TEST", 115, 121], ["MERS", "TEST", 122, 126], ["serum", "TEST", 145, 150], ["primary antibody", "TEST", 155, 171], ["TRITC", "TEST", 176, 181], ["conjugated goat anti-mouse IgG", "TREATMENT", 182, 212], ["secondary antibody", "PROBLEM", 216, 234], ["infection", "OBSERVATION", 13, 22]]], ["Cell nuclei were stained with Hoechst 33342 (Invitrogen, Oregon, USA).", [["Cell nuclei", "ANATOMY", 0, 11], ["Hoechst 33342", "CHEMICAL", 30, 43], ["Hoechst 33342", "CHEMICAL", 30, 43], ["Cell nuclei", "CELL", 0, 11], ["Hoechst 33342", "SIMPLE_CHEMICAL", 30, 43]]], ["Stained cells were analyzed with a Leica TCS SP5 laser scanning confocal microscope (Leica, Mannheim, Germany).Indirect immunofluorescence and Western blot assay ::: Materials and methodsFor Western blot assay, Vero E6 cells were infected with either VSV\u0394G-eGFP-MERS or VSV\u0394G-MERS at an MOI = 0.1.", [["cells", "ANATOMY", 8, 13], ["Vero E6 cells", "ANATOMY", 211, 224], ["cells", "CELL", 8, 13], ["Vero E6 cells", "CELL", 211, 224], ["Vero E6 cells", "CELL_LINE", 211, 224], ["VSV\u0394G-eGFP-MERS or VSV\u0394G-MERS", "DNA", 251, 280], ["Vero E6", "SPECIES", 211, 218], ["Stained cells", "PROBLEM", 0, 13], ["a Leica TCS", "TEST", 33, 44], ["Indirect immunofluorescence", "TEST", 111, 138], ["Western blot assay", "TEST", 191, 209], ["Vero E6 cells", "PROBLEM", 211, 224], ["VSV\u0394G", "TEST", 251, 256], ["MERS", "PROBLEM", 262, 266], ["VSV\u0394G", "TEST", 270, 275]]], ["At 72 h post-infection, the cells were collected and lysed, the cell lysates were mixed with protein loading buffer, subjected to SDS-PAGE and subsequently electro-transferred to nitrocellulose membranes.", [["cells", "ANATOMY", 28, 33], ["cell lysates", "ANATOMY", 64, 76], ["membranes", "ANATOMY", 194, 203], ["nitrocellulose", "CHEMICAL", 179, 193], ["cells", "CELL", 28, 33], ["cell lysates", "ORGANISM_SUBSTANCE", 64, 76], ["membranes", "CELLULAR_COMPONENT", 194, 203], ["infection", "PROBLEM", 13, 22], ["the cells", "PROBLEM", 24, 33], ["the cell lysates", "TREATMENT", 60, 76], ["protein loading buffer", "TREATMENT", 93, 115], ["nitrocellulose membranes", "TREATMENT", 179, 203], ["infection", "OBSERVATION", 13, 22]]], ["Target band(s) were detected with mouse anti S serum and Alexa Fluor 680-conjugated donkey anti mouse IgG (Invitrogen, Oregon, USA).", [["serum", "ANATOMY", 47, 52], ["Alexa Fluor 680", "CHEMICAL", 57, 72], ["mouse", "ORGANISM", 34, 39], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["Alexa Fluor 680", "SIMPLE_CHEMICAL", 57, 72], ["mouse", "ORGANISM", 96, 101], ["Alexa Fluor 680-conjugated donkey anti mouse IgG", "PROTEIN", 57, 105], ["mouse", "SPECIES", 34, 39], ["donkey", "SPECIES", 84, 90], ["mouse", "SPECIES", 96, 101], ["mouse", "SPECIES", 34, 39], ["mouse", "SPECIES", 96, 101], ["Target band(s", "TEST", 0, 13], ["mouse anti S serum", "TEST", 34, 52], ["Alexa Fluor", "TEST", 57, 68]]], ["The bands were visualized with an Odyssey digital fluorescence imaging system (LI-COR, Nebraska, USA).Immunoelectron microscopy ::: Materials and methodsVSV\u0394G-eGFP-MERS and VSV\u0394G-MERS were cultured and harvested from infected Vero E6 cells.", [["cells", "ANATOMY", 234, 239], ["methodsVSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 146, 168], ["VSV\u0394G-MERS", "CELL", 173, 183], ["Vero E6 cells", "CELL", 226, 239], ["methodsVSV\u0394G", "DNA", 146, 158], ["eGFP", "DNA", 159, 163], ["MERS", "DNA", 164, 168], ["VSV\u0394G", "DNA", 173, 178], ["MERS", "DNA", 179, 183], ["Vero E6 cells", "CELL_LINE", 226, 239], ["Vero E6", "SPECIES", 226, 233], ["The bands", "PROBLEM", 0, 9], ["an Odyssey digital fluorescence imaging system", "TEST", 31, 77], ["Immunoelectron microscopy", "TEST", 102, 127], ["Materials", "TEST", 132, 141], ["methodsVSV\u0394G", "TEST", 146, 158], ["eGFP", "TEST", 159, 163], ["MERS", "PROBLEM", 164, 168], ["VSV\u0394G", "TEST", 173, 178], ["MERS", "PROBLEM", 179, 183], ["infected Vero E6 cells", "PROBLEM", 217, 239], ["infected", "OBSERVATION_MODIFIER", 217, 225], ["Vero E6 cells", "OBSERVATION", 226, 239]]], ["Next, 1 ml supernatant was clarified by low speed centrifugation to remove cell debris, and subjected to high speed centrifugation (12,000 rpm, 10 min), after which 0.9 ml supernatant was carefully taken out and discarded.", [["supernatant", "ANATOMY", 11, 22], ["cell", "ANATOMY", 75, 79], ["supernatant", "ANATOMY", 172, 183], ["cell", "CELL", 75, 79], ["cell debris", "PROBLEM", 75, 86], ["cell debris", "OBSERVATION", 75, 86]]], ["The remaining sample was gently vortexed and prepared for electron microscopy following a previously described protocol (Ge et al., 2011).", [["sample", "ANATOMY", 14, 20], ["electron microscopy", "TEST", 58, 77]]], ["Briefly, purified virus was bound to 200-mesh Formvar carbon-coated nickel grids (Electron Microscopy Sciences, Hatfield, PA).", [["nickel", "CHEMICAL", 68, 74], ["carbon", "CHEMICAL", 54, 60], ["nickel", "CHEMICAL", 68, 74], ["nickel grids", "SIMPLE_CHEMICAL", 68, 80], ["purified virus", "PROBLEM", 9, 23], ["mesh Formvar carbon-coated nickel grids", "TREATMENT", 41, 80], ["virus", "OBSERVATION", 18, 23]]], ["For immunolabeling, grids were blocked in PBS containing 2% globulin-free BSA (Sigma-Aldrich, St. Louis, MO) and incubated with mouse anti-S antibody.", [["globulin-free BSA", "SIMPLE_CHEMICAL", 60, 77], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 79, 92], ["St. Louis", "ORGANISM", 94, 103], ["MO", "ORGANISM", 105, 107], ["mouse", "ORGANISM", 128, 133], ["anti-S antibody", "GENE_OR_GENE_PRODUCT", 134, 149], ["mouse anti-S antibody", "PROTEIN", 128, 149], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 128, 133], ["immunolabeling", "PROBLEM", 4, 18], ["PBS", "TEST", 42, 45], ["mouse anti-S antibody", "TREATMENT", 128, 149]]], ["Grids were then washed in blocking buffer and incubated with 10-nm gold particle-conjugated goat anti-mouse IgG (Sigma-Aldrich, St. Louis, MO).", [["Grids", "ANATOMY", 0, 5], ["Grids", "SIMPLE_CHEMICAL", 0, 5], ["gold particle", "SIMPLE_CHEMICAL", 67, 80], ["goat", "ORGANISM", 92, 96], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 113, 126], ["St. Louis", "ORGANISM", 128, 137], ["MO", "ORGANISM", 139, 141], ["conjugated goat anti-mouse IgG", "PROTEIN", 81, 111], ["goat", "SPECIES", 92, 96], ["anti-mouse", "SPECIES", 97, 107], ["goat", "SPECIES", 92, 96], ["blocking buffer", "TREATMENT", 26, 41]]], ["After the final wash, the grids were negatively stained with 1% phosphotungstic acid, and subsequently examined under a model H7500 transmission electron microscope (Hitachi High Technologies, Schaumburg, IL) at 80 kV.", [["phosphotungstic acid", "CHEMICAL", 64, 84], ["phosphotungstic acid", "CHEMICAL", 64, 84], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 64, 84], ["the grids", "TEST", 22, 31], ["1% phosphotungstic acid", "TREATMENT", 61, 84]]], ["Images were obtained by using an XR100 digital camera system (Advanced Microscopy Techniques, Danvers, MA).Gene expression knockdown by RNA interference ::: Materials and methodsTo knock down the expression of the human DPP4 and clathrin gene in HEK-293 cells, we used Ambion Validated Silencer Selected siRNA (Thermo Fisher, Waltham, MA) respectively targeted to the specific sequence of DPP4 or clathrin.", [["HEK-293 cells", "ANATOMY", 246, 259], ["human", "ORGANISM", 214, 219], ["DPP4", "GENE_OR_GENE_PRODUCT", 220, 224], ["clathrin", "GENE_OR_GENE_PRODUCT", 229, 237], ["HEK-293 cells", "CELL", 246, 259], ["DPP4", "GENE_OR_GENE_PRODUCT", 389, 393], ["clathrin", "GENE_OR_GENE_PRODUCT", 397, 405], ["human DPP4 and clathrin gene", "DNA", 214, 242], ["HEK-293 cells", "CELL_LINE", 246, 259], ["DPP4", "PROTEIN", 389, 393], ["clathrin", "PROTEIN", 397, 405], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["HEK-293", "SPECIES", 246, 253], ["Images", "TEST", 0, 6], ["the human DPP4", "TEST", 210, 224], ["Ambion", "TREATMENT", 269, 275], ["DPP4 or clathrin", "TREATMENT", 389, 405]]], ["Briefly, siRNA (200 nM, 5 \u03bcl per well) targeting to DPP4, clathrin, VSV L gene (positive control) or irrelevant siRNA (negative control, Ambion cat no. 4390843) was pre-arrayed on 96-well cell carrier plates (Perkin Elmer, Waltham, MA), respectively.", [["cell", "ANATOMY", 188, 192], ["DPP4", "GENE_OR_GENE_PRODUCT", 52, 56], ["clathrin", "GENE_OR_GENE_PRODUCT", 58, 66], ["VSV L", "GENE_OR_GENE_PRODUCT", 68, 73], ["cell", "CELL", 188, 192], ["DPP4", "PROTEIN", 52, 56], ["clathrin", "PROTEIN", 58, 66], ["VSV L gene", "DNA", 68, 78], ["DPP4", "TEST", 52, 56], ["clathrin", "TREATMENT", 58, 66], ["VSV L gene (positive control", "TREATMENT", 68, 96], ["irrelevant siRNA", "PROBLEM", 101, 117], ["well cell carrier plates", "TREATMENT", 183, 207]]], ["Next, 35 \u03bcl OptiMEM medium (Invitrogen, Oregon, USA) containing 0.15 \u03bcl Lipofectamine RNAiMAX transfection reagent (Invitrogen, Oregon, USA) was mixed with 60 \u03bcl OptiMEM medium containing 1 \u00d7 104 Vero E6 cells.", [["cells", "ANATOMY", 204, 209], ["Vero E6 cells", "CELL", 196, 209], ["Vero E6 cells", "CELL_LINE", 196, 209], ["\u03bcl Lipofectamine RNAiMAX transfection reagent", "TREATMENT", 69, 114], ["Vero E6 cells", "TREATMENT", 196, 209], ["E6 cells", "OBSERVATION", 201, 209]]], ["The cell-RNAiMAX mix was then added to the wells.", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["The cell-RNAiMAX mix", "TREATMENT", 0, 20]]], ["Cells were incubated for 48 h to knockdown gene expression, after which the cells were infected with VSV\u0394G-eGFP-MERS or VSV-eGFP at an MOI = 0.01.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 76, 81], ["Cells", "CELL", 0, 5], ["cells", "CELL", 76, 81], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 101, 106], ["eGFP", "GENE_OR_GENE_PRODUCT", 107, 111], ["VSV", "ORGANISM", 120, 123], ["GFP", "GENE_OR_GENE_PRODUCT", 125, 128], ["VSV\u0394G-eGFP-MERS or VSV-eGFP", "DNA", 101, 128], ["knockdown gene expression", "PROBLEM", 33, 58], ["VSV\u0394G", "TEST", 101, 106], ["eGFP", "TEST", 107, 111], ["MERS", "TEST", 112, 116], ["VSV", "TEST", 120, 123], ["an MOI", "TEST", 132, 138]]], ["At 48 h post-infection (15 h for VSV-eGFP), cells were fixed with 3% paraformaldehyde and stained with Hoechst 33342 (Invitrogen, Oregon, USA) in PBS for 1 h.", [["cells", "ANATOMY", 44, 49], ["infection", "DISEASE", 13, 22], ["Hoechst 33342", "CHEMICAL", 103, 116], ["paraformaldehyde", "CHEMICAL", 69, 85], ["Hoechst 33342", "CHEMICAL", 103, 116], ["VSV", "ORGANISM", 33, 36], ["GFP", "GENE_OR_GENE_PRODUCT", 38, 41], ["cells", "CELL", 44, 49], ["paraformaldehyde", "SIMPLE_CHEMICAL", 69, 85], ["Hoechst 33342", "SIMPLE_CHEMICAL", 103, 116], ["infection", "PROBLEM", 13, 22], ["VSV", "TEST", 33, 36], ["3% paraformaldehyde", "TREATMENT", 66, 85], ["infection", "OBSERVATION", 13, 22]]], ["Stained cells were imaged by PerkinElmer Operetta high-content system (PerkinElmer, Waltham, MA).", [["cells", "ANATOMY", 8, 13], ["cells", "CELL", 8, 13], ["Stained cells", "TEST", 0, 13]]], ["Uninfected cells served as the reference population for background fluorescence.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["Uninfected cells", "PROBLEM", 0, 16], ["background fluorescence", "PROBLEM", 56, 79]]], ["Columbus software (PerkinElmer, Waltham, MA) was used to automatically identify and quantify green fluorescence and cell nuclei.", [["cell nuclei", "ANATOMY", 116, 127], ["cell nuclei", "CELLULAR_COMPONENT", 116, 127], ["cell nuclei", "OBSERVATION", 116, 127]]], ["The infection ratio was determined according to the numbers of infected versus non-infected cells.", [["cells", "ANATOMY", 92, 97], ["infection", "DISEASE", 4, 13], ["cells", "CELL", 92, 97], ["non-infected cells", "CELL_TYPE", 79, 97], ["The infection ratio", "PROBLEM", 0, 19], ["infected versus non-infected cells", "PROBLEM", 63, 97], ["infection", "OBSERVATION", 4, 13], ["infected", "OBSERVATION", 63, 71], ["non-infected cells", "OBSERVATION", 79, 97]]], ["The assay was independently repeated three times.ELISA ::: Materials and methodsEnzyme-linked immunosorbent assay (ELISA) for determining S protein-specific IgG in mouse or monkey serum was performed as described previously (Kong et al., 2012).", [["serum", "ANATOMY", 180, 185], ["S protein", "GENE_OR_GENE_PRODUCT", 138, 147], ["IgG", "GENE_OR_GENE_PRODUCT", 157, 160], ["mouse", "ORGANISM", 164, 169], ["monkey", "ORGANISM", 173, 179], ["serum", "ORGANISM_SUBSTANCE", 180, 185], ["S protein", "PROTEIN", 138, 147], ["IgG", "PROTEIN", 157, 160], ["mouse", "SPECIES", 164, 169], ["monkey", "SPECIES", 173, 179], ["mouse", "SPECIES", 164, 169], ["monkey", "SPECIES", 173, 179], ["The assay", "TEST", 0, 9], ["methodsEnzyme", "TEST", 73, 86], ["immunosorbent assay", "TEST", 94, 113], ["ELISA", "TEST", 115, 120], ["determining S protein", "TEST", 126, 147], ["specific IgG", "TEST", 148, 160], ["monkey serum", "TEST", 173, 185]]], ["Briefly, BSR-T7/5 cells were seeded onto two wells of a 6-well plate.", [["BSR-T7/5 cells", "ANATOMY", 9, 23], ["BSR-T7/5 cells", "CELL", 9, 23], ["BSR-T7/5 cells", "CELL_LINE", 9, 23], ["BSR", "TEST", 9, 12], ["T7/5 cells", "TREATMENT", 13, 23], ["a 6-well plate", "TREATMENT", 54, 68], ["T7", "ANATOMY", 13, 15]]], ["Cells were infected with recombinant Newcastle disease virus expressing MERS-CoV S protein (Liu et al., 2017) at an MOI = 0.1.", [["Cells", "ANATOMY", 0, 5], ["Newcastle disease", "DISEASE", 37, 54], ["Cells", "CELL", 0, 5], ["Newcastle disease virus", "ORGANISM", 37, 60], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 72, 82], ["MERS-CoV S protein", "PROTEIN", 72, 90], ["Newcastle disease virus", "SPECIES", 37, 60], ["MERS-CoV", "SPECIES", 72, 80], ["recombinant Newcastle disease virus", "PROBLEM", 25, 60], ["CoV S protein", "TEST", 77, 90], ["an MOI", "TEST", 113, 119]]], ["At 24 h post-infection, the cell pellet was collected and lysed with vigorous pipetting, and the supernatant was used as coating antigen.", [["cell pellet", "ANATOMY", 28, 39], ["supernatant", "ANATOMY", 97, 108], ["cell", "CELL", 28, 32], ["infection", "PROBLEM", 13, 22], ["the cell pellet", "TEST", 24, 39], ["vigorous pipetting", "TREATMENT", 69, 87], ["the supernatant", "TREATMENT", 93, 108], ["infection", "OBSERVATION", 13, 22], ["cell pellet", "OBSERVATION", 28, 39]]], ["Antibodies were detected using HRP-labeled goat anti-mouse (or monkey) IgG (Southern Biotech, Birmingham, AL).", [["HRP", "SIMPLE_CHEMICAL", 31, 34], ["goat", "ORGANISM", 43, 47], ["monkey", "ORGANISM", 63, 69], ["IgG", "GENE_OR_GENE_PRODUCT", 71, 74], ["HRP-labeled goat anti-mouse (or monkey) IgG", "PROTEIN", 31, 74], ["goat", "SPECIES", 43, 47], ["anti-mouse", "SPECIES", 48, 58], ["goat", "SPECIES", 43, 47], ["Antibodies", "TEST", 0, 10], ["HRP", "TEST", 31, 34]]], ["A standard curve was generated by coating the ELISA plate with serially diluted purified mouse or monkey IgG (Southern Biotech, Birmingham, AL) at known concentrations.", [["mouse", "ORGANISM", 89, 94], ["monkey", "ORGANISM", 98, 104], ["IgG", "GENE_OR_GENE_PRODUCT", 105, 108], ["IgG", "PROTEIN", 105, 108], ["mouse", "SPECIES", 89, 94], ["mouse", "SPECIES", 89, 94], ["A standard curve", "TREATMENT", 0, 16], ["serially diluted purified mouse", "TREATMENT", 63, 94]]], ["A linear equation was obtained based on the standard IgG concentrations and their O.D values, thus the concentration of MERS-specific IgG was calculated according to the linear equation based on their O.D values and expressed as the amount of IgG per ml of serum (ng/ml).Neutralization assay ::: Materials and methodsMouse and monkey serum neutralizing antibody levels were determined using VSV\u0394G-eGFP-MERS.", [["serum", "ANATOMY", 257, 262], ["serum", "ANATOMY", 334, 339], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["MERS", "SIMPLE_CHEMICAL", 120, 124], ["IgG", "GENE_OR_GENE_PRODUCT", 134, 137], ["IgG", "GENE_OR_GENE_PRODUCT", 243, 246], ["serum", "ORGANISM_SUBSTANCE", 257, 262], ["Mouse", "ORGANISM", 317, 322], ["monkey", "ORGANISM", 327, 333], ["serum", "ORGANISM_SUBSTANCE", 334, 339], ["IgG", "PROTEIN", 53, 56], ["MERS", "PROTEIN", 120, 124], ["IgG", "PROTEIN", 134, 137], ["IgG", "PROTEIN", 243, 246], ["VSV\u0394G", "PROTEIN", 391, 396], ["eGFP", "DNA", 397, 401], ["MERS", "DNA", 402, 406], ["Mouse", "SPECIES", 317, 322], ["monkey", "SPECIES", 327, 333], ["Mouse", "SPECIES", 317, 322], ["monkey", "SPECIES", 327, 333], ["A linear equation", "TEST", 0, 17], ["their O.D values", "TEST", 76, 92], ["MERS-specific IgG", "TREATMENT", 120, 137], ["methodsMouse", "TEST", 310, 322], ["monkey serum neutralizing antibody levels", "TEST", 327, 368], ["VSV\u0394G", "TEST", 391, 396], ["linear", "OBSERVATION_MODIFIER", 2, 8]]], ["To perform the neutralization assay, 25 \u03bcl of 2-fold serially-diluted serum (heat inactivated at 56 \u00b0C for 30 min before use) was mixed with 25 \u03bcl DMEM containing 5 \u00d7 102 TCID50 VSV\u0394G-eGFP-MERS and incubated at 37 \u00b0C for 1 h.", [["serum", "ANATOMY", 70, 75], ["VSV\u0394G-eGFP-MERS", "CHEMICAL", 178, 193], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["eGFP", "ORGANISM", 184, 188], ["MERS", "PROTEIN", 189, 193], ["the neutralization assay", "TEST", 11, 35]]], ["After incubation, 50 \u03bcl of the pre-incubated mixture was added onto Vero E6 cells in triplicate wells of a 96-well plate.", [["cells", "ANATOMY", 76, 81], ["Vero E6 cells", "CELL", 68, 81], ["Vero E6 cells", "CELL_LINE", 68, 81], ["Vero E6", "SPECIES", 68, 75], ["the pre-incubated mixture", "TREATMENT", 27, 52], ["Vero E6 cells", "TREATMENT", 68, 81]]], ["The GFP-expressing cells were counted at 36 h post-infection under a fluorescence microscope.", [["cells", "ANATOMY", 19, 24], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 19, 24], ["GFP-expressing cells", "CELL_LINE", 4, 24], ["The GFP", "TEST", 0, 7], ["expressing cells", "PROBLEM", 8, 24], ["infection", "PROBLEM", 51, 60], ["a fluorescence microscope", "TEST", 67, 92], ["expressing cells", "OBSERVATION", 8, 24], ["infection", "OBSERVATION", 51, 60]]], ["Virus neutralization titers (VNT) were expressed as the reciprocal of the highest dilution of serum that showed at least 50% reduction in the number of fluorescent cells as compared with the negative control.Animals and immunization protocol ::: Materials and methodsFor monkey immunizations, eight 2-year old male rhesus monkeys (obtained from Academy of Military Medical Sciences, Beijing, China) were randomly divided into two groups.", [["serum", "ANATOMY", 94, 99], ["cells", "ANATOMY", 164, 169], ["Virus", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["cells", "CELL", 164, 169], ["monkey", "ORGANISM", 271, 277], ["rhesus", "ORGANISM", 315, 321], ["monkeys", "ORGANISM", 322, 329], ["fluorescent cells", "CELL_TYPE", 152, 169], ["rhesus monkeys", "SPECIES", 315, 329], ["Virus neutralization titers", "TEST", 0, 27], ["fluorescent cells", "PROBLEM", 152, 169], ["monkey immunizations", "TREATMENT", 271, 291], ["reduction", "OBSERVATION_MODIFIER", 125, 134], ["fluorescent cells", "OBSERVATION", 152, 169]]], ["Group 1 was intramuscularly (i.m) immunized with 2 \u00d7 107 FFU VSV\u0394G-MERS (preparation described below) in 2 ml medium via hind limb muscle injection under anesthesia.", [["hind limb muscle", "ANATOMY", 121, 137], ["VSV\u0394G-MERS", "CHEMICAL", 61, 71], ["hind limb", "ORGANISM_SUBDIVISION", 121, 130], ["muscle", "ORGANISM_SUBDIVISION", 131, 137], ["anesthesia", "TREATMENT", 154, 164], ["hind limb", "ANATOMY", 121, 130], ["muscle", "ANATOMY", 131, 137]]], ["Group 2 was intranasally (i.n) immunized with the same regimen as Group 1 via nostril instillation under anesthesia.", [["intranasally", "ANATOMY", 12, 24], ["nostril", "ORGANISM_SUBDIVISION", 78, 85], ["the same regimen", "TREATMENT", 46, 62], ["anesthesia", "TREATMENT", 105, 115]]], ["All monkeys were housed in separate cages in a Biosafety Level-3 laboratory equipped with stable moisture and temperature.", [["monkeys", "ORGANISM", 4, 11], ["monkeys", "SPECIES", 4, 11], ["a Biosafety Level", "TEST", 45, 62]]], ["Monkeys were fed 3 times a day with specialized monkey puffed diet and various fresh fruits and adequate drinking water.Animals and immunization protocol ::: Materials and methodsTen 6-week female Balb/c mice (Vital River, Beijing, China) were intramuscularly immunized with 1 \u00d7 106 FFU VSV\u0394G-MERS in 0.1 ml medium via hind limb muscle injection.", [["fruits", "ANATOMY", 85, 91], ["hind limb muscle", "ANATOMY", 319, 335], ["VSV\u0394G-MERS", "CHEMICAL", 287, 297], ["Monkeys", "ORGANISM", 0, 7], ["monkey", "ORGANISM", 48, 54], ["fruits", "ORGANISM_SUBDIVISION", 85, 91], ["Balb/c mice", "ORGANISM", 197, 208], ["hind limb", "ORGANISM_SUBDIVISION", 319, 328], ["muscle", "ORGANISM_SUBDIVISION", 329, 335], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 204, 208], ["specialized monkey puffed diet", "TREATMENT", 36, 66], ["hind", "ANATOMY", 319, 323], ["limb muscle", "ANATOMY", 324, 335]]], ["Ten control mice were intramuscularly injected with 0.1 ml medium.", [["mice", "ORGANISM", 12, 16], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["Ten control mice", "TREATMENT", 0, 16]]], ["Mice were monitored daily for weight changes and signs of illness for 14 days.", [["illness", "DISEASE", 58, 65], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["weight changes", "PROBLEM", 30, 44], ["illness", "PROBLEM", 58, 65]]], ["Mice were given the booster dose 3 weeks after the first dose.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["the booster dose", "TREATMENT", 16, 32]]], ["Mice blood was collected 2 weeks after the prime and boost immunizations, and mice sera were prepared for determining the MERS-specific IgG and neutralizing antibodies.Animals and immunization protocol ::: Materials and methodsAll animal usage was in strict accordance with the Guide for the Care and Use of Laboratory Animals of the Ministry of Science and Technology of the People's Republic of China.", [["blood", "ANATOMY", 5, 10], ["sera", "ANATOMY", 83, 87], ["Mice", "ORGANISM", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["mice", "ORGANISM", 78, 82], ["sera", "ORGANISM_SUBSTANCE", 83, 87], ["MERS", "GENE_OR_GENE_PRODUCT", 122, 126], ["IgG", "GENE_OR_GENE_PRODUCT", 136, 139], ["MERS", "PROTEIN", 122, 126], ["IgG", "PROTEIN", 136, 139], ["neutralizing antibodies", "PROTEIN", 144, 167], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 78, 82], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 78, 82], ["boost immunizations", "TREATMENT", 53, 72], ["the MERS", "TEST", 118, 126], ["specific IgG", "TEST", 127, 139], ["neutralizing antibodies", "TEST", 144, 167]]], ["The protocols were approved by the Animal Research Ethics Committee of Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.ELISPOT ::: Materials and methodsEnzyme-linked immunospot (ELISPOT) assay was performed to evaluate the vaccine-induced T cell responses in monkeys.", [["T cell", "ANATOMY", 270, 276], ["T cell", "CELL", 270, 276], ["monkeys", "ORGANISM", 290, 297], ["monkeys", "SPECIES", 290, 297], ["methodsEnzyme", "TEST", 176, 189], ["immunospot (ELISPOT) assay", "TEST", 197, 223]]], ["Ten days after immunization, monkey blood was drawn from lower extremity veins under anesthesia.", [["blood", "ANATOMY", 36, 41], ["lower extremity veins", "ANATOMY", 57, 78], ["monkey", "ORGANISM", 29, 35], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["lower extremity veins", "MULTI-TISSUE_STRUCTURE", 57, 78], ["monkey", "SPECIES", 29, 35], ["immunization", "TREATMENT", 15, 27], ["monkey blood", "TEST", 29, 41], ["anesthesia", "TREATMENT", 85, 95], ["lower", "ANATOMY_MODIFIER", 57, 62], ["extremity veins", "ANATOMY", 63, 78], ["anesthesia", "OBSERVATION", 85, 95]]], ["Peripheral blood mononuclear cells (PBMC) were separated by monkey lymphocyte separation buffer (TBD sciences, Tianjin, China).", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["PBMC", "ANATOMY", 36, 40], ["lymphocyte", "ANATOMY", 67, 77], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["PBMC", "CELL", 36, 40], ["monkey", "ORGANISM", 60, 66], ["lymphocyte", "CELL", 67, 77], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["PBMC", "CELL_TYPE", 36, 40], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["PBMC", "TEST", 36, 40], ["monkey lymphocyte separation buffer", "TREATMENT", 60, 95], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34]]], ["To ensure adequate cell numbers, monkey PBMCs from the same group were pooled.", [["cell", "ANATOMY", 19, 23], ["PBMCs", "ANATOMY", 40, 45], ["cell", "CELL", 19, 23], ["monkey", "ORGANISM", 33, 39], ["PBMCs", "CELL", 40, 45], ["monkey PBMCs", "CELL_TYPE", 33, 45], ["adequate cell numbers", "OBSERVATION", 10, 31]]], ["A synthetic overlapping peptide pool spanning the whole MERS-CoV S protein, which consisted of 269 peptides (15mers with 10 amino acid overlapped, designed for CD8+ T cells) was used to evaluate the specific CD8+ T cell responses.", [["CD8+ T cells", "ANATOMY", 160, 172], ["T cell", "ANATOMY", 213, 219], ["amino acid", "CHEMICAL", 124, 134], ["amino acid", "CHEMICAL", 124, 134], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 56, 66], ["amino acid", "AMINO_ACID", 124, 134], ["CD8", "GENE_OR_GENE_PRODUCT", 160, 163], ["CD8", "GENE_OR_GENE_PRODUCT", 208, 211], ["T cell", "CELL", 213, 219], ["MERS-CoV S protein", "PROTEIN", 56, 74], ["CD8", "PROTEIN", 160, 163], ["T cells", "CELL_TYPE", 165, 172], ["CD8", "PROTEIN", 208, 211], ["A synthetic overlapping peptide pool", "PROBLEM", 0, 36], ["the whole MERS", "TEST", 46, 60], ["CoV S protein", "TEST", 61, 74], ["peptides", "TEST", 99, 107], ["amino acid", "TEST", 124, 134], ["CD8+ T cells", "TREATMENT", 160, 172]]], ["Briefly, Millipore 96-well HTS HA sterile plates (Millipore, USA) were coated with 4 \u03bcg/ml purified mouse anti-human IFN-\u03b3 (BD Pharmingen, San Diego, CA) in 0.1 ml PBS at 4 \u00b0C. After 12 h, the coating solution was removed, then 0.05 ml RPMI 1640 medium containing 20 \u03bcg/ml diluted peptide was added into the well after which 5 \u00d7 105 PBMCs in 0.05 ml RPMI 1640 medium were added into the well and mixed with peptide.", [["PBMCs", "ANATOMY", 333, 338], ["mouse", "ORGANISM", 100, 105], ["anti-human", "ORGANISM", 106, 116], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 117, 122], ["PBMCs", "CELL", 333, 338], ["IFN", "PROTEIN", 117, 120], ["\u03b3", "PROTEIN", 121, 122], ["BD Pharmingen", "PROTEIN", 124, 137], ["CA", "PROTEIN", 150, 152], ["PBMCs", "CELL_TYPE", 333, 338], ["mouse", "SPECIES", 100, 105], ["mouse", "SPECIES", 100, 105], ["Millipore", "TREATMENT", 9, 18], ["HTS HA sterile plates (Millipore, USA)", "TREATMENT", 27, 65], ["mouse anti-human IFN", "TREATMENT", 100, 120], ["CA)", "TREATMENT", 150, 153], ["the coating solution", "TREATMENT", 189, 209]]], ["Cells were cultured with the peptides at 37 \u00b0C for 24 h to induce stimulation.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["the peptides", "TEST", 25, 37]]], ["The cells were removed from the plate by vigorous washing using PBST, then 0.1 ml biotin-labeled mouse anti human IFN-\u03b3 (BD Pharmingen, San Diego, CA) was added for 1 h, followed by adding 0.1 ml HRP-conjugated streptavidin (BD Pharmingen, San Diego, CA) for 1 h.", [["cells", "ANATOMY", 4, 9], ["biotin", "CHEMICAL", 82, 88], ["IFN-\u03b3", "CHEMICAL", 114, 119], ["biotin", "CHEMICAL", 82, 88], ["cells", "CELL", 4, 9], ["biotin", "SIMPLE_CHEMICAL", 82, 88], ["mouse", "ORGANISM", 97, 102], ["human", "ORGANISM", 108, 113], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 114, 119], ["HRP-conjugated streptavidin", "SIMPLE_CHEMICAL", 196, 223], ["IFN", "PROTEIN", 114, 117], ["\u03b3", "PROTEIN", 118, 119], ["BD Pharmingen", "PROTEIN", 121, 134], ["mouse", "SPECIES", 97, 102], ["human", "SPECIES", 108, 113], ["mouse", "SPECIES", 97, 102], ["human", "SPECIES", 108, 113], ["The cells", "TREATMENT", 0, 9], ["PBST", "TREATMENT", 64, 68], ["biotin", "TREATMENT", 82, 88], ["mouse anti human IFN", "TREATMENT", 97, 117], ["CA)", "TREATMENT", 147, 150], ["conjugated streptavidin", "TREATMENT", 200, 223], ["plate", "OBSERVATION_MODIFIER", 32, 37]]], ["After final wash, spots were developed by AEC substrate (BD Pharmingen, San Diego, CA).", [["AEC substrate", "PROTEIN", 42, 55], ["BD Pharmingen", "PROTEIN", 57, 70]]], ["The images of spots were acquired and counted by a ChampSpot III ELISPOT reader (Sage Creation Science, Beijing, China), and the data was analyzed by Excel software (Microsoft, Redmond, WA).", [["The images of spots", "TEST", 0, 19]]], ["The cut-off threshold was set as 100 spots compared to the negative control.", [["The cut-off threshold", "TREATMENT", 0, 21]]], ["Six peptides that stimulated the most numbers of spots were selected.", [["Six peptides", "TREATMENT", 0, 12]]], ["The information of these peptides is listed in Table 1..Statistical analysis ::: Materials and methodsTwo-way ANOVA with Bonferroni's multiple comparison tests was used for statistical analysis.", [["Bonferroni's multiple comparison tests", "TEST", 121, 159], ["statistical analysis", "TEST", 173, 193]]], ["All P-values were two-tailed and considered statistically very significant when the associated probability was less than 0.01.Construction of VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS and in vitro characterization of the viruses ::: ResultsVSV\u0394G-MERS and VSV\u0394G-eGFP-MERS were constructed and rescued based on the established VSV Indiana strain reverse genetics system (Wang et al., 2006) in which the VSV G gene was replaced by MERS-CoV S gene (an eGFP gene was inserted between the M and S gene of VSV\u0394G-MERS to construct VSV\u0394G-eGFP-MERS) as shown in Fig. 1A.", [["1A.", "CHEMICAL", 546, 549], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 142, 152], ["ResultsVSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 222, 239], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 244, 254], ["VSV", "ORGANISM", 314, 317], ["VSV", "ORGANISM", 390, 393], ["G", "GENE_OR_GENE_PRODUCT", 394, 395], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 417, 427], ["eGFP", "GENE_OR_GENE_PRODUCT", 437, 441], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 488, 498], ["VSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 512, 527], ["P-values", "DNA", 4, 12], ["VSV\u0394G", "DNA", 142, 147], ["MERS", "DNA", 148, 152], ["VSV\u0394G", "DNA", 157, 162], ["eGFP", "DNA", 163, 167], ["MERS", "DNA", 168, 172], ["ResultsVSV\u0394G-MERS and VSV\u0394G-eGFP-MERS", "DNA", 222, 259], ["VSV G gene", "DNA", 390, 400], ["MERS-CoV S gene", "DNA", 417, 432], ["eGFP gene", "DNA", 437, 446], ["M and S gene", "DNA", 472, 484], ["VSV\u0394G", "DNA", 488, 493], ["MERS", "DNA", 494, 498], ["VSV\u0394G", "DNA", 512, 517], ["eGFP", "DNA", 518, 522], ["MERS", "DNA", 523, 527], ["VSV", "SPECIES", 314, 317], ["VSV", "SPECIES", 390, 393], ["All P-values", "TEST", 0, 12], ["VSV\u0394G", "TEST", 142, 147], ["VSV\u0394G", "TEST", 157, 162], ["MERS", "PROBLEM", 168, 172], ["ResultsVSV\u0394G", "TEST", 222, 234], ["VSV\u0394G", "TEST", 244, 249], ["the VSV G gene", "TREATMENT", 386, 400], ["an eGFP gene", "TREATMENT", 434, 446], ["VSV\u0394G", "TEST", 488, 493], ["VSV\u0394G", "TEST", 512, 517], ["viruses", "OBSERVATION", 210, 217]]], ["The expression of S protein was confirmed by indirect immunofluorescence and Western blotting (Fig. 1B and C).", [["S protein", "GENE_OR_GENE_PRODUCT", 18, 27], ["S protein", "PROTEIN", 18, 27], ["S protein", "TEST", 18, 27], ["indirect immunofluorescence", "TEST", 45, 72], ["Western blotting", "TEST", 77, 93]]], ["Indirect immunofluorescence using anti-S protein antibody confirmed the surface expression of S protein in VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS-infected Vero cells (Fig. 1B). eGFP expression was confirmed in VSV\u0394G-eGFP-MERS infected Vero cells.", [["surface", "ANATOMY", 72, 79], ["VSV\u0394G-MERS", "ANATOMY", 107, 117], ["Vero cells", "ANATOMY", 147, 157], ["Vero cells", "ANATOMY", 227, 237], ["anti-S protein antibody", "GENE_OR_GENE_PRODUCT", 34, 57], ["S protein", "GENE_OR_GENE_PRODUCT", 94, 103], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 107, 117], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 122, 132], ["Vero cells", "CELL", 147, 157], ["Fig. 1B", "CELL", 159, 166], ["eGFP", "GENE_OR_GENE_PRODUCT", 169, 173], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 202, 212], ["Vero cells", "CELL", 227, 237], ["anti-S protein antibody", "PROTEIN", 34, 57], ["S protein", "PROTEIN", 94, 103], ["VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS-infected Vero cells", "CELL_LINE", 107, 157], ["eGFP", "DNA", 169, 173], ["VSV\u0394G-eGFP-MERS infected Vero cells", "CELL_LINE", 202, 237], ["Indirect immunofluorescence", "TEST", 0, 27], ["anti-S protein antibody", "TEST", 34, 57], ["S protein", "TEST", 94, 103], ["VSV\u0394G", "TEST", 107, 112], ["MERS", "TEST", 113, 117], ["VSV\u0394G", "TEST", 122, 127], ["eGFP", "TEST", 128, 132], ["MERS", "PROBLEM", 133, 137], ["infected Vero cells", "PROBLEM", 138, 157], ["eGFP expression", "TEST", 169, 184], ["VSV\u0394G", "TEST", 202, 207], ["MERS infected Vero cells", "PROBLEM", 213, 237], ["Vero cells", "OBSERVATION", 147, 157], ["Vero cells", "OBSERVATION", 227, 237]]], ["Both VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS infected cells were not stained by VSV G monoclonal antibody.", [["cells", "ANATOMY", 45, 50], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 5, 15], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 20, 30], ["cells", "CELL", 45, 50], ["VSV", "ORGANISM", 71, 74], ["VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS infected cells", "CELL_LINE", 5, 50], ["VSV G monoclonal antibody", "PROTEIN", 71, 96], ["VSV", "SPECIES", 71, 74], ["Both VSV\u0394G", "TEST", 0, 10], ["MERS", "TEST", 11, 15], ["VSV\u0394G", "TEST", 20, 25], ["eGFP", "TEST", 26, 30], ["MERS infected cells", "PROBLEM", 31, 50], ["VSV G monoclonal antibody", "TEST", 71, 96]]], ["As shown in Fig. 1C, uncleaved S protein (faint bands above 170 kDa), S1/S2 cleaved S protein (\u223c80 kDa) and S2' cleaved S protein (\u223c65 kDa) (Millet and Whittaker, 2014) was detected in the purified VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS virions indicating incorporation of S protein into the viral particles.Construction of VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS and in vitro characterization of the viruses ::: ResultsVSV\u0394G-MERS and VSV\u0394G-eGFP-MERS showed similar growth kinetics in Vero cells and their peak titers reached 1 \u00d7 107 FFU/ml at 72 h post-infection (Fig. 2).", [["Vero cells", "ANATOMY", 468, 478], ["infection", "DISEASE", 537, 546], ["1C", "GENE_OR_GENE_PRODUCT", 17, 19], ["uncleaved S protein", "GENE_OR_GENE_PRODUCT", 21, 40], ["S protein", "GENE_OR_GENE_PRODUCT", 84, 93], ["S2' cleaved S protein", "GENE_OR_GENE_PRODUCT", 108, 129], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 198, 208], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 213, 218], ["eGFP", "GENE_OR_GENE_PRODUCT", 219, 223], ["S protein", "GENE_OR_GENE_PRODUCT", 265, 274], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 316, 326], ["ResultsVSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 396, 413], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 418, 428], ["Vero cells", "CELL", 468, 478], ["uncleaved S protein", "PROTEIN", 21, 40], ["faint bands", "PROTEIN", 42, 53], ["170 kDa", "PROTEIN", 60, 67], ["S1", "PROTEIN", 70, 72], ["S2", "PROTEIN", 73, 75], ["S protein", "PROTEIN", 84, 93], ["\u223c80 kDa", "PROTEIN", 95, 102], ["S2' cleaved S protein", "PROTEIN", 108, 129], ["\u223c65 kDa", "PROTEIN", 131, 138], ["VSV\u0394G", "PROTEIN", 198, 203], ["VSV\u0394G", "PROTEIN", 213, 218], ["eGFP", "PROTEIN", 219, 223], ["S protein", "PROTEIN", 265, 274], ["VSV\u0394G", "DNA", 316, 321], ["MERS", "DNA", 322, 326], ["VSV\u0394G", "DNA", 331, 336], ["eGFP", "DNA", 337, 341], ["MERS", "DNA", 342, 346], ["ResultsVSV\u0394G-MERS and VSV\u0394G-eGFP-MERS", "DNA", 396, 433], ["Vero cells", "CELL_LINE", 468, 478], ["1C", "TEST", 17, 19], ["uncleaved S protein", "TEST", 21, 40], ["faint bands", "TEST", 42, 53], ["kDa", "TEST", 64, 67], ["S1", "TEST", 70, 72], ["S protein", "TEST", 84, 93], ["kDa", "TEST", 99, 102], ["S2' cleaved S protein", "TEST", 108, 129], ["the purified VSV\u0394G", "TEST", 185, 203], ["MERS", "PROBLEM", 204, 208], ["VSV\u0394G", "TEST", 213, 218], ["MERS virions", "PROBLEM", 224, 236], ["S protein into the viral particles", "PROBLEM", 265, 299], ["VSV\u0394G", "TEST", 316, 321], ["VSV\u0394G", "TEST", 331, 336], ["MERS", "PROBLEM", 342, 346], ["ResultsVSV\u0394G", "TEST", 396, 408], ["VSV\u0394G", "TEST", 418, 423], ["eGFP", "TEST", 424, 428], ["MERS", "PROBLEM", 429, 433], ["similar growth kinetics", "PROBLEM", 441, 464], ["Vero cells", "TEST", 468, 478], ["their peak titers", "TEST", 483, 500], ["infection", "PROBLEM", 537, 546], ["Fig", "OBSERVATION", 12, 15], ["S2", "ANATOMY", 73, 75], ["viral particles", "OBSERVATION", 284, 299], ["viruses", "OBSERVATION", 384, 391], ["Vero cells", "OBSERVATION_MODIFIER", 468, 478], ["infection", "OBSERVATION", 537, 546]]], ["The recombinant viruses showed delayed growth kinetics and decreased titers compared with native VSV that reached 1 \u00d7 109 FFU/ml at 24 h post-infection.", [["infection", "DISEASE", 142, 151], ["VSV", "ORGANISM", 97, 100], ["VSV", "SPECIES", 97, 100], ["The recombinant viruses", "PROBLEM", 0, 23], ["delayed growth kinetics", "PROBLEM", 31, 54], ["decreased titers", "PROBLEM", 59, 75], ["infection", "PROBLEM", 142, 151], ["viruses", "OBSERVATION", 16, 23], ["growth kinetics", "OBSERVATION", 39, 54], ["decreased", "OBSERVATION_MODIFIER", 59, 68], ["titers", "OBSERVATION_MODIFIER", 69, 75], ["infection", "OBSERVATION", 142, 151]]], ["The genetic stability of VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS was assessed by serially passaging the virus on Vero E6 cells for 10 passages, and the expression of S gene (plus eGFP gene for VSV\u0394G-eGFP-MERS) was confirmed by RT-PCR and immunofluorescence analyses (data not shown).MERS-CoV S incorporates into the envelope of recombinant VSV and mediates cell infection by using the receptor DPP4 ::: ResultsTo further confirm the incorporation of S protein into the viral particles, electron and immunoelectron microscopy were performed.", [["cells", "ANATOMY", 112, 117], ["cell", "ANATOMY", 348, 352], ["infection", "DISEASE", 353, 362], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 25, 35], ["VSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 40, 55], ["Vero E6 cells", "CELL", 104, 117], ["S", "GENE_OR_GENE_PRODUCT", 157, 158], ["eGFP", "GENE_OR_GENE_PRODUCT", 170, 174], ["VSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 184, 199], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 274, 284], ["recombinant VSV", "ORGANISM", 319, 334], ["cell", "CELL", 348, 352], ["DPP4", "GENE_OR_GENE_PRODUCT", 385, 389], ["electron", "SIMPLE_CHEMICAL", 477, 485], ["VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS", "DNA", 25, 55], ["Vero E6 cells", "CELL_LINE", 104, 117], ["S gene", "DNA", 157, 163], ["eGFP gene", "DNA", 170, 179], ["VSV\u0394G", "DNA", 184, 189], ["eGFP", "DNA", 190, 194], ["MERS", "DNA", 195, 199], ["MERS-CoV S", "PROTEIN", 274, 284], ["DPP4", "PROTEIN", 385, 389], ["S protein", "PROTEIN", 441, 450], ["Vero E6", "SPECIES", 104, 111], ["VSV", "SPECIES", 331, 334], ["VSV\u0394G", "TEST", 25, 30], ["MERS", "PROBLEM", 31, 35], ["VSV\u0394G", "TEST", 40, 45], ["MERS", "PROBLEM", 51, 55], ["Vero E6 cells", "TREATMENT", 104, 117], ["VSV\u0394G", "TEST", 184, 189], ["RT-PCR", "TEST", 218, 224], ["immunofluorescence analyses", "TEST", 229, 256], ["MERS-CoV S", "PROBLEM", 274, 284], ["recombinant VSV", "PROBLEM", 319, 334], ["mediates cell infection", "PROBLEM", 339, 362], ["S protein", "TEST", 441, 450], ["the viral particles", "TEST", 456, 475], ["immunoelectron microscopy", "TEST", 490, 515], ["stability", "OBSERVATION_MODIFIER", 12, 21], ["recombinant VSV", "OBSERVATION", 319, 334], ["cell infection", "OBSERVATION", 348, 362], ["viral particles", "OBSERVATION", 460, 475]]], ["Results clearly showed the S protein incorporated into VSV\u0394G-MERS, VSV\u0394G-eGFP-MERS, and VSV-MERS (Fig. 3A, long arrows).", [["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 55, 65], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 67, 77], ["VSV", "ORGANISM", 88, 91], ["S protein", "PROTEIN", 27, 36], ["VSV\u0394G", "PROTEIN", 55, 60], ["MERS", "PROTEIN", 61, 65], ["VSV\u0394G", "PROTEIN", 67, 72], ["eGFP", "DNA", 73, 77], ["MERS", "PROTEIN", 78, 82], ["MERS", "DNA", 92, 96], ["the S protein", "TEST", 23, 36], ["VSV\u0394G", "TEST", 55, 60], ["VSV\u0394G", "TEST", 67, 72], ["eGFP", "TEST", 73, 77], ["MERS", "PROBLEM", 78, 82]]], ["VSV G protein was also shown on VSV and VSV-MERS particles with discrepant shape compared with MERS-CoV S protein (Fig. 3 upper panel, short stealth arrows).", [["VSV G", "GENE_OR_GENE_PRODUCT", 0, 5], ["VSV", "ORGANISM", 32, 35], ["VSV", "ORGANISM", 40, 43], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 95, 105], ["VSV G protein", "PROTEIN", 0, 13], ["MERS-CoV S protein", "PROTEIN", 95, 113], ["VSV", "SPECIES", 0, 3], ["VSV", "SPECIES", 32, 35], ["VSV", "SPECIES", 40, 43], ["MERS-CoV", "SPECIES", 95, 103], ["VSV G protein", "TEST", 0, 13], ["VSV", "TEST", 32, 35], ["VSV", "TEST", 40, 43], ["MERS particles", "PROBLEM", 44, 58], ["discrepant shape", "PROBLEM", 64, 80], ["MERS", "TEST", 95, 99], ["CoV S protein", "TEST", 100, 113], ["Fig.", "TEST", 115, 119], ["upper panel", "TEST", 122, 133], ["short stealth arrows", "PROBLEM", 135, 155]]], ["Immunoelectron microscopy showed the binding of gold-labeled secondary antibody to the anti-S antibody-bound S protein on the VSV\u0394G-MERS, VSV\u0394G-eGFP-MERS, and VSV-MERS particles (Fig. 3A, lower panel, long arrow indicating S protein).", [["gold", "CHEMICAL", 48, 52], ["gold", "SIMPLE_CHEMICAL", 48, 52], ["eGFP", "GENE_OR_GENE_PRODUCT", 144, 148], ["VSV", "ORGANISM", 159, 162], ["gold-labeled secondary antibody", "PROTEIN", 48, 79], ["anti-S antibody", "PROTEIN", 87, 102], ["S protein", "PROTEIN", 109, 118], ["VSV\u0394G-MERS, VSV\u0394G-eGFP-MERS", "DNA", 126, 153], ["S protein", "PROTEIN", 223, 232], ["VSV", "SPECIES", 159, 162], ["Immunoelectron microscopy", "TEST", 0, 25], ["the binding of gold-labeled secondary antibody", "PROBLEM", 33, 79], ["the anti-S antibody", "TEST", 83, 102], ["S protein", "TEST", 109, 118], ["the VSV\u0394G", "TEST", 122, 131], ["MERS", "TEST", 132, 136], ["VSV\u0394G", "TEST", 138, 143], ["eGFP", "TEST", 144, 148], ["MERS", "PROBLEM", 149, 153], ["VSV", "TEST", 159, 162], ["MERS particles", "TEST", 163, 177], ["lower panel", "TEST", 188, 199]]], ["These results confirmed the incorporation of S protein into the chimeric viral particles.MERS-CoV S incorporates into the envelope of recombinant VSV and mediates cell infection by using the receptor DPP4 ::: ResultsSince VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS had the native G protein replaced with MERS-CoV S protein to execute viral attachment and entry, the viruses should use human dipeptidyl peptidase 4 (DPP4) as their entry receptor (Raj et al., 2013).", [["cell", "ANATOMY", 163, 167], ["infection", "DISEASE", 168, 177], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["recombinant VSV", "ORGANISM", 134, 149], ["cell", "CELL", 163, 167], ["DPP4", "GENE_OR_GENE_PRODUCT", 200, 204], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 222, 232], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 237, 247], ["G protein", "GENE_OR_GENE_PRODUCT", 268, 277], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 292, 302], ["human", "ORGANISM", 373, 378], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 379, 401], ["DPP4", "GENE_OR_GENE_PRODUCT", 403, 407], ["S protein", "PROTEIN", 45, 54], ["MERS-CoV S", "PROTEIN", 89, 99], ["DPP4", "PROTEIN", 200, 204], ["VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS", "DNA", 222, 252], ["native G protein", "PROTEIN", 261, 277], ["MERS-CoV S protein", "PROTEIN", 292, 310], ["human dipeptidyl peptidase 4", "PROTEIN", 373, 401], ["DPP4", "PROTEIN", 403, 407], ["entry receptor", "PROTEIN", 418, 432], ["human", "SPECIES", 373, 378], ["VSV", "SPECIES", 146, 149], ["human", "SPECIES", 373, 378], ["recombinant VSV", "PROBLEM", 134, 149], ["mediates cell infection", "PROBLEM", 154, 177], ["VSV\u0394G", "TEST", 222, 227], ["MERS", "TEST", 228, 232], ["VSV\u0394G", "TEST", 237, 242], ["eGFP", "TEST", 243, 247], ["MERS", "PROBLEM", 248, 252], ["the native G protein", "TREATMENT", 257, 277], ["MERS", "PROBLEM", 292, 296], ["CoV S protein", "TREATMENT", 297, 310], ["viral attachment", "PROBLEM", 322, 338], ["human dipeptidyl peptidase 4 (DPP4)", "TREATMENT", 373, 408], ["viral particles", "OBSERVATION", 73, 88], ["recombinant VSV", "OBSERVATION", 134, 149], ["cell infection", "OBSERVATION", 163, 177]]], ["BHK-21 cells do not express human DPP4, and are non-permissive to MERS-CoV infection so we transfected BHK-21 cells with pCAGGS-DPP4 (a eukaryotic plasmid encoding human DPP4) prior to infecting the cells with VSV\u0394G-eGFP-MERS.", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "ANATOMY", 103, 115], ["plasmid", "ANATOMY", 147, 154], ["cells", "ANATOMY", 199, 204], ["BHK-21 cells", "CELL", 0, 12], ["human", "ORGANISM", 28, 33], ["DPP4", "GENE_OR_GENE_PRODUCT", 34, 38], ["MERS-CoV", "ORGANISM", 66, 74], ["BHK-21 cells", "CELL", 103, 115], ["pCAGGS-DPP4", "GENE_OR_GENE_PRODUCT", 121, 132], ["human", "ORGANISM", 164, 169], ["DPP4", "GENE_OR_GENE_PRODUCT", 170, 174], ["cells", "CELL", 199, 204], ["eGFP", "GENE_OR_GENE_PRODUCT", 216, 220], ["BHK-21 cells", "CELL_LINE", 0, 12], ["human DPP4", "PROTEIN", 28, 38], ["BHK-21 cells", "CELL_LINE", 103, 115], ["pCAGGS", "PROTEIN", 121, 127], ["DPP4", "PROTEIN", 128, 132], ["eukaryotic plasmid", "DNA", 136, 154], ["human DPP4", "PROTEIN", 164, 174], ["VSV\u0394G-eGFP-MERS", "DNA", 210, 225], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 28, 33], ["MERS-CoV", "SPECIES", 66, 74], ["BHK-21", "SPECIES", 103, 109], ["human", "SPECIES", 164, 169], ["BHK", "TEST", 0, 3], ["human DPP4", "TEST", 28, 38], ["CoV infection", "PROBLEM", 71, 84], ["BHK", "TEST", 103, 106], ["pCAGGS", "TEST", 121, 127], ["DPP4", "TREATMENT", 128, 132], ["a eukaryotic plasmid encoding human DPP4", "TREATMENT", 134, 174], ["VSV\u0394G", "TEST", 210, 215], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["As shown in Fig. 4A, BHK-21 cells were not infected by VSV\u0394G-eGFP-MERS, while DPP4-transfected BHK-21 cells were infected by the virus.", [["BHK-21 cells", "ANATOMY", 21, 33], ["BHK-21 cells", "ANATOMY", 95, 107], ["BHK-21 cells", "CELL", 21, 33], ["eGFP", "GENE_OR_GENE_PRODUCT", 61, 65], ["DPP4", "GENE_OR_GENE_PRODUCT", 78, 82], ["BHK-21 cells", "CELL", 95, 107], ["BHK-21 cells", "CELL_LINE", 21, 33], ["eGFP", "DNA", 61, 65], ["MERS", "PROTEIN", 66, 70], ["DPP4", "PROTEIN", 78, 82], ["transfected BHK-21 cells", "CELL_LINE", 83, 107], ["BHK", "TEST", 21, 24], ["VSV\u0394G", "TEST", 55, 60], ["eGFP", "TEST", 61, 65], ["MERS", "PROBLEM", 66, 70], ["DPP4", "TEST", 78, 82], ["BHK", "TEST", 95, 98], ["Fig", "OBSERVATION", 12, 15]]], ["Vero E6 cells are permissive cells for MERS-CoV, and our results demonstrated that VSV\u0394G-eGFP-MERS and VSV\u0394G-MERS could infect Vero E6 cells and form large syncytia (Figs.", [["Vero E6 cells", "ANATOMY", 0, 13], ["cells", "ANATOMY", 29, 34], ["Vero E6 cells", "ANATOMY", 127, 140], ["syncytia", "ANATOMY", 156, 164], ["Vero E6 cells", "CELL", 0, 13], ["cells", "CELL", 29, 34], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 83, 88], ["eGFP", "GENE_OR_GENE_PRODUCT", 89, 93], ["MERS", "GENE_OR_GENE_PRODUCT", 94, 98], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 103, 113], ["Vero E6 cells", "CELL", 127, 140], ["Vero E6 cells", "CELL_LINE", 0, 13], ["VSV\u0394G", "DNA", 83, 88], ["eGFP", "DNA", 89, 93], ["MERS", "DNA", 94, 98], ["VSV\u0394G", "DNA", 103, 108], ["MERS", "DNA", 109, 113], ["Vero E6 cells", "CELL_LINE", 127, 140], ["Vero E6", "SPECIES", 0, 7], ["MERS-CoV", "SPECIES", 39, 47], ["Vero E6", "SPECIES", 127, 134], ["Vero E6 cells", "PROBLEM", 0, 13], ["MERS", "PROBLEM", 39, 43], ["VSV\u0394G", "TEST", 83, 88], ["eGFP", "TEST", 89, 93], ["MERS", "PROBLEM", 94, 98], ["VSV\u0394G", "TEST", 103, 108], ["MERS", "PROBLEM", 109, 113], ["Vero E6 cells", "PROBLEM", 127, 140], ["large syncytia", "PROBLEM", 150, 164], ["E6 cells", "OBSERVATION", 5, 13], ["permissive cells", "OBSERVATION", 18, 34], ["E6 cells", "OBSERVATION", 132, 140], ["large", "OBSERVATION_MODIFIER", 150, 155], ["syncytia", "OBSERVATION", 156, 164]]], ["We then used human DPP4 siRNA to knock-down DPP4 expression in Vero E6 cells in advance of infection, and results showed infection of VSV\u0394G-eGFP-MERS was significantly reduced (Fig. 4B).", [["Vero E6 cells", "ANATOMY", 63, 76], ["infection", "DISEASE", 91, 100], ["infection", "DISEASE", 121, 130], ["human", "ORGANISM", 13, 18], ["DPP4", "GENE_OR_GENE_PRODUCT", 19, 23], ["DPP4", "GENE_OR_GENE_PRODUCT", 44, 48], ["Vero E6 cells", "CELL", 63, 76], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 134, 144], ["DPP4", "PROTEIN", 44, 48], ["Vero E6 cells", "CELL_LINE", 63, 76], ["VSV\u0394G-eGFP-MERS", "DNA", 134, 149], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["Vero E6", "SPECIES", 63, 70], ["human DPP4 siRNA", "TREATMENT", 13, 29], ["DPP4 expression", "TREATMENT", 44, 59], ["Vero E6 cells", "TREATMENT", 63, 76], ["infection", "PROBLEM", 91, 100], ["infection", "PROBLEM", 121, 130], ["VSV\u0394G", "TEST", 134, 139], ["eGFP", "TEST", 140, 144], ["MERS", "PROBLEM", 145, 149], ["infection", "OBSERVATION", 91, 100], ["infection", "OBSERVATION", 121, 130]]], ["These results confirmed the incorporation of functional S protein into the chimeric viral particles and demonstrated their use of human DPP4 as the cellular receptor for infection.VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS enter cells partially in a clathrin-dependent endocytic pathway ::: ResultsIt has been well demonstrated that VSV enters cells by a clathrin-dependent endocytic pathway (Cureton et al., 2009).", [["cellular", "ANATOMY", 148, 156], ["cells", "ANATOMY", 217, 222], ["cells", "ANATOMY", 332, 337], ["infection", "DISEASE", 170, 179], ["human", "ORGANISM", 130, 135], ["DPP4", "GENE_OR_GENE_PRODUCT", 136, 140], ["cellular", "CELL", 148, 156], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 180, 190], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 195, 205], ["cells", "CELL", 217, 222], ["clathrin", "GENE_OR_GENE_PRODUCT", 238, 246], ["VSV", "ORGANISM", 321, 324], ["cells", "CELL", 332, 337], ["clathrin", "GENE_OR_GENE_PRODUCT", 343, 351], ["S protein", "PROTEIN", 56, 65], ["human DPP4", "PROTEIN", 130, 140], ["VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS", "DNA", 180, 210], ["clathrin", "PROTEIN", 238, 246], ["clathrin", "PROTEIN", 343, 351], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135], ["VSV", "SPECIES", 321, 324], ["functional S protein", "TREATMENT", 45, 65], ["the chimeric viral particles", "TREATMENT", 71, 99], ["human DPP4", "TREATMENT", 130, 140], ["infection", "PROBLEM", 170, 179], ["VSV\u0394G", "TEST", 180, 185], ["MERS", "PROBLEM", 186, 190], ["VSV\u0394G", "TEST", 195, 200], ["infection", "OBSERVATION", 170, 179], ["VSV", "OBSERVATION", 321, 324]]], ["To determine whether replacement of VSV G with the MERS-CoV S altered the endocytic pathway of VSV\u0394G-MERS, clathrin knockdown and viral infection assays were carried out.", [["viral infection", "DISEASE", 130, 145], ["VSV", "ORGANISM", 36, 39], ["G", "GENE_OR_GENE_PRODUCT", 40, 41], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 51, 61], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 95, 105], ["clathrin", "GENE_OR_GENE_PRODUCT", 107, 115], ["MERS-CoV S", "DNA", 51, 61], ["VSV\u0394G", "PROTEIN", 95, 100], ["MERS", "PROTEIN", 101, 105], ["clathrin", "PROTEIN", 107, 115], ["VSV", "SPECIES", 36, 39], ["MERS-CoV", "SPECIES", 51, 59], ["replacement of VSV G", "TREATMENT", 21, 41], ["VSV\u0394G", "TEST", 95, 100], ["MERS", "PROBLEM", 101, 105], ["clathrin knockdown", "TREATMENT", 107, 125], ["viral infection assays", "PROBLEM", 130, 152], ["viral infection", "OBSERVATION", 130, 145]]], ["Results showed significant reduction of VSV-eGFP and VSV\u0394G-eGFP-MERS infection after clathrin knockdown (Fig. 5).", [["infection", "DISEASE", 69, 78], ["VSV", "ORGANISM", 40, 43], ["eGFP", "GENE_OR_GENE_PRODUCT", 44, 48], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 53, 63], ["MERS", "GENE_OR_GENE_PRODUCT", 64, 68], ["clathrin", "GENE_OR_GENE_PRODUCT", 85, 93], ["clathrin", "PROTEIN", 85, 93], ["VSV", "SPECIES", 40, 43], ["significant reduction of VSV", "PROBLEM", 15, 43], ["eGFP", "TEST", 44, 48], ["VSV\u0394G", "TEST", 53, 58], ["eGFP", "PROBLEM", 59, 63], ["MERS infection", "PROBLEM", 64, 78], ["clathrin knockdown", "TREATMENT", 85, 103], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["reduction", "OBSERVATION_MODIFIER", 27, 36], ["VSV", "OBSERVATION", 40, 43]]], ["In fact, clathrin knock-down had a more severe influence on the infection rate of VSV-eGFP than for VSV\u0394G-eGFP-MERS, as indicated by the infection ratio decrease of VSV-eGFP (from \u223c70% to \u223c15%) versus that of VSV\u0394G-eGFP-MERS (from \u223c55% to \u223c20%) (Fig. 5 II).", [["infection", "DISEASE", 64, 73], ["infection", "DISEASE", 137, 146], ["clathrin", "GENE_OR_GENE_PRODUCT", 9, 17], ["VSV-eGFP", "ORGANISM", 82, 90], ["VSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 100, 115], ["VSV", "ORGANISM", 165, 168], ["eGFP", "GENE_OR_GENE_PRODUCT", 169, 173], ["VSV\u0394G-eGFP-MERS", "GENE_OR_GENE_PRODUCT", 209, 224], ["clathrin", "PROTEIN", 9, 17], ["eGFP", "DNA", 86, 90], ["VSV\u0394G", "PROTEIN", 100, 105], ["eGFP", "DNA", 106, 110], ["MERS", "PROTEIN", 111, 115], ["eGFP", "PROTEIN", 169, 173], ["VSV\u0394G", "PROTEIN", 209, 214], ["eGFP", "PROTEIN", 215, 219], ["MERS", "PROTEIN", 220, 224], ["VSV", "SPECIES", 82, 85], ["VSV", "SPECIES", 165, 168], ["clathrin knock", "TEST", 9, 23], ["a more severe influence", "PROBLEM", 33, 56], ["the infection rate of VSV", "PROBLEM", 60, 85], ["VSV\u0394G", "TEST", 100, 105], ["the infection ratio decrease of VSV", "PROBLEM", 133, 168], ["eGFP", "TEST", 169, 173], ["\u223c", "TEST", 180, 181], ["VSV\u0394G", "TEST", 209, 214], ["eGFP", "TEST", 215, 219], ["MERS", "PROBLEM", 220, 224], ["infection", "OBSERVATION", 64, 73]]], ["Taken together, our results indicated that VSV\u0394G-eGFP-MERS utilized more than one way to enter cells as shown by syncytia formation (Fig. 1B) and clathrin-mediated endocytosis (Fig. 5).VSV\u0394G-MERS induces significant MERS S-specific IgG and neutralizing antibody in mice ::: ResultsWe first characterized the safety and immunogenicity of VSV\u0394G-MERS in Balb/c mice.", [["cells", "ANATOMY", 95, 100], ["syncytia", "ANATOMY", 113, 121], ["VSV\u0394G", "CHEMICAL", 185, 190], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 43, 48], ["eGFP", "GENE_OR_GENE_PRODUCT", 49, 53], ["cells", "CELL", 95, 100], ["syncytia", "CELL", 113, 121], ["1B", "GENE_OR_GENE_PRODUCT", 138, 140], ["clathrin", "GENE_OR_GENE_PRODUCT", 146, 154], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 185, 195], ["MERS S-specific IgG", "GENE_OR_GENE_PRODUCT", 216, 235], ["mice", "ORGANISM", 265, 269], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 337, 347], ["Balb/c mice", "ORGANISM", 351, 362], ["VSV\u0394G", "PROTEIN", 43, 48], ["eGFP", "DNA", 49, 53], ["MERS", "PROTEIN", 54, 58], ["clathrin", "PROTEIN", 146, 154], ["VSV\u0394G", "PROTEIN", 185, 190], ["MERS", "PROTEIN", 191, 195], ["MERS S-specific IgG", "PROTEIN", 216, 235], ["neutralizing antibody", "PROTEIN", 240, 261], ["VSV\u0394G", "PROTEIN", 337, 342], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 358, 362], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 358, 362], ["VSV\u0394G", "TEST", 43, 48], ["MERS", "PROBLEM", 54, 58], ["clathrin-mediated endocytosis", "TREATMENT", 146, 175], ["VSV\u0394G", "TEST", 185, 190], ["significant MERS", "PROBLEM", 204, 220], ["IgG", "TEST", 232, 235], ["VSV\u0394G", "TEST", 337, 342], ["syncytia", "OBSERVATION", 113, 121], ["endocytosis", "OBSERVATION", 164, 175]]], ["Mice were intramuscularly inoculated with 1 \u00d7 106 FFU VSV\u0394G-MERS and were monitored daily to detect body weight changes and signs of illness or death.", [["body", "ANATOMY", 100, 104], ["illness", "DISEASE", 133, 140], ["death", "DISEASE", 144, 149], ["Mice", "ORGANISM", 0, 4], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["Mice", "SPECIES", 0, 4], ["body weight changes", "PROBLEM", 100, 119], ["illness", "PROBLEM", 133, 140], ["death", "PROBLEM", 144, 149]]], ["Results showed all mice were healthy and did not exhibit untoward clinical signs.", [["mice", "ORGANISM", 19, 23], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["untoward clinical signs", "PROBLEM", 57, 80]]], ["Body weight gain was similar between the experimental and the PBS control group mice for two weeks post-inoculation (Fig. 6A).", [["Body", "ANATOMY", 0, 4], ["weight gain", "DISEASE", 5, 16], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Body weight gain", "PROBLEM", 0, 16], ["the PBS control group mice", "TREATMENT", 58, 84]]], ["We then evaluated VSV\u0394G-MERS-induced humoral immune responses for S protein-specific IgG and neutralizing antibodies.", [["VSV\u0394G", "SIMPLE_CHEMICAL", 18, 23], ["S protein", "GENE_OR_GENE_PRODUCT", 66, 75], ["IgG", "GENE_OR_GENE_PRODUCT", 85, 88], ["S protein", "PROTEIN", 66, 75], ["IgG", "PROTEIN", 85, 88], ["neutralizing antibodies", "PROTEIN", 93, 116], ["VSV\u0394G", "TEST", 18, 23], ["MERS", "TEST", 24, 28], ["S protein", "TEST", 66, 75], ["specific IgG", "TEST", 76, 88], ["neutralizing antibodies", "TEST", 93, 116]]], ["Results showed high levels of specific IgG were detectable after the initial inoculation (measured day 14, 13 \u03bcg/ml), and specific IgG was significantly boosted after the second dose on day 21 (measured day 35, 20 \u03bcg/ml) (p < .05) (Fig. 6B).", [["IgG", "GENE_OR_GENE_PRODUCT", 39, 42], ["IgG", "GENE_OR_GENE_PRODUCT", 131, 134], ["IgG", "PROTEIN", 39, 42], ["IgG", "PROTEIN", 131, 134], ["high levels of specific IgG", "PROBLEM", 15, 42], ["the initial inoculation", "TEST", 65, 88], ["specific IgG", "TEST", 122, 134], ["high", "OBSERVATION_MODIFIER", 15, 19]]], ["MERS neutralizing antibody was also detected after the first dose, and was significantly boosted after the second dose (p < .05) (Fig. 6C).", [["MERS", "GENE_OR_GENE_PRODUCT", 0, 4], ["MERS neutralizing antibody", "PROTEIN", 0, 26], ["MERS neutralizing antibody", "TEST", 0, 26]]], ["Due to the fact that mice cannot be infected by VSV\u0394G-MERS, as they do not express human DPP4, these results demonstrated the potential of VSV\u0394G-MERS to serve as an inactivated MERS vaccine.Single dose intramuscular or intranasal immunization of VSV\u0394G-MERS induces significant MERS-CoV specific humoral and T cell responses in rhesus monkeys ::: ResultsTo further investigate the immunogenicity of the VSV\u0394G-MERS vaccine in non-human primates, rhesus monkeys were intramuscularly or intranasally immunized once with 2 \u00d7 107 FFU of VSV\u0394G-MERS then specific humoral and T cell responses were evaluated.", [["intramuscular", "ANATOMY", 202, 215], ["T cell", "ANATOMY", 307, 313], ["T cell", "ANATOMY", 568, 574], ["VSV\u0394G-MERS", "CHEMICAL", 246, 256], ["VSV\u0394G", "CHEMICAL", 402, 407], ["mice", "ORGANISM", 21, 25], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 48, 58], ["human", "ORGANISM", 83, 88], ["DPP4", "GENE_OR_GENE_PRODUCT", 89, 93], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 139, 149], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 202, 215], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 246, 256], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 277, 285], ["T cell", "CELL", 307, 313], ["rhesus", "ORGANISM", 327, 333], ["monkeys", "ORGANISM", 334, 341], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 402, 407], ["non-human", "ORGANISM", 424, 433], ["primates", "ORGANISM", 434, 442], ["rhesus", "ORGANISM", 444, 450], ["monkeys", "ORGANISM", 451, 458], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 531, 541], ["T cell", "CELL", 568, 574], ["VSV\u0394G", "PROTEIN", 48, 53], ["MERS", "PROTEIN", 54, 58], ["human DPP4", "PROTEIN", 83, 93], ["VSV\u0394G", "PROTEIN", 139, 144], ["MERS", "PROTEIN", 145, 149], ["mice", "SPECIES", 21, 25], ["human", "SPECIES", 83, 88], ["rhesus monkeys", "SPECIES", 327, 341], ["rhesus monkeys", "SPECIES", 444, 458], ["mice", "SPECIES", 21, 25], ["human", "SPECIES", 83, 88], ["rhesus monkeys", "SPECIES", 327, 341], ["rhesus monkeys", "SPECIES", 444, 458], ["human DPP4", "TEST", 83, 93], ["VSV\u0394G", "PROBLEM", 139, 144], ["an inactivated MERS vaccine", "TREATMENT", 162, 189], ["Single dose intramuscular", "TREATMENT", 190, 215], ["intranasal immunization", "TREATMENT", 219, 242], ["VSV\u0394G", "TEST", 246, 251], ["significant MERS", "PROBLEM", 265, 281], ["MERS vaccine", "TREATMENT", 408, 420], ["VSV\u0394G", "TEST", 531, 536]]], ["As shown in Fig. 7, single dose immunization induced significant MERS S protein specific IgG in monkeys vaccinated via both the intramuscular (i.m) and intranasal (i.n) route.", [["intramuscular", "ANATOMY", 128, 141], ["MERS S protein", "GENE_OR_GENE_PRODUCT", 65, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 89, 92], ["monkeys", "ORGANISM", 96, 103], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 128, 141], ["MERS S protein", "PROTEIN", 65, 79], ["IgG", "PROTEIN", 89, 92], ["monkeys", "SPECIES", 96, 103], ["single dose immunization", "TREATMENT", 20, 44], ["significant MERS S protein specific IgG in monkeys", "PROBLEM", 53, 103], ["intranasal", "TREATMENT", 152, 162], ["Fig", "OBSERVATION", 12, 15]]], ["IgG was detected 10-days post immunization and remained elevated for at least 42 days with the peak IgG level appearing on day 28.", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 100, 103], ["IgG", "PROTEIN", 0, 3], ["IgG", "PROTEIN", 100, 103], ["IgG", "TEST", 0, 3], ["immunization", "TREATMENT", 30, 42], ["elevated", "PROBLEM", 56, 64], ["the peak IgG level", "TEST", 91, 109]]], ["No statistical difference existed between i.m- and i.n-immunized monkeys at any time-point (Fig. 7A).", [["i.m", "SIMPLE_CHEMICAL", 42, 45], ["monkeys", "ORGANISM", 65, 72], ["statistical difference", "PROBLEM", 3, 25], ["statistical", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["Monkey MERS S protein neutralizing antibodies were induced after i.m or i.n immunization, and were detected on day 10 post immunization, reaching peak level at day 21 (Fig. 7B).", [["MERS S protein", "GENE_OR_GENE_PRODUCT", 7, 21], ["Monkey MERS S protein neutralizing antibodies", "PROTEIN", 0, 45], ["Monkey MERS S protein neutralizing antibodies", "TREATMENT", 0, 45], ["i.n immunization", "TREATMENT", 72, 88], ["immunization", "TREATMENT", 123, 135], ["peak level", "TEST", 146, 156]]], ["The neutralizing antibody titer of i.m group was significantly higher than that of the i.n group at both time-points (Fig. 7B), indicating that the i.m route might better facilitate the production of neutralizing antibodies in the case of VSV\u0394G-MERS immunization in monkeys.Single dose intramuscular or intranasal immunization of VSV\u0394G-MERS induces significant MERS-CoV specific humoral and T cell responses in rhesus monkeys ::: ResultsWe further evaluated the T cell response in immunized monkeys by ELISPOT.", [["intramuscular", "ANATOMY", 286, 299], ["T cell", "ANATOMY", 391, 397], ["T cell", "ANATOMY", 462, 468], ["VSV\u0394G-MERS", "CHEMICAL", 239, 249], ["VSV\u0394G-MERS", "CHEMICAL", 330, 340], ["i.m", "SIMPLE_CHEMICAL", 35, 38], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 239, 249], ["monkeys", "ORGANISM", 266, 273], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 286, 299], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 330, 340], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 361, 369], ["T cell", "CELL", 391, 397], ["rhesus", "ORGANISM", 411, 417], ["monkeys", "ORGANISM", 418, 425], ["T cell", "CELL", 462, 468], ["monkeys", "ORGANISM", 491, 498], ["neutralizing antibodies", "PROTEIN", 200, 223], ["monkeys", "SPECIES", 266, 273], ["rhesus monkeys", "SPECIES", 411, 425], ["monkeys", "SPECIES", 491, 498], ["rhesus monkeys", "SPECIES", 411, 425], ["The neutralizing antibody titer", "TEST", 0, 31], ["the i.m route", "TREATMENT", 144, 157], ["neutralizing antibodies", "TREATMENT", 200, 223], ["VSV\u0394G", "PROBLEM", 239, 244], ["MERS immunization", "TREATMENT", 245, 262], ["Single dose intramuscular", "TREATMENT", 274, 299], ["intranasal immunization", "TREATMENT", 303, 326], ["VSV\u0394G", "TEST", 330, 335], ["significant MERS", "PROBLEM", 349, 365], ["neutralizing", "OBSERVATION_MODIFIER", 4, 16]]], ["An overlapping peptide pool consisted of 269 peptides spanning the MERS S protein was used to stimulate the PBMCs.", [["PBMCs", "ANATOMY", 108, 113], ["MERS S", "GENE_OR_GENE_PRODUCT", 67, 73], ["PBMCs", "CELL", 108, 113], ["MERS S protein", "PROTEIN", 67, 81], ["PBMCs", "CELL_TYPE", 108, 113], ["An overlapping peptide pool", "TEST", 0, 27], ["the MERS S protein", "TREATMENT", 63, 81]]], ["The 15-mer peptides (with 10 amino acid overlap) were designed to preferentially stimulate CD8+ T cells.", [["CD8+ T cells", "ANATOMY", 91, 103], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "AMINO_ACID", 29, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 91, 94], ["CD8", "PROTEIN", 91, 94], ["T cells", "CELL_TYPE", 96, 103], ["10 amino acid overlap", "TREATMENT", 26, 47]]], ["The IFN-\u03b3 secreting cells were counted and analyzed.", [["cells", "ANATOMY", 20, 25], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 4, 9], ["cells", "CELL", 20, 25], ["IFN-\u03b3 secreting cells", "CELL_LINE", 4, 25], ["The IFN-\u03b3 secreting cells", "TREATMENT", 0, 25], ["secreting cells", "OBSERVATION", 10, 25]]], ["As shown in Fig. 8, both i.m- and i.n-immunized monkeys produced active T cell responses specific to the S protein peptide stimulation.", [["T cell", "ANATOMY", 72, 78], ["monkeys", "ORGANISM", 48, 55], ["T cell", "CELL", 72, 78], ["the S protein peptide stimulation", "TREATMENT", 101, 134]]], ["Of the 269 peptides, we selected the most \u201cdominant\u201d peptide that induced the highest level of IFN- \u03b3 secretion (900 spots/well on average) and compared responses with the PMA+IONO positive control (1500 spots/well on average).", [["PMA", "CHEMICAL", 172, 175], ["IONO", "CHEMICAL", 176, 180], ["PMA", "CHEMICAL", 172, 175], ["IONO", "CHEMICAL", 176, 180], ["IFN- \u03b3", "GENE_OR_GENE_PRODUCT", 95, 101], ["PMA", "SIMPLE_CHEMICAL", 172, 175], ["IFN", "PROTEIN", 95, 98], ["\u03b3", "PROTEIN", 100, 101], ["the PMA", "TEST", 168, 175], ["IONO positive control", "TREATMENT", 176, 197], ["highest", "OBSERVATION_MODIFIER", 78, 85]]], ["We hypothesized that these peptides potentially contained monkey S protein-specific CD8+ T cell epitopes.", [["CD8+ T cell", "ANATOMY", 84, 95], ["monkey", "ORGANISM", 58, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 84, 87], ["monkey S protein", "PROTEIN", 58, 74], ["CD8", "PROTEIN", 84, 87], ["T cell epitopes", "PROTEIN", 89, 104], ["these peptides", "TEST", 21, 35], ["monkey S protein", "TEST", 58, 74], ["T cell epitopes", "PROBLEM", 89, 104], ["cell epitopes", "OBSERVATION", 91, 104]]], ["No statistical significance was observed between i.m- and i.n-immunized groups for these selected peptides (Fig. 8).DiscussionIn this study, we successfully constructed a VSV-based recombinant chimeric virus bearing MERS-CoV S protein as its new membrane glycoprotein to replace its own G protein.", [["membrane", "ANATOMY", 246, 254], ["i.m", "SIMPLE_CHEMICAL", 49, 52], ["VSV", "ORGANISM", 171, 174], ["chimeric virus", "ORGANISM", 193, 207], ["MERS-CoV S protein", "GENE_OR_GENE_PRODUCT", 216, 234], ["membrane", "CELLULAR_COMPONENT", 246, 254], ["G protein", "GENE_OR_GENE_PRODUCT", 287, 296], ["MERS-CoV S protein", "PROTEIN", 216, 234], ["membrane glycoprotein", "PROTEIN", 246, 267], ["G protein", "PROTEIN", 287, 296], ["VSV", "SPECIES", 171, 174], ["this study", "TEST", 129, 139], ["a VSV", "TREATMENT", 169, 174], ["based recombinant chimeric virus bearing MERS-CoV S protein", "TREATMENT", 175, 234], ["its new membrane glycoprotein", "TREATMENT", 238, 267]]], ["The chimeric virus, which is replication competent in permissive cells, utilized S protein as its sole membrane anchored glycoprotein and recognized human DPP4 as its receptor to complete attachment and cell entry.", [["cells", "ANATOMY", 65, 70], ["membrane", "ANATOMY", 103, 111], ["cell", "ANATOMY", 203, 207], ["chimeric virus", "ORGANISM", 4, 18], ["cells", "CELL", 65, 70], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["human", "ORGANISM", 149, 154], ["DPP4", "GENE_OR_GENE_PRODUCT", 155, 159], ["cell", "CELL", 203, 207], ["permissive cells", "CELL_TYPE", 54, 70], ["S protein", "PROTEIN", 81, 90], ["membrane anchored glycoprotein", "PROTEIN", 103, 133], ["human DPP4", "PROTEIN", 149, 159], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 149, 154], ["The chimeric virus", "PROBLEM", 0, 18], ["S protein", "TREATMENT", 81, 90], ["its sole membrane anchored glycoprotein", "TREATMENT", 94, 133], ["human DPP4", "TREATMENT", 149, 159], ["chimeric virus", "OBSERVATION", 4, 18], ["permissive cells", "OBSERVATION", 54, 70]]], ["We further demonstrated that single-dose immunization, either by the intramuscular or intranasal route, induced a high-level and lasting MERS-CoV-specific neutralizing antibodies and T cell responses in rhesus monkeys.DiscussionTo date, there are several types of MERS vaccines reported which mainly include live attenuated vaccine, DNA vaccine, subunit vaccine, and recombinant vectored vaccine (measles virus, MVA and adenovirus); thus far the DNA vaccine and recombinant vectored vaccines have been shown to be efficacious in experimental animals (Modjarrad et al., 2016).", [["intramuscular", "ANATOMY", 69, 82], ["T cell", "ANATOMY", 183, 189], ["measles virus", "DISEASE", 397, 410], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 137, 145], ["T cell", "CELL", 183, 189], ["rhesus", "ORGANISM", 203, 209], ["monkeys", "ORGANISM", 210, 217], ["DNA", "CELLULAR_COMPONENT", 333, 336], ["measles virus", "ORGANISM", 397, 410], ["adenovirus", "ORGANISM", 420, 430], ["DNA", "CELLULAR_COMPONENT", 446, 449], ["MERS-CoV", "PROTEIN", 137, 145], ["neutralizing antibodies", "PROTEIN", 155, 178], ["rhesus monkeys", "SPECIES", 203, 217], ["measles virus", "SPECIES", 397, 410], ["rhesus monkeys", "SPECIES", 203, 217], ["measles virus", "SPECIES", 397, 410], ["MVA", "SPECIES", 412, 415], ["adenovirus", "SPECIES", 420, 430], ["single-dose immunization", "TREATMENT", 29, 53], ["a high-level and lasting MERS", "PROBLEM", 112, 141], ["CoV", "TEST", 142, 145], ["specific neutralizing antibodies", "TEST", 146, 178], ["MERS vaccines", "TREATMENT", 264, 277], ["live attenuated vaccine", "TREATMENT", 308, 331], ["DNA vaccine", "TREATMENT", 333, 344], ["subunit vaccine", "TREATMENT", 346, 361], ["recombinant vectored vaccine", "TREATMENT", 367, 395], ["measles virus", "PROBLEM", 397, 410], ["MVA and adenovirus", "TREATMENT", 412, 430], ["the DNA vaccine", "TREATMENT", 442, 457], ["recombinant vectored vaccines", "TREATMENT", 462, 491]]], ["Of note, an MVA vectored vaccine was highly immunogenic and could significantly reduce the MERS-CoV excretion in dromedary camels (Haagmans et al., 2016).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["an MVA vectored vaccine", "TREATMENT", 9, 32]]], ["A measles virus vectored vaccine was also highly immunogenic and protective in human DPP4-transgenic mice (Malczyk et al., 2015).", [["measles virus", "ORGANISM", 2, 15], ["human", "ORGANISM", 79, 84], ["DPP4", "GENE_OR_GENE_PRODUCT", 85, 89], ["mice", "ORGANISM", 101, 105], ["DPP4", "PROTEIN", 85, 89], ["A measles virus", "SPECIES", 0, 15], ["human", "SPECIES", 79, 84], ["mice", "SPECIES", 101, 105], ["measles virus", "SPECIES", 2, 15], ["human", "SPECIES", 79, 84], ["mice", "SPECIES", 101, 105], ["A measles virus vectored vaccine", "TREATMENT", 0, 32]]], ["These results clearly demonstrate the great potential of a live-vectored vaccine.", [["a live-vectored vaccine", "TREATMENT", 57, 80]]], ["However, all of these are vaccines that require multiple dosing to generate desired immune responses, thus are not ideal in emergencies that necessitate rapid immune responses to emerging infectious diseases like MERS.", [["infectious diseases", "DISEASE", 188, 207], ["vaccines", "TREATMENT", 26, 34], ["multiple dosing", "TREATMENT", 48, 63], ["emerging infectious diseases", "PROBLEM", 179, 207], ["infectious", "OBSERVATION", 188, 198]]], ["By contrast, a single dose of VSV\u0394G-MERS immunization would suffice to induce ideal immune response.DiscussionIn a previous study, we successfully generated a VSV pseudovirus bearing SARS-CoV S protein for neutralization assay and cell-entry assay (Ge et al., 2006), we further replaced the VSV G gene with the SARS-CoV S gene and successfully rescued the recombinant chimeric virus VSV\u0394G-SARS using a VSV reverse genetics system (unpublished work).", [["cell", "ANATOMY", 231, 235], ["VSV\u0394G-MERS", "CHEMICAL", 30, 40], ["SARS", "DISEASE", 389, 393], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 30, 40], ["VSV", "ORGANISM", 159, 162], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 183, 193], ["cell", "CELL", 231, 235], ["VSV", "ORGANISM", 291, 294], ["G", "GENE_OR_GENE_PRODUCT", 295, 296], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 311, 321], ["VSV", "ORGANISM", 402, 405], ["SARS-CoV S protein", "PROTEIN", 183, 201], ["VSV G gene", "DNA", 291, 301], ["SARS-CoV S gene", "DNA", 311, 326], ["VSV", "SPECIES", 159, 162], ["VSV pseudovirus", "SPECIES", 159, 174], ["SARS-CoV", "SPECIES", 183, 191], ["VSV", "SPECIES", 291, 294], ["SARS-CoV", "SPECIES", 311, 319], ["VSV", "SPECIES", 402, 405], ["VSV\u0394G", "TREATMENT", 30, 35], ["MERS immunization", "TREATMENT", 36, 53], ["a previous study", "TEST", 113, 129], ["a VSV pseudovirus bearing SARS", "TEST", 157, 187], ["CoV S protein", "TEST", 188, 201], ["neutralization assay", "TEST", 206, 226], ["the VSV G gene", "TREATMENT", 287, 301], ["the SARS-CoV S gene", "TREATMENT", 307, 326]]], ["Thus in the present study we constructed VSV\u0394G-MERS by deploying the same strategy.", [["VSV\u0394G", "DNA", 41, 46], ["MERS", "DNA", 47, 51]]], ["The rescued virus manifested delayed growth kinetics and decreased peak titer compared with the native vector virus (Fig. 2).", [["The rescued virus", "PROBLEM", 0, 17], ["delayed growth kinetics", "PROBLEM", 29, 52], ["decreased peak titer", "PROBLEM", 57, 77], ["virus", "OBSERVATION", 12, 17], ["growth kinetics", "OBSERVATION", 37, 52], ["decreased", "OBSERVATION_MODIFIER", 57, 66], ["peak titer", "OBSERVATION", 67, 77]]], ["S protein was, therefore, the sole viral membrane anchored glycoprotein instead of VSV G protein, and was critical in receptor binding and viral entry.", [["membrane", "ANATOMY", 41, 49], ["VSV G protein", "GENE_OR_GENE_PRODUCT", 83, 96], ["S protein", "PROTEIN", 0, 9], ["viral membrane anchored glycoprotein", "PROTEIN", 35, 71], ["VSV G protein", "PROTEIN", 83, 96], ["VSV", "SPECIES", 83, 86], ["S protein", "TEST", 0, 9], ["the sole viral membrane anchored glycoprotein", "TREATMENT", 26, 71], ["VSV G protein", "TREATMENT", 83, 96], ["viral entry", "OBSERVATION", 139, 150]]], ["Furthermore, the incorporation of S protein did not alter the morphology of the virus (bullet shaped virions, Fig. 3), but it did obviously alter the tropism and entry of the virus.", [["virions", "ANATOMY", 101, 108], ["S protein", "PROTEIN", 34, 43], ["the incorporation of S protein", "TEST", 13, 43], ["the virus (bullet shaped virions", "PROBLEM", 76, 108], ["the tropism", "PROBLEM", 146, 157], ["the virus", "PROBLEM", 171, 180]]], ["The recombinant virus required human DPP4 as its cellular receptor (Fig. 4A and B).", [["cellular", "ANATOMY", 49, 57], ["recombinant virus", "ORGANISM", 4, 21], ["human", "ORGANISM", 31, 36], ["DPP4", "GENE_OR_GENE_PRODUCT", 37, 41], ["cellular", "CELL", 49, 57], ["Fig. 4A", "GENE_OR_GENE_PRODUCT", 68, 75], ["B", "GENE_OR_GENE_PRODUCT", 80, 81], ["human DPP4", "PROTEIN", 31, 41], ["cellular receptor", "PROTEIN", 49, 66], ["Fig. 4A and B", "PROTEIN", 68, 81], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["The recombinant virus", "PROBLEM", 0, 21], ["human DPP4", "TREATMENT", 31, 41], ["virus", "OBSERVATION", 16, 21]]], ["The S protein also influenced the entry mode of the recombinant virus, as shown in Fig. 1B, as significant syncytia formation was observed in VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS-infected Vero E6 cells, but not in VSV-infected cells.", [["syncytia", "ANATOMY", 107, 115], ["VSV\u0394G-MERS", "ANATOMY", 142, 152], ["Vero E6 cells", "ANATOMY", 182, 195], ["cells", "ANATOMY", 221, 226], ["S protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["1B", "GENE_OR_GENE_PRODUCT", 88, 90], ["syncytia", "CELL", 107, 115], ["VSV\u0394G-MERS", "CELL", 142, 152], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 157, 167], ["Vero E6 cells", "CELL", 182, 195], ["VSV", "ORGANISM", 208, 211], ["cells", "CELL", 221, 226], ["S protein", "PROTEIN", 4, 13], ["VSV\u0394G-MERS and VSV\u0394G-eGFP-MERS-infected Vero E6 cells", "CELL_LINE", 142, 195], ["VSV-infected cells", "CELL_LINE", 208, 226], ["Vero E6", "SPECIES", 182, 189], ["VSV", "SPECIES", 208, 211], ["The S protein", "TEST", 0, 13], ["the recombinant virus", "PROBLEM", 48, 69], ["significant syncytia formation", "PROBLEM", 95, 125], ["VSV\u0394G", "TEST", 142, 147], ["VSV\u0394G", "TEST", 157, 162], ["eGFP", "TEST", 163, 167], ["MERS", "PROBLEM", 168, 172], ["infected Vero E6 cells", "PROBLEM", 173, 195], ["infected cells", "PROBLEM", 212, 226], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["syncytia", "OBSERVATION", 107, 115], ["Vero E6 cells", "OBSERVATION", 182, 195], ["infected cells", "OBSERVATION", 212, 226]]], ["This observation indicated that the virus utilized direct membrane fusion to enter cells, which was in accordance with the previous study that showed that MERS-CoV could enter the cells partially via direct membrane fusion (Qian et al., 2013).", [["membrane", "ANATOMY", 58, 66], ["cells", "ANATOMY", 83, 88], ["cells", "ANATOMY", 180, 185], ["membrane", "ANATOMY", 207, 215], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["cells", "CELL", 83, 88], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 155, 163], ["cells", "CELL", 180, 185], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["MERS-CoV", "PROTEIN", 155, 163], ["MERS-CoV", "SPECIES", 155, 163], ["This observation", "TEST", 0, 16], ["the virus", "PROBLEM", 32, 41], ["direct membrane fusion", "TREATMENT", 51, 73], ["the previous study", "TEST", 119, 137], ["MERS-CoV", "PROBLEM", 155, 163], ["direct membrane fusion", "TREATMENT", 200, 222]]], ["Our results further demonstrated clathrin played an important role in VSV\u0394G-eGFP-MERS entry, as shown in Fig. 5, where knocking down clathrin expression by siRNA in Vero E6 cells largely reduced the infection rate of VSV\u0394G-eGFP-MERS.", [["Vero E6 cells", "ANATOMY", 165, 178], ["infection", "DISEASE", 199, 208], ["clathrin", "GENE_OR_GENE_PRODUCT", 33, 41], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 70, 80], ["MERS", "GENE_OR_GENE_PRODUCT", 81, 85], ["Fig. 5", "ORGANISM", 105, 111], ["clathrin", "GENE_OR_GENE_PRODUCT", 133, 141], ["Vero E6 cells", "CELL", 165, 178], ["VSV\u0394G-eGFP", "GENE_OR_GENE_PRODUCT", 217, 227], ["clathrin", "PROTEIN", 33, 41], ["eGFP", "DNA", 76, 80], ["MERS", "PROTEIN", 81, 85], ["clathrin", "PROTEIN", 133, 141], ["Vero E6 cells", "CELL_LINE", 165, 178], ["VSV\u0394G-eGFP-MERS", "DNA", 217, 232], ["Vero E6", "SPECIES", 165, 172], ["clathrin", "TREATMENT", 33, 41], ["Vero E6 cells", "TREATMENT", 165, 178], ["the infection rate of VSV\u0394G", "PROBLEM", 195, 222], ["reduced", "OBSERVATION_MODIFIER", 187, 194], ["infection", "OBSERVATION", 199, 208]]], ["This result indicated the recombinant virus could enter cells via clathrin-mediated endocytosis, which is in agreement with studies showing MERS-CoV could enter cells either by direct membrane fusion or by clathrin-mediated endocytosis (de Wit et al., 2016).DiscussionOur in vivo results demonstrated efficacious immunogenicity of VSV\u0394G-MERS in mice and rhesus monkeys.", [["cells", "ANATOMY", 56, 61], ["cells", "ANATOMY", 161, 166], ["membrane", "ANATOMY", 184, 192], ["VSV\u0394G-MERS", "CHEMICAL", 331, 341], ["cells", "CELL", 56, 61], ["clathrin", "GENE_OR_GENE_PRODUCT", 66, 74], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 140, 148], ["cells", "CELL", 161, 166], ["membrane", "CELLULAR_COMPONENT", 184, 192], ["clathrin", "GENE_OR_GENE_PRODUCT", 206, 214], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 331, 341], ["mice", "ORGANISM", 345, 349], ["rhesus monkeys", "ORGANISM", 354, 368], ["clathrin", "PROTEIN", 66, 74], ["MERS-CoV", "PROTEIN", 140, 148], ["clathrin", "PROTEIN", 206, 214], ["VSV\u0394G", "PROTEIN", 331, 336], ["MERS", "PROTEIN", 337, 341], ["mice", "SPECIES", 345, 349], ["rhesus monkeys", "SPECIES", 354, 368], ["MERS-CoV", "SPECIES", 140, 148], ["mice", "SPECIES", 345, 349], ["rhesus monkeys", "SPECIES", 354, 368], ["the recombinant virus", "PROBLEM", 22, 43], ["studies", "TEST", 124, 131], ["MERS-CoV could enter cells", "PROBLEM", 140, 166], ["direct membrane fusion", "TREATMENT", 177, 199], ["membrane fusion", "OBSERVATION", 184, 199]]], ["Theoretically, Balb/c mice cannot be infected by VSV\u0394G-MERS due to the lack of human DPP4, thus the recombinant virus was similar to an inactivated vaccine or virus-like particle vaccine for mice.", [["Balb/c mice", "ORGANISM", 15, 26], ["VSV\u0394G-MERS", "GENE_OR_GENE_PRODUCT", 49, 59], ["human", "ORGANISM", 79, 84], ["DPP4", "GENE_OR_GENE_PRODUCT", 85, 89], ["recombinant virus", "ORGANISM", 100, 117], ["virus-like particle", "ORGANISM", 159, 178], ["mice", "ORGANISM", 191, 195], ["human DPP4", "PROTEIN", 79, 89], ["mice", "SPECIES", 22, 26], ["human", "SPECIES", 79, 84], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 22, 26], ["human", "SPECIES", 79, 84], ["mice", "SPECIES", 191, 195], ["Balb/c mice", "TREATMENT", 15, 26], ["human DPP4", "TREATMENT", 79, 89], ["the recombinant virus", "PROBLEM", 96, 117], ["an inactivated vaccine", "TREATMENT", 133, 155], ["virus", "PROBLEM", 159, 164]]], ["Our results showed that VSV\u0394G-MERS induced a robust humoral immune response in mice after a two-dose i.m immunization.", [["VSV\u0394G-MERS", "CHEMICAL", 24, 34], ["VSV\u0394G-MERS", "SIMPLE_CHEMICAL", 24, 34], ["mice", "ORGANISM", 79, 83], ["VSV\u0394G", "PROTEIN", 24, 29], ["MERS", "PROTEIN", 30, 34], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["VSV\u0394G", "TEST", 24, 29], ["MERS", "PROBLEM", 30, 34], ["a two-dose i.m immunization", "TREATMENT", 90, 117], ["humoral immune", "OBSERVATION", 52, 66]]], ["Most importantly, our results demonstrated that a single i.m or i.n inoculation dose could induce effective humoral and T cell responses in rhesus monkeys.", [["T cell", "ANATOMY", 120, 126], ["T cell", "CELL", 120, 126], ["rhesus", "ORGANISM", 140, 146], ["monkeys", "ORGANISM", 147, 154], ["rhesus monkeys", "SPECIES", 140, 154], ["rhesus monkeys", "SPECIES", 140, 154], ["i.n inoculation dose", "TREATMENT", 64, 84]]], ["Quantitative ELISA results showed that recombinant virus induced high level of S protein specific IgG in both groups, and no statistical difference existed between i.m and i.n groups at any time-point.", [["S protein", "GENE_OR_GENE_PRODUCT", 79, 88], ["IgG", "GENE_OR_GENE_PRODUCT", 98, 101], ["S protein", "PROTEIN", 79, 88], ["IgG", "PROTEIN", 98, 101], ["Quantitative ELISA", "TEST", 0, 18], ["recombinant virus", "PROBLEM", 39, 56], ["S protein specific IgG", "PROBLEM", 79, 101], ["statistical difference", "PROBLEM", 125, 147], ["no", "UNCERTAINTY", 122, 124]]], ["However, results for the neutralizing antibodies were quite different where the i.m group demonstrated significantly higher levels of neutralizing antibodies than the i.n group at all time-points.", [["neutralizing antibodies", "PROTEIN", 25, 48], ["neutralizing antibodies", "PROTEIN", 134, 157], ["the neutralizing antibodies", "TEST", 21, 48], ["neutralizing antibodies", "PROBLEM", 134, 157], ["neutralizing antibodies", "OBSERVATION", 134, 157]]], ["While i.m inoculation was more effective in generating neutralizing antibodies than the i.n route, the levels of serum neutralizing antibodies following i.n inoculation were significantly higher than baseline and not trivial.", [["serum", "ANATOMY", 113, 118], ["i.m", "SIMPLE_CHEMICAL", 6, 9], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["neutralizing antibodies", "PROTEIN", 55, 78], ["serum neutralizing antibodies", "PROTEIN", 113, 142], ["neutralizing antibodies", "PROBLEM", 55, 78], ["the levels", "TEST", 99, 109], ["serum neutralizing antibodies", "TEST", 113, 142], ["i.n inoculation", "TEST", 153, 168]]], ["We, therefore, suggest that in future application, a single dose vaccine can be given via both the i.n and i.m routes to ensure solid immunity.", [["a single dose vaccine", "TREATMENT", 51, 72]]], ["In the present study, we were unable to carry out a viral neutralizing assay using MERS-CoV due to the unavailability of MERS-CoV per se, thus we used VSV\u0394G-eGFP-MERS to mimic MERS-CoV to determine the neutralizing titers.", [["MERS-CoV", "ORGANISM", 83, 91], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 121, 129], ["eGFP", "ORGANISM", 157, 161], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 176, 184], ["VSV\u0394G", "PROTEIN", 151, 156], ["eGFP", "DNA", 157, 161], ["MERS", "DNA", 162, 166], ["MERS-CoV", "SPECIES", 83, 91], ["MERS-CoV", "SPECIES", 121, 129], ["MERS-CoV", "SPECIES", 176, 184], ["the present study", "TEST", 3, 20], ["a viral neutralizing assay", "TEST", 50, 76], ["VSV\u0394G", "TEST", 151, 156], ["the neutralizing titers", "PROBLEM", 198, 221]]], ["This method was similar to that used with the S protein bearing pseudo-viruses, such as lentiviral particles (Grehan et al., 2015, Jaume et al., 2011); while VSV\u0394G-eGFP-MERS is replication competent, it is more stable and suitable for the neutralizing antibody assay.", [["lentiviral", "ORGANISM", 88, 98], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 158, 163], ["eGFP", "GENE_OR_GENE_PRODUCT", 164, 168], ["MERS", "GENE_OR_GENE_PRODUCT", 169, 173], ["S protein", "PROTEIN", 46, 55], ["VSV\u0394G", "PROTEIN", 158, 163], ["eGFP", "DNA", 164, 168], ["MERS", "PROTEIN", 169, 173], ["the S protein bearing pseudo-viruses", "PROBLEM", 42, 78], ["VSV\u0394G", "TEST", 158, 163], ["the neutralizing antibody assay", "TEST", 235, 266], ["viruses", "OBSERVATION", 71, 78]]], ["To date, several MERS-CoV animal models have been reported, including rhesus macaques (de Wit et al., 2013, Munster et al., 2013, Yao et al., 2014), common marmosets (Falzarano et al., 2014), DPP4 transgenic mice (Agrawal et al., 2015, Pascal et al., 2015) and DPP4-expressing adenovirus transduced mice (Zhao et al., 2014).", [["MERS-CoV", "ORGANISM", 17, 25], ["rhesus", "ORGANISM", 70, 76], ["macaques", "ORGANISM", 77, 85], ["marmosets", "ORGANISM", 156, 165], ["DPP4", "GENE_OR_GENE_PRODUCT", 192, 196], ["mice", "ORGANISM", 208, 212], ["DPP4", "GENE_OR_GENE_PRODUCT", 261, 265], ["adenovirus", "ORGANISM", 277, 287], ["mice", "ORGANISM", 299, 303], ["DPP4", "PROTEIN", 192, 196], ["DPP4", "PROTEIN", 261, 265], ["rhesus macaques", "SPECIES", 70, 85], ["mice", "SPECIES", 208, 212], ["mice", "SPECIES", 299, 303], ["rhesus macaques", "SPECIES", 70, 85], ["mice", "SPECIES", 208, 212], ["mice", "SPECIES", 299, 303], ["DPP4", "TEST", 261, 265], ["common marmosets", "ANATOMY", 149, 165]]], ["Due to the unavailability of MERS-CoV, a monkey challenge study could not be undertaken in the current study setting but will be undertaken in a future study.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 29, 37], ["monkey", "ORGANISM", 41, 47], ["MERS-CoV", "SPECIES", 29, 37], ["a monkey challenge study", "TEST", 39, 63], ["a future study", "TEST", 143, 157]]], ["Considering the neutralizing antibody levels generated and the correlation between neutralizing antibody and protection, we speculate that the VSV\u0394G-MERS vaccine will confer protection against MERS-CoV.Funding informationThis study was support by National Key Technology R&D Program (2013BAD12B05).", [["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 143, 148], ["MERS-CoV", "ORGANISM", 193, 201], ["neutralizing antibody", "PROTEIN", 83, 104], ["MERS-CoV", "SPECIES", 193, 201], ["the neutralizing antibody levels", "TEST", 12, 44], ["neutralizing antibody", "TREATMENT", 83, 104], ["protection", "TREATMENT", 109, 119], ["the VSV\u0394G-MERS vaccine", "TREATMENT", 139, 161], ["This study", "TEST", 221, 231]]]], "ffe92f2e70bde6f1fcabde62bd8171da8fafcf4c": [["COVID-19 (coronavirus disease 2019) is the infectious respiratory disease caused by SARS-COV 2 virus (Severe Acute Respiratory Syndrome coronavirus 2).", [["respiratory", "ANATOMY", 54, 65], ["COVID-19", "CHEMICAL", 0, 8], ["coronavirus disease", "DISEASE", 10, 29], ["respiratory disease", "DISEASE", 54, 73], ["SARS-COV 2 virus", "DISEASE", 84, 100], ["Acute Respiratory Syndrome coronavirus", "DISEASE", 109, 147], ["coronavirus", "ORGANISM", 10, 21], ["SARS-COV 2 virus", "ORGANISM", 84, 100], ["COVID-19", "SPECIES", 0, 8], ["SARS-COV 2 virus", "SPECIES", 84, 100], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 102, 147], ["COVID", "TEST", 0, 5], ["coronavirus disease", "PROBLEM", 10, 29], ["the infectious respiratory disease", "PROBLEM", 39, 73], ["SARS", "PROBLEM", 84, 88], ["COV 2 virus", "PROBLEM", 89, 100], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 102, 147], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["respiratory disease", "OBSERVATION", 54, 73], ["Severe", "OBSERVATION_MODIFIER", 102, 108], ["Acute", "OBSERVATION_MODIFIER", 109, 114], ["Respiratory Syndrome", "OBSERVATION", 115, 135]]], ["On March 11 th ,2020 the World Health Organization (WHO) declared COVID-19 a pandemic considering the over 118,000 cases of the coronavirus illness in over 110 countries and territories around the world and the sustained risk of further global spread (Cuciotta and Vanelli, 2020) .", [["coronavirus illness", "DISEASE", 128, 147], ["coronavirus", "SPECIES", 128, 139], ["the coronavirus illness", "PROBLEM", 124, 147], ["coronavirus", "OBSERVATION", 128, 139]]], ["In order to control the spread of COVID-19, the Centers for Disease Control and Prevention (CDC) and department of health (DOH) of various states recommended isolation of sick persons, quarantine for those who may have been exposed to the virus and social distancing (CDC, 2020) .", [["persons", "ORGANISM", 176, 183], ["persons", "SPECIES", 176, 183], ["COVID", "TEST", 34, 39], ["Disease Control", "TREATMENT", 60, 75]]], ["Social distancing also referred to as physical distancing meant keeping space between people outside of their homes.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["A distance of at least 6 feet (2 meters) was recommended and people were asked not to gather in large groups, avoid crowded places and mass gatherings.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["mass", "OBSERVATION", 135, 139]]], ["Hospitals across the country were forced to make some drastic changes in order to prepare for the expected surge of COVID-19 patients.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["some drastic changes", "PROBLEM", 49, 69]]], ["In New York City, hospitals canceled all elective surgeries, closed in-patient epilepsy and stroke units and canceled all outpatient clinics.", [["epilepsy", "DISEASE", 79, 87], ["stroke", "DISEASE", 92, 98], ["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["all elective surgeries", "TREATMENT", 37, 59], ["epilepsy", "PROBLEM", 79, 87], ["stroke units", "TREATMENT", 92, 104], ["New", "OBSERVATION_MODIFIER", 3, 6]]], ["Patients were discharged from the hospitals.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Beds, especially ICU beds, and other resources such as ventilators were reserved for COVID-19 patients.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["ICU beds", "TREATMENT", 17, 25], ["ventilators", "TREATMENT", 55, 66]]], ["Physicians working in these hospitals were advised to adopt telemedicine in order to primarily maintain continuity of care for their existing patients.", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150]]]], "ef38ed2f4cc96e16ce011623cc5d15d2d8ca58c3": [["BackgroundBacterial artificial chromosomes (BACs) are ideally suited for the stable maintenance of large DNA sequences derived from viral genomes [1] .", [["chromosomes", "ANATOMY", 31, 42], ["BACs", "ANATOMY", 44, 48], ["chromosomes", "CELLULAR_COMPONENT", 31, 42], ["BACs", "CELLULAR_COMPONENT", 44, 48], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["BackgroundBacterial artificial chromosomes", "DNA", 0, 42], ["BACs", "DNA", 44, 48], ["DNA sequences", "DNA", 105, 118], ["viral genomes", "DNA", 132, 145], ["BackgroundBacterial artificial chromosomes (BACs", "TREATMENT", 0, 48], ["large DNA sequences", "PROBLEM", 99, 118], ["viral genomes", "PROBLEM", 132, 145], ["artificial chromosomes", "OBSERVATION", 20, 42], ["viral genomes", "OBSERVATION", 132, 145]]], ["A considerable number of BAC systems have been established for large DNA viruses; in particular many different herpesvirus genomes have been cloned into BACs (for review see [2] ).", [["DNA", "CELLULAR_COMPONENT", 69, 72], ["herpesvirus", "ORGANISM", 111, 122], ["herpesvirus genomes", "DNA", 111, 130], ["BACs", "DNA", 153, 157], ["BAC systems", "PROBLEM", 25, 36], ["large DNA viruses", "PROBLEM", 63, 80], ["considerable", "OBSERVATION_MODIFIER", 2, 14], ["large", "OBSERVATION_MODIFIER", 63, 68], ["DNA viruses", "OBSERVATION", 69, 80], ["herpesvirus genomes", "OBSERVATION", 111, 130]]], ["The first BAC systems using RNA virus cDNAs were described for coronaviruses [3] [4] [5] [6] and recently the first BAC containing a full-length cDNA for a negative-stranded RNA virus was described [7] .", [["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 77, 92], ["BAC", "CELLULAR_COMPONENT", 116, 119], ["BAC systems", "DNA", 10, 21], ["RNA virus cDNAs", "DNA", 28, 43], ["BAC", "DNA", 116, 119], ["full-length cDNA", "DNA", 133, 149], ["The first BAC systems", "TREATMENT", 0, 21], ["RNA virus cDNAs", "TREATMENT", 28, 43], ["coronaviruses", "TEST", 63, 76], ["a full-length cDNA", "TEST", 131, 149], ["stranded RNA virus", "PROBLEM", 165, 183]]], ["Similarly, cDNAs corresponding to the full-length genomes of members of the Flaviviridae family (Japanese encephalitis virus [8] and Dengue virus [9] ) have been inserted into BACs.BackgroundBACs containing full-length cDNAs of pestiviruses (also within the Flaviviridae), including bovine viral diarrhea virus (BVDV) and classical swine fever virus (CSFV) have recently been established [10, 11] .", [["BACs", "ANATOMY", 176, 180], ["Japanese encephalitis", "DISEASE", 97, 118], ["bovine viral diarrhea virus", "DISEASE", 283, 310], ["swine fever", "DISEASE", 332, 343], ["Flaviviridae", "ORGANISM", 76, 88], ["Japanese encephalitis virus", "ORGANISM", 97, 124], ["Dengue virus", "ORGANISM", 133, 145], ["BACs", "CELL", 176, 180], ["BackgroundBACs", "GENE_OR_GENE_PRODUCT", 181, 195], ["pestiviruses", "GENE_OR_GENE_PRODUCT", 228, 240], ["bovine viral diarrhea virus", "ORGANISM", 283, 310], ["BVDV", "ORGANISM", 312, 316], ["classical swine fever virus", "ORGANISM", 322, 349], ["CSFV", "ORGANISM", 351, 355], ["cDNAs", "DNA", 11, 16], ["full-length genomes", "DNA", 38, 57], ["BACs", "DNA", 176, 180], ["BackgroundBACs", "PROTEIN", 181, 195], ["full-length cDNAs", "DNA", 207, 224], ["Japanese encephalitis virus", "SPECIES", 97, 124], ["Dengue virus", "SPECIES", 133, 145], ["bovine", "SPECIES", 283, 289], ["viral diarrhea virus", "SPECIES", 290, 310], ["BVDV", "SPECIES", 312, 316], ["swine fever virus", "SPECIES", 332, 349], ["Japanese encephalitis virus", "SPECIES", 97, 124], ["Dengue virus", "SPECIES", 133, 145], ["bovine viral diarrhea virus", "SPECIES", 283, 310], ["BVDV", "SPECIES", 312, 316], ["classical swine fever virus", "SPECIES", 322, 349], ["CSFV", "SPECIES", 351, 355], ["Japanese encephalitis virus", "PROBLEM", 97, 124], ["Dengue virus", "PROBLEM", 133, 145], ["BackgroundBACs", "TEST", 181, 195], ["pestiviruses", "PROBLEM", 228, 240], ["bovine viral diarrhea virus", "PROBLEM", 283, 310], ["BVDV", "PROBLEM", 312, 316], ["classical swine fever virus", "PROBLEM", 322, 349], ["CSFV", "PROBLEM", 351, 355], ["pestiviruses", "OBSERVATION", 228, 240]]], ["Infectious pestiviruses can be rescued using RNA transcripts derived from these BACs.", [["BACs", "ANATOMY", 80, 84], ["BACs", "CELL", 80, 84], ["RNA transcripts", "RNA", 45, 60], ["Infectious pestiviruses", "PROBLEM", 0, 23], ["RNA transcripts", "TREATMENT", 45, 60]]], ["The pestiviruses have single stranded positive sense RNA genomes, about 12.3 kb in length, which includes a single long open reading frame, encoding a large polyprotein, flanked by 5\u2032 and 3\u2032 untranslated regions (UTRs) that are critical for autonomous replication of the genome [12, 13] .", [["pestiviruses", "GENE_OR_GENE_PRODUCT", 4, 16], ["single stranded positive sense RNA genomes", "RNA", 22, 64], ["long open reading frame", "DNA", 115, 138], ["5\u2032 and 3\u2032 untranslated regions", "DNA", 181, 211], ["UTRs", "DNA", 213, 217], ["The pestiviruses", "PROBLEM", 0, 16], ["single stranded positive sense RNA genomes", "PROBLEM", 22, 64], ["a single long open reading frame", "PROBLEM", 106, 138], ["a large polyprotein", "PROBLEM", 149, 168], ["stranded", "OBSERVATION_MODIFIER", 29, 37], ["positive", "OBSERVATION_MODIFIER", 38, 46], ["sense RNA genomes", "OBSERVATION", 47, 64], ["12.3 kb", "OBSERVATION_MODIFIER", 72, 79], ["large", "OBSERVATION_MODIFIER", 151, 156], ["polyprotein", "OBSERVATION", 157, 168]]], ["The polyprotein is cleaved by cellular and viral proteases into four structural proteins (nucleocapsid protein C, envelope glycoproteins E rns , E1 and E2) and eight nonstructural proteins (N pro , p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B).", [["cellular", "ANATOMY", 30, 38], ["cellular", "CELL", 30, 38], ["nucleocapsid protein C", "GENE_OR_GENE_PRODUCT", 90, 112], ["envelope glycoproteins E rns", "GENE_OR_GENE_PRODUCT", 114, 142], ["E1", "GENE_OR_GENE_PRODUCT", 145, 147], ["E2", "GENE_OR_GENE_PRODUCT", 152, 154], ["N pro", "GENE_OR_GENE_PRODUCT", 190, 195], ["p7", "GENE_OR_GENE_PRODUCT", 198, 200], ["NS2", "GENE_OR_GENE_PRODUCT", 202, 205], ["NS3", "GENE_OR_GENE_PRODUCT", 207, 210], ["NS4A", "GENE_OR_GENE_PRODUCT", 212, 216], ["NS4B", "GENE_OR_GENE_PRODUCT", 218, 222], ["NS5A", "GENE_OR_GENE_PRODUCT", 224, 228], ["NS5B", "GENE_OR_GENE_PRODUCT", 233, 237], ["cellular and viral proteases", "PROTEIN", 30, 58], ["structural proteins", "PROTEIN", 69, 88], ["nucleocapsid protein C", "PROTEIN", 90, 112], ["envelope glycoproteins E rns", "PROTEIN", 114, 142], ["E1", "PROTEIN", 145, 147], ["E2", "PROTEIN", 152, 154], ["nonstructural proteins", "PROTEIN", 166, 188], ["N pro", "PROTEIN", 190, 195], ["p7", "PROTEIN", 198, 200], ["NS2", "PROTEIN", 202, 205], ["NS3", "PROTEIN", 207, 210], ["NS4A", "PROTEIN", 212, 216], ["NS4B", "PROTEIN", 218, 222], ["NS5A", "PROTEIN", 224, 228], ["NS5B", "PROTEIN", 233, 237], ["The polyprotein", "TREATMENT", 0, 15], ["viral proteases", "TEST", 43, 58], ["nucleocapsid protein C", "TEST", 90, 112], ["envelope glycoproteins E rns", "TREATMENT", 114, 142], ["E1 and E2", "TREATMENT", 145, 154], ["eight nonstructural proteins", "TREATMENT", 160, 188], ["NS2", "TREATMENT", 202, 205], ["NS3", "TREATMENT", 207, 210], ["NS4A", "TREATMENT", 212, 216], ["NS4B", "TREATMENT", 218, 222], ["NS5A", "TREATMENT", 224, 228], ["NS5B", "TREATMENT", 233, 237], ["polyprotein", "OBSERVATION", 4, 15]]], ["The availability of genetically defined and stable pestivirus BACs facilitates the functional study of viral proteins or RNA structures and also the development of new marker vaccine candidates.", [["pestivirus BACs", "CELL", 51, 66], ["pestivirus BACs", "DNA", 51, 66], ["viral proteins", "PROTEIN", 103, 117], ["genetically defined and stable pestivirus BACs", "PROBLEM", 20, 66], ["the functional study", "TEST", 79, 99], ["viral proteins", "PROBLEM", 103, 117], ["RNA structures", "PROBLEM", 121, 135], ["new marker vaccine candidates", "TREATMENT", 164, 193], ["new", "OBSERVATION_MODIFIER", 164, 167]]], ["Several CSFV vaccines with marker properties based on chimeric pestiviruses have been developed over the years [14] .", [["CSFV", "ORGANISM", 8, 12], ["CSFV", "SPECIES", 8, 12], ["Several CSFV vaccines", "TREATMENT", 0, 21], ["marker properties", "TREATMENT", 27, 44], ["chimeric pestiviruses", "PROBLEM", 54, 75], ["CSFV", "OBSERVATION", 8, 12]]], ["In particular, chimeric pestiviruses with substitution of the entire E2 protein have been described [15] [16] [17] but also mutants with more subtle modifications, such as the modification of the important TAV-epitope [18] within the CSFV-E2 protein [19, 20] are promising marker vaccine candidates.BackgroundManipulation of BACs using traditional cloning procedures can be difficult (e.g. because of a lack of convenient restriction enzyme sites) and thus a range of methodologies that apply bacterial genetics, including homologous recombination (e.g. Red/ET homologous recombineering) within the E. coli host, have been developed (for review, see [21] ).", [["E2", "CHEMICAL", 69, 71], ["E2", "CHEMICAL", 239, 241], ["E2", "GENE_OR_GENE_PRODUCT", 69, 71], ["[15] [16] [17]", "SIMPLE_CHEMICAL", 100, 114], ["CSFV", "ORGANISM", 234, 238], ["BACs", "CELLULAR_COMPONENT", 325, 329], ["E. coli", "ORGANISM", 599, 606], ["chimeric pestiviruses", "PROTEIN", 15, 36], ["E2 protein", "PROTEIN", 69, 79], ["TAV", "PROTEIN", 206, 209], ["CSFV-E2 protein", "PROTEIN", 234, 249], ["BACs", "DNA", 325, 329], ["restriction enzyme sites", "DNA", 422, 446], ["E. coli", "SPECIES", 599, 606], ["CSFV", "SPECIES", 234, 238], ["E. coli", "SPECIES", 599, 606], ["chimeric pestiviruses", "PROBLEM", 15, 36], ["the entire E2 protein", "TEST", 58, 79], ["the CSFV-E2 protein", "TEST", 230, 249], ["traditional cloning procedures", "TREATMENT", 336, 366], ["convenient restriction enzyme sites", "TREATMENT", 411, 446], ["bacterial genetics", "TREATMENT", 493, 511], ["homologous recombination", "TREATMENT", 523, 547], ["Red/ET homologous recombineering", "TREATMENT", 554, 586], ["coli host", "OBSERVATION_MODIFIER", 602, 611]]], ["The use of homologous recombination allows site-directed mutagenesis of BACs [22] and, by employing a counterselection scheme, specific modifications can be obtained without leaving residual \"foreign\" sequences [23] .", [["BACs", "DNA", 72, 76], ["homologous recombination", "TREATMENT", 11, 35], ["a counterselection scheme", "TREATMENT", 100, 125]]], ["The main advantage of this method is that there are no target limitations (e.g. based on size or location) and no need for suitable restriction sites.", [["target limitations", "PROBLEM", 55, 73], ["suitable restriction sites", "TREATMENT", 123, 149], ["main", "OBSERVATION_MODIFIER", 4, 8], ["no", "UNCERTAINTY", 52, 54], ["size", "OBSERVATION_MODIFIER", 89, 93], ["no need for", "UNCERTAINTY", 111, 122]]], ["The integration of the modified sequence is performed in vivo (within E. coli) thereby potentially being more accurate than in vitro approaches like PCR-based methods.", [["E. coli", "ORGANISM", 70, 77], ["modified sequence", "DNA", 23, 40], ["E. coli", "SPECIES", 70, 77], ["E. coli", "SPECIES", 70, 77], ["the modified sequence", "TEST", 19, 40], ["PCR", "TEST", 149, 152]]], ["Although in vitro cloning approaches based on the use of high-fidelity polymerases for PCR amplification have significantly improved in recent years, the use of in vivo approaches should allow a more accurate method of mutagenesis due to the use of the cells own high-fidelity replication system which includes proof reading.", [["cells", "ANATOMY", 253, 258], ["cells", "CELL", 253, 258], ["high-fidelity polymerases", "TREATMENT", 57, 82], ["PCR amplification", "TEST", 87, 104], ["mutagenesis", "TREATMENT", 219, 230], ["significantly", "OBSERVATION_MODIFIER", 110, 123], ["improved", "OBSERVATION_MODIFIER", 124, 132]]], ["Whereas BAC recombination has been commonly used for modifying DNA viruses, there are only very few reports about the use of this technology for RNA viruses [7, 24, 25] .BackgroundHere, a generally applicable strategy for the manipulation and rescue of chimeric pestiviruses from BACs is described as a model, and the flexibility of this approach is demonstrated by generating different modifications in the viral cDNA of the new CSFV-BAC, pBeloR26, derived from the modified live vaccine strain \"C-strain Riems\".", [["BAC", "CELLULAR_COMPONENT", 8, 11], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["BACs", "CELL", 280, 284], ["CSFV-BAC", "ORGANISM", 430, 438], ["pBeloR26", "GENE_OR_GENE_PRODUCT", 440, 448], ["chimeric pestiviruses", "PROTEIN", 253, 274], ["BACs", "DNA", 280, 284], ["viral cDNA", "DNA", 408, 418], ["CSFV-BAC", "DNA", 430, 438], ["pBeloR26", "DNA", 440, 448], ["CSFV", "SPECIES", 430, 434], ["BAC recombination", "TREATMENT", 8, 25], ["modifying DNA viruses", "PROBLEM", 53, 74], ["this technology", "TREATMENT", 125, 140], ["RNA viruses", "PROBLEM", 145, 156], ["the manipulation", "TREATMENT", 222, 238], ["chimeric pestiviruses from BACs", "PROBLEM", 253, 284], ["this approach", "TREATMENT", 333, 346]]], ["The targeted recombination-mediated mutagenesis described here includes the substitution of the 9 amino acid (aa) linear TAV-epitope (TAVSPTTLR) present in the E2 protein with the corresponding region (TTVSTSTLA) of a heterologous pestivirus (border disease virus, BDV, strain \"Gifhorn\") and also the replacement of the entire CSFV E2 protein coding region with the whole E2 coding region from the same BDV, to generate marked vaccine viruses that can be discriminated using specific anti-E2 monoclonal antibodies.", [["amino acid", "CHEMICAL", 98, 108], ["E2", "CHEMICAL", 160, 162], ["E2", "CHEMICAL", 332, 334], ["E2", "CHEMICAL", 372, 374], ["amino acid", "CHEMICAL", 98, 108], ["amino acid", "AMINO_ACID", 98, 108], ["pestivirus", "GENE_OR_GENE_PRODUCT", 231, 241], ["border disease virus", "ORGANISM", 243, 263], ["BDV", "ORGANISM", 265, 268], ["BDV", "ORGANISM", 403, 406], ["anti-E2", "GENE_OR_GENE_PRODUCT", 484, 491], ["TAV", "PROTEIN", 121, 124], ["epitope", "PROTEIN", 125, 132], ["TAVSPTTLR", "PROTEIN", 134, 143], ["E2 protein", "PROTEIN", 160, 170], ["TTVSTSTLA", "PROTEIN", 202, 211], ["CSFV E2 protein coding region", "DNA", 327, 356], ["E2 coding region", "DNA", 372, 388], ["anti-E2 monoclonal antibodies", "PROTEIN", 484, 513], ["BDV", "SPECIES", 265, 268], ["CSFV", "SPECIES", 327, 331], ["BDV", "SPECIES", 403, 406], ["The targeted recombination-mediated mutagenesis", "TREATMENT", 0, 47], ["the 9 amino acid (aa) linear TAV-epitope (TAVSPTTLR)", "TREATMENT", 92, 144], ["a heterologous pestivirus (border disease virus", "PROBLEM", 216, 263], ["BDV", "PROBLEM", 265, 268], ["the replacement", "TREATMENT", 297, 312], ["the entire CSFV E2 protein coding region", "TREATMENT", 316, 356], ["the whole E2 coding region", "TREATMENT", 362, 388], ["marked vaccine viruses", "PROBLEM", 420, 442], ["specific anti-E2 monoclonal antibodies", "TEST", 475, 513], ["replacement", "OBSERVATION", 301, 312], ["marked", "OBSERVATION_MODIFIER", 420, 426]]], ["The genetic stabilities of both the BAC constructs (within E. coli) and the rescued viruses have also been assessed.Cells and virusesPorcine kidney (PK15) and sheep fetal thymoid (SFT-R) cells were grown at 37\u00b0C (with 5% (v/v) CO 2 ) in Dulbecco's minimal essential medium (DMEM) supplemented with 5% (v/v) pestivirus-free fetal calf serum.", [["Cells", "ANATOMY", 116, 121], ["kidney", "ANATOMY", 141, 147], ["PK15", "ANATOMY", 149, 153], ["fetal thymoid (SFT-R) cells", "ANATOMY", 165, 192], ["fetal calf serum", "ANATOMY", 323, 339], ["CO 2", "CHEMICAL", 227, 231], ["E. coli", "ORGANISM", 59, 66], ["Cells", "CELL", 116, 121], ["Porcine", "ORGANISM", 133, 140], ["kidney", "ORGAN", 141, 147], ["PK15", "CELL", 149, 153], ["sheep", "ORGANISM", 159, 164], ["fetal thymoid (SFT-R) cells", "CELL", 165, 192], ["pestivirus", "SIMPLE_CHEMICAL", 307, 317], ["fetal calf", "ORGANISM_SUBSTANCE", 323, 333], ["serum", "ORGANISM_SUBSTANCE", 334, 339], ["BAC constructs", "DNA", 36, 50], ["sheep fetal thymoid (SFT-R) cells", "CELL_LINE", 159, 192], ["E. coli", "SPECIES", 59, 66], ["Porcine", "SPECIES", 133, 140], ["sheep", "SPECIES", 159, 164], ["calf", "SPECIES", 329, 333], ["E. coli", "SPECIES", 59, 66], ["sheep", "SPECIES", 159, 164], ["E. coli", "PROBLEM", 59, 66], ["the rescued viruses", "PROBLEM", 72, 91], ["Cells", "TEST", 116, 121], ["virusesPorcine kidney", "TEST", 126, 147], ["PK15", "TEST", 149, 153], ["sheep fetal thymoid", "TEST", 159, 178], ["v/v", "TEST", 222, 225], ["CO", "TEST", 227, 229], ["Dulbecco", "TEST", 237, 245], ["pestivirus", "PROBLEM", 307, 317], ["free fetal calf serum", "PROBLEM", 318, 339], ["stabilities", "OBSERVATION_MODIFIER", 12, 23], ["viruses", "OBSERVATION", 84, 91], ["viruses", "OBSERVATION", 126, 133], ["kidney", "ANATOMY", 141, 147], ["calf serum", "ANATOMY", 329, 339]]], ["Virus from a bait containing the modified live vaccine CSFV \"C-strain Riems\" (Riemser Arzneimittel AG, Germany) was propagated once in PK15 cells and termed vRiemser.", [["PK15 cells", "ANATOMY", 135, 145], ["Virus", "ORGANISM", 0, 5], ["CSFV", "ORGANISM", 55, 59], ["PK15 cells", "CELL", 135, 145], ["PK15 cells", "CELL_LINE", 135, 145], ["CSFV", "SPECIES", 55, 59], ["Virus", "PROBLEM", 0, 5], ["a bait", "TREATMENT", 11, 17], ["the modified live vaccine", "TREATMENT", 29, 54]]], ["RNA obtained from BDV strain \"Gifhorn\" [26] was used for amplification of the Gifhorn E2-coding sequence.DNA oligonucleotidesOligonucleotide primers used are listed in Additional file 1: Table S1 .BAC constructsThe BAC construct, pBeloR26, was constructed using the long RT-PCR method as previously described [11] using RNA derived from the \"C-strain Riems\".", [["E2", "CHEMICAL", 86, 88], ["BDV", "ORGANISM", 18, 21], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["pBeloR26", "GENE_OR_GENE_PRODUCT", 230, 238], ["RNA", "RNA", 0, 3], ["Gifhorn E2-coding sequence", "DNA", 78, 104], ["Table S1 .BAC constructs", "DNA", 187, 211], ["BAC construct", "DNA", 215, 228], ["pBeloR26", "DNA", 230, 238], ["BDV", "SPECIES", 18, 21], ["RNA", "TEST", 0, 3], ["DNA oligonucleotides", "TREATMENT", 105, 125], ["Oligonucleotide primers", "TREATMENT", 125, 148], ["the long RT-PCR method", "TREATMENT", 262, 284], ["oligonucleotides", "OBSERVATION", 109, 125]]], ["Briefly, full-length viral cDNAs flanked by NotI sites were amplified by long RT-PCR using primers 5\u2032Cstrain_T7_Not1 (which includes a T7 promotor for in vitro transcription, a NotI site and a region corresponding to the first 44 nt of the genome) and 3\u2032CSFV_Not1 (that contains a NotI site and sequence complementary to the 3\u2032-terminal 35 nt of the genome that are conserved among many CSFVs including the Cstrain).", [["NotI", "GENE_OR_GENE_PRODUCT", 44, 48], ["Cstrain_T7_Not1", "GENE_OR_GENE_PRODUCT", 101, 116], ["NotI", "GENE_OR_GENE_PRODUCT", 177, 181], ["genome", "CELLULAR_COMPONENT", 240, 246], ["Not1", "GENE_OR_GENE_PRODUCT", 259, 263], ["NotI", "GENE_OR_GENE_PRODUCT", 281, 285], ["CSFVs", "CANCER", 387, 392], ["Cstrain", "GENE_OR_GENE_PRODUCT", 407, 414], ["full-length viral cDNAs", "DNA", 9, 32], ["NotI sites", "DNA", 44, 54], ["Cstrain_T7_Not1", "PROTEIN", 101, 116], ["T7 promotor", "DNA", 135, 146], ["NotI site", "DNA", 177, 186], ["Not1", "DNA", 259, 263], ["NotI site", "DNA", 281, 290], ["3\u2032-terminal 35 nt", "DNA", 325, 342], ["CSFVs", "DNA", 387, 392], ["Cstrain", "DNA", 407, 414], ["CSFV_Not1", "SPECIES", 254, 263], ["full-length viral cDNAs flanked", "TREATMENT", 9, 40], ["NotI sites", "PROBLEM", 44, 54], ["long RT-PCR using primers", "TREATMENT", 73, 98], ["a T7 promotor", "TREATMENT", 133, 146], ["vitro transcription", "TREATMENT", 154, 173], ["a NotI site", "PROBLEM", 175, 186], ["a NotI site", "PROBLEM", 279, 290]]], ["12.3 kbp) was digested with NotI and inserted into similarly digested pBeloBAC11 (New England Biolabs, GenBank accession U51113).", [["NotI", "GENE_OR_GENE_PRODUCT", 28, 32], ["pBeloBAC11", "GENE_OR_GENE_PRODUCT", 70, 80], ["NotI", "DNA", 28, 32], ["pBeloBAC11", "PROTEIN", 70, 80], ["New England Biolabs", "TREATMENT", 82, 101]]], ["All BACs were modified and maintained in E. coli DH10B cells (Invitrogen) grown at 37\u00b0C in LB medium containing chloramphenicol (Cam, 15 \u03bcg/ml).", [["BACs", "ANATOMY", 4, 8], ["cells", "ANATOMY", 55, 60], ["chloramphenicol", "CHEMICAL", 112, 127], ["Cam", "CHEMICAL", 129, 132], ["chloramphenicol", "CHEMICAL", 112, 127], ["Cam", "CHEMICAL", 129, 132], ["BACs", "CELL", 4, 8], ["E. coli DH10B cells", "CELL", 41, 60], ["Invitrogen", "CELL", 62, 72], ["chloramphenicol", "SIMPLE_CHEMICAL", 112, 127], ["Cam", "SIMPLE_CHEMICAL", 129, 132], ["BACs", "DNA", 4, 8], ["E. coli DH10B cells", "CELL_LINE", 41, 60], ["E. coli", "SPECIES", 41, 48], ["E. coli", "SPECIES", 41, 48], ["All BACs", "TEST", 0, 8], ["E. coli DH10B cells", "PROBLEM", 41, 60], ["Invitrogen", "TEST", 62, 72], ["chloramphenicol (Cam", "TREATMENT", 112, 132], ["coli DH10B cells", "OBSERVATION", 44, 60]]], ["The electroporation of bacteria was performed in 0.1 cm cuvettes using 1 pulse at 1800 V, 25 \u03bcF and 200 \u03a9 in a Gene Pulser Xcell (Bio-Rad).", [["Bio-Rad", "DNA", 130, 137], ["bacteria", "PROBLEM", 23, 31], ["bacteria", "OBSERVATION", 23, 31]]], ["BACs to be used as templates for long PCR or for screening by restriction enzyme digestion were purified from 4 ml overnight cultures of E. coli DH10B using the ZR BAC DNA Miniprep Kit (Zymo Research).", [["BACs", "ANATOMY", 0, 4], ["BACs", "CELL", 0, 4], ["E. coli DH10B", "CELL", 137, 150], ["E. coli", "SPECIES", 137, 144], ["E. coli", "SPECIES", 137, 144], ["BACs", "TREATMENT", 0, 4], ["long PCR", "TEST", 33, 41], ["screening", "TEST", 49, 58], ["enzyme digestion", "PROBLEM", 74, 90], ["cultures", "TEST", 125, 133], ["E. coli", "PROBLEM", 137, 144], ["the ZR BAC DNA", "TREATMENT", 157, 171], ["E. coli", "OBSERVATION", 137, 144]]], ["BACs required for direct genome sequencing were purified from 500 ml cultures using the Large-construct kit (Qiagen).Modification of the CSFV cDNA by Red/ET recombinationModifications to the full-length CSFV cDNA were accomplished in E. coli DH10B (streptomycin resistant, Strep R ) using the Counter Selection BAC Modification Kit (Gene Bridges, Heidelberg, Germany).Modification of the CSFV cDNA by Red/ET recombinationThe Red/ET recombination involved three steps (i-iii).Modification of the CSFV cDNA by Red/ET recombinationStep i) the temperature-sensitive pRedET expression plasmid (Gene Bridges) was introduced into electroporationcompetent E.coli DH10B cells containing the parental BAC (phenotype Cam R , Strep R ).", [["BACs", "ANATOMY", 0, 4], ["cells", "ANATOMY", 661, 666], ["BAC", "ANATOMY", 691, 694], ["streptomycin", "CHEMICAL", 249, 261], ["streptomycin", "CHEMICAL", 249, 261], ["BACs", "CELL", 0, 4], ["CSFV", "ORGANISM", 137, 141], ["CSFV", "ORGANISM", 203, 207], ["E. coli", "ORGANISM", 234, 241], ["DH10B", "ORGANISM", 242, 247], ["streptomycin", "SIMPLE_CHEMICAL", 249, 261], ["Strep R", "GENE_OR_GENE_PRODUCT", 273, 280], ["CSFV", "ORGANISM", 388, 392], ["CSFV", "ORGANISM", 495, 499], ["E.coli DH10B cells", "CELL", 648, 666], ["Cam R", "GENE_OR_GENE_PRODUCT", 706, 711], ["Strep R", "GENE_OR_GENE_PRODUCT", 714, 721], ["CSFV cDNA", "DNA", 137, 146], ["full-length CSFV cDNA", "DNA", 191, 212], ["CSFV cDNA", "DNA", 388, 397], ["CSFV cDNA", "DNA", 495, 504], ["pRedET expression plasmid", "DNA", 562, 587], ["Gene Bridges", "DNA", 589, 601], ["electroporationcompetent E.coli DH10B cells", "CELL_LINE", 623, 666], ["parental BAC", "DNA", 682, 694], ["Strep R", "DNA", 714, 721], ["E. coli", "SPECIES", 234, 241], ["CSFV", "SPECIES", 137, 141], ["CSFV", "SPECIES", 203, 207], ["E. coli", "SPECIES", 234, 241], ["CSFV", "SPECIES", 388, 392], ["CSFV", "SPECIES", 495, 499], ["E.coli DH10B", "SPECIES", 648, 660], ["direct genome sequencing", "TREATMENT", 18, 42], ["ml cultures", "TEST", 66, 77], ["the Large-construct kit", "TREATMENT", 84, 107], ["the CSFV cDNA", "TREATMENT", 133, 146], ["Red/ET recombinationModifications", "TREATMENT", 150, 183], ["the full-length CSFV cDNA", "TREATMENT", 187, 212], ["E. coli DH10B", "TREATMENT", 234, 247], ["streptomycin resistant", "TREATMENT", 249, 271], ["the Counter Selection BAC Modification", "TREATMENT", 289, 327], ["the CSFV cDNA", "TREATMENT", 384, 397], ["Red/ET recombination", "TREATMENT", 401, 421], ["Red/ET recombination", "TREATMENT", 425, 445], ["the CSFV cDNA", "TREATMENT", 491, 504], ["Red/ET recombinationStep i", "TREATMENT", 508, 534], ["the temperature", "TEST", 536, 551], ["sensitive pRedET expression plasmid (Gene Bridges)", "TREATMENT", 552, 602], ["E.coli DH10B cells", "PROBLEM", 648, 666], ["the parental BAC", "TEST", 678, 694], ["E.coli DH10B cells", "OBSERVATION", 648, 666]]], ["The pRedET expresses the phage lambda proteins red\u03b1, red\u03b2 and red\u03b3, under control of the arabinose-inducible pBAD promoter, allowing homologous recombination to occur.", [["arabinose", "CHEMICAL", 89, 98], ["arabinose", "CHEMICAL", 89, 98], ["pRedET", "GENE_OR_GENE_PRODUCT", 4, 10], ["red\u03b1", "GENE_OR_GENE_PRODUCT", 47, 51], ["red\u03b2", "GENE_OR_GENE_PRODUCT", 53, 57], ["red\u03b3", "GENE_OR_GENE_PRODUCT", 62, 66], ["arabinose", "SIMPLE_CHEMICAL", 89, 98], ["pBAD", "GENE_OR_GENE_PRODUCT", 109, 113], ["pRedET", "PROTEIN", 4, 10], ["phage lambda proteins", "PROTEIN", 25, 46], ["red\u03b1", "PROTEIN", 47, 51], ["red\u03b2", "PROTEIN", 53, 57], ["red\u03b3", "PROTEIN", 62, 66], ["pBAD promoter", "DNA", 109, 122], ["the arabinose-inducible pBAD promoter", "TREATMENT", 85, 122], ["homologous recombination", "TREATMENT", 133, 157]]], ["Immediately after electroporation, pre-warmed LB medium without antibiotics (1 ml) was added to the cells which were then incubated at 30\u00b0C for 1 hour, prior to spreading onto agar plates containing Cam (15 \u03bcg/ml) and tetracycline (Tet) (3 \u03bcg/ml) and then incubated at 30\u00b0C overnight to maintain the pRedET.", [["cells", "ANATOMY", 100, 105], ["Cam", "CHEMICAL", 199, 202], ["tetracycline", "CHEMICAL", 218, 230], ["Tet", "CHEMICAL", 232, 235], ["tetracycline", "CHEMICAL", 218, 230], ["cells", "CELL", 100, 105], ["Cam", "SIMPLE_CHEMICAL", 199, 202], ["tetracycline", "SIMPLE_CHEMICAL", 218, 230], ["Tet", "SIMPLE_CHEMICAL", 232, 235], ["pRedET", "DNA", 300, 306], ["antibiotics", "TREATMENT", 64, 75], ["agar plates containing Cam", "TREATMENT", 176, 202], ["tetracycline (Tet)", "TREATMENT", 218, 236]]], ["The presence of the pRedET plasmid (conferring Tet R ) was verified by visual inspection of BAC-DNA preparations from the Cam R /Tet R colonies using agarose gel electrophoresis.Modification of the CSFV cDNA by Red/ET recombinationStep ii) counter-selection marker cassettes with an extra NotI site for screening purposes (rpsL-neo, 1325 bp) were amplified by PCR using primers with 30 nt or 50 nt extensions that were homologous to the target site in the BAC using the rpsL-neo plasmid (Gene Bridges) as template and the Phusion hot start II HF DNA polymerase (Thermo Scientific) with cycling conditions as follows: 98\u00b0C for 30s, followed by 35 cycles of 98\u00b0C for 10s, 60\u00b0C for 20s, 72\u00b0C for 60s, and 1 cycle at 72\u00b0C for 4 min.", [["pRedET", "GENE_OR_GENE_PRODUCT", 20, 26], ["Tet R", "GENE_OR_GENE_PRODUCT", 47, 52], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["Cam R", "GENE_OR_GENE_PRODUCT", 122, 127], ["Tet R", "GENE_OR_GENE_PRODUCT", 129, 134], ["agarose", "SIMPLE_CHEMICAL", 150, 157], ["CSFV", "ORGANISM", 198, 202], ["NotI", "GENE_OR_GENE_PRODUCT", 289, 293], ["rpsL-neo", "GENE_OR_GENE_PRODUCT", 323, 331], ["pRedET plasmid", "DNA", 20, 34], ["Tet R", "DNA", 47, 52], ["BAC", "DNA", 92, 95], ["Cam R /Tet R colonies", "CELL_LINE", 122, 143], ["CSFV cDNA", "DNA", 198, 207], ["counter-selection marker cassettes", "DNA", 240, 274], ["NotI site", "DNA", 289, 298], ["rpsL", "DNA", 323, 327], ["neo", "DNA", 328, 331], ["30 nt or 50 nt extensions", "DNA", 383, 408], ["target site", "DNA", 437, 448], ["BAC", "DNA", 456, 459], ["rpsL-neo plasmid", "DNA", 470, 486], ["Gene Bridges", "DNA", 488, 500], ["Phusion hot start II HF DNA polymerase", "DNA", 522, 560], ["CSFV", "SPECIES", 198, 202], ["the pRedET plasmid (conferring Tet R )", "TREATMENT", 16, 54], ["visual inspection", "TEST", 71, 88], ["BAC", "TEST", 92, 95], ["DNA preparations", "TREATMENT", 96, 112], ["the Cam R /Tet R colonies", "TREATMENT", 118, 143], ["agarose gel electrophoresis", "TREATMENT", 150, 177], ["the CSFV cDNA", "TREATMENT", 194, 207], ["Red/ET recombinationStep ii)", "TREATMENT", 211, 239], ["selection marker cassettes", "TREATMENT", 248, 274], ["an extra NotI site", "TREATMENT", 280, 298], ["screening purposes", "TEST", 303, 321], ["rpsL", "TEST", 323, 327], ["neo", "TREATMENT", 328, 331], ["primers", "TREATMENT", 370, 377], ["50 nt extensions", "TREATMENT", 392, 408], ["the rpsL-neo plasmid (Gene Bridges)", "TREATMENT", 466, 501], ["the Phusion", "TREATMENT", 518, 529], ["II HF DNA polymerase", "PROBLEM", 540, 560]]], ["The PCR products (ca.", [["PCR products", "PROTEIN", 4, 16], ["The PCR products", "TREATMENT", 0, 16]]], ["1400 bp) were isolated on 1% (w/v) TBE agarose gels and purified using a GeneJET gel extraction kit (Thermo Scientific).", [["TBE", "SPECIES", 35, 38], ["bp", "TEST", 5, 7], ["w/v) TBE agarose gels", "TREATMENT", 30, 51], ["a GeneJET gel extraction", "TREATMENT", 71, 95]]], ["Samples (30 \u03bcl), from an E. coli culture containing pRedET and the parental BAC grown overnight at 30\u00b0C in LB media (Cam, Tet), were used to inoculate 1.4 ml of fresh LB media with the same antibiotics to obtain exponentially growing bacteria at 30\u00b0C. Red/ET recombination proteins were induced by adding 50 \u03bcl of 10% (w/v) L-arabinose (Sigma).", [["Samples", "ANATOMY", 0, 7], ["BAC", "ANATOMY", 76, 79], ["L-arabinose", "CHEMICAL", 324, 335], ["L-arabinose", "CHEMICAL", 324, 335], ["pRedET", "CELL", 52, 58], ["BAC", "CELL", 76, 79], ["L-arabinose", "SIMPLE_CHEMICAL", 324, 335], ["pRedET", "DNA", 52, 58], ["ET recombination proteins", "PROTEIN", 256, 281], ["E. coli", "SPECIES", 25, 32], ["E. coli", "SPECIES", 25, 32], ["Samples", "TEST", 0, 7], ["an E. coli culture", "TEST", 22, 40], ["the parental BAC", "TEST", 63, 79], ["fresh LB media", "TREATMENT", 161, 175], ["the same antibiotics", "TREATMENT", 181, 201], ["exponentially growing bacteria", "PROBLEM", 212, 242], ["Red/ET recombination proteins", "TREATMENT", 252, 281], ["bacteria", "OBSERVATION", 234, 242]]], ["The PCR product (200 ng) containing the rpsL-neo cassette was introduced into these bacteria using electroporation (as above).", [["rpsL", "GENE_OR_GENE_PRODUCT", 40, 44], ["neo", "GENE_OR_GENE_PRODUCT", 45, 48], ["rpsL", "PROTEIN", 40, 44], ["neo cassette", "DNA", 45, 57], ["The PCR product", "TREATMENT", 0, 15], ["the rpsL", "TREATMENT", 36, 44], ["neo cassette", "TREATMENT", 45, 57]]], ["Following electroporation, the cells were grown at 37\u00b0C for 70 min (to allow recombination) and then selected on plates containing Cam (15 \u03bcg/ml), Tet (3 \u03bcg/ml) and kanamycin (Kan, 15 \u03bcg/ml) overnight at 30\u00b0C to maintain the pRedET.", [["cells", "ANATOMY", 31, 36], ["Cam", "CHEMICAL", 131, 134], ["Tet", "CHEMICAL", 147, 150], ["kanamycin", "CHEMICAL", 165, 174], ["Kan", "CHEMICAL", 176, 179], ["Cam", "CHEMICAL", 131, 134], ["kanamycin", "CHEMICAL", 165, 174], ["Kan", "CHEMICAL", 176, 179], ["cells", "CELL", 31, 36], ["Cam", "SIMPLE_CHEMICAL", 131, 134], ["Tet", "SIMPLE_CHEMICAL", 147, 150], ["kanamycin", "SIMPLE_CHEMICAL", 165, 174], ["pRedET", "PROTEIN", 225, 231], ["plates containing Cam", "TREATMENT", 113, 134], ["Tet", "TREATMENT", 147, 150], ["kanamycin (Kan", "TREATMENT", 165, 179]]], ["Note, the rpsL cassette confers Streptomycin sensitivity (Strep S ) onto the resistant DH10B strain and the neo confers Kanamycin resistance (Kan R ).", [["Streptomycin", "CHEMICAL", 32, 44], ["DH10B", "CHEMICAL", 87, 92], ["Kanamycin", "CHEMICAL", 120, 129], ["Streptomycin", "CHEMICAL", 32, 44], ["Kanamycin", "CHEMICAL", 120, 129], ["rpsL", "GENE_OR_GENE_PRODUCT", 10, 14], ["Streptomycin", "SIMPLE_CHEMICAL", 32, 44], ["DH10B strain", "ORGANISM", 87, 99], ["Kanamycin", "SIMPLE_CHEMICAL", 120, 129], ["Kan R", "GENE_OR_GENE_PRODUCT", 142, 147], ["rpsL cassette", "DNA", 10, 23], ["the rpsL cassette", "TEST", 6, 23], ["Streptomycin sensitivity", "TEST", 32, 56], ["Strep S", "TEST", 58, 65], ["the resistant DH10B strain", "PROBLEM", 73, 99], ["the neo confers Kanamycin resistance", "TREATMENT", 104, 140]]], ["The correct phenotype (Cam R , Kan R , Tet R , Strep S ) of the resulting colonies was confirmed by streaking the colonies onto plates containing Cam (15 \u03bcg/ml), Tet (3 \u03bcg/ml) and Kan (15 \u03bcg/ml) and grown at 30\u00b0C. Importantly, for the third step, the replacement of the rpsL-neo cassette (using counter-selection), the selected colonies were also streaked onto plates containing Cam (15 \u03bcg/ml) plus Strep (50 \u03bcg/ml) and shown to be Strep S indicating incorporation of a functional rpsL gene.", [["colonies", "ANATOMY", 74, 82], ["colonies", "ANATOMY", 114, 122], ["colonies", "ANATOMY", 328, 336], ["Cam", "CHEMICAL", 146, 149], ["Tet", "CHEMICAL", 162, 165], ["Kan", "CHEMICAL", 180, 183], ["Cam", "CHEMICAL", 379, 382], ["Strep", "CHEMICAL", 399, 404], ["Cam R", "GENE_OR_GENE_PRODUCT", 23, 28], ["Kan R", "GENE_OR_GENE_PRODUCT", 31, 36], ["Tet R", "GENE_OR_GENE_PRODUCT", 39, 44], ["Cam", "SIMPLE_CHEMICAL", 146, 149], ["Tet", "SIMPLE_CHEMICAL", 162, 165], ["rpsL", "GENE_OR_GENE_PRODUCT", 270, 274], ["Cam", "SIMPLE_CHEMICAL", 379, 382], ["Strep", "SIMPLE_CHEMICAL", 399, 404], ["rpsL", "GENE_OR_GENE_PRODUCT", 481, 485], ["rpsL-neo cassette", "DNA", 270, 287], ["rpsL gene", "DNA", 481, 490], ["Cam R", "TEST", 23, 28], ["Kan R , Tet R , Strep S", "TEST", 31, 54], ["the resulting colonies", "PROBLEM", 60, 82], ["Tet", "TREATMENT", 162, 165], ["Kan", "TREATMENT", 180, 183], ["the replacement of the rpsL-neo cassette", "TREATMENT", 247, 287], ["counter-selection", "TREATMENT", 295, 312], ["the selected colonies", "TEST", 315, 336], ["Cam", "TEST", 379, 382], ["Strep", "PROBLEM", 399, 404], ["Strep S", "PROBLEM", 432, 439], ["a functional rpsL gene", "TREATMENT", 468, 490], ["Strep", "OBSERVATION", 432, 437], ["functional rpsL", "OBSERVATION", 470, 485]]], ["The structures of the intermediate BACs were verified by restriction enzyme analysis and sequencing around the inserts.Modification of the CSFV cDNA by Red/ET recombinationStep iii) the replacement of the rpsL-neo selection cassettes from the intermediate constructs using linear DNA fragments was achieved through counter-selection and Red/ET recombination.", [["CSFV", "ORGANISM", 139, 143], ["rpsL", "GENE_OR_GENE_PRODUCT", 205, 209], ["DNA", "CELLULAR_COMPONENT", 280, 283], ["intermediate BACs", "DNA", 22, 39], ["CSFV cDNA", "DNA", 139, 148], ["rpsL-neo selection cassettes", "DNA", 205, 233], ["intermediate constructs", "DNA", 243, 266], ["linear DNA fragments", "DNA", 273, 293], ["CSFV", "SPECIES", 139, 143], ["restriction enzyme analysis", "TEST", 57, 84], ["the CSFV cDNA", "TREATMENT", 135, 148], ["Red/ET recombinationStep iii", "TREATMENT", 152, 180], ["the replacement of the rpsL", "TREATMENT", 182, 209], ["neo selection cassettes", "TREATMENT", 210, 233], ["linear DNA fragments", "TREATMENT", 273, 293], ["counter-selection", "TREATMENT", 315, 332], ["Red/ET recombination", "TREATMENT", 337, 357], ["intermediate BACs", "OBSERVATION", 22, 39], ["rpsL", "ANATOMY", 205, 209], ["linear", "OBSERVATION_MODIFIER", 273, 279], ["DNA fragments", "OBSERVATION", 280, 293]]], ["Again, the homologous sequences at the ends of the DNA fragment were used for Red/ET mediated recombination events to replace the rpsL-neo cassette with the sequence of interest.", [["DNA", "CELLULAR_COMPONENT", 51, 54], ["DNA fragment", "DNA", 51, 63], ["rpsL-neo cassette", "DNA", 130, 147], ["the homologous sequences", "TEST", 7, 31], ["the DNA fragment", "PROBLEM", 47, 63], ["Red/ET mediated recombination", "TREATMENT", 78, 107], ["the rpsL", "TREATMENT", 126, 134], ["neo cassette", "TREATMENT", 135, 147], ["DNA fragment", "OBSERVATION", 51, 63]]], ["Counterselection against the rpsL-neo cassette (phenotype Cam R , Kan R , Tet R , Strep S ) was employed using media containing Cam (15 \u03bcg/ml) and Strep (50 \u03bcg/ml) to isolate the required derivatives (phenotype Cam R and Strep R ).Modification of the CSFV cDNA by Red/ET recombinationInitially, the intermediate construct, pBeloR26_E2rpsLneo ( Figure 1 ), was generated using Red/ET recombination by insertion of the rpsL-neo cassette with an extra NotI site for screening purposes which was amplified using primers Criems-TAVfor and Criems-TAVrev (Additional file 1: Table S1 ) in place of the TAVSPTTLR coding sequence (27 nt) .", [["Cam", "CHEMICAL", 128, 131], ["rpsL", "GENE_OR_GENE_PRODUCT", 29, 33], ["Cam R", "GENE_OR_GENE_PRODUCT", 58, 63], ["Kan R", "GENE_OR_GENE_PRODUCT", 66, 71], ["Tet R", "GENE_OR_GENE_PRODUCT", 74, 79], ["Cam", "SIMPLE_CHEMICAL", 128, 131], ["Strep", "SIMPLE_CHEMICAL", 147, 152], ["Cam R", "GENE_OR_GENE_PRODUCT", 211, 216], ["Strep R", "GENE_OR_GENE_PRODUCT", 221, 228], ["CSFV", "ORGANISM", 251, 255], ["Red/ET", "GENE_OR_GENE_PRODUCT", 264, 270], ["NotI", "GENE_OR_GENE_PRODUCT", 449, 453], ["rpsL", "DNA", 29, 33], ["neo cassette", "DNA", 34, 46], ["Kan R", "DNA", 66, 71], ["Tet R", "DNA", 74, 79], ["Strep S", "DNA", 82, 89], ["Strep R", "PROTEIN", 221, 228], ["CSFV cDNA", "DNA", 251, 260], ["intermediate construct", "DNA", 299, 321], ["pBeloR26_E2rpsLneo", "DNA", 323, 341], ["Figure 1", "DNA", 344, 352], ["rpsL", "DNA", 417, 421], ["neo cassette", "DNA", 422, 434], ["extra NotI site", "DNA", 443, 458], ["TAVfor", "DNA", 523, 529], ["Criems", "DNA", 534, 540], ["TAVrev", "DNA", 541, 547], ["TAVSPTTLR coding sequence", "DNA", 595, 620], ["CSFV", "SPECIES", 251, 255], ["Counterselection", "TEST", 0, 16], ["the rpsL", "TEST", 25, 33], ["neo cassette", "TREATMENT", 34, 46], ["Kan R , Tet R , Strep S", "TREATMENT", 66, 89], ["media containing Cam", "TREATMENT", 111, 131], ["Strep", "TREATMENT", 147, 152], ["phenotype Cam R", "TEST", 201, 216], ["Red/ET recombination", "TREATMENT", 376, 396], ["the rpsL", "TREATMENT", 413, 421], ["neo cassette", "TREATMENT", 422, 434], ["an extra NotI site", "TREATMENT", 440, 458], ["screening purposes", "TEST", 463, 481], ["primers Criems", "TEST", 508, 522], ["TAVfor", "TEST", 523, 529], ["Criems", "TEST", 534, 540], ["CSFV cDNA", "OBSERVATION", 251, 260]]], ["Secondly, the rpsL-neo cassette in this intermediate construct was then replaced using counter-selection Red/ ET recombination using a single-stranded oligonucleotide, Riems_TAV_Gifhorn (Additional file 1: Table S1 ) with the same homology arms as used for the rpsL-neo cassette, to introduce the coding sequence for the BDV \"Gifhorn\" epitope sequence (TTVSTSTLA).", [["rpsL", "GENE_OR_GENE_PRODUCT", 14, 18], ["neo", "GENE_OR_GENE_PRODUCT", 19, 22], ["rpsL", "GENE_OR_GENE_PRODUCT", 261, 265], ["BDV", "ORGANISM", 321, 324], ["rpsL-neo cassette", "DNA", 14, 31], ["Riems_TAV_Gifhorn", "DNA", 168, 185], ["homology arms", "DNA", 231, 244], ["rpsL", "DNA", 261, 265], ["neo cassette", "DNA", 266, 278], ["BDV \"Gifhorn\" epitope sequence", "DNA", 321, 351], ["BDV", "SPECIES", 321, 324], ["the rpsL", "TREATMENT", 10, 18], ["neo cassette", "TREATMENT", 19, 31], ["counter-selection", "TREATMENT", 87, 104], ["Red/ ET recombination", "TREATMENT", 105, 126], ["a single-stranded oligonucleotide", "TREATMENT", 133, 166], ["the same homology arms", "TREATMENT", 222, 244], ["the rpsL", "TREATMENT", 257, 265], ["neo cassette", "TREATMENT", 266, 278], ["the coding sequence", "TREATMENT", 293, 312]]], ["The resulting construct was named pBeloR26_TAV (Figure 1 ).", [["pBeloR26_TAV", "PROTEIN", 34, 46]]], ["The initial intermediate construct (with rpsL-neo) was then used to produce the pBeloR26_E2gif construct ( Figure 1 ).", [["rpsL", "PROTEIN", 41, 45], ["neo", "DNA", 46, 49], ["pBeloR26_E2gif construct", "DNA", 80, 104], ["rpsL-neo", "TREATMENT", 41, 49], ["intermediate construct", "OBSERVATION", 12, 34]]], ["For this, the E2 coding sequence was amplified from cDNA prepared from BDV \"Gifhorn\" RNA using two different primer pairs, one set with 50 nt homology arms (Criems_E2_gifFlong/Criems_ E2_gifRlong) and another with 30 nt homologous sequences (Criems_E2_gifF/Criems_E2_gifR).Modification of the CSFV cDNA by Red/ET recombinationFor generation of BACs with substitution of the entire E2 coding sequences, PCR products consisting of the sequence of interest flanked with homology arms identical to the target area were generated by PCR (as for the rpsLneo cassette).", [["E2", "CHEMICAL", 14, 16], ["E2", "CHEMICAL", 381, 383], ["E2", "GENE_OR_GENE_PRODUCT", 14, 16], ["BDV", "ORGANISM", 71, 74], ["CSFV", "ORGANISM", 293, 297], ["rpsLneo", "GENE_OR_GENE_PRODUCT", 544, 551], ["E2 coding sequence", "DNA", 14, 32], ["cDNA", "DNA", 52, 56], ["BDV \"Gifhorn\" RNA", "RNA", 71, 88], ["primer pairs", "DNA", 109, 121], ["50 nt homology arms", "DNA", 136, 155], ["Criems_E2_gifFlong", "DNA", 157, 175], ["Criems_ E2_gifRlong", "DNA", 176, 195], ["30 nt homologous sequences", "DNA", 214, 240], ["Criems_E2_gifF", "DNA", 242, 256], ["Criems_E2_gifR", "DNA", 257, 271], ["CSFV cDNA", "DNA", 293, 302], ["BACs", "DNA", 344, 348], ["E2 coding sequences", "DNA", 381, 400], ["PCR products", "DNA", 402, 414], ["rpsLneo cassette", "DNA", 544, 560], ["BDV", "SPECIES", 71, 74], ["CSFV", "SPECIES", 293, 297], ["the E2 coding sequence", "TEST", 10, 32], ["30 nt homologous sequences", "TREATMENT", 214, 240], ["the CSFV cDNA", "TREATMENT", 289, 302], ["Red/ET recombination", "TREATMENT", 306, 326], ["substitution", "TREATMENT", 354, 366], ["the entire E2 coding sequences", "TREATMENT", 370, 400], ["PCR products", "TREATMENT", 402, 414], ["homology arms", "TREATMENT", 467, 480], ["PCR", "TEST", 528, 531], ["the rpsLneo cassette", "TREATMENT", 540, 560]]], ["For making constructs with substitution of shorter sequences (e.g. the TAV-epitope), the recombination was achieved using synthetic single stranded oligonucleotides rather than PCR products.", [["TAV", "DNA", 71, 74], ["substitution of shorter sequences", "TREATMENT", 27, 60], ["the TAV-epitope", "TREATMENT", 67, 82], ["the recombination", "TREATMENT", 85, 102], ["synthetic single stranded oligonucleotides", "TREATMENT", 122, 164], ["PCR products", "TREATMENT", 177, 189]]], ["Pre-heating of single stranded oligonucleotides at 95\u00b0C for 2 min followed by snap-freezing, prior to electroporation, empirically showed the best results.", [["95\u00b0C", "CHEMICAL", 51, 55], ["single stranded oligonucleotides", "TREATMENT", 15, 47], ["snap", "TEST", 78, 82], ["oligonucleotides", "OBSERVATION", 31, 47]]], ["In each case, the DNA molecules were introduced into E. coli containing the BAC derivatives including the rpsL-neo cassettes together with the pRedET plasmid by electroporation as described above.", [["DNA", "CELLULAR_COMPONENT", 18, 21], ["E. coli", "ORGANISM", 53, 60], ["rpsL", "GENE_OR_GENE_PRODUCT", 106, 110], ["DNA molecules", "PROTEIN", 18, 31], ["rpsL-neo cassettes", "DNA", 106, 124], ["pRedET plasmid", "DNA", 143, 157], ["E. coli", "SPECIES", 53, 60], ["E. coli", "SPECIES", 53, 60], ["the DNA molecules", "PROBLEM", 14, 31], ["E. coli", "TREATMENT", 53, 60], ["the BAC derivatives", "TREATMENT", 72, 91], ["the rpsL", "TREATMENT", 102, 110], ["neo cassettes", "TREATMENT", 111, 124], ["the pRedET plasmid", "TREATMENT", 139, 157]]], ["The structures of the modified BACs were verified by restriction enzyme analysis and subsequent full-genome sequencing (see below).Rescue of viruses and virus growth curvesBAC DNA (1 \u03bcg) was linearized with NotI or 1 \u03bcl BAC DNA was used as template for long PCR amplification using primers 5\u2032C-strain_T7_Not1 and 3\u2032CSFV (Additional file 1: Table S1 ).", [["BACs", "CELL", 31, 35], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["NotI", "GENE_OR_GENE_PRODUCT", 207, 211], ["DNA", "CELLULAR_COMPONENT", 224, 227], ["modified BACs", "DNA", 22, 35], ["virus growth curvesBAC DNA", "DNA", 153, 179], ["NotI or 1 \u03bcl BAC DNA", "DNA", 207, 227], ["primers 5\u2032C-strain_T7_Not1", "DNA", 282, 308], ["CSFV", "SPECIES", 315, 319], ["restriction enzyme analysis", "TEST", 53, 80], ["Rescue of viruses", "PROBLEM", 131, 148], ["virus growth curvesBAC DNA", "PROBLEM", 153, 179], ["1 \u03bcl BAC DNA", "TREATMENT", 215, 227], ["long PCR amplification", "TREATMENT", 253, 275], ["primers", "TEST", 282, 289], ["\u2032C", "TEST", 291, 293], ["CSFV", "PROBLEM", 315, 319], ["viruses", "OBSERVATION", 141, 148]]], ["Linearized BACs or PCR products were purified with the GeneJet PCR purification kit (Thermo Scientific) and transcribed in vitro using a Megascript T7 kit (Invitrogen).", [["Linearized BACs", "DNA", 0, 15], ["Linearized BACs", "TREATMENT", 0, 15], ["PCR products", "TREATMENT", 19, 31], ["the GeneJet PCR", "TEST", 51, 66], ["a Megascript T7 kit (Invitrogen", "TREATMENT", 135, 166]]], ["Viruses were rescued from RNA transcripts (1 to 5 \u03bcg) by electroporation of porcine (PK15) or ovine (SFT-R) cells essentially as described previously [24] .", [["SFT-R) cells", "ANATOMY", 101, 113], ["porcine", "ORGANISM", 76, 83], ["PK15", "GENE_OR_GENE_PRODUCT", 85, 89], ["SFT-R) cells", "CELL", 101, 113], ["RNA transcripts", "RNA", 26, 41], ["porcine (PK15) or ovine (SFT-R) cells", "CELL_LINE", 76, 113], ["Viruses", "PROBLEM", 0, 7], ["RNA transcripts", "TREATMENT", 26, 41], ["porcine (PK15", "TREATMENT", 76, 89]]], ["Cells were analysed using immunofluorescence microscopy (typically after 3 days) for the expression of NS3 and E2 proteins using specific monoclonal antibodies (mAbs), these were anti-NS3 (WB103/105, pan-pestivirus), anti-CSFV E2 (WH211, WH303, both CSFV specific) and anti-BDV E2 (WB166, BVDV/BDV specific) (AHVLA Scientific, United Kingdom) together with Alexa 488 conjugated goat antimouse IgG antibody (Molecular Probes, Invitrogen).", [["Cells", "ANATOMY", 0, 5], ["E2", "CHEMICAL", 227, 229], ["E2", "CHEMICAL", 278, 280], ["Alexa 488", "CHEMICAL", 357, 366], ["Cells", "CELL", 0, 5], ["NS3", "GENE_OR_GENE_PRODUCT", 103, 106], ["E2", "GENE_OR_GENE_PRODUCT", 111, 113], ["pan-pestivirus", "CANCER", 200, 214], ["CSFV", "ORGANISM", 222, 226], ["E2", "ORGANISM", 227, 229], ["WH211", "ORGANISM", 231, 236], ["WH303", "ORGANISM", 238, 243], ["CSFV", "ORGANISM", 250, 254], ["anti-BDV E2", "SIMPLE_CHEMICAL", 269, 280], ["WB166", "ORGANISM", 282, 287], ["BVDV", "ORGANISM", 289, 293], ["BDV", "ORGANISM", 294, 297], ["Alexa 488", "SIMPLE_CHEMICAL", 357, 366], ["NS3", "PROTEIN", 103, 106], ["E2 proteins", "PROTEIN", 111, 122], ["monoclonal antibodies", "PROTEIN", 138, 159], ["mAbs", "PROTEIN", 161, 165], ["NS3", "PROTEIN", 184, 187], ["WB103", "PROTEIN", 189, 194], ["Alexa 488 conjugated goat antimouse IgG antibody", "PROTEIN", 357, 405], ["Molecular Probes", "PROTEIN", 407, 423], ["goat", "SPECIES", 378, 382], ["CSFV", "SPECIES", 222, 226], ["CSFV", "SPECIES", 250, 254], ["anti-BDV", "SPECIES", 269, 277], ["BVDV", "SPECIES", 289, 293], ["BDV", "SPECIES", 294, 297], ["goat", "SPECIES", 378, 382], ["immunofluorescence microscopy", "TEST", 26, 55], ["NS3", "PROBLEM", 103, 106], ["E2 proteins", "TREATMENT", 111, 122], ["specific monoclonal antibodies", "TEST", 129, 159], ["anti-NS3", "TEST", 179, 187], ["pan-pestivirus", "TEST", 200, 214], ["anti-CSFV E2", "TEST", 217, 229], ["anti-BDV E2", "TEST", 269, 280], ["BVDV", "TEST", 289, 293], ["Alexa", "TEST", 357, 362], ["antimouse IgG antibody", "TEST", 383, 405], ["Molecular Probes", "TREATMENT", 407, 423]]], ["The nuclei of cells were visualized using DAPI (Vector Laboratories) and images were recorded using a BX63 fluorescence microscope (Olympus).", [["nuclei", "ANATOMY", 4, 10], ["cells", "ANATOMY", 14, 19], ["DAPI", "CHEMICAL", 42, 46], ["nuclei", "CELLULAR_COMPONENT", 4, 10], ["cells", "CELL", 14, 19], ["DAPI", "SIMPLE_CHEMICAL", 42, 46], ["DAPI (Vector Laboratories", "TEST", 42, 67], ["images", "TEST", 73, 79], ["a BX63 fluorescence microscope", "TEST", 100, 130]]], ["For peroxidase staining, cells were fixed and stained for the presence of pestivirus antigens using biotinylated pig anti-CSFV/BVDV polyclonal IgG followed by avidin-conjugated horseradish peroxidase (eBioscience) as previously described [27] .", [["cells", "ANATOMY", 25, 30], ["peroxidase", "GENE_OR_GENE_PRODUCT", 4, 14], ["cells", "CELL", 25, 30], ["pig", "ORGANISM", 113, 116], ["anti-CSFV", "GENE_OR_GENE_PRODUCT", 117, 126], ["BVDV", "ORGANISM", 127, 131], ["IgG", "GENE_OR_GENE_PRODUCT", 143, 146], ["avidin", "GENE_OR_GENE_PRODUCT", 159, 165], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 177, 199], ["peroxidase", "PROTEIN", 4, 14], ["pestivirus antigens", "PROTEIN", 74, 93], ["biotinylated pig anti-CSFV", "PROTEIN", 100, 126], ["BVDV polyclonal IgG", "PROTEIN", 127, 146], ["avidin-conjugated horseradish peroxidase", "PROTEIN", 159, 199], ["eBioscience", "PROTEIN", 201, 212], ["pig", "SPECIES", 113, 116], ["BVDV", "SPECIES", 127, 131], ["horseradish", "SPECIES", 177, 188], ["pig", "SPECIES", 113, 116], ["BVDV", "SPECIES", 127, 131], ["peroxidase staining", "TEST", 4, 23], ["pestivirus antigens", "PROBLEM", 74, 93], ["biotinylated pig anti-CSFV", "TREATMENT", 100, 126], ["BVDV polyclonal IgG", "TREATMENT", 127, 146], ["avidin-conjugated horseradish peroxidase", "TREATMENT", 159, 199]]], ["The same staining procedure was also performed using the anti-E2 mAbs.", [["anti-E2 mAbs", "PROTEIN", 57, 69], ["The same staining procedure", "TREATMENT", 0, 27], ["the anti-E2 mAbs", "TREATMENT", 53, 69]]], ["Samples containing virus-positive cells were passaged onto new cells.", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 63, 68], ["cells", "CELL", 34, 39], ["cells", "CELL", 63, 68], ["virus-positive cells", "CELL_TYPE", 19, 39], ["Samples containing virus", "TEST", 0, 24], ["positive cells", "PROBLEM", 25, 39], ["positive cells", "OBSERVATION", 25, 39]]], ["Virus growth curves were generated as previously described [24] .", [["Virus", "ORGANISM", 0, 5], ["Virus growth curves", "TEST", 0, 19]]], ["Briefly, PK15 or SFT-R cells were infected at a multiplicity of infection (MOI) of 0.1 pfu/cell and grown for three days.Genome sequencingBAC DNAs (5 \u03bcg), purified using the Large-construct kit (Qiagen), or PCR products (1 \u03bcg) amplified from viral cDNA or from BACs using the long PCR method (as above) were consensus sequenced using a 454 FLX (Roche) or an Ion PGM (Life Technologies).", [["SFT-R cells", "ANATOMY", 17, 28], ["cell", "ANATOMY", 91, 95], ["infection", "DISEASE", 64, 73], ["PK15", "GENE_OR_GENE_PRODUCT", 9, 13], ["SFT-R cells", "CELL", 17, 28], ["cell", "CELL", 91, 95], ["PK15 or SFT-R cells", "CELL_LINE", 9, 28], ["Genome sequencingBAC DNAs", "DNA", 121, 146], ["Large-construct kit", "DNA", 174, 193], ["PCR products", "DNA", 207, 219], ["viral cDNA", "DNA", 242, 252], ["BACs", "DNA", 261, 265], ["PK15", "TEST", 9, 13], ["SFT-R cells", "PROBLEM", 17, 28], ["infection", "PROBLEM", 64, 73], ["Genome sequencingBAC DNAs", "TREATMENT", 121, 146], ["the Large-construct kit (Qiagen)", "TREATMENT", 170, 202], ["PCR products", "TREATMENT", 207, 219], ["viral cDNA", "PROBLEM", 242, 252], ["the long PCR method", "TEST", 272, 291], ["an Ion PGM (Life Technologies", "TREATMENT", 355, 384], ["infection", "OBSERVATION", 64, 73], ["Large", "OBSERVATION_MODIFIER", 174, 179]]], ["A combination of Samtools [29] and LoFreq SNV-caller [30] was used for downstream single nucleotide variant (SNV) analysis.", [["Samtools", "TEST", 17, 25], ["downstream single nucleotide variant", "TREATMENT", 71, 107]]], ["Finally, clone consensus sequences were aligned using MAFFT in the Geneious software platform (Biomatters).ResultsGeneration of a BAC containing full-length cDNA corresponding to the modified live vaccine \"C-strain Riems\"ResultsBACs containing the full-length cDNA corresponding to the parental vRiemser (\"C-strain Riems\") were constructed according to the method described previously for the \"Paderborn\" strain of CSFV [11] .", [["clone", "CELL", 9, 14], ["BAC", "CELLULAR_COMPONENT", 130, 133], ["ResultsBACs", "GENE_OR_GENE_PRODUCT", 221, 232], ["CSFV", "ORGANISM", 415, 419], ["clone consensus sequences", "DNA", 9, 34], ["BAC", "DNA", 130, 133], ["full-length cDNA", "DNA", 145, 161], ["C-strain Riems\"ResultsBACs", "DNA", 206, 232], ["full-length cDNA", "DNA", 248, 264], ["parental vRiemser", "DNA", 286, 303], ["CSFV", "SPECIES", 415, 419], ["clone consensus sequences", "TEST", 9, 34], ["a BAC containing full-length cDNA", "TREATMENT", 128, 161], ["the modified live vaccine", "TREATMENT", 179, 204], ["the full-length cDNA", "TREATMENT", 244, 264]]], ["BACs containing the complete CSFV cDNAs were identified by restriction Figure 1 Schematic representation of the CSFV genome organization and the BACs constructed and used in this study.", [["BACs", "CELLULAR_COMPONENT", 0, 4], ["CSFV", "ORGANISM", 29, 33], ["CSFV", "ORGANISM", 112, 116], ["CSFV cDNAs", "DNA", 29, 39], ["CSFV genome", "DNA", 112, 123], ["BACs", "DNA", 145, 149], ["CSFV", "SPECIES", 29, 33], ["CSFV", "SPECIES", 112, 116], ["BACs", "TREATMENT", 0, 4], ["the complete CSFV cDNAs", "TEST", 16, 39], ["the CSFV genome organization", "PROBLEM", 108, 136], ["the BACs", "TEST", 141, 149], ["this study", "TEST", 174, 184], ["complete", "OBSERVATION_MODIFIER", 20, 28], ["CSFV cDNAs", "OBSERVATION", 29, 39], ["CSFV genome", "OBSERVATION", 112, 123]]], ["Nucleotide (nt) and amino acid (aa) positions within R26 for the 5\u2032 and 3\u2032 termini together with the translational start and stop codons of the polyprotein coding region plus cleavage sites used to make the individual proteins (N pro , C, E rns , E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) are indicated.", [["amino acid", "CHEMICAL", 20, 30], ["Nucleotide", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 20, 30], ["amino acid", "AMINO_ACID", 20, 30], ["C", "GENE_OR_GENE_PRODUCT", 236, 237], ["E rns", "GENE_OR_GENE_PRODUCT", 239, 244], ["E1", "GENE_OR_GENE_PRODUCT", 247, 249], ["E2", "GENE_OR_GENE_PRODUCT", 251, 253], ["p7", "GENE_OR_GENE_PRODUCT", 255, 257], ["NS2", "GENE_OR_GENE_PRODUCT", 259, 262], ["NS3", "GENE_OR_GENE_PRODUCT", 264, 267], ["NS4A", "GENE_OR_GENE_PRODUCT", 269, 273], ["NS4B", "GENE_OR_GENE_PRODUCT", 275, 279], ["NS5A", "GENE_OR_GENE_PRODUCT", 281, 285], ["NS5B", "GENE_OR_GENE_PRODUCT", 290, 294], ["5\u2032 and 3\u2032 termini", "DNA", 65, 82], ["polyprotein coding region", "DNA", 144, 169], ["N pro , C, E rns", "PROTEIN", 228, 244], ["E1", "PROTEIN", 247, 249], ["E2", "PROTEIN", 251, 253], ["p7", "PROTEIN", 255, 257], ["NS2", "PROTEIN", 259, 262], ["NS3", "PROTEIN", 264, 267], ["NS4A", "PROTEIN", 269, 273], ["NS4B", "PROTEIN", 275, 279], ["NS5A", "PROTEIN", 281, 285], ["NS5B", "PROTEIN", 290, 294], ["Nucleotide (nt) and amino acid (aa) positions", "TREATMENT", 0, 45], ["the polyprotein coding region", "TREATMENT", 140, 169], ["cleavage sites", "PROBLEM", 175, 189], ["E2", "TREATMENT", 251, 253], ["NS2", "TREATMENT", 259, 262], ["NS3", "TREATMENT", 264, 267], ["NS4A", "TREATMENT", 269, 273], ["NS4B", "TREATMENT", 275, 279], ["NS5A", "TREATMENT", 281, 285], ["NS5B", "TREATMENT", 290, 294]]], ["Insertion of the rpsL-neo in place of the TAV-epitope within CSFV E2 for the intermediate construct (R26_rpsLneo) and the subsequent replacement with the TTVSTSTLA sequence (R26_TAV) and the complete substitution of the E2 sequence (R26_E2gif) are shown.", [["E2", "CHEMICAL", 66, 68], ["E2", "CHEMICAL", 220, 222], ["rpsL", "GENE_OR_GENE_PRODUCT", 17, 21], ["neo", "GENE_OR_GENE_PRODUCT", 22, 25], ["CSFV E2", "ORGANISM", 61, 68], ["TTVSTSTLA", "GENE_OR_GENE_PRODUCT", 154, 163], ["rpsL", "DNA", 17, 21], ["neo", "DNA", 22, 25], ["TAV-epitope", "PROTEIN", 42, 53], ["CSFV E2", "PROTEIN", 61, 68], ["intermediate construct", "DNA", 77, 99], ["R26_rpsLneo", "DNA", 101, 112], ["TTVSTSTLA sequence", "DNA", 154, 172], ["R26_TAV", "DNA", 174, 181], ["E2 sequence", "DNA", 220, 231], ["R26_E2gif", "DNA", 233, 242], ["CSFV", "SPECIES", 61, 65], ["the rpsL", "TREATMENT", 13, 21], ["neo", "TREATMENT", 22, 25], ["the TAV-epitope", "TREATMENT", 38, 53], ["CSFV E2", "TREATMENT", 61, 68], ["the intermediate construct (R26_rpsLneo", "TREATMENT", 73, 112], ["the subsequent replacement", "TREATMENT", 118, 144], ["the TTVSTSTLA sequence", "TEST", 150, 172], ["the E2 sequence", "TEST", 216, 231], ["rpsL", "OBSERVATION", 17, 21], ["replacement", "OBSERVATION", 133, 144]]], ["Names of BAC constructs begin with \"pBelo\" and rescued viruses with \"v\" (e.g. pBeloR26 and vR26).", [["vR26", "GENE_OR_GENE_PRODUCT", 91, 95], ["BAC constructs", "DNA", 9, 23]]], ["Cell culture passage no. of virus is indicated with \"/P\" (e.g. vR26/P-4).Resultsdigest analysis and following linearization by NotI, RNA transcripts were produced and electroporated into PK15 cells.", [["Cell", "ANATOMY", 0, 4], ["PK15 cells", "ANATOMY", 187, 197], ["Cell", "CELL", 0, 4], ["NotI", "GENE_OR_GENE_PRODUCT", 127, 131], ["PK15 cells", "CELL", 187, 197], ["NotI", "DNA", 127, 131], ["RNA transcripts", "RNA", 133, 148], ["PK15 cells", "CELL_LINE", 187, 197], ["Cell culture passage", "TEST", 0, 20], ["virus", "PROBLEM", 28, 33], ["vR26", "TEST", 63, 67], ["Resultsdigest analysis", "TEST", 73, 95], ["RNA transcripts", "TEST", 133, 148], ["virus", "OBSERVATION", 28, 33]]], ["This screening resulted in the identification of a BAC containing a cDNA insert of 12316 nt, pBeloR26 (Figure 1) , which yielded infectious virus, termed vR26, that could be propagated in SFT-R cells (Figure 2 , upper panels) and in PK15 cells (Figure 3 ).", [["SFT-R cells", "ANATOMY", 188, 199], ["PK15 cells", "ANATOMY", 233, 243], ["vR26", "GENE_OR_GENE_PRODUCT", 154, 158], ["SFT-R cells", "CELL", 188, 199], ["PK15 cells", "CELL", 233, 243], ["BAC", "DNA", 51, 54], ["cDNA insert", "DNA", 68, 79], ["12316 nt", "DNA", 83, 91], ["pBeloR26", "DNA", 93, 101], ["SFT-R cells", "CELL_LINE", 188, 199], ["PK15 cells", "CELL_LINE", 233, 243], ["This screening", "TEST", 0, 14], ["a BAC", "PROBLEM", 49, 54], ["a cDNA insert", "TREATMENT", 66, 79], ["infectious virus", "PROBLEM", 129, 145], ["Figure", "TEST", 201, 207], ["upper panels", "TEST", 212, 224], ["infectious virus", "OBSERVATION", 129, 145]]], ["The rescued vR26 displayed higher growth rate at the early stage (about 10fold difference in virus yield at 24 h) compared to the parental vaccine virus, but after 48 hours similar virus titres were obtained (Figure 3 ).", [["vR26", "GENE_OR_GENE_PRODUCT", 12, 16], ["vR26", "PROTEIN", 12, 16], ["The rescued vR26", "TEST", 0, 16], ["higher growth rate", "PROBLEM", 27, 45], ["the parental vaccine virus", "PROBLEM", 126, 152], ["similar virus titres", "TEST", 173, 193], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["growth", "OBSERVATION_MODIFIER", 34, 40], ["early stage", "OBSERVATION_MODIFIER", 53, 64]]], ["Full-genome sequencing of the cloned BAC template, pBeloR26, revealed a number of differences throughout the genome when compared to the full-length consensus sequence of the cDNA used for the cloning procedure (see Table 1 ).", [["cloned BAC template", "DNA", 30, 49], ["pBeloR26", "DNA", 51, 59], ["full-length consensus sequence", "DNA", 137, 167], ["cDNA", "DNA", 175, 179], ["the cloning procedure", "TREATMENT", 189, 210], ["number", "OBSERVATION_MODIFIER", 72, 78]]], ["These differences are non-representative variants within the cDNA.", [["cDNA", "CELLULAR_COMPONENT", 61, 65], ["cDNA", "DNA", 61, 65], ["non-representative variants within the cDNA", "PROBLEM", 22, 65], ["non-representative variants", "OBSERVATION", 22, 49]]], ["Overall, the BAC sequence differed from the cDNA sequence in 18 positions, 9 of these lead to predicted amino acid substitutions within the polyprotein; one in each of N pro , E rns , E1, E2 and NS3 and four amino acid substitutions in NS5B (Table 1) .", [["amino acid", "CHEMICAL", 104, 114], ["amino acid", "CHEMICAL", 208, 218], ["amino acid", "CHEMICAL", 104, 114], ["amino acid", "CHEMICAL", 208, 218], ["BAC", "CELLULAR_COMPONENT", 13, 16], ["amino acid", "AMINO_ACID", 104, 114], ["E rns", "GENE_OR_GENE_PRODUCT", 176, 181], ["E1", "GENE_OR_GENE_PRODUCT", 184, 186], ["E2", "GENE_OR_GENE_PRODUCT", 188, 190], ["amino acid", "AMINO_ACID", 208, 218], ["BAC sequence", "DNA", 13, 25], ["cDNA sequence", "DNA", 44, 57], ["N pro , E rns", "PROTEIN", 168, 181], ["E1", "PROTEIN", 184, 186], ["E2", "PROTEIN", 188, 190], ["NS3", "PROTEIN", 195, 198], ["NS5B", "PROTEIN", 236, 240], ["Table 1", "PROTEIN", 242, 249], ["the BAC sequence", "TEST", 9, 25], ["the cDNA sequence", "TEST", 40, 57], ["amino acid substitutions", "PROBLEM", 104, 128], ["the polyprotein", "TREATMENT", 136, 151], ["E1", "TEST", 184, 186], ["E2", "TEST", 188, 190], ["NS3", "TREATMENT", 195, 198], ["four amino acid substitutions", "TREATMENT", 203, 232], ["NS5B", "TEST", 236, 240], ["acid substitutions", "OBSERVATION", 110, 128], ["acid substitutions", "OBSERVATION", 214, 232]]], ["When compared to the published reference sequence (GenBank accession AY259122.1), the pBeloR26 BAC sequence differed at an additional 11 positions, 1 of these lead to a predicted amino acid substitution and there was one large insertion (27 nt) in the hypervariable region of the 3\u2032-UTR (Additional file 2: Table S2 ).Homologous recombination to obtain CSFV E2 chimeric constructsTo determine the utility of the targeted recombinationmediated mutagenesis system for pestiviruses, two different modifications of the E2 protein coding sequence within pBeloR26 were generated using the Red/ET recombination methodology.", [["amino acid", "CHEMICAL", 179, 189], ["E2", "CHEMICAL", 358, 360], ["E2", "CHEMICAL", 515, 517], ["amino acid", "CHEMICAL", 179, 189], ["amino acid", "AMINO_ACID", 179, 189], ["E2", "GENE_OR_GENE_PRODUCT", 515, 517], ["pBeloR26", "GENE_OR_GENE_PRODUCT", 549, 557], ["reference sequence", "DNA", 31, 49], ["pBeloR26 BAC sequence", "DNA", 86, 107], ["hypervariable region", "DNA", 252, 272], ["3\u2032-UTR", "DNA", 280, 286], ["CSFV E2 chimeric constructs", "DNA", 353, 380], ["E2 protein coding sequence", "DNA", 515, 541], ["pBeloR26", "DNA", 549, 557], ["CSFV", "SPECIES", 353, 357], ["the pBeloR26 BAC sequence", "TEST", 82, 107], ["a predicted amino acid substitution", "TREATMENT", 167, 202], ["one large insertion (27 nt) in the hypervariable region", "PROBLEM", 217, 272], ["Homologous recombination", "TREATMENT", 318, 342], ["CSFV E2 chimeric constructs", "TREATMENT", 353, 380], ["pestiviruses", "PROBLEM", 466, 478], ["the E2 protein coding sequence", "TEST", 511, 541], ["the Red/ET recombination methodology", "TREATMENT", 579, 615], ["acid substitution", "OBSERVATION", 185, 202], ["one", "OBSERVATION_MODIFIER", 217, 220], ["large", "OBSERVATION_MODIFIER", 221, 226], ["insertion", "OBSERVATION_MODIFIER", 227, 236], ["hypervariable", "ANATOMY_MODIFIER", 252, 265], ["region", "ANATOMY_MODIFIER", 266, 272]]], ["Initially, the sequence encoding the linear TAV-epitope (TAVSPTTLR) within the CSFV-E2 was substituted with the sequence encoding the corresponding region (encoding TTVSTSTLA) from the BDV strain \"Gifhorn\" as described in the Materials and Methods section.", [["CSFV-E2", "CHEMICAL", 79, 86], ["TAVSPTTLR", "GENE_OR_GENE_PRODUCT", 57, 66], ["CSFV-E2", "GENE_OR_GENE_PRODUCT", 79, 86], ["TTVSTSTLA", "GENE_OR_GENE_PRODUCT", 165, 174], ["BDV", "ORGANISM", 185, 188], ["linear TAV-epitope", "PROTEIN", 37, 55], ["TAVSPTTLR", "PROTEIN", 57, 66], ["TTVSTSTLA", "PROTEIN", 165, 174], ["CSFV", "SPECIES", 79, 83], ["BDV", "SPECIES", 185, 188], ["the linear TAV-epitope (TAVSPTTLR)", "TREATMENT", 33, 67], ["the sequence", "TEST", 108, 120], ["linear", "OBSERVATION_MODIFIER", 37, 43], ["TAV", "OBSERVATION", 44, 47], ["BDV", "ANATOMY", 185, 188]]], ["More than 90% of the colonies obtained using this procedure contained the required BACHomologous recombination to obtain CSFV E2 chimeric constructsAnti-CSFV E2 (WH211) Figure 2 Antibody reaction patterns of pestivirus infected cells.", [["colonies", "ANATOMY", 21, 29], ["cells", "ANATOMY", 228, 233], ["E2", "CHEMICAL", 126, 128], ["E2", "CHEMICAL", 158, 160], ["pestivirus infected", "DISEASE", 208, 227], ["cells", "CELL", 228, 233], ["CSFV E2 chimeric constructs", "DNA", 121, 148], ["pestivirus infected cells", "CELL_TYPE", 208, 233], ["CSFV", "SPECIES", 121, 125], ["CSFV", "SPECIES", 153, 157], ["this procedure", "TREATMENT", 45, 59], ["BACHomologous recombination", "TREATMENT", 83, 110], ["CSFV E2 chimeric constructs", "TREATMENT", 121, 148], ["Anti-CSFV E2", "TEST", 148, 160], ["Figure 2 Antibody reaction", "PROBLEM", 169, 195], ["pestivirus infected cells", "PROBLEM", 208, 233], ["CSFV", "OBSERVATION", 153, 157], ["pestivirus infected cells", "OBSERVATION", 208, 233]]], ["SFT-R cells were infected with vR26 and its two derivatives vR26_E2gif and vR26_TAV plus vGifhorn [26] .", [["SFT-R cells", "ANATOMY", 0, 11], ["SFT-R cells", "CELL", 0, 11], ["vR26", "GENE_OR_GENE_PRODUCT", 31, 35], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 60, 70], ["SFT-R cells", "CELL_LINE", 0, 11], ["vR26_TAV", "PROTEIN", 75, 83], ["SFT", "TEST", 0, 3], ["vR26", "TREATMENT", 31, 35], ["its two derivatives vR26_E2gif", "TREATMENT", 40, 70], ["vR26_TAV", "TREATMENT", 75, 83]]], ["After 72 h, the cells were fixed and stained with monoclonal antibodies against the NS3 protein (WB103/105, left column), the CSFV E2 protein (WH303 and WH211, middle columns) and the BDV E2 protein (WB166, right column) as indicated and viewed using a fluorescence microscope. structure as determined by NotI digestions.", [["cells", "ANATOMY", 16, 21], ["left column", "ANATOMY", 108, 119], ["right column", "ANATOMY", 207, 219], ["E2", "CHEMICAL", 188, 190], ["cells", "CELL", 16, 21], ["NS3", "GENE_OR_GENE_PRODUCT", 84, 87], ["CSFV", "ORGANISM", 126, 130], ["E2", "GENE_OR_GENE_PRODUCT", 131, 133], ["BDV", "ORGANISM", 184, 187], ["E2", "GENE_OR_GENE_PRODUCT", 188, 190], ["NotI", "GENE_OR_GENE_PRODUCT", 305, 309], ["monoclonal antibodies", "PROTEIN", 50, 71], ["NS3 protein", "PROTEIN", 84, 95], ["WB103", "PROTEIN", 97, 102], ["CSFV E2 protein", "PROTEIN", 126, 141], ["WH303", "PROTEIN", 143, 148], ["WH211", "PROTEIN", 153, 158], ["middle columns", "PROTEIN", 160, 174], ["BDV E2 protein", "PROTEIN", 184, 198], ["WB166", "PROTEIN", 200, 205], ["CSFV", "SPECIES", 126, 130], ["BDV", "SPECIES", 184, 187], ["the cells", "TEST", 12, 21], ["monoclonal antibodies", "TEST", 50, 71], ["the NS3 protein", "TEST", 80, 95], ["left column", "TEST", 108, 119], ["the CSFV E2 protein", "TEST", 122, 141], ["middle columns", "TEST", 160, 174], ["the BDV E2 protein", "TEST", 180, 198], ["a fluorescence microscope", "TEST", 251, 276], ["left column", "ANATOMY", 108, 119], ["middle columns", "ANATOMY", 160, 174], ["right", "ANATOMY_MODIFIER", 207, 212]]], ["The complete genome sequences of the CSFV cDNA within two selected BACs, designated pBeloR26_TAV have been verified (data not shown).", [["BACs", "ANATOMY", 67, 71], ["CSFV", "ORGANISM", 37, 41], ["BACs", "CELL", 67, 71], ["pBeloR26_TAV", "GENE_OR_GENE_PRODUCT", 84, 96], ["CSFV cDNA", "DNA", 37, 46], ["BACs", "DNA", 67, 71], ["pBeloR26_TAV", "DNA", 84, 96], ["CSFV", "SPECIES", 37, 41], ["CSFV", "SPECIES", 37, 41], ["the CSFV cDNA", "TEST", 33, 46]]], ["In addition, the complete coding sequence (1119 nt) for the CSFV-E2 protein was substituted by the corresponding sequence from BDV \"Gifhorn\".", [["E2", "CHEMICAL", 65, 67], ["CSFV-E2", "GENE_OR_GENE_PRODUCT", 60, 67], ["BDV", "ORGANISM", 127, 130], ["coding sequence", "DNA", 26, 41], ["1119 nt", "DNA", 43, 50], ["CSFV-E2 protein", "PROTEIN", 60, 75], ["CSFV", "SPECIES", 60, 64], ["BDV", "SPECIES", 127, 130], ["the CSFV-E2 protein", "TEST", 56, 75]]], ["Again more than 90% of the colonies obtained contained the required BAC and the same proportion of correctly recombined BACs was obtained using either 30 nt or 50 nt homology arms.", [["colonies", "ANATOMY", 27, 35], ["BACs", "ANATOMY", 120, 124], ["BAC", "CELLULAR_COMPONENT", 68, 71], ["BACs", "CELL", 120, 124], ["BAC", "DNA", 68, 71], ["recombined BACs", "DNA", 109, 124], ["30 nt or 50 nt homology arms", "DNA", 151, 179], ["the colonies", "TEST", 23, 35], ["BAC", "TREATMENT", 68, 71]]], ["The chimeric BAC was designated, pBeloR26_E2gif and the complete virus genome sequence (cDNA) was verified (data not shown).Rescue of modified virus from recombined BACsAfter electroporation with RNA transcripts derived from either pBeloR26_TAV or pBeloR26_E2gif a large number of CSFV NS3-positive cells could be observed (data not shown) and chimeric virus stocks, termed vR26_TAV and vR26_E2gif, were generated after further passages in cells.", [["cells", "ANATOMY", 299, 304], ["cells", "ANATOMY", 440, 445], ["pBeloR26_E2gif", "GENE_OR_GENE_PRODUCT", 33, 47], ["BACsAfter", "GENE_OR_GENE_PRODUCT", 165, 174], ["pBeloR26_TAV", "GENE_OR_GENE_PRODUCT", 232, 244], ["pBeloR26_E2gif", "GENE_OR_GENE_PRODUCT", 248, 262], ["CSFV", "ORGANISM", 281, 285], ["NS3", "GENE_OR_GENE_PRODUCT", 286, 289], ["cells", "CELL", 299, 304], ["vR26_TAV", "GENE_OR_GENE_PRODUCT", 374, 382], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 387, 397], ["cells", "CELL", 440, 445], ["chimeric BAC", "DNA", 4, 16], ["pBeloR26_E2gif", "DNA", 33, 47], ["complete virus genome sequence", "DNA", 56, 86], ["cDNA", "DNA", 88, 92], ["RNA transcripts", "RNA", 196, 211], ["pBeloR26_TAV", "PROTEIN", 232, 244], ["CSFV NS3-positive cells", "CELL_LINE", 281, 304], ["vR26_TAV", "DNA", 374, 382], ["vR26_E2gif", "DNA", 387, 397], ["CSFV", "SPECIES", 281, 285], ["modified virus", "PROBLEM", 134, 148], ["recombined BACsAfter electroporation", "TREATMENT", 154, 190], ["RNA transcripts", "TREATMENT", 196, 211], ["CSFV NS3", "TEST", 281, 289], ["positive cells", "PROBLEM", 290, 304], ["chimeric virus stocks", "PROBLEM", 344, 365], ["further passages in cells", "PROBLEM", 420, 445], ["large", "OBSERVATION_MODIFIER", 265, 270]]], ["Cells infected with these viruses and with the parental vR26 and vGifhorn strains were all stained with mAbs directed against the NS3 protein ( Figure 2 ).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["vR26", "GENE_OR_GENE_PRODUCT", 56, 60], ["vGifhorn strains", "ORGANISM", 65, 81], ["mAbs", "PROTEIN", 104, 108], ["NS3 protein", "PROTEIN", 130, 141], ["these viruses", "PROBLEM", 20, 33], ["the parental vR26", "TEST", 43, 60], ["vGifhorn strains", "PROBLEM", 65, 81], ["mAbs", "TREATMENT", 104, 108], ["the NS3 protein", "TEST", 126, 141], ["viruses", "OBSERVATION", 26, 33]]], ["However, in contrast to the parental vR26 virus, the chimeric viruses rescued from the recombined BACs were not recognized by anti-E2 mAbs specific for the CSFV-E2 proteins ( Figure 2 ) and thus, consistent with their structure, displayed the same antibody reaction pattern as vGifhorn.", [["BACs", "ANATOMY", 98, 102], ["E2", "CHEMICAL", 131, 133], ["vR26 virus", "ORGANISM", 37, 47], ["chimeric viruses", "ORGANISM", 53, 69], ["BACs", "CELL", 98, 102], ["anti-E2 mAbs", "GENE_OR_GENE_PRODUCT", 126, 138], ["CSFV-E2", "GENE_OR_GENE_PRODUCT", 156, 163], ["recombined BACs", "DNA", 87, 102], ["anti-E2 mAbs", "PROTEIN", 126, 138], ["CSFV-E2 proteins", "PROTEIN", 156, 172], ["vGifhorn", "PROTEIN", 277, 285], ["vR26 virus", "SPECIES", 37, 47], ["CSFV", "SPECIES", 156, 160], ["the chimeric viruses", "PROBLEM", 49, 69], ["anti-E2 mAbs", "TREATMENT", 126, 138], ["the CSFV-E2 proteins", "TEST", 152, 172], ["the same antibody reaction pattern", "PROBLEM", 239, 273], ["consistent with", "UNCERTAINTY", 196, 211]]], ["Two different anti-CSFV E2 mAbs, WH211 and WH303, were used for the staining and the latter has been shown previously to target the TAV-epitope [18] .", [["E2", "CHEMICAL", 24, 26], ["WH211", "SIMPLE_CHEMICAL", 33, 38], ["anti-CSFV E2 mAbs", "PROTEIN", 14, 31], ["WH211", "PROTEIN", 33, 38], ["WH303", "PROTEIN", 43, 48], ["TAV", "PROTEIN", 132, 135], ["Two different anti-CSFV E2 mAbs", "TREATMENT", 0, 31], ["the staining", "TEST", 64, 76]]], ["As anticipated, cells infected with either the vGifhorn or with the chimeric vR26_E2gif could be shown to express the \"Gifhorn\" E2 protein using staining with an anti-BDV mAb ( Figure 2 ).", [["cells", "ANATOMY", 16, 21], ["E2", "CHEMICAL", 128, 130], ["cells", "CELL", 16, 21], ["vGifhorn", "GENE_OR_GENE_PRODUCT", 47, 55], ["vR26_", "GENE_OR_GENE_PRODUCT", 77, 82], ["E2gif", "GENE_OR_GENE_PRODUCT", 82, 87], ["E2", "GENE_OR_GENE_PRODUCT", 128, 130], ["vGifhorn", "DNA", 47, 55], ["chimeric vR26_", "PROTEIN", 68, 82], ["E2gif", "PROTEIN", 82, 87], ["Gifhorn\" E2 protein", "PROTEIN", 119, 138], ["anti-BDV mAb", "PROTEIN", 162, 174], ["an anti-BDV mAb", "TREATMENT", 159, 174]]], ["The presence of the BDV epitope TTVSTSTLA in vR26_ TAV was insufficient to permit efficient recognition by this anti-BDV mab, although a weak signal was observed in some cells.Genetic stability of the BACs in the bacterial hostThe BAC constructs pBeloR26 and pBeloR26_E2gif were analysed for the genetic stability of the cDNA to determine the suitability of the BAC vector for maintaining full-length pestivirus cDNAs.", [["cells", "ANATOMY", 170, 175], ["BDV", "ORGANISM", 20, 23], ["vR26_ TAV", "ORGANISM", 45, 54], ["mab", "GENE_OR_GENE_PRODUCT", 121, 124], ["cells", "CELL", 170, 175], ["BACs", "CELLULAR_COMPONENT", 201, 205], ["pBeloR26", "GENE_OR_GENE_PRODUCT", 246, 254], ["pBeloR26_E2gif", "GENE_OR_GENE_PRODUCT", 259, 273], ["BDV epitope", "PROTEIN", 20, 31], ["TTVSTSTLA", "PROTEIN", 32, 41], ["vR26_ TAV", "PROTEIN", 45, 54], ["anti-BDV mab", "PROTEIN", 112, 124], ["BACs", "DNA", 201, 205], ["BAC constructs", "DNA", 231, 245], ["pBeloR26", "DNA", 246, 254], ["pBeloR26_E2gif", "DNA", 259, 273], ["cDNA", "DNA", 321, 325], ["BAC vector", "DNA", 362, 372], ["full-length pestivirus cDNAs", "DNA", 389, 417], ["BDV", "SPECIES", 20, 23], ["anti-BDV", "SPECIES", 112, 120], ["the BDV epitope TTVSTSTLA in vR26_ TAV", "TREATMENT", 16, 54], ["this anti-BDV mab", "TREATMENT", 107, 124], ["a weak signal", "PROBLEM", 135, 148], ["the BACs in the bacterial host", "PROBLEM", 197, 227], ["pBeloR26_E2gif", "TREATMENT", 259, 273], ["the BAC vector", "TREATMENT", 358, 372], ["full-length pestivirus cDNAs", "TREATMENT", 389, 417], ["BDV epitope", "OBSERVATION", 20, 31], ["some cells", "OBSERVATION", 165, 175], ["stability", "OBSERVATION_MODIFIER", 184, 193], ["bacterial host", "OBSERVATION_MODIFIER", 213, 227]]], ["E. coli DH10B cells containing the BACs were passaged 15 times, by overnight growth, and the complete viral cDNAs within the BACs were sequenced after the 1st and the 15th passage.", [["cells", "ANATOMY", 14, 19], ["BACs", "ANATOMY", 35, 39], ["BACs", "ANATOMY", 125, 129], ["E. coli", "ORGANISM", 0, 7], ["DH10B cells", "CELL", 8, 19], ["BACs", "CELL", 35, 39], ["BACs", "CELL", 125, 129], ["DH10B cells", "CELL_LINE", 8, 19], ["BACs", "DNA", 35, 39], ["viral cDNAs", "DNA", 102, 113], ["BACs", "DNA", 125, 129], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli DH10B cells", "PROBLEM", 0, 19], ["the BACs", "TEST", 31, 39], ["the complete viral cDNAs within the BACs", "PROBLEM", 89, 129], ["coli DH10B cells", "OBSERVATION", 3, 19], ["viral cDNAs", "OBSERVATION", 102, 113]]], ["No mutations were observed within the 12316 nt virus cDNA sequences after this extensive propagation of the BACs in the bacterial host, indicating a highly stable system for the maintenance of complete pestivirus cDNA sequences.Genetic stability of viruses rescued from the BACsThe viruses, vR26 and vR26_E2gif, rescued from their respective BAC constructs, were also tested for their genetic stability within mammalian cells.", [["BACs", "ANATOMY", 108, 112], ["cells", "ANATOMY", 420, 425], ["BACs", "CELLULAR_COMPONENT", 108, 112], ["vR26", "GENE_OR_GENE_PRODUCT", 291, 295], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 300, 310], ["mammalian cells", "CELL", 410, 425], ["12316 nt virus cDNA sequences", "DNA", 38, 67], ["BACs", "DNA", 108, 112], ["pestivirus cDNA sequences", "DNA", 202, 227], ["BACs", "DNA", 274, 278], ["vR26", "DNA", 291, 295], ["vR26_E2gif", "DNA", 300, 310], ["BAC constructs", "DNA", 342, 356], ["mammalian cells", "CELL_TYPE", 410, 425], ["pestivirus", "SPECIES", 202, 212], ["mutations", "PROBLEM", 3, 12], ["the 12316 nt virus cDNA sequences", "TREATMENT", 34, 67], ["the BACs in the bacterial host", "PROBLEM", 104, 134], ["complete pestivirus cDNA sequences", "TEST", 193, 227], ["Genetic stability of viruses", "PROBLEM", 228, 256], ["The viruses", "TEST", 278, 289], ["vR26", "TEST", 291, 295], ["vR26_E2gif", "TEST", 300, 310], ["mutations", "OBSERVATION", 3, 12], ["bacterial host", "OBSERVATION", 120, 134], ["highly", "OBSERVATION_MODIFIER", 149, 155], ["stable", "OBSERVATION", 156, 162], ["stability", "OBSERVATION_MODIFIER", 236, 245], ["viruses", "OBSERVATION", 249, 256], ["viruses", "OBSERVATION", 282, 289], ["mammalian cells", "OBSERVATION", 410, 425]]], ["Linearized BAC DNA was transcribed in vitro and the RNA was electroporated into PK15 cells.", [["PK15 cells", "ANATOMY", 80, 90], ["BAC", "CELLULAR_COMPONENT", 11, 14], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["PK15 cells", "CELL", 80, 90], ["BAC DNA", "DNA", 11, 18], ["PK15 cells", "CELL_LINE", 80, 90], ["Linearized BAC DNA", "PROBLEM", 0, 18], ["BAC DNA", "OBSERVATION", 11, 18], ["PK15 cells", "OBSERVATION", 80, 90]]], ["Three days after electroporation the cells were stained with the anti-NS3 antibody to detect the presence of replicating virus.", [["cells", "ANATOMY", 37, 42], ["cells", "CELL", 37, 42], ["anti-NS3", "GENE_OR_GENE_PRODUCT", 65, 73], ["anti-NS3 antibody", "PROTEIN", 65, 82], ["electroporation the cells", "TREATMENT", 17, 42], ["the anti-NS3 antibody", "TEST", 61, 82], ["replicating virus", "PROBLEM", 109, 126], ["replicating virus", "OBSERVATION", 109, 126]]], ["Samples containing virus positive cells were passaged onto new cells, this processT A A*Nt position 10665 in vR26/P-12 is reverted from A to G as in the parental cDNA.T A Awas repeated for 12 separate passages (each of three days).", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 63, 68], ["cells", "CELL", 34, 39], ["cells", "CELL", 63, 68], ["A to G", "GENE_OR_GENE_PRODUCT", 136, 142], ["virus positive cells", "CELL_TYPE", 19, 39], ["processT A A*Nt position 10665", "DNA", 75, 105], ["vR26/P-12", "DNA", 109, 118], ["parental cDNA", "DNA", 153, 166], ["Samples containing virus positive cells", "PROBLEM", 0, 39], ["virus positive cells", "OBSERVATION", 19, 39]]], ["The virus titre (as TCID 50 /ml) was determined for each passage.", [["The virus titre", "TREATMENT", 0, 15], ["virus titre", "OBSERVATION", 4, 15]]], ["Passage of the rescued vR26_E2gif chimeric virus in PK15 cells resulted in rapidly decreasing virus titres and was discontinued after the 2nd passage ( Figure 4A ).", [["PK15 cells", "ANATOMY", 52, 62], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 23, 33], ["PK15 cells", "CELL", 52, 62], ["vR26_E2gif", "PROTEIN", 23, 33], ["PK15 cells", "CELL_LINE", 52, 62], ["the rescued vR26_E2gif chimeric virus in PK15 cells", "TREATMENT", 11, 62], ["rapidly decreasing virus titres", "PROBLEM", 75, 106], ["rapidly", "OBSERVATION_MODIFIER", 75, 82], ["decreasing", "OBSERVATION_MODIFIER", 83, 93], ["virus titres", "OBSERVATION", 94, 106]]], ["Instead, further passage of this chimeric virus was performed in ovine SFT-R cells (the preferred cell type for BDV) and resulted in much higher titers of the chimeric virus.", [["SFT-R cells", "ANATOMY", 71, 82], ["cell", "ANATOMY", 98, 102], ["ovine", "ORGANISM", 65, 70], ["SFT-R cells", "CELL", 71, 82], ["cell type", "CELL", 98, 107], ["BDV", "ORGANISM", 112, 115], ["chimeric virus", "ORGANISM", 159, 173], ["ovine SFT-R cells", "CELL_LINE", 65, 82], ["BDV", "SPECIES", 112, 115], ["this chimeric virus", "PROBLEM", 28, 47], ["BDV", "PROBLEM", 112, 115], ["the chimeric virus", "PROBLEM", 155, 173], ["chimeric virus", "OBSERVATION", 159, 173]]], ["Virus titers reached more than 10 6 TCID 50 /ml after the 1st passage and remained stable for 12 passages ( Figure 4A ).", [["Virus", "ORGANISM", 0, 5], ["Virus titers", "TEST", 0, 12], ["stable", "OBSERVATION", 83, 89]]], ["The rescued vR26 was also efficiently propagated on the SFT-R cells but maintained a slightly lower titer than the vR26_E2gif chimeric virus ( Figure 4A ).T A ATo check that the viruses retained their antibody reaction properties ( Figure 2 ) after these passages, cells were infected with viruses from the 12th SFT-R cell culture passage (termed vR26/P-12 and vR26_E2gif/P-12) and stained with a polyclonal anti-pestivirus serum and with specific mAbs directed against the CSFV-E2 and BDV-E2 proteins ( Figure 4B ).", [["SFT-R cells", "ANATOMY", 56, 67], ["cells", "ANATOMY", 265, 270], ["SFT-R cell", "ANATOMY", 312, 322], ["serum", "ANATOMY", 424, 429], ["vR26", "GENE_OR_GENE_PRODUCT", 12, 16], ["SFT-R cells", "CELL", 56, 67], ["vR26_E2gif chimeric virus", "ORGANISM", 115, 140], ["cells", "CELL", 265, 270], ["SFT-R cell", "CELL", 312, 322], ["serum", "ORGANISM_SUBSTANCE", 424, 429], ["CSFV-E2", "ORGANISM", 474, 481], ["BDV-E2", "GENE_OR_GENE_PRODUCT", 486, 492], ["vR26", "PROTEIN", 12, 16], ["SFT-R cells", "CELL_LINE", 56, 67], ["P", "DNA", 352, 353], ["vR26_E2gif", "DNA", 361, 371], ["P-12", "DNA", 372, 376], ["mAbs", "PROTEIN", 448, 452], ["CSFV-E2 and BDV-E2 proteins", "PROTEIN", 474, 501], ["Figure 4B", "PROTEIN", 504, 513], ["CSFV", "SPECIES", 474, 478], ["BDV", "SPECIES", 486, 489], ["a slightly lower titer", "PROBLEM", 83, 105], ["A ATo check", "TEST", 157, 168], ["the viruses", "PROBLEM", 174, 185], ["their antibody reaction properties", "PROBLEM", 195, 229], ["these passages, cells", "PROBLEM", 249, 270], ["viruses", "PROBLEM", 290, 297], ["the 12th SFT", "TEST", 303, 315], ["vR26", "TEST", 347, 351], ["P", "TEST", 352, 353], ["vR26_E2gif/P", "TEST", 361, 373], ["a polyclonal anti-pestivirus serum", "TEST", 395, 429], ["specific mAbs", "TEST", 439, 452], ["the CSFV", "TEST", 470, 478], ["BDV", "TEST", 486, 489], ["slightly", "OBSERVATION_MODIFIER", 85, 93], ["viruses", "OBSERVATION", 178, 185]]], ["Cells infected with either the vR26/P-12 or the chimeric vR26_E2gif/P-12 were each detected by the polyclonal anti-pestivirus serum as expected.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 126, 131], ["Cells", "CELL", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["vR26/P-12", "DNA", 31, 40], ["chimeric vR26_E2gif/P-12", "DNA", 48, 72], ["anti-pestivirus", "SPECIES", 110, 125], ["Cells infected", "PROBLEM", 0, 14], ["the vR26", "TEST", 27, 35], ["the chimeric vR26_E2gif/P", "TEST", 44, 69], ["the polyclonal anti-pestivirus serum", "TEST", 95, 131]]], ["The anti-CSFV-E2 mAb specifically detected cells infected with vR26/P-12 but not cells infected by the chimeric virus containing the BDV-E2 protein (consistent with the results shown in Figure 2 ).", [["cells", "ANATOMY", 43, 48], ["vR26/P-12", "ANATOMY", 63, 72], ["cells", "ANATOMY", 81, 86], ["anti-CSFV-E2", "CHEMICAL", 4, 16], ["anti-CSFV-E2", "GENE_OR_GENE_PRODUCT", 4, 16], ["cells", "CELL", 43, 48], ["vR26/P-12", "CELL", 63, 72], ["cells", "CELL", 81, 86], ["chimeric virus", "ORGANISM", 103, 117], ["BDV-E2", "GENE_OR_GENE_PRODUCT", 133, 139], ["anti-CSFV", "PROTEIN", 4, 13], ["E2 mAb", "PROTEIN", 14, 20], ["BDV-E2 protein", "PROTEIN", 133, 147], ["BDV", "SPECIES", 133, 136], ["The anti-CSFV-E2 mAb", "TEST", 0, 20], ["vR26", "TEST", 63, 67], ["cells infected", "PROBLEM", 81, 95], ["the chimeric virus", "PROBLEM", 99, 117], ["the BDV-E2 protein", "TEST", 129, 147]]], ["In contrast, the anti-BDV-E2 mAb specifically detected infection by the vR26_E2gif/P-12 and did not recognize cells infected with vR26/P-12.", [["cells", "ANATOMY", 110, 115], ["anti-BDV-E2", "CHEMICAL", 17, 28], ["infection", "DISEASE", 55, 64], ["anti-BDV-E2", "GENE_OR_GENE_PRODUCT", 17, 28], ["cells", "CELL", 110, 115], ["anti-BDV", "PROTEIN", 17, 25], ["E2 mAb", "PROTEIN", 26, 32], ["vR26_E2gif/P-12", "DNA", 72, 87], ["vR26/P", "PROTEIN", 130, 136], ["the anti-BDV-E2 mAb", "TEST", 13, 32], ["infection", "PROBLEM", 55, 64], ["the vR26_E2gif/P", "TEST", 68, 84], ["vR26/P", "TEST", 130, 136], ["infection", "OBSERVATION", 55, 64]]], ["Each result is in accord with the structure of the viruses.", [["viruses", "OBSERVATION", 51, 58]]], ["The 4th passage of vR26 (vR26/P-4) displayed a slower growth rate than the virus obtained after 12 passages (see Figure 5A ).", [["vR26/P-4", "ANATOMY", 25, 33], ["vR26", "GENE_OR_GENE_PRODUCT", 19, 23], ["vR26", "DNA", 19, 23], ["vR26", "TEST", 19, 23], ["a slower growth rate", "PROBLEM", 45, 65], ["the virus", "PROBLEM", 71, 80]]], ["It also had a reduced growth rate compared to both the vR26_E2gif/P-4 and vR26_E2gif/P-12.", [["vR26_E2gif", "DNA", 55, 65], ["P", "DNA", 66, 67], ["vR26_E2gif", "DNA", 74, 84], ["P-12", "DNA", 85, 89], ["a reduced growth rate", "PROBLEM", 12, 33], ["reduced", "OBSERVATION_MODIFIER", 14, 21], ["growth", "OBSERVATION_MODIFIER", 22, 28]]], ["The fulllength sequence of pBeloR26 had revealed ten non-silent mutations compared to the reference sequence (AY25 9122.1) for this virus (Additional file 2: Table S2 ).", [["pBeloR26", "GENE_OR_GENE_PRODUCT", 27, 35], ["fulllength sequence", "DNA", 4, 23], ["pBeloR26", "DNA", 27, 35], ["The fulllength sequence of pBeloR26", "TEST", 0, 35], ["ten non-silent mutations", "PROBLEM", 49, 73], ["this virus", "PROBLEM", 127, 137]]], ["Any of these mutations could be responsible for the impaired growth acting alone or in concert.", [["these mutations", "PROBLEM", 7, 22]]], ["For further investigation of this issue, full length cDNAs prepared from vR26/ P-4, vR26/P-12, vR26_E2gif/P-4 and vR26_E2gif/P-12 were deep-sequenced using both the 454 FLX and Ion PGM platforms for comparison and to determine the quasispecies distribution (Additional file 3: Figure S1 and Additional file 4: Figure S2 ).", [["vR26/ P-4", "ORGANISM", 73, 82], ["vR26", "GENE_OR_GENE_PRODUCT", 84, 88], ["cDNAs", "DNA", 53, 58], ["vR26", "DNA", 73, 77], ["P", "DNA", 79, 80], ["vR26", "DNA", 84, 88], ["P", "DNA", 89, 90], ["vR26_", "DNA", 95, 100], ["E2gif", "DNA", 100, 105], ["P", "DNA", 106, 107], ["vR26_E2gif", "DNA", 114, 124], ["P-12", "DNA", 125, 129], ["454 FLX and Ion PGM platforms", "DNA", 165, 194], ["vR26", "TEST", 84, 88], ["P", "TEST", 89, 90], ["vR26_", "TEST", 95, 100], ["E2gif", "TEST", 100, 105], ["P", "TEST", 106, 107], ["vR26_E2gif/P", "TEST", 114, 126], ["Ion PGM platforms", "TEST", 177, 194]]], ["Sequencing data from both platforms revealed that both the vR26/P-12 and vR26_E2gif/P-12 were close to 100% changed at nt position A10665G compared to the BAC clones (resulting in the predicted amino acid substitution D3431G within the NS5B protein, the RNAdependent RNA polymerase, see Figure 5B ).", [["amino acid", "CHEMICAL", 194, 204], ["amino acid", "CHEMICAL", 194, 204], ["vR26/P-12", "GENE_OR_GENE_PRODUCT", 59, 68], ["amino acid", "AMINO_ACID", 194, 204], ["vR26", "DNA", 59, 63], ["/P", "DNA", 63, 65], ["vR26_E2gif", "DNA", 73, 83], ["P", "DNA", 84, 85], ["BAC clones", "DNA", 155, 165], ["NS5B protein", "PROTEIN", 236, 248], ["RNAdependent RNA polymerase", "PROTEIN", 254, 281], ["Sequencing data", "TEST", 0, 15], ["vR26_E2gif/P", "TEST", 73, 85], ["the BAC clones", "PROBLEM", 151, 165], ["the predicted amino acid substitution", "TREATMENT", 180, 217], ["the NS5B protein", "TREATMENT", 232, 248], ["the RNAdependent RNA polymerase", "TREATMENT", 250, 281]]], ["This adaptation is a reversion back to the consensus cDNA sequence of the parental vaccine virus, vRiemser (Additional file 2: Table S2 ).", [["consensus cDNA sequence", "DNA", 43, 66], ["the parental vaccine virus", "TREATMENT", 70, 96]]], ["Additionally, vR26/P-4 and vR26_E2gif/P-4 already showed evidence for this reversion being present within the population.", [["vR26", "DNA", 14, 18], ["P", "DNA", 19, 20], ["vR26_E2gif", "DNA", 27, 37], ["P", "DNA", 38, 39], ["vR26", "TEST", 14, 18], ["P", "TEST", 19, 20], ["vR26_E2gif/P", "TEST", 27, 39], ["this reversion", "PROBLEM", 70, 84], ["evidence for", "UNCERTAINTY", 57, 69]]], ["For vR26/P-4, the level of reversion was 57%, while for vR26_E2gif/P-4 the extent of change was 73% (see Figure 5B ).DiscussionIn this study, we have established the first BAC containing the full-length cDNA of a CSFV vaccine strain.", [["CSFV", "ORGANISM", 213, 217], ["vR26", "DNA", 4, 8], ["P", "DNA", 9, 10], ["vR26_E2gif", "PROTEIN", 56, 66], ["P", "DNA", 67, 68], ["BAC", "DNA", 172, 175], ["full-length cDNA", "DNA", 191, 207], ["CSFV", "SPECIES", 213, 217], ["vR26", "TEST", 4, 8], ["vR26_E2gif/P", "TEST", 56, 68], ["this study", "TEST", 130, 140], ["a CSFV vaccine strain", "TREATMENT", 211, 232], ["CSFV", "OBSERVATION", 213, 217]]], ["The BAC differed from the parental cDNA sequence in 18 positions leading to 9 aa substitutions ( Table 1 ).", [["BAC", "CELLULAR_COMPONENT", 4, 7], ["BAC", "DNA", 4, 7], ["parental cDNA sequence", "DNA", 26, 48], ["the parental cDNA sequence", "TEST", 22, 48]]], ["The method that has been used for the generation of pBeloR26 is based on full genome amplification of cDNA followed by direct cloning to obtain the BACs [11] .", [["pBeloR26", "GENE_OR_GENE_PRODUCT", 52, 60], ["pBeloR26", "DNA", 52, 60], ["cDNA", "DNA", 102, 106], ["The method", "TREATMENT", 0, 10], ["the generation of pBeloR26", "TREATMENT", 34, 60]]], ["This approach results in cDNA clones that reflect the quasispecies composition of the parental viral RNA and thus it is not guaranteed to obtain cDNA clones corresponding to the consensus sequence of the cDNA used.", [["cDNA clones", "CELL", 25, 36], ["cDNA clones", "DNA", 25, 36], ["parental viral RNA", "RNA", 86, 104], ["cDNA clones", "DNA", 145, 156], ["consensus sequence", "DNA", 178, 196], ["cDNA", "DNA", 204, 208], ["cDNA clones", "PROBLEM", 25, 36], ["the parental viral RNA", "PROBLEM", 82, 104], ["cDNA clones", "PROBLEM", 145, 156], ["quasispecies", "OBSERVATION", 54, 66], ["viral RNA", "OBSERVATION", 95, 104]]], ["However, it is possible to correct the mutations using the BAC recombination approach if a consensus clone is needed.", [["BAC", "CELLULAR_COMPONENT", 59, 62], ["clone", "CELL", 101, 106], ["consensus clone", "DNA", 91, 106], ["the mutations", "PROBLEM", 35, 48], ["the BAC recombination approach", "TREATMENT", 55, 85], ["a consensus clone", "PROBLEM", 89, 106]]], ["To demonstrate the utility of the Red/ET mediated recombination method we have generated a series of modified BACs derived from this CSFV full-length cDNA.", [["BACs", "CELL", 110, 114], ["CSFV", "ORGANISM", 133, 137], ["modified BACs", "DNA", 101, 114], ["CSFV full-length cDNA", "DNA", 133, 154], ["CSFV", "SPECIES", 133, 137], ["the Red/ET mediated recombination method", "TREATMENT", 30, 70], ["modified BACs", "TREATMENT", 101, 114], ["this CSFV full-length cDNA", "TREATMENT", 128, 154]]], ["These include BACs with substitution of the linear TAV-epitope present in the E2 protein and also BACs with substitution of the complete E2 protein with heterologous pestivirus sequences.", [["E2", "CHEMICAL", 78, 80], ["E2", "CHEMICAL", 137, 139], ["E2", "GENE_OR_GENE_PRODUCT", 78, 80], ["E2", "GENE_OR_GENE_PRODUCT", 137, 139], ["linear TAV-epitope", "PROTEIN", 44, 62], ["E2 protein", "PROTEIN", 78, 88], ["E2 protein", "PROTEIN", 137, 147], ["heterologous pestivirus sequences", "DNA", 153, 186], ["substitution", "TREATMENT", 24, 36], ["the linear TAV", "TREATMENT", 40, 54], ["the E2 protein", "TEST", 74, 88], ["the complete E2 protein", "TEST", 124, 147], ["heterologous pestivirus sequences", "PROBLEM", 153, 186], ["linear", "OBSERVATION_MODIFIER", 44, 50], ["TAV", "OBSERVATION", 51, 54]]], ["We have also used the same approach for a range of different targeted modifications within CSFV BACs including specific deletions and substitutions in the 5\u2032UTR of CSFV [24] and for insertions of heterologous reporter sequences into CSFV replicons [25] .", [["BACs", "ANATOMY", 96, 100], ["CSFV", "ORGANISM", 91, 95], ["CSFV BACs", "DNA", 91, 100], ["5\u2032UTR", "DNA", 155, 160], ["heterologous reporter sequences", "DNA", 196, 227], ["CSFV", "SPECIES", 91, 95], ["CSFV", "SPECIES", 164, 168], ["CSFV", "SPECIES", 233, 237], ["the same approach", "TREATMENT", 18, 35], ["a range of different targeted modifications", "TREATMENT", 40, 83], ["CSFV BACs", "TREATMENT", 91, 100], ["specific deletions", "PROBLEM", 111, 129], ["substitutions in the 5\u2032UTR of CSFV", "TREATMENT", 134, 168], ["insertions of heterologous reporter sequences", "TREATMENT", 182, 227], ["CSFV replicons", "TREATMENT", 233, 247]]], ["Using Red/ET recombinationmediated mutagenesis for the targeted design, the work can be expedited and focused, in principal, on any sequence within the viral genome and is not dependent on the use of internal restriction sites.", [["viral genome", "DNA", 152, 164], ["internal restriction sites", "DNA", 200, 226], ["Red/ET recombinationmediated mutagenesis", "TREATMENT", 6, 46], ["internal restriction sites", "TREATMENT", 200, 226], ["viral genome", "OBSERVATION", 152, 164]]], ["The results demonstrate that Red/ ET recombination-mediated mutagenesis of pestivirus BAC cDNAs provides a useful tool for advancing the construction of modified pestiviruses.", [["ET", "GENE_OR_GENE_PRODUCT", 34, 36], ["pestiviruses", "CANCER", 162, 174], ["pestivirus BAC cDNAs", "DNA", 75, 95], ["pestivirus", "SPECIES", 75, 85], ["Red/ ET recombination", "TREATMENT", 29, 50], ["pestivirus BAC cDNAs", "TREATMENT", 75, 95], ["modified pestiviruses", "PROBLEM", 153, 174]]], ["Cells infected with the parental vR26 virus were recognized by the two anti-E2 mAbs (WH211 and WH303) specific for the CSFV-E2 proteins, in contrast cells infected with the modified viruses vR26_TAV and vR26_E2gif, rescued from the recombined BACs, were not detected by these mAbs.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 149, 154], ["BACs", "ANATOMY", 243, 247], ["E2", "CHEMICAL", 76, 78], ["Cells", "CELL", 0, 5], ["vR26 virus", "ORGANISM", 33, 43], ["WH303", "GENE_OR_GENE_PRODUCT", 95, 100], ["CSFV-E2", "GENE_OR_GENE_PRODUCT", 119, 126], ["cells", "CELL", 149, 154], ["vR26_TAV", "GENE_OR_GENE_PRODUCT", 190, 198], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 203, 213], ["BACs", "CELL", 243, 247], ["anti-E2 mAbs", "PROTEIN", 71, 83], ["WH211", "PROTEIN", 85, 90], ["WH303", "PROTEIN", 95, 100], ["CSFV-E2 proteins", "PROTEIN", 119, 135], ["vR26_E2gif", "PROTEIN", 203, 213], ["recombined BACs", "DNA", 232, 247], ["mAbs", "PROTEIN", 276, 280], ["vR26 virus", "SPECIES", 33, 43], ["CSFV", "SPECIES", 119, 123], ["Cells infected", "PROBLEM", 0, 14], ["the parental vR26 virus", "PROBLEM", 20, 43], ["the CSFV-E2 proteins", "TEST", 115, 135], ["the modified viruses vR26_TAV", "TREATMENT", 169, 198], ["vR26_E2gif", "TREATMENT", 203, 213]]], ["Furthermore, as expected, cells infected with the vR26_E2gif were recognized by the anti-BDV mAb (WB166) whereas no staining was observed with this antibody in vR26 infected cells or in cells with vR26_TAV.", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 174, 179], ["cells", "ANATOMY", 186, 191], ["cells", "CELL", 26, 31], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 50, 60], ["BDV", "ORGANISM", 89, 92], ["cells", "CELL", 174, 179], ["cells", "CELL", 186, 191], ["vR26_TAV", "CELL", 197, 205], ["vR26_E2gif", "PROTEIN", 50, 60], ["BDV mAb", "PROTEIN", 89, 96], ["WB166", "PROTEIN", 98, 103], ["vR26 infected cells", "CELL_LINE", 160, 179], ["vR26_TAV", "PROTEIN", 197, 205], ["BDV", "SPECIES", 89, 92], ["cells infected", "PROBLEM", 26, 40], ["the vR26_E2gif", "TREATMENT", 46, 60], ["the anti-BDV mAb", "TEST", 80, 96], ["staining", "PROBLEM", 116, 124], ["this antibody", "TEST", 143, 156], ["vR26 infected cells", "PROBLEM", 160, 179], ["vR26_TAV", "TEST", 197, 205], ["infected cells", "OBSERVATION", 165, 179]]], ["The mAb WH303 recognizes the CSFV TAV-epitope [18] and the difference in 4 aa between the TAV-epitope and the corresponding sequence from BDV strain \"Gifhorn\" is enough to completely abolish the recognition by this mAb.", [["mAb", "GENE_OR_GENE_PRODUCT", 4, 7], ["BDV", "ORGANISM", 138, 141], ["mAb", "GENE_OR_GENE_PRODUCT", 215, 218], ["mAb WH303", "PROTEIN", 4, 13], ["TAV-epitope", "PROTEIN", 90, 101], ["mAb", "PROTEIN", 215, 218], ["CSFV", "SPECIES", 29, 33], ["BDV", "SPECIES", 138, 141], ["The mAb", "TREATMENT", 0, 7], ["the TAV-epitope", "TREATMENT", 86, 101], ["CSFV TAV", "OBSERVATION", 29, 37]]], ["The lack of staining of vR26_TAV infected cells by the WH211 indicated that the TAV-sequence is also important for the epitope recognized by this mAb.", [["cells", "ANATOMY", 42, 47], ["vR26_TAV", "GENE_OR_GENE_PRODUCT", 24, 32], ["cells", "CELL", 42, 47], ["WH211", "GENE_OR_GENE_PRODUCT", 55, 60], ["mAb", "GENE_OR_GENE_PRODUCT", 146, 149], ["vR26_TAV infected cells", "CELL_TYPE", 24, 47], ["WH211", "PROTEIN", 55, 60], ["TAV-sequence", "DNA", 80, 92], ["mAb", "PROTEIN", 146, 149], ["vR26_TAV infected cells", "PROBLEM", 24, 47], ["the TAV-sequence", "TEST", 76, 92], ["the epitope", "PROBLEM", 115, 126], ["this mAb", "TREATMENT", 141, 149], ["infected cells", "OBSERVATION", 33, 47]]], ["Thus, the chimeric pestiviruses, vR26_TAV and vR26_E2gif, containing heterologous E2 sequences can be readily discriminated from the vR26 using specific anti-E2 monoclonal antibodies.", [["E2", "CHEMICAL", 82, 84], ["pestiviruses", "GENE_OR_GENE_PRODUCT", 19, 31], ["vR26_TAV", "GENE_OR_GENE_PRODUCT", 33, 41], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 46, 56], ["E2", "GENE_OR_GENE_PRODUCT", 82, 84], ["vR26", "GENE_OR_GENE_PRODUCT", 133, 137], ["anti-E2", "GENE_OR_GENE_PRODUCT", 153, 160], ["chimeric pestiviruses", "PROTEIN", 10, 31], ["vR26_TAV", "PROTEIN", 33, 41], ["vR26_E2gif", "PROTEIN", 46, 56], ["heterologous E2 sequences", "DNA", 69, 94], ["vR26", "PROTEIN", 133, 137], ["anti-E2 monoclonal antibodies", "PROTEIN", 153, 182], ["the chimeric pestiviruses", "TEST", 6, 31], ["vR26_TAV", "TEST", 33, 41], ["vR26_E2gif", "TREATMENT", 46, 56], ["heterologous E2 sequences", "TEST", 69, 94], ["specific anti-E2 monoclonal antibodies", "TEST", 144, 182]]], ["These new chimeric pestiviruses represents Cstrain based marked vaccine candidates with the characteristics desired for safe and efficacious DIVA vaccines against CSFV.", [["Cstrain", "CHEMICAL", 43, 50], ["CSFV", "ORGANISM", 163, 167], ["DIVA", "SPECIES", 141, 145], ["CSFV", "SPECIES", 163, 167], ["These new chimeric pestiviruses", "PROBLEM", 0, 31], ["Cstrain", "PROBLEM", 43, 50], ["marked vaccine candidates", "TREATMENT", 57, 82], ["safe and efficacious DIVA vaccines", "TREATMENT", 120, 154], ["CSFV", "PROBLEM", 163, 167], ["new", "OBSERVATION_MODIFIER", 6, 9], ["chimeric pestiviruses", "OBSERVATION", 10, 31], ["marked", "OBSERVATION_MODIFIER", 57, 63]]], ["Indeed, vR26_E2gif vaccinated pigs could be efficiently discriminated from C-strain vaccinated pigs and from CSFV infected pigs using CSFV-E2 specific antibody ELISAs (Rasmussen et al., unpublished results).Genetic stability in the bacterial hostNucleotide sequence data for the pBeloR26 showed a number of changes from the published reference sequence for \"C-strain Riems\".", [["CSFV infected", "DISEASE", 109, 122], ["CSFV-E2", "CHEMICAL", 134, 141], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 8, 18], ["pigs", "ORGANISM", 30, 34], ["C-strain", "ORGANISM", 75, 83], ["pigs", "ORGANISM", 95, 99], ["CSFV", "ORGANISM", 109, 113], ["pigs", "ORGANISM", 123, 127], ["CSFV", "ORGANISM", 134, 138], ["pBeloR26", "DNA", 279, 287], ["pigs", "SPECIES", 30, 34], ["pigs", "SPECIES", 95, 99], ["CSFV", "SPECIES", 109, 113], ["pigs", "SPECIES", 123, 127], ["pigs", "SPECIES", 30, 34], ["pigs", "SPECIES", 95, 99], ["CSFV", "SPECIES", 109, 113], ["pigs", "SPECIES", 123, 127], ["CSFV", "SPECIES", 134, 138], ["vR26_E2gif vaccinated pigs", "TREATMENT", 8, 34], ["C-strain vaccinated pigs", "TREATMENT", 75, 99], ["CSFV infected pigs", "TREATMENT", 109, 127], ["CSFV", "TEST", 134, 138], ["E2 specific antibody ELISAs", "TEST", 139, 166], ["Nucleotide sequence data", "TEST", 246, 270], ["the pBeloR26", "TEST", 275, 287], ["stability", "OBSERVATION_MODIFIER", 215, 224]]], ["Some of these differences are present in the cDNA derived from the vaccine stock at a detectable level whereas others may represent low-level variants within the cDNA or errors introduced by the RT-PCR amplification.", [["cDNA", "DNA", 45, 49], ["cDNA", "DNA", 162, 166], ["the vaccine stock", "TREATMENT", 63, 80], ["low-level variants", "PROBLEM", 132, 150], ["the RT-PCR amplification", "TREATMENT", 191, 215], ["may represent", "UNCERTAINTY", 118, 131], ["low-", "OBSERVATION_MODIFIER", 132, 136], ["level variants", "OBSERVATION", 136, 150]]], ["Full-length sequencing revealed that no changes occurred in the cDNA during extensive propagation in E. coli DH10B of the pBeloR26 and the E2chimeric derivative, pBeloR26_E2gif, indicating a very high stability of these BAC-cloned CSFV cDNAs.", [["E. coli", "ORGANISM", 101, 108], ["DH10B", "ORGANISM", 109, 114], ["pBeloR26", "GENE_OR_GENE_PRODUCT", 122, 130], ["pBeloR26_E2gif", "GENE_OR_GENE_PRODUCT", 162, 176], ["CSFV", "ORGANISM", 231, 235], ["cDNA", "DNA", 64, 68], ["pBeloR26", "DNA", 122, 130], ["E2chimeric derivative", "DNA", 139, 160], ["BAC-cloned CSFV cDNAs", "DNA", 220, 241], ["E. coli", "SPECIES", 101, 108], ["E. coli", "SPECIES", 101, 108], ["CSFV", "SPECIES", 231, 235], ["Full-length sequencing", "TEST", 0, 22], ["the cDNA", "PROBLEM", 60, 68], ["the E2chimeric derivative", "TREATMENT", 135, 160], ["pBeloR26_E2gif", "TREATMENT", 162, 176], ["these BAC", "PROBLEM", 214, 223], ["no", "UNCERTAINTY", 37, 39], ["E. coli", "OBSERVATION", 101, 108], ["very", "OBSERVATION_MODIFIER", 191, 195], ["high", "OBSERVATION_MODIFIER", 196, 200], ["stability", "OBSERVATION", 201, 210], ["CSFV cDNAs", "OBSERVATION", 231, 241]]], ["This is essential if this system is to be useful for cloning and sequence manipulation, and contrasts with stability problems encountered with conventional plasmids containing fulllength pestivirus cDNAs [31] .", [["plasmids", "ANATOMY", 156, 164], ["plasmids", "DNA", 156, 164], ["fulllength pestivirus cDNAs", "DNA", 176, 203], ["cloning and sequence manipulation", "TEST", 53, 86], ["stability problems", "PROBLEM", 107, 125], ["conventional plasmids", "TREATMENT", 143, 164], ["fulllength pestivirus cDNAs", "PROBLEM", 176, 203]]], ["The stability of these BACs is consistent with previous reports on the stability of BACs containing other viruses of the family Flaviviridae in E. coli [8, 10] .Genetic stability of rescued virusesExtensive passaging of the rescued vR26 and the chimeric virus derivative, vR26_E2gif, resulted in a change at nucleotide position A10665G (resulting in the predicted aa", [["vR26_E2gif", "CHEMICAL", 272, 282], ["nucleotide", "CHEMICAL", 308, 318], ["nucleotide", "CHEMICAL", 308, 318], ["BACs", "CELLULAR_COMPONENT", 84, 88], ["E. coli", "ORGANISM", 144, 151], ["vR26", "GENE_OR_GENE_PRODUCT", 232, 236], ["chimeric virus derivative", "ORGANISM", 245, 270], ["vR26_E2gif", "GENE_OR_GENE_PRODUCT", 272, 282], ["BACs", "DNA", 23, 27], ["BACs", "DNA", 84, 88], ["vR26", "DNA", 232, 236], ["E. coli", "SPECIES", 144, 151], ["E. coli", "SPECIES", 144, 151], ["rescued viruses", "PROBLEM", 182, 197], ["the rescued vR26", "TREATMENT", 220, 236], ["the chimeric virus derivative", "TREATMENT", 241, 270], ["a change at nucleotide position A10665G", "PROBLEM", 296, 335], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["consistent with", "UNCERTAINTY", 31, 46], ["stability", "OBSERVATION_MODIFIER", 169, 178], ["rescued viruses", "OBSERVATION", 182, 197]]]], "cb91fc4ab4d7aff52357bfc8830954bcacdf5f30": [["In vitro and ex vivo analyses of co-infections with swine influenza and porcine reproductive and respiratory syndrome virusesIntroductionBacterial and viral respiratory diseases are still a major health issue in pigs reared under confined conditions on intensive breeding farms.", [["respiratory", "ANATOMY", 157, 168], ["co-infections", "DISEASE", 33, 46], ["swine influenza", "DISEASE", 52, 67], ["porcine reproductive and respiratory syndrome viruses", "DISEASE", 72, 125], ["viral respiratory diseases", "DISEASE", 151, 177], ["swine influenza", "ORGANISM", 52, 67], ["porcine reproductive and respiratory syndrome viruses", "ORGANISM", 72, 125], ["pigs", "ORGANISM", 212, 216], ["swine", "SPECIES", 52, 57], ["porcine", "SPECIES", 72, 79], ["pigs", "SPECIES", 212, 216], ["swine", "SPECIES", 52, 57], ["porcine reproductive and respiratory syndrome viruses", "SPECIES", 72, 125], ["pigs", "SPECIES", 212, 216], ["co-infections", "PROBLEM", 33, 46], ["swine influenza", "PROBLEM", 52, 67], ["porcine reproductive", "TREATMENT", 72, 92], ["respiratory syndrome viruses", "PROBLEM", 97, 125], ["IntroductionBacterial and viral respiratory diseases", "PROBLEM", 125, 177], ["respiratory syndrome", "OBSERVATION", 97, 117], ["viral", "OBSERVATION_MODIFIER", 151, 156], ["respiratory diseases", "OBSERVATION", 157, 177]]], ["Billions of dollars are spent every year to control these diseases.", [["these diseases", "PROBLEM", 52, 66], ["diseases", "OBSERVATION", 58, 66]]], ["Most often, multiple infectious agents are involved (Bosch et al., 2013; Choi et al., 2003; Fablet et al., 2012a Fablet et al., ,b, 2011 Opriessnig et al., 2011) .", [["multiple", "OBSERVATION_MODIFIER", 12, 20], ["infectious", "OBSERVATION", 21, 31]]], ["In a retrospective analysis of diagnostic data from 2872 cases of respiratory disease in pigs received at the Minnesota Veterinary Diagnostic Laboratory over an 18 month period, authors showed that two or more pathogens were detected in 88.2% of the cases (Choi et al., 2003) .IntroductionRespiratory infectious agents can be divided into primary and secondary pathogens.", [["respiratory", "ANATOMY", 66, 77], ["respiratory disease", "DISEASE", 66, 85], ["pigs", "ORGANISM", 89, 93], ["pigs", "SPECIES", 89, 93], ["pigs", "SPECIES", 89, 93], ["diagnostic data", "TEST", 31, 46], ["respiratory disease", "PROBLEM", 66, 85], ["IntroductionRespiratory infectious agents", "TREATMENT", 277, 318], ["secondary pathogens", "PROBLEM", 351, 370], ["respiratory disease", "OBSERVATION", 66, 85], ["infectious", "OBSERVATION", 301, 311], ["secondary pathogens", "OBSERVATION", 351, 370]]], ["Primary pathogens include bacteria such as Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, and Mycoplasma hyopneumoniae, and viruses including porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza virus (SIV), pseudorabies virus, and porcine circovirus type 2 (Opriessnig et al., 2011) .", [["Bordetella bronchiseptica", "DISEASE", 76, 101], ["Mycoplasma hyopneumoniae", "DISEASE", 107, 131], ["porcine reproductive and respiratory syndrome virus", "DISEASE", 155, 206], ["swine influenza virus (SIV), pseudorabies virus", "DISEASE", 216, 263], ["Actinobacillus pleuropneumoniae", "ORGANISM", 43, 74], ["Bordetella bronchiseptica", "ORGANISM", 76, 101], ["Mycoplasma hyopneumoniae", "ORGANISM", 107, 131], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 155, 206], ["PRRSV", "ORGANISM", 208, 213], ["swine influenza virus", "ORGANISM", 216, 237], ["SIV", "ORGANISM", 239, 242], ["pseudorabies virus", "ORGANISM", 245, 263], ["porcine circovirus type 2", "ORGANISM", 269, 294], ["Actinobacillus pleuropneumoniae", "SPECIES", 43, 74], ["Bordetella bronchiseptica", "SPECIES", 76, 101], ["Mycoplasma hyopneumoniae", "SPECIES", 107, 131], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 155, 206], ["PRRSV", "SPECIES", 208, 213], ["swine influenza virus", "SPECIES", 216, 237], ["pseudorabies virus", "SPECIES", 245, 263], ["porcine circovirus", "SPECIES", 269, 287], ["Actinobacillus pleuropneumoniae", "SPECIES", 43, 74], ["Bordetella bronchiseptica", "SPECIES", 76, 101], ["Mycoplasma hyopneumoniae", "SPECIES", 107, 131], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 155, 206], ["PRRSV", "SPECIES", 208, 213], ["swine influenza virus", "SPECIES", 216, 237], ["SIV", "SPECIES", 239, 242], ["pseudorabies virus", "SPECIES", 245, 263], ["porcine circovirus type 2", "SPECIES", 269, 294], ["Primary pathogens", "PROBLEM", 0, 17], ["bacteria", "PROBLEM", 26, 34], ["Actinobacillus pleuropneumoniae", "PROBLEM", 43, 74], ["Bordetella bronchiseptica", "PROBLEM", 76, 101], ["Mycoplasma hyopneumoniae", "PROBLEM", 107, 131], ["viruses", "PROBLEM", 137, 144], ["porcine reproductive", "PROBLEM", 155, 175], ["respiratory syndrome virus", "PROBLEM", 180, 206], ["PRRSV", "PROBLEM", 208, 213], ["swine influenza virus", "PROBLEM", 216, 237], ["pseudorabies virus", "PROBLEM", 245, 263], ["porcine circovirus type", "TREATMENT", 269, 292], ["Actinobacillus pleuropneumoniae", "OBSERVATION", 43, 74], ["Bordetella bronchiseptica", "OBSERVATION", 76, 101], ["Mycoplasma hyopneumoniae", "OBSERVATION", 107, 131], ["respiratory syndrome", "OBSERVATION", 180, 200]]], ["Other primary pathogens are described but they are rarely encountered or have less impact on porcine health.", [["porcine", "ORGANISM", 93, 100], ["porcine", "SPECIES", 93, 100], ["Other primary pathogens", "PROBLEM", 0, 23], ["primary", "OBSERVATION_MODIFIER", 6, 13], ["pathogens", "OBSERVATION", 14, 23]]], ["Among the secondary pathogens, common bacteria such as Actinobacillus suis, Haemophilus parasuis, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis are frequently reported (Choi et al., 2003; Fablet et al., 2012a Fablet et al., ,b, 2011 Opriessnig et al., 2011) .", [["Haemophilus parasuis", "DISEASE", 76, 96], ["Streptococcus suis", "DISEASE", 150, 168], ["Actinobacillus suis", "ORGANISM", 55, 74], ["Haemophilus parasuis", "ORGANISM", 76, 96], ["Pasteurella multocida", "ORGANISM", 98, 119], ["Salmonella choleraesuis", "ORGANISM", 121, 144], ["Streptococcus suis", "ORGANISM", 150, 168], ["Actinobacillus suis", "SPECIES", 55, 74], ["Haemophilus parasuis", "SPECIES", 76, 96], ["Pasteurella multocida", "SPECIES", 98, 119], ["Salmonella choleraesuis", "SPECIES", 121, 144], ["Streptococcus suis", "SPECIES", 150, 168], ["Actinobacillus suis", "SPECIES", 55, 74], ["Haemophilus parasuis", "SPECIES", 76, 96], ["Pasteurella multocida", "SPECIES", 98, 119], ["Salmonella choleraesuis", "SPECIES", 121, 144], ["Streptococcus suis", "SPECIES", 150, 168], ["the secondary pathogens", "PROBLEM", 6, 29], ["common bacteria", "PROBLEM", 31, 46], ["Actinobacillus suis", "PROBLEM", 55, 74], ["Haemophilus parasuis", "PROBLEM", 76, 96], ["Pasteurella multocida", "PROBLEM", 98, 119], ["Salmonella choleraesuis", "PROBLEM", 121, 144], ["Streptococcus suis", "PROBLEM", 150, 168], ["secondary", "OBSERVATION_MODIFIER", 10, 19], ["pathogens", "OBSERVATION", 20, 29]]], ["Together, primary and secondary pathogens are involved in the well-described porcine respiratory disease complex (PRDC) (Hallbur, 1998) .", [["respiratory", "ANATOMY", 85, 96], ["porcine respiratory disease", "DISEASE", 77, 104], ["porcine", "ORGANISM", 77, 84], ["secondary pathogens", "PROBLEM", 22, 41], ["the well-described porcine respiratory disease complex", "PROBLEM", 58, 112], ["secondary", "OBSERVATION_MODIFIER", 22, 31], ["pathogens", "OBSERVATION", 32, 41], ["respiratory disease", "OBSERVATION", 85, 104]]], ["PRRSV and SIV, together and individually, are frequently encountered in the fields (Choi et al., 2003; Fablet et al., 2012a Fablet et al., , 2011 .", [["PRRSV", "ORGANISM", 0, 5], ["SIV", "ORGANISM", 10, 13], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["SIV", "SPECIES", 10, 13], ["PRRSV", "PROBLEM", 0, 5], ["SIV", "OBSERVATION", 10, 13]]], ["In a study by Choi and collaborators, 109 samples (17%) of 636 SIV-positive cases were also positive for co-infections with PRRSV, behind P. multocida (148 samples, 23.2%) and M. hyopneumoniae (122 samples, 19.2%) (Choi et al., 2003) .", [["samples", "ANATOMY", 42, 49], ["samples", "ANATOMY", 156, 163], ["samples", "ANATOMY", 198, 205], ["co-infections", "DISEASE", 105, 118], ["PRRSV, behind P. multocida", "DISEASE", 124, 150], ["SIV", "ORGANISM", 63, 66], ["PRRSV", "ORGANISM", 124, 129], ["P. multocida", "ORGANISM", 138, 150], ["samples", "CANCER", 156, 163], ["M. hyopneumoniae", "ORGANISM", 176, 192], ["PRRSV", "SPECIES", 124, 129], ["P. multocida", "SPECIES", 138, 150], ["M. hyopneumoniae", "SPECIES", 176, 192], ["SIV", "SPECIES", 63, 66], ["PRRSV", "SPECIES", 124, 129], ["P. multocida", "SPECIES", 138, 150], ["M. hyopneumoniae", "SPECIES", 176, 192], ["a study", "TEST", 3, 10], ["samples", "TEST", 42, 49], ["SIV-positive cases", "TEST", 63, 81], ["co-infections", "PROBLEM", 105, 118], ["PRRSV", "PROBLEM", 124, 129], ["P. multocida", "TEST", 138, 150], ["samples", "TEST", 156, 163], ["M. hyopneumoniae", "PROBLEM", 176, 192], ["samples", "TEST", 198, 205], ["hyopneumoniae", "OBSERVATION", 179, 192]]], ["Previous studies dealing with PRRSV/SIV dual infections (Pol et al., 1997; Van Reeth et al., 1996 showed various outcomes with respect to dual infection.", [["PRRSV/SIV dual infections", "DISEASE", 30, 55], ["infection", "DISEASE", 143, 152], ["PRRSV", "ORGANISM", 30, 35], ["SIV", "ORGANISM", 36, 39], ["PRRSV", "SPECIES", 30, 35], ["PRRSV/SIV", "SPECIES", 30, 39], ["Previous studies", "TEST", 0, 16], ["PRRSV/SIV dual infections", "PROBLEM", 30, 55], ["dual infection", "PROBLEM", 138, 152], ["infection", "OBSERVATION", 143, 152]]], ["In a study where feeder pigs were infected first with PRRSV, then with porcine respiratory coronavirus or SIV, more severe disease and growth retardation were observed with dual infection than with PRRSV infection alone (Van Reeth et al., 1996) .", [["respiratory coronavirus", "DISEASE", 79, 102], ["growth retardation", "DISEASE", 135, 153], ["infection", "DISEASE", 178, 187], ["PRRSV infection", "DISEASE", 198, 213], ["pigs", "ORGANISM", 24, 28], ["PRRSV", "ORGANISM", 54, 59], ["porcine", "ORGANISM", 71, 78], ["respiratory coronavirus", "ORGANISM", 79, 102], ["SIV", "ORGANISM", 106, 109], ["PRRSV", "ORGANISM", 198, 203], ["pigs", "SPECIES", 24, 28], ["PRRSV", "SPECIES", 54, 59], ["porcine respiratory coronavirus", "SPECIES", 71, 102], ["pigs", "SPECIES", 24, 28], ["PRRSV", "SPECIES", 54, 59], ["porcine respiratory coronavirus", "SPECIES", 71, 102], ["SIV", "SPECIES", 106, 109], ["PRRSV", "SPECIES", 198, 203], ["a study", "TEST", 3, 10], ["feeder pigs", "TREATMENT", 17, 28], ["PRRSV", "PROBLEM", 54, 59], ["porcine respiratory coronavirus", "PROBLEM", 71, 102], ["SIV", "PROBLEM", 106, 109], ["more severe disease", "PROBLEM", 111, 130], ["growth retardation", "PROBLEM", 135, 153], ["dual infection", "PROBLEM", 173, 187], ["PRRSV infection", "PROBLEM", 198, 213], ["respiratory coronavirus", "OBSERVATION", 79, 102], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["disease", "OBSERVATION", 123, 130], ["infection", "OBSERVATION", 204, 213]]], ["In another study where 3-week-old specific-pathogen-free piglets were intra-nasally infected with PRRSV, followed one week later with a H3N2 SIV strain, observations indicated that the previous PRRSV infection did not influence clinical signs during influenza infection (Pol et al., 1997) .", [["PRRSV infection", "DISEASE", 194, 209], ["influenza infection", "DISEASE", 250, 269], ["piglets", "ORGANISM", 57, 64], ["PRRSV", "ORGANISM", 98, 103], ["H3N2", "ORGANISM", 136, 140], ["SIV", "ORGANISM", 141, 144], ["PRRSV", "ORGANISM", 194, 199], ["piglets", "SPECIES", 57, 64], ["PRRSV", "SPECIES", 98, 103], ["H3N2 SIV", "SPECIES", 136, 144], ["PRRSV", "SPECIES", 98, 103], ["SIV", "SPECIES", 141, 144], ["PRRSV", "SPECIES", 194, 199], ["another study", "TEST", 3, 16], ["pathogen", "PROBLEM", 43, 51], ["a H3N2 SIV strain", "TREATMENT", 134, 151], ["the previous PRRSV infection", "PROBLEM", 181, 209], ["clinical signs during influenza infection", "PROBLEM", 228, 269], ["infection", "OBSERVATION", 200, 209]]], ["Then, in a study with PRRSV and a European H1N1 SIV strain, authors observed variable clinical outcomes of dual PRRSV-SIV infection, depending on both the time interval between infections and the health status of pigs used in the study (Van Reeth et al., 2001) .", [["PRRSV-SIV infection", "DISEASE", 112, 131], ["infections", "DISEASE", 177, 187], ["PRRSV", "ORGANISM", 22, 27], ["SIV", "ORGANISM", 48, 51], ["PRRSV", "ORGANISM", 112, 117], ["SIV", "ORGANISM", 118, 121], ["pigs", "ORGANISM", 213, 217], ["H1N1 SIV", "SPECIES", 43, 51], ["pigs", "SPECIES", 213, 217], ["PRRSV", "SPECIES", 22, 27], ["European H1N1 SIV", "SPECIES", 34, 51], ["PRRSV-SIV", "SPECIES", 112, 121], ["a study", "TEST", 9, 16], ["PRRSV", "PROBLEM", 22, 27], ["a European H1N1 SIV strain", "TREATMENT", 32, 58], ["dual PRRSV-SIV infection", "PROBLEM", 107, 131], ["infections", "PROBLEM", 177, 187], ["the study", "TEST", 226, 235], ["dual PRRSV", "OBSERVATION", 107, 117], ["SIV infection", "OBSERVATION", 118, 131], ["infections", "OBSERVATION", 177, 187]]], ["Aside from these various following co-infections, our understanding of the impact of one virus on the other at the molecular level is still extremely limited.", [["co-infections", "PROBLEM", 35, 48], ["one virus", "PROBLEM", 85, 94], ["co-infections", "OBSERVATION", 35, 48], ["virus", "OBSERVATION", 89, 94]]], ["Most of the studies on PRRSV/SIV co-infections were performed more than ten years ago at a time where the porcine toolbox was much less developed.", [["PRRSV/SIV co-infections", "DISEASE", 23, 46], ["PRRSV", "ORGANISM", 23, 28], ["SIV", "ORGANISM", 29, 32], ["porcine", "ORGANISM", 106, 113], ["PRRSV", "SPECIES", 23, 28], ["SIV", "SPECIES", 29, 32], ["the studies", "TEST", 8, 19], ["PRRSV/SIV co-infections", "PROBLEM", 23, 46], ["the porcine toolbox", "TEST", 102, 121]]], ["Thus, the aim of the current study was to determine at the molecular level how dual infections, compared to single infections, influence the response of porcine alveolar macrophages (PAMs) and precision cut lung slices (PCLS) to PRRSV and SIV.", [["alveolar macrophages", "ANATOMY", 161, 181], ["PAMs", "ANATOMY", 183, 187], ["lung slices", "ANATOMY", 207, 218], ["PCLS", "ANATOMY", 220, 224], ["infections", "DISEASE", 84, 94], ["infections", "DISEASE", 115, 125], ["porcine", "ORGANISM", 153, 160], ["alveolar macrophages", "CELL", 161, 181], ["PAMs", "CELL", 183, 187], ["lung slices", "MULTI-TISSUE_STRUCTURE", 207, 218], ["PRRSV", "ORGANISM", 229, 234], ["SIV", "ORGANISM", 239, 242], ["porcine alveolar macrophages", "CELL_TYPE", 153, 181], ["PAMs", "CELL_TYPE", 183, 187], ["porcine", "SPECIES", 153, 160], ["PRRSV", "SPECIES", 229, 234], ["SIV", "SPECIES", 239, 242], ["the current study", "TEST", 17, 34], ["dual infections", "PROBLEM", 79, 94], ["single infections", "PROBLEM", 108, 125], ["porcine alveolar macrophages (PAMs)", "TREATMENT", 153, 188], ["precision cut lung slices", "TEST", 193, 218], ["PRRSV", "PROBLEM", 229, 234], ["infections", "OBSERVATION", 84, 94], ["infections", "OBSERVATION", 115, 125], ["alveolar macrophages", "OBSERVATION", 161, 181], ["lung", "ANATOMY", 207, 211]]], ["PAMs and PCLS were used because of their relevance in the context of infections with PRRSV and SIV.", [["infections", "DISEASE", 69, 79], ["PCLS", "SIMPLE_CHEMICAL", 9, 13], ["PRRSV", "ORGANISM", 85, 90], ["SIV", "ORGANISM", 95, 98], ["PRRSV", "SPECIES", 85, 90], ["PRRSV", "SPECIES", 85, 90], ["SIV", "SPECIES", 95, 98], ["PCLS", "TREATMENT", 9, 13], ["infections", "PROBLEM", 69, 79], ["PRRSV", "PROBLEM", 85, 90], ["infections", "OBSERVATION", 69, 79]]], ["PAMs, pulmonary intravascular macrophages (PIMs), and interstitial macrophages (ISMs) are the main targets of PRRSV (Meulenberg, 2000; Sang et al., 2011) .", [["pulmonary intravascular macrophages", "ANATOMY", 6, 41], ["PIMs", "ANATOMY", 43, 47], ["interstitial macrophages", "ANATOMY", 54, 78], ["ISMs", "ANATOMY", 80, 84], ["PAMs", "CELL", 0, 4], ["pulmonary intravascular macrophages", "CELL", 6, 41], ["PIMs", "CELL", 43, 47], ["interstitial macrophages", "CELL", 54, 78], ["ISMs", "CELLULAR_COMPONENT", 80, 84], ["PRRSV", "ORGANISM", 110, 115], ["PAMs", "CELL_TYPE", 0, 4], ["pulmonary intravascular macrophages", "CELL_TYPE", 6, 41], ["PIMs", "CELL_TYPE", 43, 47], ["interstitial macrophages", "CELL_TYPE", 54, 78], ["ISMs", "CELL_TYPE", 80, 84], ["PRRSV", "SPECIES", 110, 115], ["pulmonary intravascular macrophages (PIMs)", "PROBLEM", 6, 48], ["interstitial macrophages (ISMs)", "PROBLEM", 54, 85], ["pulmonary", "ANATOMY", 6, 15], ["intravascular macrophages", "OBSERVATION", 16, 41], ["interstitial", "ANATOMY_MODIFIER", 54, 66], ["macrophages", "OBSERVATION", 67, 78], ["main", "OBSERVATION_MODIFIER", 94, 98], ["targets", "OBSERVATION_MODIFIER", 99, 106]]], ["PAMs can also be infected by SIV (Crisci et al., 2013; Taubenberger and Morens, 2008) .", [["SIV", "ORGANISM", 29, 32], ["SIV", "SPECIES", 29, 32], ["infected", "OBSERVATION_MODIFIER", 17, 25]]], ["PCLS have previously been used for infection studies in birds (Abd El Rahman et al., 2010) , cattle (Goris et al., 2009) , and pigs (Punyadarsaniya et al., 2011) .", [["PCLS", "CHEMICAL", 0, 4], ["infection", "DISEASE", 35, 44], ["birds", "ORGANISM", 56, 61], ["pigs", "ORGANISM", 127, 131], ["cattle", "SPECIES", 93, 99], ["pigs", "SPECIES", 127, 131], ["cattle", "SPECIES", 93, 99], ["pigs", "SPECIES", 127, 131], ["PCLS", "TEST", 0, 4], ["infection studies", "TEST", 35, 52], ["Abd", "ANATOMY", 63, 66]]], ["The PCLS culture system has several advantages over other systems: (1) slices can be obtained in large numbers; (2) the general architecture of the tissue is preserved so differentiated epithelial cells, which are the main target cells of SIV, and various other cellular types are maintained in situ; and (3) the slice viability extends past 7 days (Punyadarsaniya et al., 2011) .", [["slices", "ANATOMY", 71, 77], ["tissue", "ANATOMY", 148, 154], ["epithelial cells", "ANATOMY", 186, 202], ["cells", "ANATOMY", 230, 235], ["cellular", "ANATOMY", 262, 270], ["slice", "ANATOMY", 313, 318], ["slices", "MULTI-TISSUE_STRUCTURE", 71, 77], ["tissue", "TISSUE", 148, 154], ["epithelial cells", "CELL", 186, 202], ["cells", "CELL", 230, 235], ["SIV", "ORGANISM", 239, 242], ["cellular", "CELL", 262, 270], ["PCLS culture", "CELL_LINE", 4, 16], ["differentiated epithelial cells", "CELL_TYPE", 171, 202], ["SIV", "SPECIES", 239, 242], ["The PCLS culture system", "TEST", 0, 23], ["differentiated epithelial cells", "PROBLEM", 171, 202], ["tissue", "ANATOMY", 148, 154], ["preserved", "OBSERVATION", 158, 167], ["differentiated", "OBSERVATION_MODIFIER", 171, 185], ["epithelial cells", "OBSERVATION", 186, 202], ["main", "OBSERVATION_MODIFIER", 218, 222], ["target cells", "OBSERVATION", 223, 235], ["SIV", "OBSERVATION_MODIFIER", 239, 242], ["various", "OBSERVATION_MODIFIER", 248, 255], ["cellular types", "OBSERVATION", 262, 276], ["situ", "OBSERVATION_MODIFIER", 295, 299]]], ["Moreover, PAMs and PCLS systems together allow us to study host/ pathogen interactions in a single cell type population versus a multi-cellular tissue, granting more accurate analysis of the contribution of PAMs to the global disease response.Ethics statementA total of 10 eight-week-old York-type crossbred commercial pigs were purchased from the Prairie Swine Centre, University of Saskatchewan.", [["cell", "ANATOMY", 99, 103], ["multi-cellular tissue", "ANATOMY", 129, 150], ["cell type", "CELL", 99, 108], ["tissue", "TISSUE", 144, 150], ["pigs", "ORGANISM", 319, 323], ["PAMs", "CELL_TYPE", 10, 14], ["pigs", "SPECIES", 319, 323], ["pigs", "SPECIES", 319, 323], ["PCLS systems", "TEST", 19, 31], ["a multi-cellular tissue", "PROBLEM", 127, 150], ["PAMs", "PROBLEM", 207, 211], ["the global disease response", "PROBLEM", 215, 242], ["multi-cellular tissue", "OBSERVATION_MODIFIER", 129, 150], ["global", "OBSERVATION_MODIFIER", 219, 225], ["disease", "OBSERVATION", 226, 233]]], ["Pigs were healthy and showed no clinical symptoms or serological evidence of respiratory (e.g. SIV, M. hyopneumoniae, PRRSV) or systemic diseases.", [["respiratory", "ANATOMY", 77, 88], ["respiratory (e.g. SIV, M. hyopneumoniae, PRRSV) or systemic diseases", "DISEASE", 77, 145], ["Pigs", "ORGANISM", 0, 4], ["SIV", "ORGANISM", 95, 98], ["M. hyopneumoniae", "ORGANISM", 100, 116], ["PRRSV", "ORGANISM", 118, 123], ["Pigs", "SPECIES", 0, 4], ["M. hyopneumoniae", "SPECIES", 100, 116], ["SIV", "SPECIES", 95, 98], ["M. hyopneumoniae", "SPECIES", 100, 116], ["PRRSV", "SPECIES", 118, 123], ["clinical symptoms", "PROBLEM", 32, 49], ["respiratory (e.g. SIV", "PROBLEM", 77, 98], ["M. hyopneumoniae", "PROBLEM", 100, 116], ["PRRSV", "PROBLEM", 118, 123], ["systemic diseases", "PROBLEM", 128, 145], ["respiratory", "ANATOMY", 77, 88], ["systemic", "OBSERVATION_MODIFIER", 128, 136], ["diseases", "OBSERVATION", 137, 145]]], ["All experiments were conducted in accordance with the ethical guidelines of the University of Saskatchewan and the Canadian Council on Animal Care.", [["Animal Care", "TREATMENT", 135, 146]]], ["Pigs were euthanized with 360 mg/kg sodium pentobarbital (Ethanyl, Bimeda-MTC, Animal Health Inc., Cambridge, ON, Canada) administered intravenously.", [["intravenously", "ANATOMY", 135, 148], ["sodium pentobarbital", "CHEMICAL", 36, 56], ["Ethanyl, Bimeda-MTC", "CHEMICAL", 58, 77], ["sodium pentobarbital", "CHEMICAL", 36, 56], ["Ethanyl", "CHEMICAL", 58, 65], ["Pigs", "ORGANISM", 0, 4], ["sodium", "SIMPLE_CHEMICAL", 36, 42], ["pentobarbital", "SIMPLE_CHEMICAL", 43, 56], ["Ethanyl", "SIMPLE_CHEMICAL", 58, 65], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["sodium pentobarbital", "TREATMENT", 36, 56], ["Ethanyl", "TREATMENT", 58, 65], ["Bimeda", "TREATMENT", 67, 73]]], ["All efforts were made to minimize suffering.Precision-cut lung slicesPCLS were prepared from lungs of 4 eight-week-old pigs.", [["lung slicesPCLS", "ANATOMY", 58, 73], ["lungs", "ANATOMY", 93, 98], ["lung slicesPCLS", "CANCER", 58, 73], ["lungs", "ORGAN", 93, 98], ["pigs", "ORGANISM", 119, 123], ["pigs", "SPECIES", 119, 123], ["Precision", "TEST", 44, 53], ["cut lung slicesPCLS", "PROBLEM", 54, 73], ["lung", "ANATOMY", 58, 62], ["slicesPCLS", "OBSERVATION", 63, 73], ["lungs", "ANATOMY", 93, 98]]], ["Immediately after euthanasia, lungs were carefully removed and the left cranial, middle, and caudal lobes were filled with 37 8C warm low-gelling temperature agarose (Sigma-Aldrich, Oakville, ON, Canada) followed by polymerization on ice.", [["lungs", "ANATOMY", 30, 35], ["left cranial", "ANATOMY", 67, 79], ["caudal lobes", "ANATOMY", 93, 105], ["lungs", "ORGAN", 30, 35], ["cranial", "ORGAN", 72, 79], ["caudal lobes", "MULTI-TISSUE_STRUCTURE", 93, 105], ["lungs", "ANATOMY", 30, 35], ["left", "ANATOMY_MODIFIER", 67, 71], ["cranial", "ANATOMY", 72, 79], ["middle", "ANATOMY_MODIFIER", 81, 87], ["caudal lobes", "ANATOMY", 93, 105], ["filled", "OBSERVATION", 111, 117]]], ["Tissue was excised in cylindrical portions (8-mm tissue coring tool) and around 200 slices/ pig approximately 250 mm thick were prepared by using a Krumdieck tissue slicer (model MD6000, TSE systems, Chesterfield, MO, USA) with a cycle speed of 60 slices/min.", [["Tissue", "ANATOMY", 0, 6], ["tissue", "ANATOMY", 49, 55], ["slices", "ANATOMY", 84, 90], ["tissue", "ANATOMY", 158, 164], ["Tissue", "TISSUE", 0, 6], ["tissue", "TISSUE", 49, 55], ["pig", "ORGANISM", 92, 95], ["tissue", "TISSUE", 158, 164], ["pig", "SPECIES", 92, 95], ["tissue coring tool", "TEST", 49, 67], ["a Krumdieck tissue slicer", "TREATMENT", 146, 171], ["cylindrical", "ANATOMY_MODIFIER", 22, 33], ["portions", "ANATOMY_MODIFIER", 34, 42], ["8-mm", "OBSERVATION_MODIFIER", 44, 48]]], ["PCLS were incubated in 1 ml of RPMI 1640 medium (GIBCO 1 -BRL, Burlington, ON, Canada), supplemented with 1% antibiotic/antimycotic (Anti-Anti 100\u00c2, GIBCO 1 -BRL), clotrimazole 1 mg/ml (Sigma-Aldrich), enrofloxacin 10 mg/ml (Bayer Inc., Toronto, ON), and kanamycin 80 mg/ml (GIBCO 1 -BRL) in a 24-well plate at 37 8C and 5% CO 2 .", [["PCLS", "CHEMICAL", 0, 4], ["GIBCO 1 -BRL", "CHEMICAL", 49, 61], ["GIBCO 1 -BRL", "CHEMICAL", 149, 161], ["clotrimazole", "CHEMICAL", 164, 176], ["enrofloxacin", "CHEMICAL", 202, 214], ["kanamycin", "CHEMICAL", 255, 264], ["GIBCO 1 -BRL", "CHEMICAL", 275, 287], ["clotrimazole", "CHEMICAL", 164, 176], ["enrofloxacin", "CHEMICAL", 202, 214], ["kanamycin", "CHEMICAL", 255, 264], ["CO 2", "CHEMICAL", 324, 328], ["PCLS", "SIMPLE_CHEMICAL", 0, 4], ["clotrimazole", "SIMPLE_CHEMICAL", 164, 176], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 186, 199], ["enrofloxacin", "SIMPLE_CHEMICAL", 202, 214], ["kanamycin", "SIMPLE_CHEMICAL", 255, 264], ["PCLS", "TEST", 0, 4], ["RPMI", "TEST", 31, 35], ["GIBCO", "TEST", 49, 54], ["1% antibiotic", "TREATMENT", 106, 119], ["antimycotic (Anti-Anti", "TREATMENT", 120, 142], ["GIBCO", "TREATMENT", 149, 154], ["clotrimazole", "TREATMENT", 164, 176], ["enrofloxacin", "TREATMENT", 202, 214], ["kanamycin", "TREATMENT", 255, 264]]], ["The medium was changed every hour during the first 4 h and once after 24 h, prior to infection.", [["infection", "DISEASE", 85, 94], ["infection", "PROBLEM", 85, 94], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 85, 94]]], ["Viability was analyzed by observing ciliary activity under a light microscope (Olympus CKX31, Tokyo, Japan).", [["ciliary", "ANATOMY", 36, 43], ["ciliary", "MULTI-TISSUE_STRUCTURE", 36, 43], ["a light microscope", "TEST", 59, 77]]], ["In selected samples, slices were analyzed for bronchoconstriction by addition of 10 \u00c04 M methacholine (acetyl-bmethylcholine chloride, Sigma-Aldrich), as previously described (Vietmeier et al., 2007) .Cells and virusesPorcine alveolar macrophages (PAMs) were obtained by lung lavage of 6 eight-week-old pigs and maintained in RPMI 1640 (GIBCO 1 -BRL) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Anti-Anti 100\u00c2, GIBCO 1 -BRL).", [["samples", "ANATOMY", 12, 19], ["slices", "ANATOMY", 21, 27], ["Cells", "ANATOMY", 201, 206], ["alveolar macrophages", "ANATOMY", 226, 246], ["PAMs", "ANATOMY", 248, 252], ["lung lavage", "ANATOMY", 271, 282], ["fetal bovine serum", "ANATOMY", 373, 391], ["FBS", "ANATOMY", 393, 396], ["methacholine", "CHEMICAL", 89, 101], ["acetyl-bmethylcholine chloride", "CHEMICAL", 103, 133], ["GIBCO 1 -BRL", "CHEMICAL", 337, 349], ["GIBCO 1 -BRL", "CHEMICAL", 445, 457], ["methacholine", "CHEMICAL", 89, 101], ["acetyl-bmethylcholine chloride", "CHEMICAL", 103, 133], ["slices", "MULTI-TISSUE_STRUCTURE", 21, 27], ["methacholine", "SIMPLE_CHEMICAL", 89, 101], ["acetyl-bmethylcholine chloride", "SIMPLE_CHEMICAL", 103, 133], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 135, 148], ["Cells", "CELL", 201, 206], ["Porcine", "ORGANISM", 218, 225], ["alveolar macrophages", "CELL", 226, 246], ["PAMs", "CELL", 248, 252], ["lung lavage", "MULTI-TISSUE_STRUCTURE", 271, 282], ["pigs", "ORGANISM", 303, 307], ["GIBCO 1 -BRL", "CELL", 337, 349], ["bovine", "ORGANISM", 379, 385], ["serum", "ORGANISM_SUBSTANCE", 386, 391], ["FBS", "ORGANISM_SUBSTANCE", 393, 396], ["Porcine alveolar macrophages", "CELL_TYPE", 218, 246], ["PAMs", "CELL_TYPE", 248, 252], ["Porcine", "SPECIES", 218, 225], ["pigs", "SPECIES", 303, 307], ["bovine", "SPECIES", 379, 385], ["pigs", "SPECIES", 303, 307], ["slices", "TEST", 21, 27], ["bronchoconstriction", "PROBLEM", 46, 65], ["10 \u00c04 M methacholine (acetyl-bmethylcholine chloride", "TREATMENT", 81, 133], ["Cells", "TEST", 201, 206], ["virusesPorcine alveolar macrophages", "PROBLEM", 211, 246], ["lung lavage", "TEST", 271, 282], ["GIBCO", "TEST", 337, 342], ["10% fetal bovine serum (FBS", "TREATMENT", 369, 396], ["1% antibiotic", "TREATMENT", 402, 415], ["antimycotic", "TREATMENT", 416, 427], ["Anti-Anti", "TREATMENT", 429, 438], ["GIBCO", "TEST", 445, 450], ["alveolar macrophages", "OBSERVATION", 226, 246], ["lung", "ANATOMY", 271, 275], ["lavage", "OBSERVATION", 276, 282]]], ["In healthy animals, PAMs represent >90% of cells in broncho-alveolar lavage fluid as previously reported (White et al., 2007) .", [["cells", "ANATOMY", 43, 48], ["broncho-alveolar lavage fluid", "ANATOMY", 52, 81], ["PAMs", "CELL", 20, 24], ["cells", "CELL", 43, 48], ["broncho-alveolar lavage fluid", "ORGANISM_SUBSTANCE", 52, 81], ["PAMs", "TEST", 20, 24], ["broncho-alveolar lavage fluid", "TEST", 52, 81], ["alveolar", "ANATOMY", 60, 68], ["lavage fluid", "OBSERVATION", 69, 81]]], ["Madin-Darby canine kidney (MDCK, ATCC CCL-34) cells were cultured in minimal essential medium (MEM) supplemented with 10% FBS.", [["kidney", "ANATOMY", 19, 25], ["MDCK", "ANATOMY", 27, 31], ["ATCC CCL-34) cells", "ANATOMY", 33, 51], ["FBS", "ANATOMY", 122, 125], ["MDCK", "CELL", 27, 31], ["ATCC CCL-34) cells", "CELL", 33, 51], ["FBS", "ORGANISM_SUBSTANCE", 122, 125], ["Madin-Darby canine kidney (MDCK, ATCC CCL-34) cells", "CELL_LINE", 0, 51], ["ATCC CCL-34", "SPECIES", 33, 44], ["Madin", "TREATMENT", 0, 5], ["Darby canine kidney (MDCK, ATCC CCL", "TREATMENT", 6, 41], ["kidney", "ANATOMY", 19, 25]]], ["MARC-145 monkey cells (ATCC CRL-12231) were grown in MEM (GIBCO 1 -BRL) supplemented with 10% FBS and 1% antibiotic/antimycotic (Anti-Anti 100\u00c2, GIBCO 1 -BRL).Cells and virusesThe influenza strain A/Sw/Saskatchewan/18789/02 (SIV/Sk02) of H1N1 subtype was isolated from pigs on a 1200-sow, farrow-to-finish farm in Saskatchewan in May 2002 (Karasin et al., 2004) .", [["MARC-145 monkey cells", "ANATOMY", 0, 21], ["ATCC CRL-12231", "ANATOMY", 23, 37], ["FBS", "ANATOMY", 94, 97], ["Cells", "ANATOMY", 159, 164], ["MARC-145", "CHEMICAL", 0, 8], ["CRL-12231", "CHEMICAL", 28, 37], ["MEM", "CHEMICAL", 53, 56], ["GIBCO 1 -BRL", "CHEMICAL", 58, 70], ["GIBCO 1 -BRL", "CHEMICAL", 145, 157], ["MARC-145 monkey cells", "CELL", 0, 21], ["ATCC CRL-12231", "CELL", 23, 37], ["GIBCO 1 -BRL", "CELL", 58, 70], ["FBS", "ORGANISM_SUBSTANCE", 94, 97], ["Cells", "CELL", 159, 164], ["influenza strain A/Sw/Saskatchewan/18789/02", "ORGANISM", 180, 223], ["SIV/Sk02", "ORGANISM", 225, 233], ["H1N1 subtype", "ORGANISM", 238, 250], ["pigs", "ORGANISM", 269, 273], ["MARC-145 monkey cells", "CELL_LINE", 0, 21], ["ATCC CRL-12231", "CELL_LINE", 23, 37], ["monkey", "SPECIES", 9, 15], ["pigs", "SPECIES", 269, 273], ["MARC-145 monkey", "SPECIES", 0, 15], ["ATCC CRL-12231", "SPECIES", 23, 37], ["A/Sw/Saskatchewan/18789/02 (SIV/Sk02", "SPECIES", 197, 233], ["pigs", "SPECIES", 269, 273], ["MARC", "TEST", 0, 4], ["ATCC CRL", "TEST", 23, 31], ["GIBCO", "TEST", 58, 63], ["10% FBS", "TREATMENT", 90, 97], ["1% antibiotic", "TREATMENT", 102, 115], ["antimycotic", "TREATMENT", 116, 127], ["Anti-Anti", "TREATMENT", 129, 138], ["GIBCO", "TREATMENT", 145, 150], ["viruses", "PROBLEM", 169, 176], ["The influenza strain", "PROBLEM", 176, 196], ["H1N1 subtype", "PROBLEM", 238, 250], ["viruses", "OBSERVATION", 169, 176]]], ["It was isolated and grown in MDCK cells in the presence of 0.5 mg/ml human neutrophil elastase (Serva Electrophoresis GmbH, Heidelberg, Germany).", [["MDCK cells", "ANATOMY", 29, 39], ["neutrophil", "ANATOMY", 75, 85], ["MDCK cells", "CELL", 29, 39], ["human", "ORGANISM", 69, 74], ["neutrophil", "CELL", 75, 85], ["MDCK cells", "CELL_LINE", 29, 39], ["human neutrophil elastase", "PROTEIN", 69, 94], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["MDCK cells", "TEST", 29, 39], ["neutrophil elastase", "TEST", 75, 94], ["grown", "OBSERVATION_MODIFIER", 20, 25], ["MDCK cells", "OBSERVATION", 29, 39], ["neutrophil elastase", "OBSERVATION", 75, 94]]], ["Titer was determined on MDCK cells by a plaque assay, as described previously (Shin et al., 2007) .", [["MDCK cells", "ANATOMY", 24, 34], ["plaque", "ANATOMY", 40, 46], ["MDCK cells", "CELL", 24, 34], ["MDCK cells", "CELL_LINE", 24, 34], ["a plaque assay", "TEST", 38, 52], ["plaque", "OBSERVATION", 40, 46]]], ["Stock of the virus reached titer of 9.5 \u00c2 10 7 plaque forming units (pfu)/ml after purification.Cells and virusesThe virulent PRRSV strain ISU-12-SAH was obtained from ATCC (ATCC VR-2385, Hanassas, VA, USA).", [["Cells", "ANATOMY", 96, 101], ["ATCC", "ANATOMY", 168, 172], ["ISU-12-", "CHEMICAL", 139, 146], ["SAH", "DISEASE", 146, 149], ["Cells", "CELL", 96, 101], ["PRRSV", "ORGANISM", 126, 131], ["ISU-12-SAH", "ORGANISM", 139, 149], ["ATCC", "CELL", 168, 172], ["ATCC VR-2385", "CELL", 174, 186], ["PRRSV", "SPECIES", 126, 131], ["PRRSV", "SPECIES", 126, 131], ["ATCC", "SPECIES", 168, 172], ["ATCC VR-2385", "SPECIES", 174, 186], ["the virus", "PROBLEM", 9, 18], ["viruses", "PROBLEM", 106, 113], ["The virulent PRRSV strain ISU", "TEST", 113, 142], ["SAH", "PROBLEM", 146, 149], ["ATCC", "TEST", 168, 172], ["ATCC VR", "TEST", 174, 181], ["virus", "OBSERVATION", 13, 18], ["viruses", "OBSERVATION", 106, 113], ["virulent", "OBSERVATION_MODIFIER", 117, 125], ["PRRSV strain", "OBSERVATION", 126, 138]]], ["Quantitation of PRRSV stock was performed in MARC-145 cells and the titer (1.5 \u00c2 10 6 ) was calculated and expressed as TCID 50 /ml (Reed and Muench, 1938) .Virus infectionSix wells of PAMs (10 5 cells/well, one well corresponding to one pig) in a 24-well plate were single-infected or co-infected with SIV and PRRSV at a MOI of 10.", [["MARC-145 cells", "ANATOMY", 45, 59], ["cells", "ANATOMY", 196, 201], ["PRRSV", "ORGANISM", 16, 21], ["MARC-145 cells", "CELL", 45, 59], ["Virus", "ORGANISM", 157, 162], ["PAMs", "CELL", 185, 189], ["cells", "CELL", 196, 201], ["pig", "ORGANISM", 238, 241], ["SIV", "ORGANISM", 303, 306], ["PRRSV", "ORGANISM", 311, 316], ["MARC-145 cells", "CELL_LINE", 45, 59], ["PAMs", "CELL_TYPE", 185, 189], ["pig", "SPECIES", 238, 241], ["PRRSV", "SPECIES", 16, 21], ["MARC-145", "SPECIES", 45, 53], ["pig", "SPECIES", 238, 241], ["SIV", "SPECIES", 303, 306], ["PRRSV", "SPECIES", 311, 316], ["Quantitation of PRRSV stock", "TEST", 0, 27], ["the titer", "TEST", 64, 73], ["Virus infectionSix wells of PAMs", "PROBLEM", 157, 189], ["SIV", "PROBLEM", 303, 306], ["PRRSV stock", "OBSERVATION", 16, 27], ["145 cells", "OBSERVATION_MODIFIER", 50, 59], ["infected", "OBSERVATION", 274, 282], ["co-infected", "OBSERVATION", 286, 297]]], ["Additionally 6 non-infected wells were used as controls.", [["non-infected wells", "TREATMENT", 15, 33]]], ["The same six pigs were used for each condition.", [["pigs", "ORGANISM", 13, 17], ["pigs", "SPECIES", 13, 17], ["pigs", "SPECIES", 13, 17], ["The same six pigs", "TREATMENT", 0, 17]]], ["Virus attachment was allowed for 1 h at 4 8C.", [["Virus", "ORGANISM", 0, 5], ["Virus attachment", "PROBLEM", 0, 16]]], ["Cells were then incubated at 37 8C.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["One hour after the temperature shift, the cells were washed once with phosphate buffered saline (PBS) and maintained at 37 8C in 1 ml of RPMI 1640 (GIBCO 1 -BRL) supplemented with 10% FBS and 1% antibiotic/antimycotic (Anti-Anti 100\u00c2, GIBCO 1 -BRL).", [["cells", "ANATOMY", 42, 47], ["FBS", "ANATOMY", 184, 187], ["phosphate", "CHEMICAL", 70, 79], ["GIBCO 1 -BRL", "CHEMICAL", 148, 160], ["GIBCO 1 -BRL", "CHEMICAL", 235, 247], ["phosphate", "CHEMICAL", 70, 79], ["cells", "CELL", 42, 47], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 70, 95], ["FBS", "ORGANISM_SUBSTANCE", 184, 187], ["the cells", "TREATMENT", 38, 47], ["phosphate buffered saline (PBS", "TREATMENT", 70, 100], ["GIBCO", "TEST", 148, 153], ["10% FBS", "TREATMENT", 180, 187], ["1% antibiotic", "TREATMENT", 192, 205], ["antimycotic", "TREATMENT", 206, 217], ["Anti-Anti", "TREATMENT", 219, 228], ["GIBCO", "TREATMENT", 235, 240]]], ["Eighteen hours after the temperature shift the culture medium was removed, clarified twice by centrifugation (1000 \u00c2 g), divided into aliquots, and stored at \u00c080 8C.", [["the culture medium", "TEST", 43, 61]]], ["For PCLS single-infections and co-infection, the procedure was identical except that 10 6 pfu of SIV and 10 6 TCID 50 of PRRSV were used as it is not possible to determine the number of target cells in a slice.", [["cells", "ANATOMY", 193, 198], ["slice", "ANATOMY", 204, 209], ["PCLS", "CHEMICAL", 4, 8], ["infections", "DISEASE", 16, 26], ["SIV", "ORGANISM", 97, 100], ["PRRSV", "ORGANISM", 121, 126], ["cells", "CELL", 193, 198], ["target cells", "CELL_TYPE", 186, 198], ["SIV", "SPECIES", 97, 100], ["PRRSV", "SPECIES", 121, 126], ["PCLS single-infections", "PROBLEM", 4, 26], ["co-infection", "PROBLEM", 31, 43], ["the procedure", "TREATMENT", 45, 58], ["SIV", "TREATMENT", 97, 100], ["PRRSV", "TREATMENT", 121, 126], ["infections", "OBSERVATION", 16, 26], ["co-infection", "OBSERVATION", 31, 43], ["not possible", "UNCERTAINTY", 146, 158], ["target cells", "OBSERVATION", 186, 198]]], ["Six slices, prepared from the same left lung lobe, were used for each condition.", [["slices", "ANATOMY", 4, 10], ["left lung lobe", "ANATOMY", 35, 49], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 40, 49], ["Six slices", "TEST", 0, 10], ["left lung", "ANATOMY", 35, 44], ["lobe", "ANATOMY_MODIFIER", 45, 49]]], ["The experiment was repeated four times using 4 different animals.Virus infectionFor superinfections, six wells of PAMs (10 5 cells/well, one well corresponding to one pig) were first infected with SIV (MOI of 10), then superinfected with PRRSV (MOI of 10) 3 h later.", [["cells", "ANATOMY", 125, 130], ["Virus infection", "DISEASE", 65, 80], ["Virus", "ORGANISM", 65, 70], ["PAMs", "CELL", 114, 118], ["cells", "CELL", 125, 130], ["pig", "ORGANISM", 167, 170], ["SIV", "ORGANISM", 197, 200], ["PRRSV", "ORGANISM", 238, 243], ["PAMs", "CELL_TYPE", 114, 118], ["pig", "SPECIES", 167, 170], ["pig", "SPECIES", 167, 170], ["SIV", "SPECIES", 197, 200], ["PRRSV", "SPECIES", 238, 243], ["Virus infection", "PROBLEM", 65, 80], ["superinfections", "PROBLEM", 84, 99], ["PAMs", "PROBLEM", 114, 118], ["infection", "OBSERVATION", 71, 80]]], ["In parallel, six wells of PAMs were infected with PRRSV (MOI of 10) and superinfected with SIV (MOI of 10) 3 h after infection with PRRSV.", [["infection", "DISEASE", 117, 126], ["PAMs", "CELL", 26, 30], ["PRRSV", "ORGANISM", 50, 55], ["SIV", "ORGANISM", 91, 94], ["PRRSV", "ORGANISM", 132, 137], ["PRRSV", "SPECIES", 50, 55], ["SIV", "SPECIES", 91, 94], ["PRRSV", "SPECIES", 132, 137], ["PAMs", "PROBLEM", 26, 30], ["PRRSV (MOI", "TREATMENT", 50, 60], ["infection", "PROBLEM", 117, 126], ["PRRSV", "PROBLEM", 132, 137], ["infection", "OBSERVATION", 117, 126]]], ["The 3 h delay between infections was selected based on previous studies where interference between related viruses of another family was intensively assessed in vitro and in vivo (Banfield et al., 2003; Glazenburg et al., 1994; Meurens et al., 2004a,b; Schynts et al., 2003) .", [["infections", "DISEASE", 22, 32], ["The 3 h delay between infections", "PROBLEM", 0, 32], ["previous studies", "TEST", 55, 71], ["infections", "OBSERVATION", 22, 32]]], ["Many interference mechanisms take place early in the viral cycle .", [["Many interference mechanisms", "PROBLEM", 0, 28], ["interference", "OBSERVATION", 5, 17]]], ["After the first infection, virus attachment was allowed for 1 h at 4 8C.", [["infection", "DISEASE", 16, 25], ["the first infection", "PROBLEM", 6, 25], ["virus attachment", "PROBLEM", 27, 43], ["infection", "OBSERVATION", 16, 25]]], ["Cells were then further incubated at 37 8C and superinfections were performed 3 h after the temperature shift.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["superinfections", "PROBLEM", 47, 62], ["the temperature shift", "TEST", 88, 109]]], ["One hour after the temperature shift and 1 h after each superinfection cells were washed once with PBS and further incubated at 37 8C in 1 ml of RPMI 1640 (GIBCO 1 -BRL) supplemented with 10% FBS and 1% antibiotic/antimycotic (Anti-Anti 100\u00c2, GIBCO 1 -BRL).", [["cells", "ANATOMY", 71, 76], ["FBS", "ANATOMY", 192, 195], ["GIBCO 1 -BRL", "CHEMICAL", 156, 168], ["GIBCO 1 -BRL", "CHEMICAL", 243, 255], ["cells", "CELL", 71, 76], ["FBS", "ORGANISM_SUBSTANCE", 192, 195], ["superinfection cells", "CELL_TYPE", 56, 76], ["the temperature shift", "TREATMENT", 15, 36], ["each superinfection cells", "TREATMENT", 51, 76], ["PBS", "TREATMENT", 99, 102], ["GIBCO", "TEST", 156, 161], ["10% FBS", "TREATMENT", 188, 195], ["1% antibiotic", "TREATMENT", 200, 213], ["antimycotic", "TREATMENT", 214, 225], ["Anti-Anti", "TREATMENT", 227, 236], ["GIBCO", "TREATMENT", 243, 248]]], ["Additionally 6 non-infected wells were used as controls.", [["non-infected wells", "TREATMENT", 15, 33]]], ["Fifteen hours post-superinfection, the culture medium was removed, clarified twice by centrifugation (1000 \u00c2 g), divided into aliquots, and stored at \u00c080 8C.", [["superinfection", "PROBLEM", 19, 33], ["the culture medium", "TEST", 35, 53], ["superinfection", "OBSERVATION", 19, 33]]], ["For PCLS the procedure was identical except that 10 6 pfu of SIV and 10 6 TCID 50 of PRRSV were administered.", [["SIV", "ORGANISM", 61, 64], ["PRRSV", "ORGANISM", 85, 90], ["SIV", "SPECIES", 61, 64], ["PRRSV", "SPECIES", 85, 90], ["PCLS the procedure", "TREATMENT", 4, 22], ["SIV", "TEST", 61, 64], ["PRRSV", "TREATMENT", 85, 90]]], ["Six slices, prepared from the same left lung lobe, were used for each condition.", [["slices", "ANATOMY", 4, 10], ["left lung lobe", "ANATOMY", 35, 49], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 40, 49], ["Six slices", "TEST", 0, 10], ["left lung", "ANATOMY", 35, 44], ["lobe", "ANATOMY_MODIFIER", 45, 49]]], ["The experiment was repeated four times using 4 different animals.Immunofluorescence analysis of precision-cut lung slicesStaining was performed after fixation of the slices with 3% paraformaldehyde (Sigma-Aldrich).", [["lung slices", "ANATOMY", 110, 121], ["slices", "ANATOMY", 166, 172], ["paraformaldehyde", "CHEMICAL", 181, 197], ["lung slices", "MULTI-TISSUE_STRUCTURE", 110, 121], ["paraformaldehyde", "SIMPLE_CHEMICAL", 181, 197], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 199, 212], ["Immunofluorescence analysis", "TEST", 65, 92], ["precision", "TEST", 96, 105], ["Staining", "TEST", 121, 129], ["fixation of the slices", "TREATMENT", 150, 172], ["3% paraformaldehyde (Sigma-Aldrich)", "TREATMENT", 178, 213], ["lung", "ANATOMY", 110, 114]]], ["For permeabilization, cells were treated with 0.2% Triton X-100 (Sigma-Aldrich), and then immunostained with sequential incubations of appropriate antibodies.", [["cells", "ANATOMY", 22, 27], ["Triton X-100", "CHEMICAL", 51, 63], ["Triton X-100", "CHEMICAL", 51, 63], ["cells", "CELL", 22, 27], ["Triton X-100", "SIMPLE_CHEMICAL", 51, 63], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 65, 78], ["antibodies", "PROTEIN", 147, 157], ["permeabilization", "PROBLEM", 4, 20], ["sequential incubations", "TREATMENT", 109, 131]]], ["To identify cells infected by SIV, rabbit polyclonal antibodies (Predicala and Zhou, 2013) recognizing viral nucleoprotein (dilution 1/500) were used followed by an appropriate goat anti-rabbit secondary antibody coupled to Alexafluor594 (dilution 1/ 400) (Invitrogen, Carlsbad, CA, USA) or Cy2 (dilution 1/400) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA).", [["cells", "ANATOMY", 12, 17], ["Alexafluor594", "CHEMICAL", 224, 237], ["Alexafluor594", "CHEMICAL", 224, 237], ["cells", "CELL", 12, 17], ["SIV", "ORGANISM", 30, 33], ["rabbit", "ORGANISM", 35, 41], ["goat", "ORGANISM", 177, 181], ["Alexafluor594", "SIMPLE_CHEMICAL", 224, 237], ["Cy2", "SIMPLE_CHEMICAL", 291, 294], ["rabbit polyclonal antibodies", "PROTEIN", 35, 63], ["2013", "PROTEIN", 85, 89], ["viral nucleoprotein", "PROTEIN", 103, 122], ["dilution 1/500", "PROTEIN", 124, 138], ["goat anti-rabbit secondary antibody", "PROTEIN", 177, 212], ["rabbit", "SPECIES", 35, 41], ["goat", "SPECIES", 177, 181], ["anti-rabbit", "SPECIES", 182, 193], ["SIV", "SPECIES", 30, 33], ["rabbit", "SPECIES", 35, 41], ["goat", "SPECIES", 177, 181], ["anti-rabbit", "SPECIES", 182, 193], ["ImmunoResearch", "SPECIES", 321, 335], ["cells infected", "PROBLEM", 12, 26], ["SIV", "TEST", 30, 33], ["rabbit polyclonal antibodies", "TEST", 35, 63], ["viral nucleoprotein (dilution", "TREATMENT", 103, 132], ["an appropriate goat anti-rabbit secondary antibody", "TREATMENT", 162, 212]]], ["To identify cells infected by PRRSV, a monoclonal antibody-fluorescein conjugate targeting the virus nucleocapsid protein was used (dilution 1/100) (Rural Technologies Inc., Brookings, SD, USA).", [["cells", "ANATOMY", 12, 17], ["fluorescein", "CHEMICAL", 59, 70], ["fluorescein", "CHEMICAL", 59, 70], ["cells", "CELL", 12, 17], ["PRRSV", "ORGANISM", 30, 35], ["fluorescein conjugate", "SIMPLE_CHEMICAL", 59, 80], ["monoclonal antibody", "PROTEIN", 39, 58], ["fluorescein conjugate", "PROTEIN", 59, 80], ["virus nucleocapsid protein", "PROTEIN", 95, 121], ["PRRSV", "SPECIES", 30, 35], ["PRRSV", "SPECIES", 30, 35], ["cells infected", "PROBLEM", 12, 26], ["PRRSV", "PROBLEM", 30, 35], ["a monoclonal antibody", "TEST", 37, 58], ["fluorescein conjugate", "TREATMENT", 59, 80], ["the virus nucleocapsid protein", "PROBLEM", 91, 121]]], ["Cy3-labeled monoclonal antibody recognizing beta-tubulin (dilution 1/600) (Sigma-Aldrich) was used as ciliated cell marker.Immunofluorescence analysis of precision-cut lung slicesCell nuclei of prepared slides were stained by incubation with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI) (Life Technologies Inc., Burlington, ON, Canada).", [["ciliated cell", "ANATOMY", 102, 115], ["lung slices", "ANATOMY", 168, 179], ["Cell nuclei", "ANATOMY", 179, 190], ["Cy3", "CHEMICAL", 0, 3], ["4 0 ,6 0 -diamidino-2-phenylindole", "CHEMICAL", 242, 276], ["4 0 ,6 0 -diamidino-2-phenylindole", "CHEMICAL", 242, 276], ["DAPI", "CHEMICAL", 278, 282], ["Cy3", "SIMPLE_CHEMICAL", 0, 3], ["beta-tubulin", "GENE_OR_GENE_PRODUCT", 44, 56], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 75, 88], ["ciliated cell", "CELL", 102, 115], ["lung slices", "MULTI-TISSUE_STRUCTURE", 168, 179], ["Cell", "CELL", 179, 183], ["4 0 ,6 0 -diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 242, 276], ["DAPI", "SIMPLE_CHEMICAL", 278, 282], ["Cy3-labeled monoclonal antibody", "PROTEIN", 0, 31], ["beta-tubulin", "PROTEIN", 44, 56], ["dilution 1/600", "PROTEIN", 58, 72], ["Cy3", "TEST", 0, 3], ["monoclonal antibody", "TEST", 12, 31], ["beta-tubulin (dilution", "TREATMENT", 44, 66], ["Sigma-Aldrich)", "TREATMENT", 75, 89], ["Immunofluorescence analysis", "TEST", 123, 150], ["precision", "TEST", 154, 163], ["diamidino", "TREATMENT", 252, 261], ["cell marker", "OBSERVATION", 111, 122], ["lung", "ANATOMY", 168, 172]]], ["For this purpose, DAPI was added to the slices and removed after incubation for 15 min (37 8C).", [["slices", "ANATOMY", 40, 46], ["DAPI", "CHEMICAL", 18, 22], ["DAPI", "SIMPLE_CHEMICAL", 18, 22], ["DAPI", "TREATMENT", 18, 22]]], ["Then, the cells were washed three times with PBS, and finally embedded in Mowiol 4-88 resin (Sigma-Aldrich) covered by no. 1\u00bd circular micro-cover glass (12 mm) (Electron Microscopy Sciences, Hatfield, PA, USA).", [["cells", "ANATOMY", 10, 15], ["Mowiol 4-88 resin", "CHEMICAL", 74, 91], ["cells", "CELL", 10, 15], ["Mowiol 4-88 resin", "SIMPLE_CHEMICAL", 74, 91], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 93, 106], ["the cells", "TREATMENT", 6, 15], ["PBS", "TREATMENT", 45, 48], ["circular micro-cover glass", "TEST", 126, 152], ["Electron Microscopy", "TEST", 162, 181], ["circular", "OBSERVATION_MODIFIER", 126, 134], ["cover glass", "OBSERVATION_MODIFIER", 141, 152]]], ["Image data were collected using a Leica SP5 laser-scanning microscope (Leica Microsystems Inc., Concord, ON, Canada).Immunofluorescence analysis of precision-cut lung slices2.6.", [["lung slices2.6", "ANATOMY", 162, 176], ["lung", "ORGAN", 162, 166], ["Image data", "TEST", 0, 10], ["a Leica SP5 laser", "TREATMENT", 32, 49], ["scanning microscope", "TEST", 50, 69], ["Immunofluorescence analysis", "TEST", 117, 144], ["precision", "TEST", 148, 157], ["lung", "ANATOMY", 162, 166]]], ["Validation of reference genes and transcript expression analysis using quantitative real-time polymerizing chain reaction All the selected transcript sequences were available in genome databases (http://www.ensembl.org/index.html and http://www.ncbi.nlm.nih.gov/nucleotide).", [["reference genes", "DNA", 14, 29], ["transcript expression analysis", "TEST", 34, 64], ["quantitative real-time polymerizing chain reaction", "TREATMENT", 71, 121]]], ["Slices and cells were suspended in Trizol reagent (Invitrogen) with ceramic beads (BioSpec Products, OK, USA) and total RNA was isolated using RNeasy Plus Mini Kit (Qiagen, Mississauga, ON, Canada).", [["Slices", "ANATOMY", 0, 6], ["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["Invitrogen", "SIMPLE_CHEMICAL", 51, 61], ["Slices and cells", "TREATMENT", 0, 16], ["Trizol reagent (Invitrogen", "TREATMENT", 35, 61], ["ceramic beads (BioSpec Products", "TREATMENT", 68, 99], ["total RNA", "TREATMENT", 114, 123], ["RNeasy Plus Mini Kit (Qiagen, Mississauga", "TREATMENT", 143, 184]]], ["The absence of genomic DNA contamination was verified using prepared RNA as a template for reverse transcription-quantitative real-time PCR (RT-qPCR).", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["genomic DNA contamination", "PROBLEM", 15, 40], ["reverse transcription", "TEST", 91, 112], ["time PCR", "TEST", 131, 139], ["DNA contamination", "OBSERVATION", 23, 40]]], ["RNA concentration was determined by measuring optical density at 260 nm (OD260) and the RNA quality was assessed by calculating OD260/OD280 ratio and by capillary electrophoresis (Agilent 2100 Bioanalyzer, Agilent Technologies Inc., Santa-Clara, USA). cDNA was generated from 100 to 200 ng of RNA per reaction and RT-PCR was performed using the SuperScript TM III Platinum 1 Two-Step RT-qPCR Kit as per the manufacturer's recommendations (Invitrogen).", [["capillary", "TISSUE", 153, 162], ["OD260", "PROTEIN", 128, 133], ["cDNA", "DNA", 252, 256], ["RNA concentration", "TEST", 0, 17], ["the RNA quality", "TEST", 84, 99], ["capillary electrophoresis", "TEST", 153, 178], ["cDNA", "TEST", 252, 256], ["RT-PCR", "TEST", 314, 320], ["the SuperScript TM III Platinum", "TREATMENT", 341, 372], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["The generated cDNA was stored at \u00c080 8C.", [["cDNA", "DNA", 14, 18]]], ["Diluted cDNA (3\u00c2) was combined with primer/ probe sets and IQ SYBR Green Supermix (Bio-Rad, Hercules, CA) according to the manufacturer's recommendations.", [["Diluted cDNA (3\u00c2)", "DNA", 0, 17], ["Diluted cDNA", "TREATMENT", 0, 12], ["primer/ probe sets", "TREATMENT", 36, 54], ["IQ SYBR", "TEST", 59, 66]]], ["The qPCR conditions were: 95 8C for 3 min, 45 cycles each of 15 s at 95 8C (denaturation), 30 s at the appropriate annealing temperature (Table 1) and 30 s at 72 8C (elongation).", [["The qPCR conditions", "TEST", 0, 19], ["denaturation", "TEST", 76, 88]]], ["Real-time assays were run on a Bio-Rad Cycler iQ (Bio-Rad).", [["a Bio-Rad Cycler iQ", "TREATMENT", 29, 48]]], ["The specificity of the qPCR reactions was assessed by analysing the melting curves of the products and size verification of the amplicons.", [["the qPCR reactions", "PROBLEM", 19, 37], ["the products", "TREATMENT", 86, 98], ["the amplicons", "PROBLEM", 124, 137], ["size", "OBSERVATION_MODIFIER", 103, 107]]], ["Samples were normalized internally using an average Cycle quantification (Cq) of the three most suitable reference genes out of seven in each sample to avoid any variation or artifacts in the target gene.", [["Samples", "ANATOMY", 0, 7], ["target gene", "DNA", 192, 203], ["Samples", "TEST", 0, 7], ["an average Cycle quantification", "TEST", 41, 72], ["artifacts in the target gene", "PROBLEM", 175, 203], ["artifacts", "OBSERVATION", 175, 184]]], ["These suitable reference genes were selected amongst beta-actin (ActB), beta-2-microglobulin (B2MI), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase 2 (HMBS), hypoxanthine phosphoribosyltransferase-1 (HPRT-1), ribosomal protein L-19 (RPL-19), and TATA box binding protein 1 (TPB-1).", [["glyceraldehyde-3-phosphate", "CHEMICAL", 101, 127], ["hypoxanthine", "CHEMICAL", 190, 202], ["glyceraldehyde-3-phosphate", "CHEMICAL", 101, 127], ["hydroxymethylbilane", "CHEMICAL", 151, 170], ["hypoxanthine", "CHEMICAL", 190, 202], ["beta-actin", "GENE_OR_GENE_PRODUCT", 53, 63], ["ActB", "GENE_OR_GENE_PRODUCT", 65, 69], ["beta-2-microglobulin", "GENE_OR_GENE_PRODUCT", 72, 92], ["B2MI", "GENE_OR_GENE_PRODUCT", 94, 98], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 101, 141], ["GAPDH", "GENE_OR_GENE_PRODUCT", 143, 148], ["hydroxymethylbilane synthase 2", "GENE_OR_GENE_PRODUCT", 151, 181], ["HMBS", "GENE_OR_GENE_PRODUCT", 183, 187], ["hypoxanthine phosphoribosyltransferase-1", "GENE_OR_GENE_PRODUCT", 190, 230], ["HPRT-1", "GENE_OR_GENE_PRODUCT", 232, 238], ["ribosomal protein L-19", "GENE_OR_GENE_PRODUCT", 241, 263], ["RPL-19", "GENE_OR_GENE_PRODUCT", 265, 271], ["TATA box binding protein 1", "GENE_OR_GENE_PRODUCT", 278, 304], ["TPB-1", "GENE_OR_GENE_PRODUCT", 306, 311], ["reference genes", "DNA", 15, 30], ["beta-actin", "PROTEIN", 53, 63], ["ActB", "PROTEIN", 65, 69], ["beta-2-microglobulin", "PROTEIN", 72, 92], ["B2MI", "PROTEIN", 94, 98], ["glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 101, 141], ["GAPDH", "PROTEIN", 143, 148], ["hydroxymethylbilane synthase 2", "PROTEIN", 151, 181], ["HMBS", "PROTEIN", 183, 187], ["hypoxanthine phosphoribosyltransferase-1", "PROTEIN", 190, 230], ["HPRT", "PROTEIN", 232, 236], ["ribosomal protein L-19 (RPL-19", "PROTEIN", 241, 271], ["TATA box binding protein 1", "PROTEIN", 278, 304], ["TPB-1", "PROTEIN", 306, 311], ["ActB", "TEST", 65, 69], ["beta-2-microglobulin (B2MI", "TEST", 72, 98], ["glyceraldehyde", "TEST", 101, 115], ["phosphate dehydrogenase (GAPDH", "TEST", 118, 148], ["hydroxymethylbilane synthase", "TREATMENT", 151, 179], ["hypoxanthine phosphoribosyltransferase-1", "TEST", 190, 230], ["HPRT", "TEST", 232, 236], ["ribosomal protein L", "TEST", 241, 260], ["RPL", "TEST", 265, 268], ["TATA box binding protein", "TREATMENT", 278, 302]]], ["The stability of these reference genes was determined using the geNorm application software (Vandesompele et al., 2002) .", [["reference genes", "DNA", 23, 38], ["stability", "OBSERVATION_MODIFIER", 4, 13]]], ["The correlation coefficients of the standard curves were >0.995 and the concentration of the test samples were calculated from the standard curves, according to the formula y = \u00c0M \u00c2 Cq + B, where M is the slope of the curve, Cq the first positive second derivative maximum of amplification curve calculated using PCR Miner (http://www.ewindup.info/miner/version2/data_submit.htm) (Zhao and Fernald, 2005) , and B the y-axis intercept.", [["the standard curves", "TEST", 32, 51], ["the test samples", "TEST", 89, 105], ["the standard curves", "TEST", 127, 146], ["the formula y", "TEST", 161, 174], ["the curve", "TEST", 214, 223], ["amplification curve", "TEST", 276, 295]]], ["All qPCRs assays, displaying efficiency between 90% and 110%, were performed following MIQE guidelines (Bustin et al., 2009; Taylor et al., 2010) . qPCR data were expressed as relative values after Genex macro analysis (Bio-Rad) (Vandesompele et al., 2002) using the Cq from the samples for the different transcripts.Interferon alpha and beta enzyme-linked immunosorbent assaysPig IFN enzyme-linked immunosorbent assays (ELI-SAs) were performed with a homemade ELISA using an R&D Systems antibody (Minneapolis, MN, USA) for IFNa and a MyBioSource kit (San Diego, CA, USA) commercial ELISA for IFNb.", [["Interferon alpha", "GENE_OR_GENE_PRODUCT", 317, 333], ["beta enzyme", "GENE_OR_GENE_PRODUCT", 338, 349], ["IFNb", "GENE_OR_GENE_PRODUCT", 593, 597], ["Interferon alpha", "PROTEIN", 317, 333], ["IFN", "PROTEIN", 381, 384], ["IFNb", "PROTEIN", 593, 597], ["Pig", "SPECIES", 377, 380], ["Pig", "SPECIES", 377, 380], ["All qPCRs assays", "TEST", 0, 16], ["efficiency", "TEST", 29, 39], ["qPCR data", "TEST", 148, 157], ["Genex macro analysis", "TEST", 198, 218], ["Interferon alpha", "TREATMENT", 317, 333], ["beta enzyme", "TEST", 338, 349], ["immunosorbent assays", "TEST", 357, 377], ["Pig IFN enzyme", "TEST", 377, 391], ["immunosorbent assays", "TEST", 399, 419], ["a homemade ELISA", "TEST", 450, 466], ["IFNa", "PROBLEM", 524, 528]]], ["For IFNa detection, polystyrene microtiter plates (Immulon 2, Dynex Technology Inc., Chantilly, VA, USA) were coated with the capture antibody mouse anti-recombinant porcine IFNa clone K9 (R&D no. 27100-1) at a concentration of 1 mg/ml in coating buffer.Interferon alpha and beta enzyme-linked immunosorbent assaysRecombinant porcine IFNa (Endogen, Rockford, IL, USA; rPo IFNa; 2000 pg/ml) was used as standard.", [["polystyrene", "CHEMICAL", 20, 31], ["mouse", "ORGANISM", 143, 148], ["porcine", "ORGANISM", 166, 173], ["Interferon alpha", "GENE_OR_GENE_PRODUCT", 254, 270], ["beta enzyme", "GENE_OR_GENE_PRODUCT", 275, 286], ["porcine", "ORGANISM", 326, 333], ["IFNa", "GENE_OR_GENE_PRODUCT", 334, 338], ["IFNa", "PROTEIN", 4, 8], ["Interferon alpha", "PROTEIN", 254, 270], ["mouse", "SPECIES", 143, 148], ["porcine", "SPECIES", 166, 173], ["porcine", "SPECIES", 326, 333], ["mouse", "SPECIES", 143, 148], ["porcine", "SPECIES", 326, 333], ["IFNa detection", "TEST", 4, 18], ["polystyrene microtiter plates", "TEST", 20, 49], ["Immulon", "TEST", 51, 58], ["Interferon alpha", "TREATMENT", 254, 270], ["beta enzyme", "TEST", 275, 286], ["immunosorbent assays", "TEST", 294, 314], ["Recombinant porcine IFNa (Endogen, Rockford, IL", "TREATMENT", 314, 361]]], ["Standards and culture supernatants were diluted in tris-buffered saline and Tween 20 (TBST, Sigma-Aldrich)-0.1% skim milk and added to the coated plates.", [["supernatants", "ANATOMY", 22, 34], ["skim milk", "ANATOMY", 112, 121], ["tris", "CHEMICAL", 51, 55], ["Tween 20", "CHEMICAL", 76, 84], ["tris-buffered saline", "SIMPLE_CHEMICAL", 51, 71], ["Tween 20", "SIMPLE_CHEMICAL", 76, 84], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 92, 105], ["skim", "ORGANISM", 112, 116], ["milk", "ORGANISM_SUBSTANCE", 117, 121], ["culture supernatants", "TEST", 14, 34], ["buffered saline", "TREATMENT", 56, 71], ["Tween", "TREATMENT", 76, 81], ["Sigma-Aldrich)", "TREATMENT", 92, 106], ["the coated plates", "TREATMENT", 135, 152]]], ["After overnight incubation at 4 8C, biotinylated mouse anti-recombinant porcine IFN-a clone F17 (R&D no. 27105-1; 1/1000) detection antibody was added to the appropriate wells.", [["mouse", "ORGANISM", 49, 54], ["porcine", "ORGANISM", 72, 79], ["IFN", "GENE_OR_GENE_PRODUCT", 80, 83], ["clone", "ORGANISM", 86, 91], ["IFN", "PROTEIN", 80, 83], ["mouse", "SPECIES", 49, 54], ["porcine", "SPECIES", 72, 79], ["mouse", "SPECIES", 49, 54], ["biotinylated mouse anti-recombinant porcine IFN", "TREATMENT", 36, 83], ["detection antibody", "TEST", 122, 140]]], ["Sample concentrations were calculated using Softmax Pro 5.2 version software (Molecular Devices, Sunnyvale, CA, USA).", [["Sample concentrations", "TEST", 0, 21], ["Softmax Pro", "TREATMENT", 44, 55]]], ["IFNb ELISA was performed according to the supplier's protocol.Statistical analysisData for the comparison of differences in relative mRNA expression between cells and tissues were expressed as relative values.", [["cells", "ANATOMY", 157, 162], ["tissues", "ANATOMY", 167, 174], ["IFNb", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 157, 162], ["tissues", "TISSUE", 167, 174], ["IFNb", "PROTEIN", 0, 4], ["relative mRNA expression between cells and tissues", "PROBLEM", 124, 174]]], ["All statistical analyses were done using computer software Prism 6 for Windows (version 6.02; GraphPad Software, San Diego, CA, USA).", [["All statistical analyses", "TEST", 0, 24]]], ["To account for the non-normal distribution of the data, all data were sorted by rank status prior to ANOVA statistical analysis.", [["all data", "TEST", 56, 64], ["ANOVA statistical analysis", "TEST", 101, 127]]], ["Tukey's test was used to compare the means of the ranks among the groups.", [["Tukey's test", "TEST", 0, 12]]], ["P values less than 0.05 were considered significant.Viability of porcine precision-cut lung slicesAround 200 PCLS per lung were generated for each pig, sufficient to perform all of the experiments.", [["lung slices", "ANATOMY", 87, 98], ["lung", "ANATOMY", 118, 122], ["porcine", "ORGANISM", 65, 72], ["lung slices", "MULTI-TISSUE_STRUCTURE", 87, 98], ["lung", "ORGAN", 118, 122], ["pig", "ORGANISM", 147, 150], ["porcine", "SPECIES", 65, 72], ["pig", "SPECIES", 147, 150], ["P values", "TEST", 0, 8], ["porcine precision", "TEST", 65, 82], ["porcine precision", "OBSERVATION", 65, 82], ["lung", "ANATOMY", 87, 91], ["lung", "ANATOMY", 118, 122]]], ["In the PCLS, the beating of the ciliated bronchial epithelium was observable 24 h and 96 h after their preparation (Fig. 1A) .", [["bronchial epithelium", "ANATOMY", 41, 61], ["ciliated bronchial epithelium", "TISSUE", 32, 61], ["PCLS", "ANATOMY", 7, 11], ["ciliated", "ANATOMY_MODIFIER", 32, 40], ["bronchial epithelium", "ANATOMY", 41, 61]]], ["Additionally, bronchoconstriction could be triggered by the use of methacholine 10 \u00c04 M in the four days following slice preparation (Fig. 1B) and subsequently reversed by removal of the drug (Fig. 1C) .", [["slice", "ANATOMY", 115, 120], ["methacholine", "CHEMICAL", 67, 79], ["methacholine", "CHEMICAL", 67, 79], ["bronchoconstriction", "PROBLEM", 14, 33], ["methacholine", "TREATMENT", 67, 79], ["slice preparation (Fig", "TREATMENT", 115, 137], ["the drug (Fig", "TREATMENT", 183, 196], ["bronchoconstriction", "OBSERVATION", 14, 33]]], ["These observations provide evidence that porcine PCLS remained viable for up to 96 h under the incubation conditions described.Different cellular targets for PRRSV and SIV in lung explantsConfocal microscopy was utilized to visualize cells in situ upon infection with PRRSV and/or SIV.", [["cellular", "ANATOMY", 137, 145], ["lung explants", "ANATOMY", 175, 188], ["cells", "ANATOMY", 234, 239], ["situ", "ANATOMY", 243, 247], ["PCLS", "CHEMICAL", 49, 53], ["infection", "DISEASE", 253, 262], ["porcine", "ORGANISM", 41, 48], ["PCLS", "SIMPLE_CHEMICAL", 49, 53], ["cellular", "CELL", 137, 145], ["PRRSV", "ORGANISM", 158, 163], ["SIV", "ORGANISM", 168, 171], ["lung", "ORGAN", 175, 179], ["cells", "CELL", 234, 239], ["PRRSV", "ORGANISM", 268, 273], ["SIV", "ORGANISM", 281, 284], ["porcine", "SPECIES", 41, 48], ["PRRSV", "SPECIES", 158, 163], ["porcine", "SPECIES", 41, 48], ["PRRSV", "SPECIES", 158, 163], ["SIV", "SPECIES", 168, 171], ["PRRSV", "SPECIES", 268, 273], ["SIV", "SPECIES", 281, 284], ["porcine PCLS", "TREATMENT", 41, 53], ["Different cellular targets", "TREATMENT", 127, 153], ["PRRSV", "PROBLEM", 158, 163], ["SIV in lung explants", "TREATMENT", 168, 188], ["Confocal microscopy", "TEST", 188, 207], ["infection", "PROBLEM", 253, 262], ["PRRSV", "PROBLEM", 268, 273], ["SIV", "PROBLEM", 281, 284], ["cellular targets", "OBSERVATION", 137, 153], ["lung", "ANATOMY", 175, 179], ["infection", "OBSERVATION", 253, 262]]], ["In all the infected slices, we observed that SIV was restricted to the bronchial epithelial cells ( Fig. 2A and C) , and no viral nucleoproteins were detected in other parts of the slices -for instance, alveolar epithelial cells and macrophages-.", [["slices", "ANATOMY", 20, 26], ["bronchial epithelial cells", "ANATOMY", 71, 97], ["slices", "ANATOMY", 181, 187], ["alveolar epithelial cells", "ANATOMY", 203, 228], ["macrophages", "ANATOMY", 233, 244], ["slices", "MULTI-TISSUE_STRUCTURE", 20, 26], ["SIV", "ORGANISM", 45, 48], ["bronchial epithelial cells", "CELL", 71, 97], ["Fig. 2A", "CELL", 100, 107], ["C", "CELL", 112, 113], ["slices", "MULTI-TISSUE_STRUCTURE", 181, 187], ["alveolar epithelial cells", "CELL", 203, 228], ["macrophages", "CELL", 233, 244], ["bronchial epithelial cells", "CELL_TYPE", 71, 97], ["viral nucleoproteins", "PROTEIN", 124, 144], ["alveolar epithelial cells", "CELL_TYPE", 203, 228], ["macrophages", "CELL_TYPE", 233, 244], ["SIV", "SPECIES", 45, 48], ["SIV", "PROBLEM", 45, 48], ["the bronchial epithelial cells", "TEST", 67, 97], ["viral nucleoproteins", "PROBLEM", 124, 144], ["the slices", "TEST", 177, 187], ["alveolar epithelial cells", "PROBLEM", 203, 228], ["macrophages", "PROBLEM", 233, 244], ["infected", "OBSERVATION", 11, 19], ["bronchial epithelial", "ANATOMY", 71, 91], ["no", "UNCERTAINTY", 121, 123], ["viral nucleoproteins", "OBSERVATION", 124, 144], ["alveolar", "ANATOMY_MODIFIER", 203, 211], ["epithelial cells", "OBSERVATION", 212, 228], ["macrophages", "OBSERVATION", 233, 244]]], ["Even if the possible infection of the cells cannot be excluded, it appears to be an infrequent event in the conditions examined here.", [["cells", "ANATOMY", 38, 43], ["infection", "DISEASE", 21, 30], ["cells", "CELL", 38, 43], ["infection of the cells", "PROBLEM", 21, 43], ["possible", "UNCERTAINTY", 12, 20], ["infection", "OBSERVATION", 21, 30], ["cannot be excluded", "UNCERTAINTY", 44, 62], ["infrequent", "OBSERVATION_MODIFIER", 84, 94]]], ["On the contrary, PRRSV nucleocapsid was only detected in deeper layers of the tissue, below the epithelium and in alveoli (Figs.", [["deeper layers", "ANATOMY", 57, 70], ["tissue", "ANATOMY", 78, 84], ["epithelium", "ANATOMY", 96, 106], ["alveoli", "ANATOMY", 114, 121], ["PRRSV", "ORGANISM", 17, 22], ["layers", "TISSUE", 64, 70], ["tissue", "TISSUE", 78, 84], ["epithelium", "TISSUE", 96, 106], ["alveoli", "MULTI-TISSUE_STRUCTURE", 114, 121], ["PRRSV nucleocapsid", "PROTEIN", 17, 35], ["PRRSV", "SPECIES", 17, 22], ["PRRSV nucleocapsid", "PROBLEM", 17, 35], ["nucleocapsid", "OBSERVATION", 23, 35], ["deeper", "ANATOMY_MODIFIER", 57, 63], ["layers", "ANATOMY_MODIFIER", 64, 70], ["tissue", "ANATOMY", 78, 84], ["epithelium", "ANATOMY_MODIFIER", 96, 106], ["alveoli", "ANATOMY", 114, 121]]], ["In the alveolus, the PRRSV staining was associated with cells stretched across a large surface of the alveolus, likely type 1 pneumocytes (Fig. 3) .", [["alveolus", "ANATOMY", 7, 15], ["cells", "ANATOMY", 56, 61], ["surface", "ANATOMY", 87, 94], ["alveolus", "ANATOMY", 102, 110], ["type 1 pneumocytes", "ANATOMY", 119, 137], ["alveolus", "ORGAN", 7, 15], ["PRRSV", "ORGANISM", 21, 26], ["cells", "CELL", 56, 61], ["surface", "CELLULAR_COMPONENT", 87, 94], ["alveolus", "ORGAN", 102, 110], ["PRRSV", "SPECIES", 21, 26], ["the PRRSV staining", "PROBLEM", 17, 35], ["cells", "PROBLEM", 56, 61], ["type 1 pneumocytes", "PROBLEM", 119, 137], ["alveolus", "ANATOMY", 7, 15], ["PRRSV staining", "OBSERVATION", 21, 35], ["large", "OBSERVATION_MODIFIER", 81, 86], ["surface", "OBSERVATION_MODIFIER", 87, 94], ["alveolus", "ANATOMY", 102, 110], ["likely", "UNCERTAINTY", 112, 118], ["type 1", "OBSERVATION_MODIFIER", 119, 125], ["pneumocytes", "OBSERVATION", 126, 137]]], ["Additionally, the staining was also associated with cells presenting a macrophage-like appearance (Fig. 3) .", [["cells", "ANATOMY", 52, 57], ["macrophage", "ANATOMY", 71, 81], ["cells", "CELL", 52, 57], ["macrophage", "CELL", 71, 81], ["the staining", "PROBLEM", 14, 26], ["cells", "PROBLEM", 52, 57], ["macrophage", "OBSERVATION_MODIFIER", 71, 81]]], ["No detection was observed in cells co-infected by PRRSV and SIV in slices (see for instance Figs.", [["cells", "ANATOMY", 29, 34], ["slices", "ANATOMY", 67, 73], ["cells", "CELL", 29, 34], ["PRRSV", "ORGANISM", 50, 55], ["SIV", "ORGANISM", 60, 63], ["slices", "MULTI-TISSUE_STRUCTURE", 67, 73], ["PRRSV", "SPECIES", 50, 55], ["PRRSV", "SPECIES", 50, 55], ["SIV", "SPECIES", 60, 63]]], ["2C and 3), while many single-infected cells were observed throughout the tissue.", [["cells", "ANATOMY", 38, 43], ["tissue", "ANATOMY", 73, 79], ["cells", "CELL", 38, 43], ["tissue", "TISSUE", 73, 79], ["single-infected cells", "CELL_TYPE", 22, 43], ["many single-infected cells", "PROBLEM", 17, 43], ["infected cells", "OBSERVATION", 29, 43], ["tissue", "ANATOMY", 73, 79]]], ["Regarding PRRSV VR-2385 nucleoprotein transcript expression in the PCLS, no expression was observed in the control slices or the slices only infected with SIV H1N1 (Fig. 4) .", [["PCLS", "ANATOMY", 67, 71], ["slices", "ANATOMY", 115, 121], ["slices", "ANATOMY", 129, 135], ["PRRSV", "ORGANISM", 10, 15], ["VR-2385", "GENE_OR_GENE_PRODUCT", 16, 23], ["PCLS", "CANCER", 67, 71], ["SIV H1N1", "ORGANISM", 155, 163], ["PRRSV", "SPECIES", 10, 15], ["SIV H1N1", "SPECIES", 155, 163], ["PRRSV VR-2385", "SPECIES", 10, 23], ["SIV H1N1", "SPECIES", 155, 163], ["PRRSV VR", "TEST", 10, 18], ["nucleoprotein transcript expression in the PCLS", "PROBLEM", 24, 71], ["PCLS", "ANATOMY", 67, 71], ["no", "UNCERTAINTY", 73, 75]]], ["In most of the conditions where the PRRSV viruses were used, PRRSV transcript expression was detected at similar levels (detection around Cq 22) with no statistically significant differences between conditions (Fig. 4) .", [["PRRSV", "ORGANISM", 36, 41], ["PRRSV", "ORGANISM", 61, 66], ["PRRSV viruses", "SPECIES", 36, 49], ["PRRSV", "SPECIES", 61, 66], ["the PRRSV viruses", "PROBLEM", 32, 49], ["PRRSV transcript expression", "TREATMENT", 61, 88], ["PRRSV viruses", "OBSERVATION", 36, 49]]], ["PRRSV transcript expression was only significantly lower (P < 0.05) than in the ''PRRSV'' condition when slices were superinfected with PRRSV 3 h after SIV infection (SIV-3h-PRRSV) (Fig. 4) .", [["slices", "ANATOMY", 105, 111], ["SIV infection", "DISEASE", 152, 165], ["PRRSV", "ORGANISM", 0, 5], ["PRRSV", "ORGANISM", 82, 87], ["PRRSV", "ORGANISM", 136, 141], ["SIV", "ORGANISM", 152, 155], ["SIV-3h-PRRSV", "ORGANISM", 167, 179], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 82, 87], ["PRRSV", "SPECIES", 136, 141], ["SIV", "SPECIES", 152, 155], ["SIV-3h-PRRSV", "SPECIES", 167, 179], ["PRRSV transcript expression", "TEST", 0, 27], ["PRRSV", "PROBLEM", 136, 141], ["SIV infection", "PROBLEM", 152, 165], ["SIV", "TEST", 167, 170], ["significantly", "OBSERVATION_MODIFIER", 37, 50], ["lower", "OBSERVATION_MODIFIER", 51, 56]]], ["Similar observations were made for SIV (M protein transcripts) in PCLS (detection around Cq 20), except for ''SIV-3h-PRRSV'', where the transcript expression was not significantly lower than in the other conditions where SIV had been used (Fig. 4) .Different cellular targets for PRRSV and SIV in lung explantsIn PAMs, PRRSV transcript expression was also not identified in the control slices or the slices infected only with SIV (Fig. 4) .", [["PCLS", "ANATOMY", 66, 70], ["cellular", "ANATOMY", 259, 267], ["lung explants", "ANATOMY", 297, 310], ["slices", "ANATOMY", 386, 392], ["slices", "ANATOMY", 400, 406], ["SIV", "ORGANISM", 35, 38], ["M protein", "GENE_OR_GENE_PRODUCT", 40, 49], ["PCLS", "PATHOLOGICAL_FORMATION", 66, 70], ["SIV", "ORGANISM", 110, 113], ["PRRSV", "ORGANISM", 117, 122], ["SIV", "ORGANISM", 221, 224], ["cellular", "CELL", 259, 267], ["PRRSV", "ORGANISM", 280, 285], ["SIV", "ORGANISM", 290, 293], ["lung", "ORGAN", 297, 301], ["PRRSV", "ORGANISM", 319, 324], ["SIV", "ORGANISM", 426, 429], ["PAMs", "CELL_TYPE", 313, 317], ["PRRSV", "SPECIES", 280, 285], ["SIV", "SPECIES", 35, 38], ["SIV-3h-PRRSV", "SPECIES", 110, 122], ["SIV", "SPECIES", 221, 224], ["PRRSV", "SPECIES", 280, 285], ["SIV", "SPECIES", 290, 293], ["PRRSV", "SPECIES", 319, 324], ["SIV", "SPECIES", 426, 429], ["SIV (M protein transcripts", "TREATMENT", 35, 61], ["PCLS", "TEST", 66, 70], ["SIV", "PROBLEM", 221, 224], ["Different cellular targets", "TREATMENT", 249, 275], ["PRRSV", "PROBLEM", 280, 285], ["SIV in lung explants", "TREATMENT", 290, 310], ["PRRSV transcript expression", "PROBLEM", 319, 346], ["significantly", "OBSERVATION_MODIFIER", 166, 179], ["lower", "OBSERVATION_MODIFIER", 180, 185], ["cellular targets", "OBSERVATION", 259, 275], ["lung", "ANATOMY", 297, 301], ["PAMs", "OBSERVATION", 313, 317], ["PRRSV", "OBSERVATION", 319, 324], ["transcript expression", "OBSERVATION", 325, 346]]], ["When PRRSV was used to superinfect the cells 3 h after SIV (SIV-3h-PRRSV), the transcript expression was significantly lower (P < 0.05) than in the condition where PRRSV was used alone (detection around Cq 13) and the condition ''PRRSV-3h-SIV'' (Fig. 4) .", [["cells", "ANATOMY", 39, 44], ["PRRSV", "ORGANISM", 5, 10], ["cells", "CELL", 39, 44], ["SIV", "ORGANISM", 55, 58], ["SIV-3h-PRRSV", "ORGANISM", 60, 72], ["PRRSV", "ORGANISM", 164, 169], ["SIV", "ORGANISM", 239, 242], ["PRRSV", "SPECIES", 5, 10], ["SIV", "SPECIES", 55, 58], ["SIV-3h-PRRSV", "SPECIES", 60, 72], ["PRRSV", "SPECIES", 164, 169], ["PRRSV-3h-SIV", "SPECIES", 230, 242], ["PRRSV", "PROBLEM", 5, 10], ["SIV", "TEST", 55, 58], ["the transcript expression", "TEST", 75, 100], ["PRRSV", "PROBLEM", 164, 169], ["Cq", "TEST", 203, 205], ["the condition", "TEST", 214, 227], ["PRRSV", "TEST", 230, 235], ["significantly", "OBSERVATION_MODIFIER", 105, 118], ["lower", "OBSERVATION_MODIFIER", 119, 124]]], ["Regarding SIV, transcript expression was only observed in the conditions where the virus was used, as anticipated (Fig. 4) (detection around Cq 18).", [["SIV", "ORGANISM", 10, 13], ["SIV", "SPECIES", 10, 13], ["SIV", "PROBLEM", 10, 13], ["transcript expression", "PROBLEM", 15, 36], ["the virus", "PROBLEM", 79, 88]]], ["Conditions ''PRRSV + SIV'' or ''PRRSV-3h-SIV'', showed lower expression of the SIV transcripts.", [["PRRSV", "ORGANISM", 13, 18], ["SIV", "ORGANISM", 21, 24], ["''PRRSV-3h-SIV", "ORGANISM", 30, 44], ["SIV", "ORGANISM", 79, 82], ["SIV transcripts", "RNA", 79, 94], ["PRRSV", "SPECIES", 13, 18], ["PRRSV", "SPECIES", 32, 37], ["SIV", "SPECIES", 21, 24], ["PRRSV-3h-SIV", "SPECIES", 32, 44], ["SIV", "SPECIES", 79, 82], ["SIV transcripts", "OBSERVATION", 79, 94]]], ["The expression of SIV transcripts was significantly lower (P < 0.05) in the co-infection conditions than in the condition ''SIV-3h-PRRSV'' (Fig. 4) .Host transcript expression in the precision-cut lung slices and the alveolar macrophagesNext, various host genes involved in the response to the viral infections were analyzed (Tables 1 and 2) for alterations in mRNA levels.", [["lung slices", "ANATOMY", 197, 208], ["alveolar macrophages", "ANATOMY", 217, 237], ["co-infection", "DISEASE", 76, 88], ["viral infections", "DISEASE", 294, 310], ["SIV", "ORGANISM", 18, 21], ["SIV-3h-PRRSV", "ORGANISM", 124, 136], ["lung slices", "MULTI-TISSUE_STRUCTURE", 197, 208], ["alveolar macrophages", "CELL", 217, 237], ["SIV transcripts", "RNA", 18, 33], ["alveolar macrophages", "CELL_TYPE", 217, 237], ["SIV", "SPECIES", 18, 21], ["SIV-3h-PRRSV", "SPECIES", 124, 136], ["SIV transcripts", "PROBLEM", 18, 33], ["the co-infection conditions", "PROBLEM", 72, 99], ["cut lung slices", "TEST", 193, 208], ["the alveolar macrophages", "PROBLEM", 213, 237], ["the viral infections", "PROBLEM", 290, 310], ["alterations in mRNA levels", "PROBLEM", 346, 372], ["SIV transcripts", "OBSERVATION", 18, 33], ["lung", "ANATOMY", 197, 201], ["alveolar macrophages", "ANATOMY", 217, 237]]], ["To study the response of PCLS and PAMs to both viruses using RT-qPCR assays, a selection of seven reference genes was chosen based on previous studies (Delgado-Ortega et al., 2013; Erkens et al., 2006; Nygard et al., 2007) .", [["PCLS", "CELL", 25, 29], ["PCLS", "CELL_TYPE", 25, 29], ["PCLS", "TEST", 25, 29], ["PAMs", "PROBLEM", 34, 38], ["RT-qPCR assays", "TEST", 61, 75], ["previous studies", "TEST", 134, 150]]], ["Amongst these genes, we identified HMBS2, HPRT-1, and TBP-1 as the three most suitable genes for transcript normalization for the PCLS.", [["HMBS2", "GENE_OR_GENE_PRODUCT", 35, 40], ["HPRT-1", "GENE_OR_GENE_PRODUCT", 42, 48], ["TBP-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["HMBS2", "DNA", 35, 40], ["HPRT-1", "DNA", 42, 48], ["TBP-1", "DNA", 54, 59], ["HMBS2", "TEST", 35, 40], ["HPRT", "TEST", 42, 46], ["TBP", "TEST", 54, 57]]], ["For these three reference genes, the M values (0.211, 0.211, and 0.305, respectively) were below the threshold (M value = 1) defined for stably expressed reference genes in heterogeneous samples (Hellemans et al., 2007) .", [["samples", "ANATOMY", 187, 194], ["reference genes", "DNA", 154, 169], ["the M values", "TEST", 33, 45], ["heterogeneous", "OBSERVATION_MODIFIER", 173, 186]]], ["Regarding PAMs, the three most stable reference genes were HPRT-1, RPL-19, and HMBS2 (M values: 0.441, 0.366, and 0.366, respectively) (supplementary Fig. 1) .", [["HPRT-1", "GENE_OR_GENE_PRODUCT", 59, 65], ["RPL-19", "GENE_OR_GENE_PRODUCT", 67, 73], ["HMBS2", "GENE_OR_GENE_PRODUCT", 79, 84], ["reference genes", "DNA", 38, 53], ["HPRT-1", "DNA", 59, 65], ["RPL", "DNA", 67, 70], ["HMBS2", "DNA", 79, 84], ["PAMs", "PROBLEM", 10, 14], ["HPRT", "TEST", 59, 63], ["RPL", "TEST", 67, 70], ["HMBS2", "TEST", 79, 84], ["M values", "TEST", 86, 94]]], ["The M values for these genes were below the threshold (M value = 0.5) defined for stably expressed genes in homogeneous sample panels (Hellemans et al., 2007) .Transcripts involved in viral recognitionRegarding transcripts involved in viral recognition (Tables 1 and 2) , several observations were made in experiments where PCLS (Fig. 5A) and PAMs (Fig. 5B) were used.", [["The M values", "TEST", 0, 12], ["these genes", "TEST", 17, 28], ["PCLS (Fig. 5A", "TREATMENT", 324, 337], ["PAMs (Fig. 5B)", "TREATMENT", 343, 357]]], ["None of the pathogen recognition receptor (PRR) transcripts was significantly over-expressed in response to PRRSV in the PCLS although one of them (TLR9) had a small, but not statistically significant, increase (Fig. 5A) .", [["PCLS", "ANATOMY", 121, 125], ["pathogen recognition receptor", "GENE_OR_GENE_PRODUCT", 12, 41], ["PRR", "GENE_OR_GENE_PRODUCT", 43, 46], ["PRRSV", "ORGANISM", 108, 113], ["PCLS", "CANCER", 121, 125], ["TLR9", "GENE_OR_GENE_PRODUCT", 148, 152], ["pathogen recognition receptor (PRR) transcripts", "RNA", 12, 59], ["TLR9", "PROTEIN", 148, 152], ["PRRSV", "SPECIES", 108, 113], ["PRRSV", "PROBLEM", 108, 113], ["small", "OBSERVATION_MODIFIER", 160, 165], ["increase", "OBSERVATION_MODIFIER", 202, 210]]], ["On the contrary, SIV significantly (P < 0.05) induced the expression of DAI, LGP2, MDA5, RIG-I, and TLR3 genes (Fig. 5A) .", [["SIV", "ORGANISM", 17, 20], ["DAI", "GENE_OR_GENE_PRODUCT", 72, 75], ["LGP2", "GENE_OR_GENE_PRODUCT", 77, 81], ["MDA5", "GENE_OR_GENE_PRODUCT", 83, 87], ["RIG-I", "GENE_OR_GENE_PRODUCT", 89, 94], ["TLR3", "GENE_OR_GENE_PRODUCT", 100, 104], ["DAI, LGP2, MDA5, RIG-I, and TLR3 genes", "DNA", 72, 110], ["SIV", "SPECIES", 17, 20], ["DAI", "PROBLEM", 72, 75], ["LGP2", "TEST", 77, 81], ["MDA5", "TEST", 83, 87], ["DAI", "OBSERVATION", 72, 75], ["MDA5", "ANATOMY", 83, 87], ["TLR3 genes", "OBSERVATION", 100, 110]]], ["These transcripts were generally expressed at a similar level to when PRRSV was superinfecting the PCLS 3 h after SIV (SIV-3h-PRRSV) (Fig. 5A) .", [["PRRSV", "ORGANISM", 70, 75], ["SIV", "ORGANISM", 114, 117], ["SIV-3h-PRRSV", "ORGANISM", 119, 131], ["PRRSV", "SPECIES", 70, 75], ["SIV", "SPECIES", 114, 117], ["SIV-3h-PRRSV", "SPECIES", 119, 131], ["PRRSV", "PROBLEM", 70, 75], ["SIV", "TEST", 114, 117]]], ["However, when PRRSV was administered to the slices 3 h prior to SIV (PRRSV-3h-SIV), a lower expression than in the coinfection condition ''PRRSV + SIV'' was observed for most of the transcripts, with the exception of TLR8 and TLR9.", [["slices", "ANATOMY", 44, 50], ["coinfection", "DISEASE", 115, 126], ["PRRSV", "ORGANISM", 14, 19], ["SIV", "ORGANISM", 64, 67], ["PRRSV-3h-SIV", "ORGANISM", 69, 81], ["PRRSV", "ORGANISM", 139, 144], ["SIV", "ORGANISM", 147, 150], ["TLR8", "GENE_OR_GENE_PRODUCT", 217, 221], ["TLR9", "GENE_OR_GENE_PRODUCT", 226, 230], ["TLR8", "PROTEIN", 217, 221], ["TLR9", "PROTEIN", 226, 230], ["PRRSV", "SPECIES", 14, 19], ["SIV", "SPECIES", 64, 67], ["PRRSV-3h-SIV", "SPECIES", 69, 81], ["PRRSV + SIV", "SPECIES", 139, 150], ["PRRSV", "TREATMENT", 14, 19], ["SIV", "TEST", 64, 67], ["PRRSV", "TEST", 69, 74], ["a lower expression", "PROBLEM", 84, 102], ["the coinfection condition", "PROBLEM", 111, 136], ["PRRSV", "PROBLEM", 139, 144], ["TLR8 and TLR9", "TREATMENT", 217, 230], ["coinfection", "OBSERVATION", 115, 126], ["TLR8", "OBSERVATION", 217, 221]]], ["This lower induction was statistically significant for MDA5, RIG-I, and TLR3 transcripts in some conditions (see Fig. 5A ).", [["MDA5", "GENE_OR_GENE_PRODUCT", 55, 59], ["RIG-I", "GENE_OR_GENE_PRODUCT", 61, 66], ["TLR3", "GENE_OR_GENE_PRODUCT", 72, 76], ["MDA5, RIG-I, and TLR3 transcripts", "RNA", 55, 88], ["MDA5", "PROBLEM", 55, 59], ["TLR3 transcripts", "TREATMENT", 72, 88], ["TLR3 transcripts", "OBSERVATION", 72, 88]]], ["Except for TLR3 and RIG-I, the induction of transcript expression was not statistically higher in the situation of co-infection compared to single infections (Fig. 5A ).", [["co-infection", "DISEASE", 115, 127], ["infections", "DISEASE", 147, 157], ["TLR3", "GENE_OR_GENE_PRODUCT", 11, 15], ["RIG-I", "GENE_OR_GENE_PRODUCT", 20, 25], ["TLR3", "PROTEIN", 11, 15], ["RIG-I", "PROTEIN", 20, 25], ["TLR3", "PROBLEM", 11, 15], ["transcript expression", "PROBLEM", 44, 65], ["co-infection", "PROBLEM", 115, 127], ["single infections", "PROBLEM", 140, 157], ["co-infection", "OBSERVATION", 115, 127]]], ["In PAMs, PRRSV did not significantly induce the expression of viral recognition transcripts, similarly to PCLS (Fig. 5B ).", [["PRRSV", "ORGANISM", 9, 14], ["viral recognition transcripts", "PROTEIN", 62, 91], ["PCLS", "PROTEIN", 106, 110], ["PRRSV", "SPECIES", 9, 14], ["PRRSV", "PROBLEM", 9, 14], ["viral recognition transcripts", "PROBLEM", 62, 91], ["PAMs", "OBSERVATION", 3, 7]]], ["However, for DAI, LGP2, MDA5, RIG-I, and TLR7 there was a marked increase in the expression of the transcripts in response to PRRSV when compared to controls (Fig. 5B) .", [["LGP2", "GENE_OR_GENE_PRODUCT", 18, 22], ["MDA5", "GENE_OR_GENE_PRODUCT", 24, 28], ["RIG-I", "GENE_OR_GENE_PRODUCT", 30, 35], ["TLR7", "GENE_OR_GENE_PRODUCT", 41, 45], ["PRRSV", "ORGANISM", 126, 131], ["DAI", "PROTEIN", 13, 16], ["LGP2", "PROTEIN", 18, 22], ["MDA5", "PROTEIN", 24, 28], ["RIG", "PROTEIN", 30, 33], ["TLR7", "PROTEIN", 41, 45], ["PRRSV", "SPECIES", 126, 131], ["DAI", "PROBLEM", 13, 16], ["LGP2", "TEST", 18, 22], ["TLR7", "TREATMENT", 41, 45], ["a marked increase", "PROBLEM", 56, 73], ["PRRSV", "TREATMENT", 126, 131], ["marked", "OBSERVATION_MODIFIER", 58, 64], ["increase", "OBSERVATION_MODIFIER", 65, 73]]], ["Similarly to what was observed in PCLS, the expression of transcripts for DAI, LGP2, MDA5, and RIG-I was significantly higher in the SIV infected cells (P < 0.05) than in the controls (Fig. 5B ).", [["cells", "ANATOMY", 146, 151], ["SIV infected", "DISEASE", 133, 145], ["PCLS", "CANCER", 34, 38], ["DAI", "GENE_OR_GENE_PRODUCT", 74, 77], ["LGP2", "GENE_OR_GENE_PRODUCT", 79, 83], ["MDA5", "GENE_OR_GENE_PRODUCT", 85, 89], ["RIG-I", "GENE_OR_GENE_PRODUCT", 95, 100], ["SIV", "ORGANISM", 133, 136], ["cells", "CELL", 146, 151], ["DAI", "PROTEIN", 74, 77], ["LGP2", "PROTEIN", 79, 83], ["MDA5", "PROTEIN", 85, 89], ["RIG-I", "PROTEIN", 95, 100], ["SIV infected cells", "CELL_TYPE", 133, 151], ["SIV", "SPECIES", 133, 136], ["DAI", "PROBLEM", 74, 77], ["LGP2", "TEST", 79, 83], ["MDA5", "TEST", 85, 89], ["SIV", "OBSERVATION", 133, 136], ["infected cells", "OBSERVATION", 137, 151]]], ["Regarding TLR3, TLR8, and TLR9 transcripts, no significant difference was observed between control and SIV conditions (Fig. 5B) , although expression of TLR3 transcripts seemed higher with SIV than PRRSV.", [["TLR3", "GENE_OR_GENE_PRODUCT", 10, 14], ["TLR8", "GENE_OR_GENE_PRODUCT", 16, 20], ["TLR9", "GENE_OR_GENE_PRODUCT", 26, 30], ["SIV", "ORGANISM", 103, 106], ["TLR3", "GENE_OR_GENE_PRODUCT", 153, 157], ["SIV", "ORGANISM", 189, 192], ["PRRSV", "ORGANISM", 198, 203], ["TLR3, TLR8, and TLR9 transcripts", "RNA", 10, 42], ["TLR3 transcripts", "RNA", 153, 169], ["SIV", "SPECIES", 103, 106], ["SIV", "SPECIES", 189, 192], ["PRRSV", "SPECIES", 198, 203], ["TLR3", "TEST", 10, 14], ["TLR8", "TREATMENT", 16, 20], ["TLR9 transcripts", "TREATMENT", 26, 42], ["significant difference", "PROBLEM", 47, 69], ["TLR3 transcripts", "PROBLEM", 153, 169], ["TLR8", "ANATOMY", 16, 20], ["no", "UNCERTAINTY", 44, 46], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["TLR3 transcripts", "OBSERVATION", 153, 169]]], ["However, this observation was not confirmed by statistical analysis.", [["this observation", "TEST", 9, 25], ["statistical analysis", "TEST", 47, 67]]], ["Furthermore, no statistically significant differences were identified between the various conditions for TLR transcripts, with the exception of TLR7 transcripts (Fig. 5B) .", [["TLR", "GENE_OR_GENE_PRODUCT", 105, 108], ["TLR7", "GENE_OR_GENE_PRODUCT", 144, 148], ["TLR transcripts", "RNA", 105, 120], ["TLR7 transcripts", "RNA", 144, 160], ["TLR transcripts", "TREATMENT", 105, 120], ["TLR7 transcripts", "TREATMENT", 144, 160], ["no", "UNCERTAINTY", 13, 15]]], ["Moreover, ''SIV'' condition was not significantly different amongst the co-infection and superinfection conditions for all the transcripts (Fig. 5B) .Interferon transcriptsNext, the expressions of interferon transcripts were analyzed using the same viral infection combinations discussed above in PCLS and PAMs ( Fig. 6 and Table 2 ).", [["co-infection", "DISEASE", 72, 84], ["superinfection", "DISEASE", 89, 103], ["viral infection", "DISEASE", 249, 264], ["SIV", "ORGANISM", 12, 15], ["Interferon", "GENE_OR_GENE_PRODUCT", 150, 160], ["interferon", "GENE_OR_GENE_PRODUCT", 197, 207], ["Interferon transcripts", "RNA", 150, 172], ["interferon transcripts", "RNA", 197, 219], ["the co-infection", "PROBLEM", 68, 84], ["superinfection conditions", "PROBLEM", 89, 114], ["Interferon transcripts", "TREATMENT", 150, 172], ["interferon transcripts", "TREATMENT", 197, 219], ["the same viral infection", "PROBLEM", 240, 264], ["co-infection", "OBSERVATION", 72, 84], ["superinfection", "OBSERVATION", 89, 103], ["infection", "OBSERVATION", 255, 264]]], ["In PCLS, no statistically significant differences between conditions were reported for IFNa mRNA (Fig. 6) .", [["PCLS", "CANCER", 3, 7], ["IFNa", "GENE_OR_GENE_PRODUCT", 87, 91], ["IFNa mRNA", "RNA", 87, 96], ["statistically significant differences between conditions", "PROBLEM", 12, 68], ["no", "UNCERTAINTY", 9, 11]]], ["IFNb transcripts were expressed at higher levels in response to SIV alone or in association with PRRSV ( Fig. 6 ) (P < 0.05).", [["IFNb", "GENE_OR_GENE_PRODUCT", 0, 4], ["SIV", "ORGANISM", 64, 67], ["IFNb transcripts", "RNA", 0, 16], ["SIV", "SPECIES", 64, 67], ["PRRSV", "SPECIES", 97, 102]]], ["When SIV was co-administered with PRRSV, the expres-sion of the transcript was significantly higher than when SIV and PRRSV were administered alone (Fig. 6 ) (P < 0.05).", [["SIV", "ORGANISM", 5, 8], ["PRRSV", "ORGANISM", 34, 39], ["SIV", "ORGANISM", 110, 113], ["PRRSV", "ORGANISM", 118, 123], ["SIV", "SPECIES", 5, 8], ["PRRSV", "SPECIES", 34, 39], ["SIV", "SPECIES", 110, 113], ["PRRSV", "SPECIES", 118, 123], ["PRRSV", "TREATMENT", 34, 39], ["SIV and PRRSV", "TREATMENT", 110, 123], ["higher", "OBSERVATION_MODIFIER", 93, 99]]], ["The median of relative expression in the ''PRRSV + SIV'' condition is higher than the sum of the median of relative expression of ''PRRSV'' and ''SIV'' conditions.", [["PRRSV", "ORGANISM", 43, 48], ["SIV", "ORGANISM", 51, 54], ["PRRSV", "ORGANISM", 132, 137], ["PRRSV + SIV", "SPECIES", 43, 54], ["PRRSV", "SPECIES", 132, 137], ["SIV", "SPECIES", 146, 149], ["higher", "OBSERVATION_MODIFIER", 70, 76]]], ["For IFNg, only the conditions ''PRRSV + SIV'' and ''SIV-3h-PRRSV'' showed significantly higher expression of the transcripts than in the ''control'' and ''PRRSV'' conditions (Fig. 6) .", [["IFNg", "GENE_OR_GENE_PRODUCT", 4, 8], ["PRRSV", "ORGANISM", 32, 37], ["SIV", "ORGANISM", 40, 43], ["SIV-3h-PRRSV", "ORGANISM", 52, 64], ["SIV", "SPECIES", 40, 43], ["SIV-3h-PRRSV", "SPECIES", 52, 64], ["PRRSV", "SPECIES", 155, 160], ["IFNg", "PROBLEM", 4, 8], ["PRRSV", "PROBLEM", 59, 64], ["the ''control''", "TREATMENT", 133, 148]]], ["In PAMs, a significant increase of IFNa transcript expression compared to the control was only observed in superinfection conditions (Fig. 6) .", [["superinfection", "DISEASE", 107, 121], ["IFNa", "GENE_OR_GENE_PRODUCT", 35, 39], ["PAMs", "CELL_TYPE", 3, 7], ["IFNa", "PROTEIN", 35, 39], ["IFNa transcript expression", "TREATMENT", 35, 61], ["superinfection conditions", "PROBLEM", 107, 132], ["PAMs", "OBSERVATION", 3, 7], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["superinfection", "OBSERVATION", 107, 121]]], ["For IFNb the transcript expression was higher than in the control in all the conditions where the PRRSV was administered (Fig. 6) .", [["IFNb", "GENE_OR_GENE_PRODUCT", 4, 8], ["PRRSV", "ORGANISM", 98, 103], ["IFNb", "PROTEIN", 4, 8], ["PRRSV", "SPECIES", 98, 103], ["the PRRSV", "TREATMENT", 94, 103], ["higher", "OBSERVATION_MODIFIER", 39, 45]]], ["No expression of IFNg transcripts was observed in any conditions (Fig. 6) .Antiviral transcripts in response to interferonsIn response to the IFNs, various antiviral transcripts may be expressed (Tables 1 and 2 ).", [["IFNg", "GENE_OR_GENE_PRODUCT", 17, 21], ["interferons", "GENE_OR_GENE_PRODUCT", 112, 123], ["IFNs", "GENE_OR_GENE_PRODUCT", 142, 146], ["IFNg transcripts", "RNA", 17, 33], ["Antiviral transcripts", "PROTEIN", 75, 96], ["interferons", "PROTEIN", 112, 123], ["IFNs", "PROTEIN", 142, 146], ["antiviral transcripts", "RNA", 156, 177], ["IFNg transcripts", "PROBLEM", 17, 33], ["Antiviral transcripts", "TREATMENT", 75, 96], ["interferons", "TREATMENT", 112, 123], ["the IFNs", "TREATMENT", 138, 146], ["various antiviral transcripts", "TREATMENT", 148, 177], ["IFNg transcripts", "OBSERVATION", 17, 33]]], ["In PCLS, PRRSV did not induce any significant increase in the expression of the transcripts under study, while SIV was able to significantly induce (P < 0.05) their expression (Fig. 7) .", [["PRRSV", "ORGANISM", 9, 14], ["SIV", "ORGANISM", 111, 114], ["PRRSV", "SPECIES", 9, 14], ["SIV", "SPECIES", 111, 114], ["PRRSV", "PROBLEM", 9, 14], ["SIV", "PROBLEM", 111, 114], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54]]], ["Similarly, when co-infected (PRRSV + SIV), the expressions of antiviral transcripts were significantly higher (P < 0.05) than in the ''control'' conditions (Fig. 7) .", [["PRRSV + SIV", "ORGANISM", 29, 40], ["antiviral transcripts", "RNA", 62, 83], ["PRRSV", "SPECIES", 29, 34], ["SIV", "SPECIES", 37, 40], ["antiviral transcripts", "TREATMENT", 62, 83], ["antiviral transcripts", "OBSERVATION", 62, 83]]], ["In the superinfection condition, ''PRRSV-3h-SIV'', the expression of the transcripts was slightly higher for some (Mx2 and PKR) but not all (Mx1 and OAS1), relative to the control (Fig. 7) .", [["superinfection", "DISEASE", 7, 21], ["PRRSV", "ORGANISM", 35, 40], ["SIV", "ORGANISM", 44, 47], ["Mx2", "GENE_OR_GENE_PRODUCT", 115, 118], ["PKR", "GENE_OR_GENE_PRODUCT", 123, 126], ["Mx2", "PROTEIN", 115, 118], ["PKR", "PROTEIN", 123, 126], ["Mx1", "PROTEIN", 141, 144], ["OAS1", "PROTEIN", 149, 153], ["PRRSV-3h-SIV", "SPECIES", 35, 47], ["the superinfection condition", "PROBLEM", 3, 31], ["PRRSV", "TEST", 35, 40], ["PKR", "TEST", 123, 126], ["superinfection", "OBSERVATION", 7, 21]]], ["When PRRSV was administered 3 h after SIV (SIV-3h-PRRSV), the expressions of transcripts were similar to when both viruses were administered together or when the SIV was administered alone (Fig. 7) .", [["PRRSV", "ORGANISM", 5, 10], ["SIV", "ORGANISM", 38, 41], ["SIV-3h-PRRSV", "ORGANISM", 43, 55], ["SIV", "ORGANISM", 162, 165], ["PRRSV", "SPECIES", 5, 10], ["SIV", "SPECIES", 38, 41], ["SIV-3h-PRRSV", "SPECIES", 43, 55], ["SIV", "SPECIES", 162, 165], ["SIV", "PROBLEM", 38, 41], ["PRRSV", "PROBLEM", 50, 55], ["both viruses", "PROBLEM", 110, 122], ["the SIV", "TREATMENT", 158, 165]]], ["In the PAMs, PRRSV was unable to induce a statistically significant stimulation in the expression of the various transcripts, despite the subtle increase observed (Fig. 7) .", [["PRRSV", "ORGANISM", 13, 18], ["PRRSV", "SPECIES", 13, 18], ["subtle", "OBSERVATION_MODIFIER", 138, 144], ["increase", "OBSERVATION_MODIFIER", 145, 153]]], ["In nearly all the conditions where SIV was administered, a higher expression of the transcripts (P < 0.05) was observed (Fig. 7) .", [["SIV", "ORGANISM", 35, 38], ["SIV", "SPECIES", 35, 38]]], ["5A and 6), the increase was less important and sometimes not statistically significant comparatively to the control when the PRRSV was administered 3 h before SIV (Fig. 7) .Cytokines and related transcriptsRegarding major inflammatory cytokines involved in innate immune response such as IL1b and TNFa, regulatory cytokine IL10, and the inflammasome-associated PRR, NLRP3, no significant differences were observed between the different infection combinations in PCLS (supplementary Fig. 2 and supplementary Fig. 3) .", [["infection", "DISEASE", 436, 445], ["PCLS", "CHEMICAL", 462, 466], ["PRRSV", "ORGANISM", 125, 130], ["SIV", "ORGANISM", 159, 162], ["IL1b", "GENE_OR_GENE_PRODUCT", 288, 292], ["TNFa", "GENE_OR_GENE_PRODUCT", 297, 301], ["IL10", "GENE_OR_GENE_PRODUCT", 323, 327], ["PRR", "GENE_OR_GENE_PRODUCT", 361, 364], ["NLRP3", "GENE_OR_GENE_PRODUCT", 366, 371], ["Cytokines", "PROTEIN", 173, 182], ["transcripts", "RNA", 195, 206], ["major inflammatory cytokines", "PROTEIN", 216, 244], ["IL1b", "PROTEIN", 288, 292], ["TNFa", "PROTEIN", 297, 301], ["regulatory cytokine", "PROTEIN", 303, 322], ["IL10", "PROTEIN", 323, 327], ["PRR", "PROTEIN", 361, 364], ["NLRP3", "PROTEIN", 366, 371], ["PRRSV", "SPECIES", 125, 130], ["SIV", "SPECIES", 159, 162], ["the PRRSV", "TREATMENT", 121, 130], ["Cytokines", "PROBLEM", 173, 182], ["related transcripts", "PROBLEM", 187, 206], ["major inflammatory cytokines", "PROBLEM", 216, 244], ["IL1b", "TEST", 288, 292], ["TNFa", "TEST", 297, 301], ["regulatory cytokine IL10", "TEST", 303, 327], ["the inflammasome", "TEST", 333, 349], ["NLRP3", "TREATMENT", 366, 371], ["significant differences", "PROBLEM", 376, 399], ["the different infection", "PROBLEM", 422, 445], ["PCLS (supplementary Fig.", "TREATMENT", 462, 486], ["supplementary Fig", "TREATMENT", 493, 510], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["transcripts", "OBSERVATION", 195, 206], ["inflammatory cytokines", "OBSERVATION", 222, 244], ["cytokine IL10", "OBSERVATION", 314, 327], ["different", "OBSERVATION_MODIFIER", 426, 435], ["infection", "OBSERVATION", 436, 445]]], ["Again, PRRSV administration did not alter the expression of any transcripts in the PCLS comparative to control, despite a minimal trend toward an increase for IL10 and TNFa (supplementary Fig. 3) .", [["PCLS", "ANATOMY", 83, 87], ["PRRSV", "ORGANISM", 7, 12], ["IL10", "GENE_OR_GENE_PRODUCT", 159, 163], ["TNFa", "GENE_OR_GENE_PRODUCT", 168, 172], ["IL10", "PROTEIN", 159, 163], ["TNFa", "PROTEIN", 168, 172], ["PRRSV", "SPECIES", 7, 12], ["PRRSV administration", "TREATMENT", 7, 27], ["a minimal trend", "PROBLEM", 120, 135], ["IL10 and TNFa (supplementary Fig", "TREATMENT", 159, 191]]], ["IL6, SOCS1 and TRAIL transcripts were significantly (P < 0.05) induced in response to SIV administration in the PCLS but were not remarkable when PRRSV was administered 3 h before SIV (supplementary Fig. 2 and supplementary Fig. 3 ).", [["PCLS", "ANATOMY", 112, 116], ["IL6", "GENE_OR_GENE_PRODUCT", 0, 3], ["SOCS1", "GENE_OR_GENE_PRODUCT", 5, 10], ["TRAIL", "GENE_OR_GENE_PRODUCT", 15, 20], ["SIV", "ORGANISM", 86, 89], ["PCLS", "CANCER", 112, 116], ["PRRSV", "ORGANISM", 146, 151], ["SIV", "ORGANISM", 180, 183], ["IL6, SOCS1 and TRAIL transcripts", "RNA", 0, 32], ["SIV", "SPECIES", 86, 89], ["PRRSV", "SPECIES", 146, 151], ["SIV", "SPECIES", 180, 183], ["IL6", "PROBLEM", 0, 3], ["SOCS1 and TRAIL transcripts", "TREATMENT", 5, 32], ["SIV administration", "TREATMENT", 86, 104], ["the PCLS", "TEST", 108, 116], ["PRRSV", "TREATMENT", 146, 151], ["SIV (supplementary Fig.", "TREATMENT", 180, 203], ["SOCS1", "OBSERVATION", 5, 10]]], ["IL1b transcripts were not detected in PAMs in any conditions under study (supplementary Fig. 2 ).", [["IL1b", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL1b transcripts", "RNA", 0, 16], ["IL1b transcripts", "PROBLEM", 0, 16]]], ["In PAMs, most of the transcripts (IL6, NLRP3, SOCS1 and TRAIL) had little impact upon PRRSV infection (supplementary Fig. 2 and supplementary Fig. 3) , while for IL10 and TNFa there was a significant increase (P < 0.05) in response to the virus (supplementary Fig. 3) .", [["PRRSV infection", "DISEASE", 86, 101], ["IL6", "GENE_OR_GENE_PRODUCT", 34, 37], ["NLRP3", "GENE_OR_GENE_PRODUCT", 39, 44], ["SOCS1", "GENE_OR_GENE_PRODUCT", 46, 51], ["TRAIL", "GENE_OR_GENE_PRODUCT", 56, 61], ["PRRSV", "ORGANISM", 86, 91], ["IL10", "GENE_OR_GENE_PRODUCT", 162, 166], ["TNFa", "GENE_OR_GENE_PRODUCT", 171, 175], ["PAMs", "CELL_TYPE", 3, 7], ["IL6", "PROTEIN", 34, 37], ["NLRP3", "PROTEIN", 39, 44], ["SOCS1", "PROTEIN", 46, 51], ["TRAIL", "PROTEIN", 56, 61], ["IL10", "PROTEIN", 162, 166], ["TNFa", "PROTEIN", 171, 175], ["PRRSV", "SPECIES", 86, 91], ["IL6", "TEST", 34, 37], ["SOCS1 and TRAIL", "TREATMENT", 46, 61], ["PRRSV infection", "PROBLEM", 86, 101], ["IL10 and TNFa", "TREATMENT", 162, 175], ["a significant increase", "PROBLEM", 186, 208], ["the virus (supplementary Fig", "TREATMENT", 235, 263], ["PAMs", "OBSERVATION", 3, 7], ["PRRSV infection", "OBSERVATION", 86, 101], ["significant", "OBSERVATION_MODIFIER", 188, 199], ["increase", "OBSERVATION_MODIFIER", 200, 208]]], ["SIV alone induced marked expression of SOCS1 and TRAIL transcripts only in PAMs (P < 0.05) (supplementary Figs.", [["SIV", "ORGANISM", 0, 3], ["SOCS1", "GENE_OR_GENE_PRODUCT", 39, 44], ["TRAIL", "GENE_OR_GENE_PRODUCT", 49, 54], ["SOCS1 and TRAIL transcripts", "RNA", 39, 66], ["SIV", "SPECIES", 0, 3], ["SOCS1", "PROBLEM", 39, 44], ["TRAIL transcripts", "TREATMENT", 49, 66], ["marked", "OBSERVATION_MODIFIER", 18, 24], ["SOCS1", "OBSERVATION", 39, 44]]], ["In the co-infection and superinfection conditions, IL6, SOCS1, TNFa, and TRAIL transcripts were substantiallyIFNa and IFNb quantificationProtein expression of IFNa and IFNb was assessed by ELISA using the supernatants collected from the same experimental conditions as those for RT-qPCR analysis.", [["supernatants", "ANATOMY", 205, 217], ["co-infection", "DISEASE", 7, 19], ["superinfection", "DISEASE", 24, 38], ["IL6", "GENE_OR_GENE_PRODUCT", 51, 54], ["SOCS1", "GENE_OR_GENE_PRODUCT", 56, 61], ["TNFa", "GENE_OR_GENE_PRODUCT", 63, 67], ["TRAIL", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFNb", "GENE_OR_GENE_PRODUCT", 118, 122], ["IFNa", "GENE_OR_GENE_PRODUCT", 159, 163], ["IFNb", "GENE_OR_GENE_PRODUCT", 168, 172], ["IL6, SOCS1, TNFa, and TRAIL transcripts", "RNA", 51, 90], ["IFNb", "PROTEIN", 118, 122], ["IFNa", "PROTEIN", 159, 163], ["IFNb", "PROTEIN", 168, 172], ["the co-infection", "PROBLEM", 3, 19], ["superinfection conditions", "PROBLEM", 24, 49], ["IL6", "TREATMENT", 51, 54], ["TNFa", "TREATMENT", 63, 67], ["TRAIL transcripts", "TREATMENT", 73, 90], ["Protein expression of IFNa", "PROBLEM", 137, 163], ["ELISA", "TEST", 189, 194], ["the supernatants", "TEST", 201, 217], ["RT-qPCR analysis", "TEST", 279, 295], ["co-infection", "OBSERVATION", 7, 19], ["superinfection", "OBSERVATION", 24, 38]]], ["No protein was detected 18 h post-infection in all conditions examined (control, single infected, co-infected, and superinfected) (data not shown).DiscussionAmong viruses contributing to porcine lung infectious diseases, PRRSV and SIV, alone or in combination, are the two main known contributors (Choi et al., 2003; Fablet et al., 2012a Fablet et al., , 2011 Opriessnig et al., 2011) .", [["lung", "ANATOMY", 195, 199], ["infection", "DISEASE", 34, 43], ["lung infectious diseases", "DISEASE", 195, 219], ["porcine", "ORGANISM", 187, 194], ["lung", "ORGAN", 195, 199], ["PRRSV", "ORGANISM", 221, 226], ["SIV", "ORGANISM", 231, 234], ["porcine", "SPECIES", 187, 194], ["PRRSV", "SPECIES", 221, 226], ["PRRSV", "SPECIES", 221, 226], ["SIV", "SPECIES", 231, 234], ["protein", "PROBLEM", 3, 10], ["infection in all conditions", "PROBLEM", 34, 61], ["single infected, co-infected", "PROBLEM", 81, 109], ["porcine lung infectious diseases", "PROBLEM", 187, 219], ["PRRSV", "PROBLEM", 221, 226], ["protein", "OBSERVATION", 3, 10], ["infection", "OBSERVATION", 34, 43], ["lung", "ANATOMY", 195, 199], ["infectious", "OBSERVATION", 200, 210]]], ["Studies assessing the impact of co-infections with these two viruses have not been frequent since the 1990s (Pol et al., 1997; Van Reeth et al., 1996 .", [["co-infections", "DISEASE", 32, 45], ["Studies", "TEST", 0, 7], ["co-infections", "PROBLEM", 32, 45], ["these two viruses", "PROBLEM", 51, 68], ["co-infections", "OBSERVATION", 32, 45]]], ["Moreover, none of these studies specifically addressed the question of the impact of polymicrobial infections at the molecular level.", [["infections", "DISEASE", 99, 109], ["these studies", "TEST", 18, 31], ["polymicrobial infections", "PROBLEM", 85, 109], ["polymicrobial", "OBSERVATION_MODIFIER", 85, 98], ["infections", "OBSERVATION", 99, 109]]], ["In the current report, the impact of PRRSV/SIV co-infection versus single infections on the immune response of PAMs and PCLS with respect to alterations in viral replication and associated host gene transcripts was assessed.DiscussionIn a study by Van Reeth and collaborators, results suggested that the SIV replication was only slightly affected by the prior infection with the Lelystad virus strain of PRRSV (Van Reeth et al., 1996) .", [["co-infection", "DISEASE", 47, 59], ["infections", "DISEASE", 74, 84], ["infection", "DISEASE", 360, 369], ["PRRSV", "ORGANISM", 37, 42], ["SIV", "ORGANISM", 43, 46], ["PAMs", "CELL", 111, 115], ["PCLS", "CANCER", 120, 124], ["SIV", "ORGANISM", 304, 307], ["Lelystad virus", "ORGANISM", 379, 393], ["PRRSV", "ORGANISM", 404, 409], ["PRRSV", "SPECIES", 404, 409], ["PRRSV", "SPECIES", 37, 42], ["SIV", "SPECIES", 43, 46], ["SIV", "SPECIES", 304, 307], ["Lelystad virus", "SPECIES", 379, 393], ["PRRSV", "SPECIES", 404, 409], ["PRRSV/SIV co-infection", "PROBLEM", 37, 59], ["single infections", "PROBLEM", 67, 84], ["PAMs", "PROBLEM", 111, 115], ["PCLS", "TREATMENT", 120, 124], ["viral replication", "TREATMENT", 156, 173], ["host gene transcripts", "PROBLEM", 189, 210], ["the SIV replication", "PROBLEM", 300, 319], ["the prior infection", "PROBLEM", 350, 369], ["PRRSV", "OBSERVATION", 37, 42], ["SIV co-infection", "OBSERVATION", 43, 59], ["infections", "OBSERVATION", 74, 84], ["viral replication", "OBSERVATION", 156, 173], ["host gene transcripts", "OBSERVATION", 189, 210], ["infection", "OBSERVATION", 360, 369]]], ["In that experiment, the pigs were inoculated first by aerosol with PRRSV and three days later with SIV (Van Reeth et al., 1996) .", [["pigs", "ORGANISM", 24, 28], ["PRRSV", "ORGANISM", 67, 72], ["SIV", "ORGANISM", 99, 102], ["pigs", "SPECIES", 24, 28], ["pigs", "SPECIES", 24, 28], ["PRRSV", "SPECIES", 67, 72], ["SIV", "SPECIES", 99, 102], ["the pigs", "TREATMENT", 20, 28]]], ["Viral excretion in the PRRSV-SIV group was delayed by two days, not only with regard to the presence of virus, but also with respect to the peak amount (Van Reeth et al., 1996) .", [["Viral", "ORGANISM", 0, 5], ["PRRSV", "ORGANISM", 23, 28], ["SIV", "ORGANISM", 29, 32], ["PRRSV-SIV", "SPECIES", 23, 32], ["PRRSV-SIV", "SPECIES", 23, 32], ["Viral excretion", "TEST", 0, 15], ["virus", "PROBLEM", 104, 109], ["excretion", "OBSERVATION", 6, 15], ["virus", "OBSERVATION", 104, 109]]], ["In our PCLS experiment, SIV transcript expression was not altered in the condition where SIV was administered to slices 3 h after PRRSV.", [["slices", "ANATOMY", 113, 119], ["SIV", "ORGANISM", 24, 27], ["SIV", "ORGANISM", 89, 92], ["PRRSV", "ORGANISM", 130, 135], ["SIV", "SPECIES", 24, 27], ["SIV", "SPECIES", 89, 92], ["PRRSV", "SPECIES", 130, 135], ["SIV transcript expression", "PROBLEM", 24, 49], ["SIV", "TREATMENT", 89, 92], ["PRRSV", "PROBLEM", 130, 135], ["SIV transcript", "OBSERVATION", 24, 38]]], ["The timing, the experimental settings (in vivo versus ex vivo), and the different genotypes of the viral strains used could account for this small difference in the results obtained.", [["the viral strains", "PROBLEM", 95, 112], ["this small difference", "PROBLEM", 136, 157], ["viral strains", "OBSERVATION", 99, 112]]], ["Similarly, superinfection with PRRSV after SIV infection did not impact the SIV replication.", [["superinfection", "DISEASE", 11, 25], ["SIV infection", "DISEASE", 43, 56], ["PRRSV", "ORGANISM", 31, 36], ["SIV", "ORGANISM", 43, 46], ["SIV", "ORGANISM", 76, 79], ["PRRSV", "SPECIES", 31, 36], ["PRRSV", "SPECIES", 31, 36], ["SIV", "SPECIES", 43, 46], ["SIV", "SPECIES", 76, 79], ["superinfection", "PROBLEM", 11, 25], ["PRRSV", "PROBLEM", 31, 36], ["SIV infection", "PROBLEM", 43, 56], ["the SIV replication", "TREATMENT", 72, 91], ["superinfection", "OBSERVATION", 11, 25], ["SIV infection", "OBSERVATION", 43, 56], ["SIV replication", "OBSERVATION", 76, 91]]], ["On the contrary, PRRSV superinfection 3 h after SIV infection significantly reduced the replication of the PRRSV.", [["superinfection", "DISEASE", 23, 37], ["SIV infection", "DISEASE", 48, 61], ["PRRSV", "ORGANISM", 17, 22], ["SIV", "ORGANISM", 48, 51], ["PRRSV", "ORGANISM", 107, 112], ["PRRSV", "SPECIES", 107, 112], ["PRRSV", "SPECIES", 17, 22], ["SIV", "SPECIES", 48, 51], ["PRRSV", "SPECIES", 107, 112], ["PRRSV superinfection", "PROBLEM", 17, 37], ["SIV infection", "PROBLEM", 48, 61], ["superinfection", "OBSERVATION", 23, 37], ["infection", "OBSERVATION", 52, 61]]], ["Because no other studies have looked at the impact of PRRSV superinfection on SIV replication, it is difficult to make comparisons.", [["superinfection", "DISEASE", 60, 74], ["PRRSV", "ORGANISM", 54, 59], ["SIV", "ORGANISM", 78, 81], ["PRRSV", "SPECIES", 54, 59], ["SIV", "SPECIES", 78, 81], ["other studies", "TEST", 11, 24], ["PRRSV superinfection", "PROBLEM", 54, 74], ["SIV replication", "TREATMENT", 78, 93], ["PRRSV", "OBSERVATION_MODIFIER", 54, 59], ["superinfection", "OBSERVATION", 60, 74], ["SIV replication", "OBSERVATION", 78, 93]]], ["The reduction in the PRRSV replication, however, has to be interpreted carefully since a lower number of PRSSV transcripts detected could also be a consequence of the shorter replication time allowed for the superinfecting virus (15 h versus 18 h).", [["PRRSV", "ORGANISM", 21, 26], ["PRSSV", "GENE_OR_GENE_PRODUCT", 105, 110], ["PRSSV transcripts", "RNA", 105, 122], ["PRRSV", "SPECIES", 21, 26], ["The reduction", "TREATMENT", 0, 13], ["the PRRSV replication", "TREATMENT", 17, 38], ["a lower number of PRSSV transcripts", "PROBLEM", 87, 122], ["the superinfecting virus", "PROBLEM", 204, 228], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["PRRSV replication", "OBSERVATION", 21, 38]]], ["Interestingly, when the two viruses were co-administered, there was a noticeable decrease in PRRSV replication.", [["PRRSV", "ORGANISM", 93, 98], ["PRRSV", "SPECIES", 93, 98], ["a noticeable decrease in PRRSV replication", "PROBLEM", 68, 110], ["noticeable", "OBSERVATION_MODIFIER", 70, 80], ["decrease", "OBSERVATION_MODIFIER", 81, 89], ["PRRSV replication", "OBSERVATION", 93, 110]]], ["However, it was not statistically significant.", [["significant", "OBSERVATION_MODIFIER", 34, 45]]], ["The results obtained in PAMs were noticeably different than in the PCLS.", [["PAMs", "CELL", 24, 28], ["PAMs", "TEST", 24, 28], ["PCLS", "ANATOMY", 67, 71]]], ["SIV replication was reduced when the PRRSV was co-administered with SIV (P < 0.05), or prior to SIV (however, P > 0.05).", [["SIV", "ORGANISM", 0, 3], ["PRRSV", "ORGANISM", 37, 42], ["SIV", "ORGANISM", 68, 71], ["SIV", "ORGANISM", 96, 99], ["SIV", "SPECIES", 0, 3], ["PRRSV", "SPECIES", 37, 42], ["SIV", "SPECIES", 68, 71], ["SIV", "SPECIES", 96, 99], ["SIV replication", "TREATMENT", 0, 15], ["the PRRSV", "TREATMENT", 33, 42], ["P", "TEST", 110, 111]]], ["Regarding PRRSV replication, again the pre-infection of the PAMs with SIV was accompanied by a significant decrease in PRRSV replication (P < 0.05).", [["PRRSV", "ORGANISM", 10, 15], ["SIV", "ORGANISM", 70, 73], ["PRRSV", "ORGANISM", 119, 124], ["PRRSV", "SPECIES", 10, 15], ["SIV", "SPECIES", 70, 73], ["PRRSV", "SPECIES", 119, 124], ["PRRSV replication", "TREATMENT", 10, 27], ["SIV", "PROBLEM", 70, 73], ["a significant decrease in PRRSV replication", "PROBLEM", 93, 136], ["PRRSV replication", "OBSERVATION", 10, 27], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["decrease", "OBSERVATION_MODIFIER", 107, 115], ["PRRSV replication", "OBSERVATION", 119, 136]]], ["Similarly, the replication of PRRSV seemed also decreased when PAMs were co-infected with PRRSV and SIV (P > 0.05).", [["PRRSV", "ORGANISM", 30, 35], ["PRRSV", "ORGANISM", 90, 95], ["SIV", "ORGANISM", 100, 103], ["PRRSV", "SPECIES", 90, 95], ["PRRSV", "SPECIES", 30, 35], ["PRRSV", "SPECIES", 90, 95], ["SIV", "SPECIES", 100, 103], ["PRRSV", "PROBLEM", 30, 35], ["PAMs", "PROBLEM", 63, 67], ["PRRSV", "TEST", 90, 95], ["PRRSV", "OBSERVATION", 30, 35], ["decreased", "OBSERVATION_MODIFIER", 48, 57]]], ["Taken together, our data suggest a slightly negative impact of the first virus on the replication of the second virus regardless the order of viral infection especially in PAMs.", [["viral infection", "DISEASE", 142, 157], ["the first virus", "PROBLEM", 63, 78], ["the second virus", "TREATMENT", 101, 117], ["viral infection", "PROBLEM", 142, 157], ["slightly", "OBSERVATION_MODIFIER", 35, 43], ["negative", "OBSERVATION", 44, 52], ["viral", "OBSERVATION_MODIFIER", 142, 147], ["infection", "OBSERVATION", 148, 157]]], ["As both viruses are RNA viruses using the same cellular machinery, especially in the PAMs where infections were performed at high MOI, an interference of one virus cycle on the cycle of the second is not surprising.", [["cellular", "ANATOMY", 47, 55], ["infections", "DISEASE", 96, 106], ["cellular", "CELL", 47, 55], ["RNA viruses", "PROBLEM", 20, 31], ["infections", "PROBLEM", 96, 106], ["viruses", "OBSERVATION", 8, 15], ["RNA viruses", "OBSERVATION", 20, 31], ["infections", "OBSERVATION", 96, 106], ["virus cycle", "OBSERVATION", 158, 169]]], ["Penetration kinetics of both viruses could also account for the observed differences as previously described in another family of respiratory viruses (Meurens et al., 2004a) .DiscussionTo analyze the transcript expression in PCLS and PAMs (Table 2) three stable reference genes were used for each system.", [["PCLS", "ANATOMY", 225, 229], ["respiratory viruses", "DISEASE", 130, 149], ["PCLS", "CELL", 225, 229], ["PCLS", "CELL_TYPE", 225, 229], ["PAMs", "CELL_TYPE", 234, 238], ["reference genes", "DNA", 262, 277], ["Penetration kinetics of both viruses", "PROBLEM", 0, 36], ["both viruses", "OBSERVATION", 24, 36], ["could also account for", "UNCERTAINTY", 37, 59]]], ["As previously observed in lung tissue (Delgado-Ortega et al., 2011) , HPRT-1, along with RPL-19, were two of the three most stable reference genes in both PCLS and PAMs.", [["lung tissue", "ANATOMY", 26, 37], ["PCLS", "ANATOMY", 155, 159], ["lung tissue", "TISSUE", 26, 37], ["HPRT-1", "GENE_OR_GENE_PRODUCT", 70, 76], ["RPL-19", "GENE_OR_GENE_PRODUCT", 89, 95], ["PCLS", "CELL", 155, 159], ["PAMs", "CELL", 164, 168], ["HPRT-1", "DNA", 70, 76], ["RPL-19", "DNA", 89, 95], ["reference genes", "DNA", 131, 146], ["PAMs", "CELL_TYPE", 164, 168], ["Delgado", "TEST", 39, 46], ["HPRT", "TEST", 70, 74], ["RPL", "TEST", 89, 92], ["lung", "ANATOMY", 26, 30], ["tissue", "ANATOMY_MODIFIER", 31, 37], ["RPL", "ANATOMY", 89, 92], ["stable", "OBSERVATION", 124, 130], ["both", "ANATOMY_MODIFIER", 150, 154], ["PCLS", "ANATOMY", 155, 159], ["PAMs", "OBSERVATION", 164, 168]]], ["The third gene, HMBS2, was not tested in the study mentioned above, but was chosen based on rank from the reference gene stability analysis.", [["HMBS2", "GENE_OR_GENE_PRODUCT", 16, 21], ["third gene", "DNA", 4, 14], ["HMBS2", "DNA", 16, 21], ["the study", "TEST", 41, 50]]], ["In the PCLS, PRRSV had very little impact on the transcriptional expression of viral recognition, interferon, interferon-induced, and cytokine genes, while in the PAMs, we observed a statistically significant increase in transcript expression of IFNb, IL10, and TNFa transcripts in response to the viral infection.DiscussionRegarding the PRR transcripts (DAI, LGP2, MDA5, RIG-I, and TLR7) in PAMs, PRRSV showed a positive trend toward an increase in their expression; however it was not statistically significant, possibly due to the small number of samples examined.", [["samples", "ANATOMY", 550, 557], ["viral infection", "DISEASE", 298, 313], ["PRRSV", "ORGANISM", 13, 18], ["interferon", "GENE_OR_GENE_PRODUCT", 98, 108], ["interferon", "GENE_OR_GENE_PRODUCT", 110, 120], ["IFNb", "GENE_OR_GENE_PRODUCT", 246, 250], ["IL10", "GENE_OR_GENE_PRODUCT", 252, 256], ["TNFa", "GENE_OR_GENE_PRODUCT", 262, 266], ["PRR", "GENE_OR_GENE_PRODUCT", 338, 341], ["LGP2", "GENE_OR_GENE_PRODUCT", 360, 364], ["MDA5", "GENE_OR_GENE_PRODUCT", 366, 370], ["RIG-I", "GENE_OR_GENE_PRODUCT", 372, 377], ["TLR7", "GENE_OR_GENE_PRODUCT", 383, 387], ["PRRSV", "ORGANISM", 398, 403], ["samples", "CANCER", 550, 557], ["interferon", "PROTEIN", 98, 108], ["interferon", "PROTEIN", 110, 120], ["cytokine genes", "DNA", 134, 148], ["PAMs", "CELL_TYPE", 163, 167], ["IFNb, IL10, and TNFa transcripts", "RNA", 246, 278], ["PRR transcripts", "PROTEIN", 338, 353], ["DAI", "PROTEIN", 355, 358], ["LGP2", "PROTEIN", 360, 364], ["MDA5", "PROTEIN", 366, 370], ["RIG", "PROTEIN", 372, 375], ["TLR7", "PROTEIN", 383, 387], ["PRRSV", "SPECIES", 13, 18], ["PRRSV", "SPECIES", 398, 403], ["viral recognition", "PROBLEM", 79, 96], ["interferon", "TREATMENT", 98, 108], ["interferon", "TREATMENT", 110, 120], ["cytokine genes", "PROBLEM", 134, 148], ["transcript expression of IFNb", "TREATMENT", 221, 250], ["IL10", "TREATMENT", 252, 256], ["TNFa transcripts", "TREATMENT", 262, 278], ["the viral infection", "PROBLEM", 294, 313], ["PRRSV", "PROBLEM", 398, 403], ["a positive trend", "PROBLEM", 411, 427], ["viral recognition", "OBSERVATION", 79, 96], ["significant", "OBSERVATION_MODIFIER", 197, 208], ["increase", "OBSERVATION_MODIFIER", 209, 217], ["transcript expression", "OBSERVATION", 221, 242], ["viral infection", "OBSERVATION", 298, 313], ["increase", "OBSERVATION_MODIFIER", 438, 446], ["possibly due to", "UNCERTAINTY", 514, 529], ["small", "OBSERVATION_MODIFIER", 534, 539]]], ["One hypothesis to explain the complete absence of transcript over-expression in response to the PRRSV in the PCLS is the relatively small percentage of macrophages in the slices and their cellular heterogeneity in comparison to a pure population such as PAMs.", [["macrophages", "ANATOMY", 152, 163], ["slices", "ANATOMY", 171, 177], ["cellular", "ANATOMY", 188, 196], ["PRRSV", "ORGANISM", 96, 101], ["PCLS", "CANCER", 109, 113], ["macrophages", "CELL", 152, 163], ["slices", "MULTI-TISSUE_STRUCTURE", 171, 177], ["cellular", "CELL", 188, 196], ["PAMs", "CELL", 254, 258], ["macrophages", "CELL_TYPE", 152, 163], ["PAMs", "CELL_TYPE", 254, 258], ["PRRSV", "SPECIES", 96, 101], ["their cellular heterogeneity", "PROBLEM", 182, 210], ["PAMs", "PROBLEM", 254, 258], ["PCLS", "ANATOMY", 109, 113], ["relatively", "OBSERVATION_MODIFIER", 121, 131], ["small", "OBSERVATION_MODIFIER", 132, 137], ["percentage", "OBSERVATION_MODIFIER", 138, 148], ["macrophages", "OBSERVATION", 152, 163], ["cellular", "OBSERVATION_MODIFIER", 188, 196], ["heterogeneity", "OBSERVATION_MODIFIER", 197, 210], ["PAMs", "OBSERVATION", 254, 258]]], ["In the literature, PRRSV was associated with an increase of most, if not all, viral-sensing TLRs in the lungs, including TLR2, TLR3, TLR4, TLR7, TLR8, and TLR9 (Liu et al., 2009; Xiao et al., 2010a,b) .", [["lungs", "ANATOMY", 104, 109], ["PRRSV", "ORGANISM", 19, 24], ["TLRs", "GENE_OR_GENE_PRODUCT", 92, 96], ["lungs", "ORGAN", 104, 109], ["TLR2", "GENE_OR_GENE_PRODUCT", 121, 125], ["TLR3", "GENE_OR_GENE_PRODUCT", 127, 131], ["TLR4", "GENE_OR_GENE_PRODUCT", 133, 137], ["TLR7", "GENE_OR_GENE_PRODUCT", 139, 143], ["TLR8", "GENE_OR_GENE_PRODUCT", 145, 149], ["TLR9", "GENE_OR_GENE_PRODUCT", 155, 159], ["TLRs", "PROTEIN", 92, 96], ["TLR2", "PROTEIN", 121, 125], ["TLR3", "PROTEIN", 127, 131], ["TLR4", "PROTEIN", 133, 137], ["TLR7", "PROTEIN", 139, 143], ["TLR8", "PROTEIN", 145, 149], ["TLR9", "PROTEIN", 155, 159], ["PRRSV", "SPECIES", 19, 24], ["PRRSV", "PROBLEM", 19, 24], ["TLR2", "TEST", 121, 125], ["TLR3", "TEST", 127, 131], ["TLR4", "TEST", 133, 137], ["TLR7", "TEST", 139, 143], ["TLR8", "TEST", 145, 149], ["increase", "OBSERVATION_MODIFIER", 48, 56], ["lungs", "ANATOMY", 104, 109], ["TLR2", "ANATOMY_MODIFIER", 121, 125], ["TLR7", "ANATOMY", 139, 143], ["TLR8", "ANATOMY", 145, 149]]], ["In our study, after 18 h of infection, an increase in expression was demonstrated for TLR7.", [["infection", "DISEASE", 28, 37], ["TLR7", "GENE_OR_GENE_PRODUCT", 86, 90], ["TLR7", "PROTEIN", 86, 90], ["our study", "TEST", 3, 12], ["infection", "PROBLEM", 28, 37], ["an increase in expression", "PROBLEM", 39, 64], ["TLR7", "PROBLEM", 86, 90], ["infection", "OBSERVATION", 28, 37], ["increase", "OBSERVATION_MODIFIER", 42, 50]]], ["Notably, the relative expression of TLR3 transcripts was particularly high in ''PRRSV/SIV'' condition in PCLS.", [["PCLS", "ANATOMY", 105, 109], ["TLR3", "GENE_OR_GENE_PRODUCT", 36, 40], ["PRRSV", "ORGANISM", 80, 85], ["SIV", "ORGANISM", 86, 89], ["PCLS", "CANCER", 105, 109], ["TLR3 transcripts", "RNA", 36, 52], ["PRRSV/SIV", "SPECIES", 80, 89], ["TLR3 transcripts", "PROBLEM", 36, 52], ["TLR3 transcripts", "OBSERVATION", 36, 52]]], ["For TLR8 and TLR9, there were no statistically significant alterations in transcriptional expression in all infection conditions.", [["infection", "DISEASE", 108, 117], ["TLR8", "GENE_OR_GENE_PRODUCT", 4, 8], ["TLR9", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR8", "PROTEIN", 4, 8], ["TLR9", "PROTEIN", 13, 17], ["TLR8 and TLR9", "TREATMENT", 4, 17], ["statistically significant alterations", "PROBLEM", 33, 70], ["transcriptional expression in all infection conditions", "PROBLEM", 74, 128], ["no", "UNCERTAINTY", 30, 32], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["alterations", "OBSERVATION", 59, 70], ["transcriptional expression", "OBSERVATION", 74, 100], ["infection", "OBSERVATION", 108, 117]]], ["In agreement with previous reports (Xiao et al., 2010a,b) , our data suggest a significant stimulation of RIG-I and MDA5 after infection of lungs with another type 2 PRRSV.", [["lungs", "ANATOMY", 140, 145], ["infection", "DISEASE", 127, 136], ["RIG-I", "GENE_OR_GENE_PRODUCT", 106, 111], ["MDA5", "GENE_OR_GENE_PRODUCT", 116, 120], ["lungs", "ORGAN", 140, 145], ["PRRSV", "ORGANISM", 166, 171], ["RIG-I", "PROTEIN", 106, 111], ["MDA5", "PROTEIN", 116, 120], ["PRRSV", "SPECIES", 166, 171], ["infection of lungs", "PROBLEM", 127, 145], ["another type 2 PRRSV", "PROBLEM", 151, 171], ["infection", "OBSERVATION", 127, 136], ["lungs", "ANATOMY", 140, 145]]], ["Additionally, after PRRSV infection, we observed an increase in the mRNA expression of two known detectors of virally derived RNA and DNA, DAI and LGP2 transcripts (Pichlmair and Reis e Sousa, 2007; Sang et al., 2011) .", [["PRRSV infection", "DISEASE", 20, 35], ["PRRSV", "ORGANISM", 20, 25], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["LGP2", "GENE_OR_GENE_PRODUCT", 147, 151], ["virally derived RNA", "RNA", 110, 129], ["DAI and LGP2 transcripts", "RNA", 139, 163], ["PRRSV", "SPECIES", 20, 25], ["PRRSV infection", "PROBLEM", 20, 35], ["virally derived RNA", "PROBLEM", 110, 129], ["DNA", "PROBLEM", 134, 137], ["DAI", "PROBLEM", 139, 142], ["infection", "OBSERVATION", 26, 35], ["increase", "OBSERVATION_MODIFIER", 52, 60]]], ["Contrary to PRRSV, SIV significantly induced the upregulation of the expression of all the selected transcripts (i.e. DAI, LGP2, MDA5, and RIG-I) and TLR3 transcripts in the PCLS (P < 0.05).", [["PCLS", "ANATOMY", 174, 178], ["PRRSV", "ORGANISM", 12, 17], ["SIV", "ORGANISM", 19, 22], ["DAI", "GENE_OR_GENE_PRODUCT", 118, 121], ["LGP2", "GENE_OR_GENE_PRODUCT", 123, 127], ["MDA5", "GENE_OR_GENE_PRODUCT", 129, 133], ["RIG-I", "GENE_OR_GENE_PRODUCT", 139, 144], ["TLR3", "GENE_OR_GENE_PRODUCT", 150, 154], ["DAI, LGP2, MDA5, and RIG-I", "RNA", 118, 144], ["TLR3 transcripts", "RNA", 150, 166], ["PRRSV", "SPECIES", 12, 17], ["SIV", "SPECIES", 19, 22], ["PRRSV", "PROBLEM", 12, 17], ["DAI", "TEST", 118, 121], ["LGP2", "TEST", 123, 127], ["MDA5", "TEST", 129, 133], ["TLR3 transcripts", "TREATMENT", 150, 166], ["the PCLS", "TEST", 170, 178], ["TLR3 transcripts", "OBSERVATION", 150, 166], ["PCLS", "ANATOMY", 174, 178]]], ["In the PAMs, increases in the expression of viral recognition transcripts were statistically significant (DAI, LGP2, MDA5, and RIG-I) or showed a slight but not significant increase (TLR3 and TLR7).", [["LGP2", "GENE_OR_GENE_PRODUCT", 111, 115], ["MDA5", "GENE_OR_GENE_PRODUCT", 117, 121], ["RIG-I", "GENE_OR_GENE_PRODUCT", 127, 132], ["TLR3", "GENE_OR_GENE_PRODUCT", 183, 187], ["TLR7", "GENE_OR_GENE_PRODUCT", 192, 196], ["viral recognition transcripts", "PROTEIN", 44, 73], ["DAI", "PROTEIN", 106, 109], ["LGP2", "PROTEIN", 111, 115], ["MDA5", "PROTEIN", 117, 121], ["RIG-I", "PROTEIN", 127, 132], ["TLR3", "PROTEIN", 183, 187], ["TLR7", "PROTEIN", 192, 196], ["viral recognition transcripts", "PROBLEM", 44, 73], ["LGP2", "TEST", 111, 115], ["MDA5", "TEST", 117, 121], ["significant increase (TLR3 and TLR7)", "PROBLEM", 161, 197], ["PAMs", "OBSERVATION_MODIFIER", 7, 11], ["increases", "OBSERVATION_MODIFIER", 13, 22], ["slight", "OBSERVATION_MODIFIER", 146, 152], ["not", "UNCERTAINTY", 157, 160], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["increase", "OBSERVATION", 173, 181]]], ["These results are in agreement with previous studies in pigs (Husser et al., 2011; Li et al., 2011) and other species .", [["pigs", "ORGANISM", 56, 60], ["pigs", "SPECIES", 56, 60], ["pigs", "SPECIES", 56, 60], ["previous studies", "TEST", 36, 52], ["other species", "PROBLEM", 104, 117]]], ["Conversely, NLRP3, a detector of SIV replication (Wu et al., 2011), was not induced but rather slightly repressed in our conditions.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 12, 17], ["SIV", "ORGANISM", 33, 36], ["NLRP3", "PROTEIN", 12, 17], ["SIV", "SPECIES", 33, 36]]], ["This is possibly due to the chosen time point after viral infection.", [["viral infection", "DISEASE", 52, 67], ["viral infection", "PROBLEM", 52, 67], ["possibly due to", "UNCERTAINTY", 8, 23], ["infection", "OBSERVATION", 58, 67]]], ["In co-infection and superinfection conditions, relative expression of the viral recognition transcripts was not generally statistically different from relative expression of the same transcripts in response to SIV infection alone.", [["co-infection", "DISEASE", 3, 15], ["superinfection", "DISEASE", 20, 34], ["SIV infection", "DISEASE", 210, 223], ["SIV", "ORGANISM", 210, 213], ["viral recognition transcripts", "RNA", 74, 103], ["SIV", "SPECIES", 210, 213], ["co-infection", "PROBLEM", 3, 15], ["superinfection conditions", "PROBLEM", 20, 45], ["the viral recognition transcripts", "PROBLEM", 70, 103], ["SIV infection", "PROBLEM", 210, 223], ["co-infection", "OBSERVATION", 3, 15], ["superinfection", "OBSERVATION", 20, 34], ["SIV infection", "OBSERVATION", 210, 223]]], ["However, in the case of TLR3 and RIG-I transcripts in the PCLS, they were clearly additive and even displayed synergistic effects of the two viruses with possible contribution of TLR7 transcripts to the additive effects (Fig. 5A) .", [["PCLS", "ANATOMY", 58, 62], ["TLR3", "GENE_OR_GENE_PRODUCT", 24, 28], ["RIG-I", "GENE_OR_GENE_PRODUCT", 33, 38], ["PCLS", "CANCER", 58, 62], ["TLR7", "GENE_OR_GENE_PRODUCT", 179, 183], ["TLR3 and RIG-I transcripts", "RNA", 24, 50], ["TLR7 transcripts", "RNA", 179, 195], ["TLR3 and RIG-I transcripts", "TREATMENT", 24, 50], ["the two viruses", "PROBLEM", 133, 148], ["TLR7 transcripts", "TREATMENT", 179, 195], ["PCLS", "ANATOMY", 58, 62], ["viruses", "OBSERVATION", 141, 148], ["TLR7 transcripts", "OBSERVATION", 179, 195]]], ["When a 3 h delay was introduced between the administration of the two viruses, observations were similar, with the exception of ''PRRSV-3h-SIV'' in PCLS, where expression of the transcripts was generally lower.", [["PCLS", "ANATOMY", 148, 152], ["PRRSV-3h-SIV", "ORGANISM", 130, 142], ["PCLS", "CANCER", 148, 152], ["PRRSV-3h-SIV", "SPECIES", 130, 142], ["the two viruses", "TREATMENT", 62, 77], ["''PRRSV", "TEST", 128, 135], ["lower", "OBSERVATION_MODIFIER", 204, 209]]], ["Again, the 15 h incubation time versus 18 h could account for the observed difference even if we cannot exclude a PRRSV-specific effect.DiscussionIFNa transcript expression was very similar in all PCLS, while some significant expression differences were observed in the PAMs especially in superinfection conditions.", [["PCLS", "ANATOMY", 197, 201], ["superinfection", "DISEASE", 289, 303], ["PCLS", "CANCER", 197, 201], ["PRRSV", "SPECIES", 114, 119], ["a PRRSV", "PROBLEM", 112, 119], ["superinfection conditions", "PROBLEM", 289, 314], ["PRRSV", "OBSERVATION", 114, 119], ["superinfection", "OBSERVATION", 289, 303]]], ["The higher expression of IFNa transcripts in ''PRRSV-3h-SIV and SIV-3h-PRRSV'' conditions could be a consequence of both additive effects and viral kinetics.", [["IFNa", "GENE_OR_GENE_PRODUCT", 25, 29], ["PRRSV-3h-SIV", "ORGANISM", 47, 59], ["SIV-3h-PRRSV", "ORGANISM", 64, 76], ["IFNa transcripts", "RNA", 25, 41], ["SIV-3h-PRRSV", "SPECIES", 64, 76], ["IFNa transcripts", "PROBLEM", 25, 41], ["PRRSV'' conditions", "PROBLEM", 71, 89], ["viral kinetics", "PROBLEM", 142, 156], ["viral kinetics", "OBSERVATION", 142, 156]]], ["Indeed, based on other findings in our laboratory (unpublished data) and another study in pig PAMs (Genini et al., 2008) , it was shown that IFNa mRNA is usually detected earlier than IFNb mRNA after SIV infection.", [["SIV infection", "DISEASE", 200, 213], ["pig", "ORGANISM", 90, 93], ["IFNa", "GENE_OR_GENE_PRODUCT", 141, 145], ["IFNb", "GENE_OR_GENE_PRODUCT", 184, 188], ["SIV", "ORGANISM", 200, 203], ["IFNa mRNA", "RNA", 141, 150], ["IFNb mRNA", "RNA", 184, 193], ["pig", "SPECIES", 90, 93], ["pig", "SPECIES", 90, 93], ["SIV", "SPECIES", 200, 203], ["another study", "TEST", 73, 86], ["IFNa mRNA", "PROBLEM", 141, 150], ["SIV infection", "PROBLEM", 200, 213], ["SIV infection", "OBSERVATION", 200, 213]]], ["In the PCLS, IFNb transcripts were mostly produced in response to SIV virus with a synergy in their expression when SIV was coadministered with PRRSV.", [["PCLS", "CANCER", 7, 11], ["IFNb", "GENE_OR_GENE_PRODUCT", 13, 17], ["SIV", "ORGANISM", 66, 69], ["SIV", "ORGANISM", 116, 119], ["PRRSV", "ORGANISM", 144, 149], ["IFNb transcripts", "RNA", 13, 29], ["SIV virus", "SPECIES", 66, 75], ["SIV", "SPECIES", 116, 119], ["PRRSV", "SPECIES", 144, 149], ["IFNb transcripts", "TREATMENT", 13, 29], ["SIV virus", "PROBLEM", 66, 75], ["a synergy", "PROBLEM", 81, 90], ["PRRSV", "PROBLEM", 144, 149], ["PCLS", "ANATOMY", 7, 11], ["SIV virus", "OBSERVATION", 66, 75]]], ["The same trend was observed in response to PRRSV infection in PAMs.", [["PRRSV infection", "DISEASE", 43, 58], ["PRRSV", "ORGANISM", 43, 48], ["PRRSV", "SPECIES", 43, 48], ["PRRSV infection in PAMs", "PROBLEM", 43, 66], ["PRRSV infection", "OBSERVATION", 43, 58]]], ["This observation is a bit surprising because it has been shown that PRRSV actively suppresses IFNb in macrophages, at least in MARC-145 cells and some human cells (Miller et al., 2004; Sang et al., 2011) .", [["macrophages", "ANATOMY", 102, 113], ["MARC-145 cells", "ANATOMY", 127, 141], ["cells", "ANATOMY", 157, 162], ["PRRSV", "ORGANISM", 68, 73], ["IFNb", "GENE_OR_GENE_PRODUCT", 94, 98], ["macrophages", "CELL", 102, 113], ["MARC-145 cells", "CELL", 127, 141], ["human", "ORGANISM", 151, 156], ["cells", "CELL", 157, 162], ["IFNb", "PROTEIN", 94, 98], ["macrophages", "CELL_TYPE", 102, 113], ["MARC-145 cells", "CELL_LINE", 127, 141], ["human cells", "CELL_TYPE", 151, 162], ["human", "SPECIES", 151, 156], ["PRRSV", "SPECIES", 68, 73], ["human", "SPECIES", 151, 156], ["PRRSV", "PROBLEM", 68, 73], ["some human cells", "PROBLEM", 146, 162], ["145 cells", "OBSERVATION_MODIFIER", 132, 141]]], ["However, in a study using porcine PAMs (Genini et al., 2008) , the authors observed a strong upregulation of IFNb transcripts 12 h post-infection, in support of our data.", [["infection", "DISEASE", 136, 145], ["porcine", "ORGANISM", 26, 33], ["IFNb", "GENE_OR_GENE_PRODUCT", 109, 113], ["IFNb transcripts", "RNA", 109, 125], ["a study", "TEST", 12, 19], ["porcine PAMs", "TREATMENT", 26, 38], ["IFNb transcripts", "TREATMENT", 109, 125], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145]]], ["Regarding IFNg, transcript expression was only observed in the PCLS with a significant increase in co-infection and superinfection conditions, suggesting again synergistic effects of the two infections.", [["PCLS", "ANATOMY", 63, 67], ["co-infection", "DISEASE", 99, 111], ["superinfection", "DISEASE", 116, 130], ["infections", "DISEASE", 191, 201], ["IFNg", "GENE_OR_GENE_PRODUCT", 10, 14], ["PCLS", "CANCER", 63, 67], ["IFNg", "PROTEIN", 10, 14], ["transcript expression", "PROBLEM", 16, 37], ["co-infection", "PROBLEM", 99, 111], ["superinfection conditions", "PROBLEM", 116, 141], ["the two infections", "PROBLEM", 183, 201], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["co-infection", "OBSERVATION", 99, 111], ["superinfection", "OBSERVATION", 116, 130], ["infections", "OBSERVATION", 191, 201]]], ["At the protein level, no interferons (a and b) was detected at 18 h post-infection, suggesting either very low expression under the limits of detection of the kit or some posttranscriptional regulatory mechanisms preventing protein expression as previously described (Lee et al., 2004; Wang and Christopher-Hennings, 2012) .", [["infection", "DISEASE", 73, 82], ["interferons", "GENE_OR_GENE_PRODUCT", 25, 36], ["kit", "GENE_OR_GENE_PRODUCT", 159, 162], ["interferons", "PROTEIN", 25, 36], ["the protein level", "TEST", 3, 20], ["interferons", "PROBLEM", 25, 36], ["infection", "PROBLEM", 73, 82], ["the kit", "PROBLEM", 155, 162], ["protein expression", "PROBLEM", 224, 242], ["no", "UNCERTAINTY", 22, 24], ["infection", "OBSERVATION", 73, 82], ["very", "OBSERVATION_MODIFIER", 102, 106], ["low expression", "OBSERVATION", 107, 121], ["protein expression", "OBSERVATION", 224, 242]]], ["However it seems, to some level, sufficient amounts of interferons were produced; at least in response to SIV, as interferon response genes (IRGs) were induced in PCLS and PAMs.", [["PCLS", "ANATOMY", 163, 167], ["SIV", "ORGANISM", 106, 109], ["interferon response genes", "GENE_OR_GENE_PRODUCT", 114, 139], ["IRGs", "GENE_OR_GENE_PRODUCT", 141, 145], ["PCLS", "CELL", 163, 167], ["interferons", "PROTEIN", 55, 66], ["interferon response genes", "DNA", 114, 139], ["IRGs", "DNA", 141, 145], ["SIV", "SPECIES", 106, 109], ["interferons", "TREATMENT", 55, 66], ["SIV", "PROBLEM", 106, 109], ["interferon response genes", "TREATMENT", 114, 139], ["PAMs", "PROBLEM", 172, 176]]], ["Generally, interferons need to be produced in order to trigger the induction of IRGs, although a direct induction of IRGs such as OAS1 and protein kinase R by viral nucleic acids has been reported (Player and Torrence, 1998; Williams, 2001) .DiscussionAmongst the cytokines tested in response to single, coand superinfections, IL6, IL10, TNFa and TRAIL were frequently induced.", [["nucleic acids", "CHEMICAL", 165, 178], ["IRGs", "GENE_OR_GENE_PRODUCT", 80, 84], ["IRGs", "GENE_OR_GENE_PRODUCT", 117, 121], ["OAS1", "GENE_OR_GENE_PRODUCT", 130, 134], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 139, 155], ["IL6", "GENE_OR_GENE_PRODUCT", 327, 330], ["IL10", "GENE_OR_GENE_PRODUCT", 332, 336], ["TNFa", "GENE_OR_GENE_PRODUCT", 338, 342], ["TRAIL", "GENE_OR_GENE_PRODUCT", 347, 352], ["interferons", "PROTEIN", 11, 22], ["IRGs", "PROTEIN", 80, 84], ["IRGs", "PROTEIN", 117, 121], ["OAS1", "PROTEIN", 130, 134], ["protein kinase R", "PROTEIN", 139, 155], ["cytokines", "PROTEIN", 264, 273], ["IL6", "PROTEIN", 327, 330], ["IL10", "PROTEIN", 332, 336], ["TNFa", "PROTEIN", 338, 342], ["TRAIL", "PROTEIN", 347, 352], ["interferons", "TREATMENT", 11, 22], ["IRGs", "TREATMENT", 80, 84], ["a direct induction of IRGs", "TREATMENT", 95, 121], ["OAS1", "TEST", 130, 134], ["protein kinase", "TEST", 139, 153], ["viral nucleic acids", "TEST", 159, 178], ["the cytokines", "TEST", 260, 273], ["single, coand superinfections", "PROBLEM", 296, 325], ["IL6", "TREATMENT", 327, 330], ["IL10", "TREATMENT", 332, 336], ["TNFa", "TREATMENT", 338, 342], ["TRAIL", "TREATMENT", 347, 352], ["superinfections", "OBSERVATION", 310, 325]]], ["IL6 mRNA was up-regulated in response to SIV but not to PRRSV in PCLS.", [["PCLS", "ANATOMY", 65, 69], ["IL6", "GENE_OR_GENE_PRODUCT", 0, 3], ["SIV", "ORGANISM", 41, 44], ["PRRSV", "ORGANISM", 56, 61], ["PCLS", "CANCER", 65, 69], ["IL6 mRNA", "RNA", 0, 8], ["SIV", "SPECIES", 41, 44], ["PRRSV", "SPECIES", 56, 61], ["IL6 mRNA", "TEST", 0, 8]]], ["In PAMs, the up-regulation was more significant in co-infection and superinfection conditions, TNFa mRNA in particular, in agreement with previous studies (Choi et al., 2002; Gao et al., 2012; Van Reeth et al., 2002) .", [["co-infection", "DISEASE", 51, 63], ["superinfection", "DISEASE", 68, 82], ["TNFa", "GENE_OR_GENE_PRODUCT", 95, 99], ["TNFa mRNA", "RNA", 95, 104], ["co-infection", "PROBLEM", 51, 63], ["superinfection conditions", "PROBLEM", 68, 93], ["previous studies", "TEST", 138, 154], ["PAMs", "OBSERVATION", 3, 7], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["co-infection", "OBSERVATION", 51, 63], ["superinfection", "OBSERVATION", 68, 82]]], ["TRAIL, which is produced by alveolar macrophages and contributes to epithelial cell apoptosis (Herold et al., 2008; , showed the most significant induction by SIV in both PCLS and PAMs.", [["alveolar macrophages", "ANATOMY", 28, 48], ["epithelial cell", "ANATOMY", 68, 83], ["PCLS", "ANATOMY", 171, 175], ["TRAIL", "CHEMICAL", 0, 5], ["TRAIL", "GENE_OR_GENE_PRODUCT", 0, 5], ["alveolar macrophages", "CELL", 28, 48], ["epithelial cell", "CELL", 68, 83], ["SIV", "ORGANISM", 159, 162], ["TRAIL", "PROTEIN", 0, 5], ["alveolar macrophages", "CELL_TYPE", 28, 48], ["SIV", "SPECIES", 159, 162], ["alveolar macrophages", "PROBLEM", 28, 48], ["epithelial cell apoptosis", "PROBLEM", 68, 93], ["alveolar macrophages", "OBSERVATION", 28, 48], ["epithelial cell apoptosis", "OBSERVATION", 68, 93], ["both", "ANATOMY_MODIFIER", 166, 170], ["PCLS", "ANATOMY", 171, 175], ["PAMs", "OBSERVATION", 180, 184]]], ["IL10 transcript expression was significantly up-regulated in PAMs in the conditions examined here, similar to previous observations (Suradhat et al., 2003; Thanawongnuwech and Suradhat, 2010) .", [["IL10", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL10", "PROTEIN", 0, 4], ["IL10 transcript expression", "PROBLEM", 0, 26]]], ["SOCS1, a regulator of immune response (Delgado-Ortega et al., 2013) , was clearly up-regulated in response to SIV in both PCLS and PAMs while there was only a slight increase in response to PRRSV, contrary to what was observed in other studies (Wysocki et al., 2012; Zhou et al., 2011) .", [["PCLS", "ANATOMY", 122, 126], ["SOCS1", "GENE_OR_GENE_PRODUCT", 0, 5], ["SIV", "ORGANISM", 110, 113], ["PCLS", "CELL", 122, 126], ["PRRSV", "ORGANISM", 190, 195], ["SOCS1", "PROTEIN", 0, 5], ["PCLS", "CELL_TYPE", 122, 126], ["PAMs", "CELL_TYPE", 131, 135], ["SIV", "SPECIES", 110, 113], ["PRRSV", "SPECIES", 190, 195], ["a slight increase", "PROBLEM", 157, 174], ["PRRSV", "TREATMENT", 190, 195], ["slight", "OBSERVATION_MODIFIER", 159, 165], ["increase", "OBSERVATION_MODIFIER", 166, 174], ["response to PRRSV", "OBSERVATION", 178, 195]]], ["This discrepancy could be explained by some differences in experimental conditions (infection time, heterogeneous mixed versus single cell population).", [["cell", "ANATOMY", 134, 138], ["infection", "DISEASE", 84, 93], ["cell", "CELL", 134, 138], ["experimental conditions (infection time", "PROBLEM", 59, 98], ["heterogeneous mixed versus single cell population", "PROBLEM", 100, 149], ["could be explained", "UNCERTAINTY", 17, 35], ["experimental conditions", "OBSERVATION", 59, 82], ["heterogeneous", "OBSERVATION_MODIFIER", 100, 113], ["mixed", "OBSERVATION_MODIFIER", 114, 119]]], ["Moreover, while the role of SOCS1 in the host response to influenza virus has been clearly demonstrated in other species (Pothlichet et al., 2008) , its role in PRRSV pathogenesis is still unclear.DiscussionConfocal microscopy was utilized to visualize infected cells in situ upon infection with PRRSV and/or SIV.", [["cells", "ANATOMY", 262, 267], ["situ", "ANATOMY", 271, 275], ["influenza virus", "DISEASE", 58, 73], ["infection", "DISEASE", 281, 290], ["SOCS1", "GENE_OR_GENE_PRODUCT", 28, 33], ["influenza virus", "ORGANISM", 58, 73], ["PRRSV", "ORGANISM", 161, 166], ["cells", "CELL", 262, 267], ["PRRSV", "ORGANISM", 296, 301], ["SIV", "ORGANISM", 309, 312], ["SOCS1", "PROTEIN", 28, 33], ["infected cells", "CELL_TYPE", 253, 267], ["influenza virus", "SPECIES", 58, 73], ["PRRSV", "SPECIES", 161, 166], ["influenza virus", "SPECIES", 58, 73], ["PRRSV", "SPECIES", 161, 166], ["PRRSV", "SPECIES", 296, 301], ["SIV", "SPECIES", 309, 312], ["SOCS1", "PROBLEM", 28, 33], ["influenza virus", "PROBLEM", 58, 73], ["PRRSV pathogenesis", "PROBLEM", 161, 179], ["Confocal microscopy", "TEST", 207, 226], ["infected cells", "PROBLEM", 253, 267], ["infection", "PROBLEM", 281, 290], ["PRRSV", "PROBLEM", 296, 301], ["SIV", "PROBLEM", 309, 312], ["SOCS1", "OBSERVATION", 28, 33], ["influenza virus", "OBSERVATION", 58, 73], ["PRRSV pathogenesis", "OBSERVATION", 161, 179], ["infected cells", "OBSERVATION", 253, 267], ["infection", "OBSERVATION", 281, 290]]], ["Upon coinfection of PCLS, we did not detect any co-infected cells, confirming the importance of bronchial epithelial cells and alveolar macrophages as the main target of SIV and PRRSV in lung, respectively (Crisci et al., 2013; Meulenberg, 2000; Sang et al., 2011; Taubenberger and Morens, 2008) .", [["PCLS", "ANATOMY", 20, 24], ["cells", "ANATOMY", 60, 65], ["bronchial epithelial cells", "ANATOMY", 96, 122], ["alveolar macrophages", "ANATOMY", 127, 147], ["lung", "ANATOMY", 187, 191], ["PCLS", "CANCER", 20, 24], ["cells", "CELL", 60, 65], ["bronchial epithelial cells", "CELL", 96, 122], ["alveolar macrophages", "CELL", 127, 147], ["SIV", "ORGANISM", 170, 173], ["PRRSV", "ORGANISM", 178, 183], ["lung", "ORGAN", 187, 191], ["co-infected cells", "CELL_TYPE", 48, 65], ["bronchial epithelial cells", "CELL_TYPE", 96, 122], ["alveolar macrophages", "CELL_TYPE", 127, 147], ["SIV", "SPECIES", 170, 173], ["PRRSV", "SPECIES", 178, 183], ["PCLS", "PROBLEM", 20, 24], ["any co-infected cells", "PROBLEM", 44, 65], ["bronchial epithelial cells", "PROBLEM", 96, 122], ["alveolar macrophages", "PROBLEM", 127, 147], ["coinfection", "OBSERVATION", 5, 16], ["bronchial", "ANATOMY", 96, 105], ["epithelial cells", "OBSERVATION", 106, 122], ["alveolar macrophages", "OBSERVATION", 127, 147], ["main", "OBSERVATION_MODIFIER", 155, 159], ["target", "OBSERVATION_MODIFIER", 160, 166], ["SIV", "OBSERVATION", 170, 173], ["lung", "ANATOMY", 187, 191]]], ["However, our study also confirms that some alveolar epithelial cells such as pneumocyte type 1 can be infected by PRRSV virus as previously reported (Sur et al., 1996) .", [["alveolar epithelial cells", "ANATOMY", 43, 68], ["pneumocyte type 1", "ANATOMY", 77, 94], ["alveolar epithelial cells", "CELL", 43, 68], ["pneumocyte type 1", "CELL", 77, 94], ["PRRSV virus", "ORGANISM", 114, 125], ["alveolar epithelial cells", "CELL_TYPE", 43, 68], ["PRRSV", "SPECIES", 114, 119], ["PRRSV virus", "SPECIES", 114, 125], ["our study", "TEST", 9, 18], ["some alveolar epithelial cells", "PROBLEM", 38, 68], ["pneumocyte type 1", "PROBLEM", 77, 94], ["PRRSV virus", "PROBLEM", 114, 125], ["some", "OBSERVATION_MODIFIER", 38, 42], ["alveolar epithelial cells", "OBSERVATION", 43, 68], ["PRRSV virus", "OBSERVATION", 114, 125]]], ["Many different cell types are present in the PCLS, e.g. macrophages, epithelial cells, pneumocytes type 1 and 2, endothelial cells, fibroblast, and dendritic cells.", [["cell", "ANATOMY", 15, 19], ["PCLS", "ANATOMY", 45, 49], ["macrophages", "ANATOMY", 56, 67], ["epithelial cells", "ANATOMY", 69, 85], ["pneumocytes type 1", "ANATOMY", 87, 105], ["endothelial cells", "ANATOMY", 113, 130], ["fibroblast", "ANATOMY", 132, 142], ["dendritic cells", "ANATOMY", 148, 163], ["cell", "CELL", 15, 19], ["PCLS", "CELL", 45, 49], ["macrophages", "CELL", 56, 67], ["epithelial cells", "CELL", 69, 85], ["pneumocytes type 1", "CELL", 87, 105], ["2", "CELL", 110, 111], ["endothelial cells", "CELL", 113, 130], ["fibroblast", "CELL", 132, 142], ["dendritic cells", "CELL", 148, 163], ["PCLS", "CELL_TYPE", 45, 49], ["macrophages", "CELL_TYPE", 56, 67], ["epithelial cells", "CELL_TYPE", 69, 85], ["pneumocytes type 1 and 2, endothelial cells", "CELL_TYPE", 87, 130], ["fibroblast", "CELL_TYPE", 132, 142], ["dendritic cells", "CELL_TYPE", 148, 163], ["Many different cell types", "PROBLEM", 0, 25], ["epithelial cells", "PROBLEM", 69, 85], ["pneumocytes type 1", "PROBLEM", 87, 105], ["endothelial cells, fibroblast, and dendritic cells", "PROBLEM", 113, 163], ["different cell types", "OBSERVATION", 5, 25], ["PCLS", "ANATOMY", 45, 49], ["macrophages", "ANATOMY", 56, 67], ["epithelial cells", "OBSERVATION", 69, 85], ["pneumocytes type", "OBSERVATION", 87, 103], ["endothelial cells", "ANATOMY", 113, 130], ["fibroblast", "OBSERVATION_MODIFIER", 132, 142], ["dendritic cells", "OBSERVATION", 148, 163]]], ["This cellular diversity could account for some of the differences observed in our study between PAMs and PCLS.", [["cellular", "ANATOMY", 5, 13], ["cellular", "CELL", 5, 13], ["PCLS", "CANCER", 105, 109], ["our study", "TEST", 78, 87], ["PCLS", "TEST", 105, 109], ["cellular diversity", "OBSERVATION", 5, 23], ["could account for", "UNCERTAINTY", 24, 41]]], ["Moreover, many PAMs are probably removed from the PCLS because of the multiples washes performed during their preparation while PIMs and especially ISMs are more intimately associated to the tissue.DiscussionAltogether, the results of our study (Table 2) show that co-infection with PRRSV VR-2385 and SIV (A/Sw/Saskatchewan/18789/02) demonstrate additive effects on the expression of several types of virally induced transcripts.", [["tissue", "ANATOMY", 191, 197], ["co-infection", "DISEASE", 265, 277], ["PAMs", "CELL", 15, 19], ["ISMs", "GENE_OR_GENE_PRODUCT", 148, 152], ["tissue", "TISSUE", 191, 197], ["PRRSV VR-2385", "ORGANISM", 283, 296], ["SIV", "ORGANISM", 301, 304], ["A/Sw/Saskatchewan/18789/02", "ORGANISM", 306, 332], ["virally induced transcripts", "RNA", 401, 428], ["PRRSV", "SPECIES", 283, 288], ["PRRSV VR-2385", "SPECIES", 283, 296], ["SIV (A/Sw/Saskatchewan/18789/02", "SPECIES", 301, 332], ["many PAMs", "PROBLEM", 10, 19], ["the multiples washes", "TREATMENT", 66, 86], ["PIMs", "PROBLEM", 128, 132], ["ISMs", "PROBLEM", 148, 152], ["our study", "TEST", 235, 244], ["co-infection", "PROBLEM", 265, 277], ["PRRSV VR", "TEST", 283, 291], ["virally induced transcripts", "TREATMENT", 401, 428], ["many", "OBSERVATION_MODIFIER", 10, 14], ["PAMs", "OBSERVATION", 15, 19], ["probably", "UNCERTAINTY", 24, 32], ["removed", "OBSERVATION", 33, 40], ["washes", "OBSERVATION", 80, 86], ["tissue", "OBSERVATION", 191, 197], ["co-infection", "OBSERVATION", 265, 277]]], ["Moreover, a synergy was observed for some specific targets such as TLR3, RIG-I, and IFNb transcripts in the PCLS when the two viruses were administered concomitantly.", [["PCLS", "ANATOMY", 108, 112], ["TLR3", "GENE_OR_GENE_PRODUCT", 67, 71], ["RIG-I", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFNb", "GENE_OR_GENE_PRODUCT", 84, 88], ["PCLS", "CANCER", 108, 112], ["TLR3, RIG-I, and IFNb transcripts", "RNA", 67, 100], ["TLR3", "TEST", 67, 71], ["IFNb transcripts", "TREATMENT", 84, 100], ["the two viruses", "PROBLEM", 118, 133], ["PCLS", "ANATOMY", 108, 112]]], ["The impact of such a synergy on the clinical outcome is difficult to establish as it can either increase symptoms and be detrimental for the host or, on the contrary, assist in the rapid clearance of the infections.", [["infections", "DISEASE", 204, 214], ["increase symptoms", "PROBLEM", 96, 113], ["the infections", "PROBLEM", 200, 214], ["infections", "OBSERVATION", 204, 214]]], ["The lower host response to superinfecting virus after an initial infection with PRRSV, if confirmed, could contribute to the development of more severe forms of SIV infection and needs further study to accurately determine how PRRSV modulates the immune response to superinfecting SIV.", [["infection", "DISEASE", 65, 74], ["SIV infection", "DISEASE", 161, 174], ["superinfecting virus", "ORGANISM", 27, 47], ["PRRSV", "ORGANISM", 80, 85], ["SIV", "ORGANISM", 161, 164], ["PRRSV", "ORGANISM", 227, 232], ["SIV", "ORGANISM", 281, 284], ["PRRSV", "SPECIES", 80, 85], ["SIV", "SPECIES", 161, 164], ["PRRSV", "SPECIES", 227, 232], ["SIV", "SPECIES", 281, 284], ["superinfecting virus", "PROBLEM", 27, 47], ["an initial infection", "PROBLEM", 54, 74], ["PRRSV", "PROBLEM", 80, 85], ["SIV infection", "PROBLEM", 161, 174], ["further study", "TEST", 185, 198], ["lower host", "OBSERVATION_MODIFIER", 4, 14], ["infection", "OBSERVATION", 65, 74], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["SIV infection", "OBSERVATION", 161, 174]]], ["On the virus side, the absence of synergy between the two viruses for their replication is already beneficial for the host.", [["synergy between the two viruses", "PROBLEM", 34, 65], ["viruses", "OBSERVATION", 58, 65]]], ["The delay introduced between the two infections had most generally limited impact and we only observed a decrease in the tissue response when the PRRSV was administered first.", [["tissue", "ANATOMY", 121, 127], ["infections", "DISEASE", 37, 47], ["tissue", "TISSUE", 121, 127], ["PRRSV", "ORGANISM", 146, 151], ["PRRSV", "SPECIES", 146, 151], ["The delay", "PROBLEM", 0, 9], ["the two infections", "PROBLEM", 29, 47], ["a decrease in the tissue response", "PROBLEM", 103, 136], ["the PRRSV", "TREATMENT", 142, 151], ["infections", "OBSERVATION", 37, 47], ["decrease", "OBSERVATION_MODIFIER", 105, 113]]], ["The limited impact of superinfection delay may be due to the differences in cellular targeting between the two viruses.", [["cellular", "ANATOMY", 76, 84], ["superinfection", "DISEASE", 22, 36], ["cellular", "CELL", 76, 84], ["superinfection delay", "PROBLEM", 22, 42], ["superinfection", "OBSERVATION", 22, 36], ["may be due to", "UNCERTAINTY", 43, 56], ["viruses", "OBSERVATION", 111, 118]]], ["In conclusion, the current study opened the door to further research in the exciting and intriguing field of viral co-infection and superinfection research.", [["viral co-infection", "DISEASE", 109, 127], ["superinfection", "DISEASE", 132, 146], ["the current study", "TEST", 15, 32], ["viral co-infection", "PROBLEM", 109, 127], ["superinfection research", "TREATMENT", 132, 155], ["viral co-infection", "OBSERVATION", 109, 127], ["superinfection", "OBSERVATION", 132, 146]]]], "PMC7094332": [["IntroductionThe presence and likely impact of contagion are critical issues that surround a bioterrorist attack, the natural emergence of a new disease, or the accidental release of a dangerous pathogen into the natural environment.", [["critical issues", "PROBLEM", 60, 75], ["a bioterrorist attack", "PROBLEM", 90, 111], ["a new disease", "PROBLEM", 138, 151], ["new", "OBSERVATION_MODIFIER", 140, 143], ["disease", "OBSERVATION", 144, 151]]], ["Even if effective countermeasures are available, a failure to completely contain a contagious disease may give rise to a far-reaching epidemic with considerable social disruption and economic impact.", [["a failure", "PROBLEM", 49, 58], ["a contagious disease", "PROBLEM", 81, 101], ["a far-reaching epidemic", "PROBLEM", 119, 142], ["considerable social disruption", "PROBLEM", 148, 178], ["considerable", "OBSERVATION_MODIFIER", 148, 160], ["social disruption", "OBSERVATION", 161, 178]]], ["Both civilian and military homeland biodefense planners are thus faced with a broad spectrum of contagious disease threats and a sound conceptual framework is necessary to shape and plan threat responses.", [["contagious disease threats", "PROBLEM", 96, 122]]], ["Arguably, well-designed epidemic modeling studies can contribute significantly to such a conceptual framework.IntroductionSevere acute respiratory syndrome (SARS) is the first new contagious disease to emerge in the 21st century.", [["acute respiratory syndrome", "DISEASE", 129, 155], ["SARS", "DISEASE", 157, 161], ["epidemic modeling studies", "TEST", 24, 49], ["acute respiratory syndrome", "PROBLEM", 129, 155], ["SARS", "PROBLEM", 157, 161], ["the first new contagious disease", "PROBLEM", 166, 198], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["respiratory syndrome", "OBSERVATION", 135, 155], ["new", "OBSERVATION_MODIFIER", 176, 179], ["contagious disease", "OBSERVATION", 180, 198]]], ["Initial SARS cases occurred in southern China during November of 2002 and international air travel quickly spread the disease through Asia, North America and Europe.", [["SARS", "DISEASE", 8, 12], ["Initial SARS cases", "PROBLEM", 0, 18]]], ["On the 5th of July 2003, the World Health Organization announced the global containment of SARS cases.", [["SARS", "DISEASE", 91, 95], ["global", "OBSERVATION_MODIFIER", 69, 75], ["containment", "OBSERVATION_MODIFIER", 76, 87]]], ["This international outbreak was responsible for about 8100 cases and 775 deaths.", [["deaths", "DISEASE", 73, 79]]], ["Moreover, Asian economies (for example) suffered losses in the neighborhood of 15 billion dollars (plus additional billions of dollars for economic stimulus packages) [1].IntroductionThe SARS outbreaks of 2002 and 2003 are instructive for several reasons.", [["SARS", "DISEASE", 187, 191], ["economic stimulus packages", "TREATMENT", 139, 165]]], ["First, modern pharmaceuticals could neither prevent SARS infections nor abort the natural course of SARS cases.", [["SARS infections", "DISEASE", 52, 67], ["SARS", "DISEASE", 100, 104], ["modern pharmaceuticals", "TREATMENT", 7, 29], ["SARS infections", "PROBLEM", 52, 67]]], ["Each affected country controlled the spread of SARS in traditional ways: (a) case identification and contact tracing, (b) case-patient isolation (hospital infection control), and (c) exposure management (quarantine).", [["SARS", "DISEASE", 47, 51], ["infection", "DISEASE", 155, 164], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["contact tracing", "TEST", 101, 116], ["patient isolation (hospital infection control", "TREATMENT", 127, 172], ["exposure management", "TREATMENT", 183, 202]]], ["Second, disease surveillance shortcomings and public health capacity limitations constrained SARS responses of Asian governments.", [["SARS", "DISEASE", 93, 97], ["Second, disease surveillance shortcomings", "PROBLEM", 0, 41], ["disease", "OBSERVATION", 8, 15]]], ["Third and last, a great deal of SARS epidemiological information has already been published and more SARS data is likely to appear in the scientific literature.IntroductionThe available SARS outbreak data has prompted researchers to reexamine the question of how best to quantitatively describe outbreak dynamics when traditional outbreak controls are the only viable countermeasures [2], [3], [4], [5].", [["SARS", "DISEASE", 32, 36], ["SARS", "DISEASE", 101, 105], ["SARS", "DISEASE", 186, 190], ["[3]", "SIMPLE_CHEMICAL", 389, 392], ["[4]", "SIMPLE_CHEMICAL", 394, 397]]], ["Good answers to this question have been (and will be) essential to the development of sound biodefense requirements and plans.IntroductionEpidemic models have long been valuable tools for studying the dynamics of contagious diseases in human populations.", [["human", "ORGANISM", 236, 241], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["contagious diseases in human populations", "PROBLEM", 213, 253]]], ["Assuming an unstructured population and the standard incidence, disease transmission occurs by means of homogeneous mixing, where each contagious individual is free to contact and infect any susceptible individual.", [["an unstructured population", "PROBLEM", 9, 35], ["disease transmission", "PROBLEM", 64, 84], ["unstructured", "OBSERVATION_MODIFIER", 12, 24], ["population", "OBSERVATION", 25, 35]]], ["But if the population is structured according to cultural, socio-economic, demographic or geographic factors, there is a mixing matrix that constrains opportunities for disease-causing contacts.", [["matrix", "CELLULAR_COMPONENT", 128, 134], ["disease", "PROBLEM", 169, 176]]], ["It is also true that sufficient data is seldom accessible to quantitatively define key mixing matrix elements for a large and highly structured population.IntroductionViewing a structured population as a contact network, nodes or vertices in this network represent individuals and links or edges indicate potential disease-causing contacts.", [["nodes", "ANATOMY", 221, 226], ["a large and highly structured population", "PROBLEM", 114, 154], ["potential disease", "PROBLEM", 305, 322], ["mixing matrix", "OBSERVATION", 87, 100], ["large", "OBSERVATION_MODIFIER", 116, 121], ["highly", "OBSERVATION_MODIFIER", 126, 132], ["structured", "OBSERVATION_MODIFIER", 133, 143], ["population", "OBSERVATION", 144, 154], ["nodes", "OBSERVATION", 221, 226]]], ["Mounting evidence shows that various real-world networks are scale-free; i.e., the probability distribution for the number of links per node (or the node \u2018degree\u2019) follows a power law [7], [8].", [["node", "ANATOMY", 136, 140], ["node", "ANATOMY", 149, 153], ["node", "OBSERVATION", 136, 140], ["node", "ANATOMY", 149, 153]]], ["This power law is associable with network evolution or growth.", [["growth", "OBSERVATION_MODIFIER", 55, 61]]], ["More specifically, in contrast to classical random graphs, a scale-free network is a growing open system that accommodates a new node by attaching it to certain preexisting network nodes.", [["node", "ANATOMY", 129, 133], ["network nodes", "ANATOMY", 173, 186], ["node", "MULTI-TISSUE_STRUCTURE", 129, 133], ["network nodes", "MULTI-TISSUE_STRUCTURE", 173, 186], ["a growing open system", "PROBLEM", 83, 104], ["a new node", "PROBLEM", 123, 133], ["preexisting network nodes", "PROBLEM", 161, 186], ["new", "OBSERVATION_MODIFIER", 125, 128], ["node", "OBSERVATION", 129, 133], ["network nodes", "OBSERVATION", 173, 186]]], ["The growth process for a scale-free network gives rise to another distinguishing feature, correlated degrees of connected nodes [9].", [["a scale", "TEST", 23, 30], ["connected nodes", "PROBLEM", 112, 127], ["nodes", "OBSERVATION", 122, 127]]], ["In the absence of node degree correlation, network-based epidemic models often entail proportionate (random) mixing assumptions.IntroductionMay and Lloyd seem to have been the first researchers to incorporate scale-free network characteristics in a basic SIR (susceptible-infectious-removed) model for structured populations [10].", [["node", "ANATOMY", 18, 22], ["node", "MULTI-TISSUE_STRUCTURE", 18, 22], ["node degree correlation", "TEST", 18, 41], ["node degree", "OBSERVATION", 18, 29]]], ["These investigators relied upon a random mixing matrix and treated the discrete node degree as a continuous variable.", [["node", "ANATOMY", 80, 84], ["node", "MULTI-TISSUE_STRUCTURE", 80, 84], ["a random mixing matrix", "TREATMENT", 32, 54], ["the discrete node degree", "PROBLEM", 67, 91], ["discrete", "OBSERVATION_MODIFIER", 71, 79], ["node", "OBSERVATION", 80, 84], ["degree", "OBSERVATION_MODIFIER", 85, 91]]], ["They derived mathematical expressions and obtained numerical results describing (a) the infected fraction of the entire population as a function of a basic reproductive parameter and (b) the infected fraction by node degree for selected parameter values.", [["node", "ANATOMY", 212, 216], ["node", "MULTI-TISSUE_STRUCTURE", 212, 216], ["the infected fraction", "PROBLEM", 187, 208], ["selected parameter values", "TEST", 228, 253], ["infected", "OBSERVATION", 191, 199], ["node degree", "OBSERVATION", 212, 223]]], ["These researchers focused on epidemic threshold issues and they did not discuss how a scale-free network could affect outbreak dynamics.IntroductionBarthelemy, Barrat, Boguna, Pastor-Satorras and Vespignani have published a series of interesting and informative papers that explore network effects on outbreak dynamics [11], [12], [13], [14], [15], [16].", [["[12]", "SIMPLE_CHEMICAL", 325, 329], ["[13]", "SIMPLE_CHEMICAL", 331, 335], ["[14], [15]", "SIMPLE_CHEMICAL", 337, 347], ["[16]", "SIMPLE_CHEMICAL", 349, 353], ["epidemic threshold issues", "PROBLEM", 29, 54], ["IntroductionBarthelemy", "TEST", 136, 158], ["outbreak dynamics", "TEST", 301, 318]]], ["They have mathematically defined important properties of scale-free networks and examined epidemiological implications of these properties using susceptible-infectious (SI), susceptible-infectious-susceptible (SIS) and SIR models.", [["infectious (SI), susceptible-infectious-susceptible (SIS) and SIR", "DISEASE", 157, 222], ["susceptible-infectious (SI)", "PROBLEM", 145, 172], ["infectious", "OBSERVATION", 157, 167], ["infectious", "OBSERVATION", 186, 196]]], ["In their network-based SI, SIS and SIR analyses, Barthelemy and coauthors routinely assumed an unbounded total population and employed a uniform initial condition (forcing all node degree or connectivity classes to be initially infected at the same level); additionally, they concentrated on an epidemic\u2019s exponential growth phase.", [["a uniform initial condition", "PROBLEM", 135, 162], ["growth phase", "OBSERVATION_MODIFIER", 318, 330]]], ["The principal finding of these analyses is that, once high connectivity classes become infected, a cascade of infection occurs and affects lower and lower connectivity classes over time.", [["infection", "DISEASE", 110, 119], ["these analyses", "TEST", 25, 39], ["infected", "PROBLEM", 87, 95], ["infection", "PROBLEM", 110, 119], ["infected", "OBSERVATION", 87, 95], ["infection", "OBSERVATION", 110, 119], ["lower connectivity", "OBSERVATION_MODIFIER", 149, 167]]], ["Lastly, with regard to a non-uniform initial condition, the investigators found that confining all initially infected individuals to a single high-connectivity class would lead to an outbreak involving a faster rise and a faster invasion of the network.IntroductionTwo published studies describe stochastic SARS outbreak simulations based upon lattices or grids and \u2018small world\u2019 linkages.", [["a non-uniform initial condition", "PROBLEM", 23, 54], ["infected individuals", "PROBLEM", 109, 129], ["an outbreak", "PROBLEM", 180, 191], ["a faster rise", "PROBLEM", 202, 215], ["a faster invasion of the network", "PROBLEM", 220, 252], ["stochastic SARS outbreak simulations", "PROBLEM", 296, 332], ["infected", "OBSERVATION", 109, 117], ["faster", "OBSERVATION_MODIFIER", 222, 228], ["invasion", "OBSERVATION", 229, 237], ["small", "OBSERVATION_MODIFIER", 367, 372]]], ["Masuda, Konno and Aihara [17] argue that their simulations of the 2003 SARS outbreak in Singapore (as well as the general nature of SARS epidemics) are inconsistent with clustering properties and epidemic thresholds of scale-free networks.", [["SARS", "DISEASE", 71, 75], ["SARS", "DISEASE", 132, 136], ["Masuda", "TREATMENT", 0, 6], ["SARS epidemics", "PROBLEM", 132, 146]]], ["On the other hand, findings of the present author indicate that a finite scale-free network with node degree correlation is consistent with the 2003 SARS outbreak in Taiwan.", [["node", "ANATOMY", 97, 101], ["SARS", "DISEASE", 149, 153], ["node", "MULTI-TISSUE_STRUCTURE", 97, 101], ["a finite scale", "TEST", 64, 78], ["consistent with", "UNCERTAINTY", 124, 139]]], ["Small and Tse [18] discuss their simulation of the 2003 SARS outbreak in Hong Kong and they make the following observations: (a) a small world network with long distance links can exhibit scale-free behavior and (b) further work must be done to ascertain whether their simulation results reveal that type of behavior.", [["SARS", "DISEASE", 56, 60]]], ["Although clear evidence of scale-free contact networks is at hand for sexually transmitted diseases [19], similar published evidence of SARS-related contact networks is currently unavailable.IntroductionThe main objectives of the present study are to: (a) develop congruent epidemic models for unstructured and structured populations that can better exploit currently available information on SARS progression and outbreak controls; (b) demonstrate the utility of these models by carefully reconstructing the dynamics of a historical SARS outbreak; and (c) employ historical time-varying rates of SARS transmission to assess effects of control measures in possible future outbreaks.", [["sexually transmitted diseases", "DISEASE", 70, 99], ["SARS", "DISEASE", 136, 140], ["SARS", "DISEASE", 393, 397], ["SARS", "DISEASE", 534, 538], ["SARS", "DISEASE", 597, 601], ["contact networks", "MULTI-TISSUE_STRUCTURE", 38, 54], ["hand", "ORGANISM_SUBDIVISION", 61, 65], ["contact networks", "MULTI-TISSUE_STRUCTURE", 149, 165], ["sexually transmitted diseases", "PROBLEM", 70, 99], ["SARS", "PROBLEM", 136, 140], ["congruent epidemic models", "PROBLEM", 264, 289], ["unstructured and structured populations", "PROBLEM", 294, 333], ["SARS progression", "PROBLEM", 393, 409], ["a historical SARS outbreak", "PROBLEM", 521, 547], ["SARS transmission", "TREATMENT", 597, 614], ["control measures", "TREATMENT", 636, 652], ["clear", "OBSERVATION", 9, 14], ["main", "OBSERVATION_MODIFIER", 207, 211]]], ["Zoonotic infections and ordinary human activities in Asia may again be responsible for major SARS outbreaks, but it is also conceivable that a bioterrorist attack (for example, human vectors and intentional person-to-person SARS transmission) would cause even more human suffering and deaths.", [["Zoonotic infections", "DISEASE", 0, 19], ["SARS", "DISEASE", 93, 97], ["SARS", "DISEASE", 224, 228], ["deaths", "DISEASE", 285, 291], ["human", "ORGANISM", 33, 38], ["human", "ORGANISM", 177, 182], ["human", "ORGANISM", 265, 270], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 177, 182], ["person", "SPECIES", 207, 213], ["person", "SPECIES", 217, 223], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 265, 270], ["Zoonotic infections", "PROBLEM", 0, 19], ["major SARS outbreaks", "PROBLEM", 87, 107], ["infections", "OBSERVATION", 9, 19]]], ["Epidemic models are clearly needed to quantitatively understand both natural and unnatural outbreaks of contagious diseases and to help improve or delimit outbreak response capabilities of health care systems.IntroductionThis paper puts forward two complementary epidemic models for unstructured and structured populations.", [["contagious diseases", "PROBLEM", 104, 123]]], ["The SEIR-like compartmental framework1 for both models is deterministic and encompasses the standard incidence.", [["SEIR-like compartmental framework1", "DNA", 4, 38], ["The SEIR", "TEST", 0, 8]]], ["An \u2018X\u2019 compartment (with XS, XE and XI sub-compartments) is also a feature of this framework and it facilitates quantitative characterizations of outbreak control measures (quarantine, contact tracing and patient isolation).", [["patient", "ORGANISM", 205, 212], ["patient", "SPECIES", 205, 212], ["XS", "TEST", 25, 27], ["outbreak control measures", "TREATMENT", 146, 171]]], ["Most importantly, in order to enhance epidemiological realism, the two models accommodate a time-varying transmission rate and probability density functions (PDFs) for several important time intervals: namely, latent (incubational), contagious, onset-to-diagnosis, admission-to-discharge (from a hospital) and onset-to-death.IntroductionWhen exponential PDFs govern the latent and contagious periods, only mean values of these random variables enter a typical SEIR model.", [["death", "DISEASE", 319, 324], ["latent", "OBSERVATION_MODIFIER", 370, 376], ["contagious", "OBSERVATION_MODIFIER", 381, 391]]], ["But alternative SEIR formulations make the assumption of exponentially distributed time intervals unnecessary.", [["alternative SEIR formulations", "TREATMENT", 4, 33]]], ["This is to say, by replacing differential equations (DEs) with integro-differential equations (IDEs), previous investigators have utilized non-exponential PDFs in fully characterizing latent and contagious periods [20], [21].", [["non-exponential PDFs", "TREATMENT", 139, 159]]], ["The present author adopts a similar approach and obtains IDEs containing general PDFs for all key time intervals.", [["general PDFs", "TREATMENT", 73, 85]]], ["Although numerical algorithms for these IDEs can require substantially more computer time than those for exponential PDFs and associated DEs, the higher level of epidemiological realism helps to confidently resolve critical dynamical aspects of network-based models.IntroductionThe finite and discrete scale-free network of primary interest is the product of a rigorous mathematical analysis and the derived node degree PDF is in good agreement with results of numerical simulations [22].", [["node", "ANATOMY", 408, 412], ["network", "MULTI-TISSUE_STRUCTURE", 245, 252], ["node", "MULTI-TISSUE_STRUCTURE", 408, 412], ["numerical algorithms", "TEST", 9, 29], ["exponential PDFs and associated DEs", "PROBLEM", 105, 140], ["a rigorous mathematical analysis", "TEST", 359, 391], ["the derived node degree PDF", "PROBLEM", 396, 423], ["node", "OBSERVATION", 408, 412]]], ["Network characteristics enter our epidemic model for a structured population through (a) the node degree PDF and (b) the Pearson correlation coefficient for degrees of connected nodes.", [["node", "ANATOMY", 93, 97], ["nodes", "MULTI-TISSUE_STRUCTURE", 178, 183], ["the node degree PDF", "PROBLEM", 89, 108], ["connected nodes", "PROBLEM", 168, 183], ["node", "OBSERVATION", 93, 97], ["nodes", "OBSERVATION", 178, 183]]], ["The size of the total population and the node degree PDF determine sizes of all connectivity classes, which are the selected sub-populations for the epidemic model.", [["node", "ANATOMY", 41, 45], ["the total population", "TREATMENT", 12, 32], ["the node degree PDF", "PROBLEM", 37, 56], ["size", "OBSERVATION_MODIFIER", 4, 8], ["total", "OBSERVATION_MODIFIER", 16, 21], ["population", "OBSERVATION_MODIFIER", 22, 32], ["node degree", "OBSERVATION", 41, 52], ["sizes", "OBSERVATION_MODIFIER", 67, 72], ["all", "OBSERVATION_MODIFIER", 76, 79], ["connectivity classes", "OBSERVATION", 80, 100]]], ["This correlation coefficient has been evaluated for some scale-free social networks [23], but it is essentially an unknown quantity in the realm of SARS outbreaks and contact networks.", [["SARS", "DISEASE", 148, 152]]], ["Numerical results in the main body of this paper thus cover a range of correlation coefficient values as well as different locations (connectivity classes) of the index case.IntroductionUtilizing a network-based model to analytically reconstruct a historical outbreak indicates the model\u2019s explanatory value and also ties its dynamical behavior to real epidemiological circumstances.", [["body", "ORGANISM_SUBDIVISION", 30, 34], ["main body", "ANATOMY_MODIFIER", 25, 34]]], ["For instance, if the analytical reconstruction of a 2003 SARS outbreak demonstrates a cascade of infection (from higher to lower connectivity classes) within the selected contact network, this resultant chain of disease transmission is at least connected with (a) the observed progression of one specific disease, (b) specific social (including health care) settings and (c) modern implementations of traditional control measures.IntroductionSince it has received relatively little attention from the epidemic modeling community at large, the 2003 SARS outbreak in Taiwan is analyzed herein.", [["SARS", "DISEASE", 57, 61], ["infection", "DISEASE", 97, 106], ["SARS", "DISEASE", 548, 552], ["infection", "PROBLEM", 97, 106], ["disease transmission", "PROBLEM", 212, 232], ["one specific disease", "PROBLEM", 292, 312], ["traditional control measures", "TREATMENT", 401, 429], ["infection", "OBSERVATION", 97, 106], ["chain", "OBSERVATION_MODIFIER", 203, 208], ["disease", "OBSERVATION", 212, 219], ["progression", "OBSERVATION_MODIFIER", 277, 288]]], ["Ying-Hen Hsieh at the National Chung Hsing University (along with colleagues at other universities and government organizations in Taiwan) co-authored some interesting descriptive and analytical papers dealing with the Taiwan SARS outbreak.", [["SARS", "DISEASE", 226, 230]]], ["Hsieh and colleagues used SARS hospitalization and fatality data spanning one month (May 5 through June 4, 2003) to obtain parameter values for an epidemic model (i.e., a system of ordinary DEs) without quarantine or hospital isolation [24].", [["SARS", "DISEASE", 26, 30], ["fatality data", "TEST", 51, 64], ["parameter values", "TEST", 123, 139], ["an epidemic model", "PROBLEM", 144, 161]]], ["Subsequently, these researchers included a two-level quarantine and hospital isolation in another system of ordinary DEs and they performed a stability analysis that identified necessary quarantine rates for outbreak containment [25].IntroductionA number of investigators have developed epidemic models (systems of ordinary DEs) that match certain temporal data from SARS outbreaks.", [["SARS", "DISEASE", 367, 371], ["hospital isolation", "TREATMENT", 68, 86], ["ordinary DEs", "TREATMENT", 108, 120], ["a stability analysis", "TEST", 140, 160], ["SARS outbreaks", "PROBLEM", 367, 381]]], ["In their study of SARS transmission and control in China, Zhou, Ma and Brauer assumed an inexhaustible supply of susceptible individuals, formulated a system of linear difference equations, and followed a process of trial and error in obtaining a time-varying transmission rate that enabled the model to closely match data on diagnosed cases per day [26].", [["SARS", "DISEASE", 18, 22], ["susceptible individuals", "PROBLEM", 113, 136]]], ["A more complex model of the SARS outbreak in China was later put forward by Zhang, Lou, Ma and Wu [27].", [["SARS", "DISEASE", 28, 32], ["more complex", "OBSERVATION_MODIFIER", 2, 14], ["SARS", "OBSERVATION", 28, 32]]], ["These authors first quantified their \u2018basic adequate contact rate\u2019 using about three weeks of data on diagnosed SARS cases and then they obtained model results for the daily number of SARS patients (in good agreement with epidemiological data).", [["SARS", "DISEASE", 112, 116], ["SARS", "DISEASE", 184, 188], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197]]], ["Lastly, Gumel and co-authors studied a system of ordinary DEs with constant parameters and the chosen values of the two free parameters (transmission rates for contacts involving contagious individuals within and without hospital isolation) provided the \u2018best\u2019 agreement between calculated and reported cumulative SARS fatalities over time.", [["SARS", "DISEASE", 314, 318], ["ordinary DEs", "TREATMENT", 49, 61]]], ["After obtaining values of the two free parameters for four SARS outbreaks (Toronto, Hong Kong, Singapore and Beijing), calculations of cumulative probable cases over time generally conformed to reported data for each outbreak [28].IntroductionThe three previously-summarized studies are just a few examples of how simpler SARS outbreak models (systems of ordinary DEs) have been structured and parameterized to produce results that fully or partially agree with selected epidemiological data.", [["SARS", "DISEASE", 59, 63], ["SARS", "DISEASE", 322, 326]]], ["In other words, even though an epidemic model is capable of emulating a particular temporal feature of an outbreak, this does not mean that the underlying modeling approach is necessarily a systematic or suitable vehicle for analyzing outbreak dynamics on the whole.", [["outbreak", "OBSERVATION", 106, 114]]], ["To examine the relative value of the proposed epidemic models of intermediate complexity, the present author also formulates and numerically evaluates a parallel or companion system of ordinary DEs.Basic epidemic model for an unstructured populationThe dashed curve in the lower graph of Fig. 1identifies daily onsets of illness during the Taiwan outbreak [29], but this curve excludes the index case to draw attention to the new infections.2 These 670 onsets of illness (without the index case) were originally classified as probable new SARS cases.", [["illness", "DISEASE", 321, 328], ["infections", "DISEASE", 430, 440], ["illness", "DISEASE", 463, 470], ["SARS", "DISEASE", 539, 543], ["The dashed curve", "TEST", 249, 265], ["illness", "PROBLEM", 321, 328], ["this curve", "TEST", 366, 376], ["the new infections", "PROBLEM", 422, 440], ["illness", "PROBLEM", 463, 470], ["new SARS cases", "PROBLEM", 535, 549], ["intermediate complexity", "OBSERVATION_MODIFIER", 65, 88], ["new", "OBSERVATION_MODIFIER", 426, 429], ["infections", "OBSERVATION", 430, 440]]], ["But the Center for Disease Control in Taiwan later published separate epidemic curves for both probable and laboratory-confirmed SARS cases [30].", [["SARS", "DISEASE", 129, 133], ["Disease Control", "TREATMENT", 19, 34], ["epidemic curves", "TEST", 70, 85], ["SARS cases", "TEST", 129, 139]]], ["Only 346 probable SARS cases were confirmed through laboratory testing.", [["SARS", "DISEASE", 18, 22], ["SARS cases", "TEST", 18, 28], ["laboratory testing", "TEST", 52, 70]]], ["Arguably, the true number of SARS cases in Taiwan could have been larger (even substantially larger) than 346.", [["SARS", "DISEASE", 29, 33], ["larger", "OBSERVATION_MODIFIER", 66, 72]]], ["As a consequence, an epidemic curve representing a total of 671 probable onsets in Taiwan is deemed to be adequate for our modeling purposes.Basic epidemic model for an unstructured populationOne way of inferring new infections from symptom onsets is to uniformly shift these onsets backward in time according to the mean latent period.", [["infections", "DISEASE", 217, 227], ["an epidemic curve", "TEST", 18, 35], ["our modeling purposes", "TEST", 119, 140], ["inferring new infections", "PROBLEM", 203, 227], ["symptom onsets", "PROBLEM", 233, 247], ["new", "OBSERVATION_MODIFIER", 213, 216], ["infections", "OBSERVATION", 217, 227]]], ["On the other hand, the Monte Carlo method is a more rigorous way to obtain average new infections per day.", [["infections", "DISEASE", 87, 97], ["new", "OBSERVATION_MODIFIER", 83, 86], ["infections", "OBSERVATION", 87, 97]]], ["First, obtain random latent periods for all onsets of illness (excluding the index case).", [["illness", "DISEASE", 54, 61], ["illness", "PROBLEM", 54, 61]]], ["Second, backtrack in time to determine when all infections began.", [["infections", "DISEASE", 48, 58], ["all infections", "PROBLEM", 44, 58], ["infections", "OBSERVATION", 48, 58]]], ["Averaging scores per day for a large number of Monte Carlo trials yields the desired infections per day.Basic epidemic model for an unstructured populationThe solid curve (vice points) in the upper graph of Fig. 1 comes from 50 000 Monte Carlo trials.", [["Monte Carlo", "CHEMICAL", 47, 58], ["infections", "DISEASE", 85, 95], ["Monte Carlo trials", "TREATMENT", 47, 65], ["The solid curve", "TEST", 155, 170], ["upper", "ANATOMY_MODIFIER", 192, 197]]], ["In these trials, the assumed PDF for the latent period was a Gamma distribution, G1(x).", [["PDF", "GENE_OR_GENE_PRODUCT", 29, 32], ["PDF", "DNA", 29, 32], ["Gamma distribution", "OBSERVATION", 61, 79]]], ["The mean value (\u03bc1) and standard deviation (\u03c31) of the latent period are in Table 1with a supporting note and reference.", [["The mean value", "TEST", 0, 14], ["standard deviation", "TEST", 24, 42], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["latent", "OBSERVATION_MODIFIER", 55, 61]]], ["This table likewise displays mean values and standard deviations of several additional random time intervals that, by assumption, follow Gamma distributions [31], [32], [33], [34], [35], [36].Basic epidemic model for an unstructured populationSolid curves in the upper and lower graphs of Fig. 1 are related by means of a mathematical convolution.", [["upper", "ORGANISM_SUBDIVISION", 263, 268], ["mean values", "PROBLEM", 29, 40], ["mean values", "OBSERVATION", 29, 40], ["Solid curves", "OBSERVATION", 243, 255], ["upper", "ANATOMY_MODIFIER", 263, 268], ["lower", "ANATOMY_MODIFIER", 273, 278], ["Fig", "OBSERVATION", 289, 292]]], ["Treating the time t as a continuous independent variable, the desired convolution integral can be expressed in the following manner:(1)p\u2217G1=\u222b0tp(u)G1(t-u)du.The function p(u) is the new infection rate at time u, whereas G1(t\u2212u) du is essentially the probability of developing SARS at time t after becoming infected at time u.", [["infection", "DISEASE", 186, 195], ["SARS", "DISEASE", 276, 280], ["the new infection rate", "PROBLEM", 178, 200], ["developing SARS", "PROBLEM", 265, 280], ["new", "OBSERVATION_MODIFIER", 182, 185], ["infection", "OBSERVATION", 186, 195], ["SARS", "OBSERVATION", 276, 280], ["infected", "OBSERVATION", 306, 314]]], ["(1) defines the expected onsets of illness per unit time [37].", [["illness", "DISEASE", 35, 42]]], ["Regarding the numerical evaluation of this convolution integral, series of discrete p and G1 values and fast Fourier transforms (FFTs) led to the calculated onsets (solid curve) in the lower graph of Fig. 1.Basic epidemic model for an unstructured population\u2018Nested\u2019 convolution integrals appear in many of the equations that follow and the notation of Eq.", [["the numerical evaluation", "TEST", 10, 34], ["discrete p and G1 values", "TEST", 75, 99], ["the calculated onsets (solid curve", "PROBLEM", 142, 176], ["lower", "ANATOMY_MODIFIER", 185, 190]]], ["Two examples using these functions demonstrate the extended notation for nested convolution integrals, namely,fA\u2217(fB\u2217fC)=\u222b0tfA(u)\u222b0t-ufB(v)fC(t-u-v)dvduandfA\u2217(fB\u2217(fC\u2217fD))=\u222b0tfA(u)\u222b0t-ufB(v)\u222b0t-u-vfC(w)fD(t-u-v-w)dwdvdu.", [["fA\u2217", "PROTEIN", 110, 113], ["0t", "PROTEIN", 130, 132], ["ufB(v)fC(t-u", "CELL_LINE", 133, 145], ["fC\u2217fD", "PROTEIN", 163, 168], ["t-u-v-w)", "PROTEIN", 204, 212], ["these functions", "TEST", 19, 34], ["nested convolution integrals", "TEST", 73, 101], ["fA\u2217", "TEST", 110, 113], ["B\u2217fC", "TEST", 115, 119], ["0t", "TEST", 130, 132], ["C", "TEST", 140, 141], ["u", "TEST", 144, 145], ["dvduandfA\u2217(fB\u2217", "TEST", 148, 162], ["fC\u2217fD", "TEST", 163, 168], ["u)", "TEST", 177, 179], ["B(v)", "TEST", 185, 189], ["fD(", "TEST", 201, 204]]]], "24e80cf35ffa92207daaf1e351d4437ed5309fdc": [["The closure of legislative offices meant e-mail and social media became the preferred means of communication to hear from constituents.", [["closure", "OBSERVATION", 4, 11]]], ["Throughout the first week of June, AONL held a series of webinars to prepare nurse leaders to effectively advocate for the inclusion of nursing's priorities ( Figure 1 ) in COVID 4.0 legislation and FY 2021 appropriations.HIGHLIGHTS AND CHALLENGESOn June 4, nurse leaders sent more than 150 personalized e-mails and social media messages to their federal legislators requesting increased funding for nursing education and workforce infrastructure programs; for support services that promote clinician resiliency and mental health; and to expand the ability of providers to use telehealth.", [["nursing's priorities", "TREATMENT", 136, 156], ["nursing education", "TREATMENT", 400, 417]]], ["Nurse leaders illustrated the need for funding these priorities by sharing stories from their health organization, showing how clinicians cared for COVID-19 patients and how funding will help their teams heal from the effects of this crisis.", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["this crisis", "PROBLEM", 229, 240]]], ["Funding also is crucial to prepare the nursing workforce for future events.HIGHLIGHTS AND CHALLENGESHow do you build a sense of excitement, elevate the voice of nursing leadership, and help participants understand how their personal experiences relate to the complex legislative issues included in AONL's request of Congress?", [["participants", "SPECIES", 190, 202]]], ["A virtual advocacy day presented the additional challenge of addressing all these issues without face-to-face interaction.IMPORTANCE OF SOCIAL MEDIASocial media is a valuable tool to create awareness and allow people to engage.", [["people", "ORGANISM", 210, 216], ["people", "SPECIES", 210, 216]]], ["AONL and advocacy day participants used it differently this year.", [["participants", "SPECIES", 22, 34]]], ["Previously, participants primarily used digital media to post pictures of their Capitol Hill meetings, tagging legislators to say thank you for meeting with them.", [["participants", "SPECIES", 12, 24]]], ["AONL developed a social media toolkit complete with graphics and sample tweets participants could use to engage with their legislators on social media and elevate the voice of nursing leadership online by using #AONLAdvocacy and #NurseLeaders.IMPORTANCE OF SOCIAL MEDIAAs we move past the pandemic, it is important to incorporate the lessons learned from AONL's first virtual advocacy day.", [["participants", "SPECIES", 79, 91]]], ["Social media and traditional letter writing are equally important tools to incorporate into our evolving strategy for engaging nurse leaders in health policy and civic engagement.IMPORTANCE OF SOCIAL MEDIAIt is critical that legislators hear directly from nurse leaders on the pandemic frontline about the issues facing our patients, our nurses, and our health care organizations.", [["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 324, 332]]], ["Below, read the experience of a nurse executive, Rosa Hickey, who has attended AONL Advocacy Day for the past 5 years.May 15, 2019More than 125 nurse leaders are visiting Washington, DC today.", [["DC", "ANATOMY", 183, 185], ["DC", "CELL_TYPE", 183, 185]]], ["We just heard a briefing on AONL's advocacy agenda and education Invest in nursing education infrastructure and practice to allow institutions to move into distance education-online learning and simulation labs.May 15, 2019Close the nursing experience gap by creating residency and fellowship programs to help graduates transition into practice.Support Clinician Resiliency and Mental HealthDedicate a funding stream that invests in nurses combating COVID-19, which may include retraining furloughed nurses and supporting mental health needs for those responding to this pandemic.Support Clinician Resiliency and Mental HealthEstablish a grant program within the Department of Health and Human Services to allow health care employers or facilities to confidentially assess and treat the mental health of health care workers on the front lines of treating COVID-19 patients.Promote Innovation and Telehealth\u2022 Increase access to care by making permanent the waivers CMS made to allow nurse practitioners and certified nurse specialists to practice the full scope of their licensure and training.", [["COVID", "DISEASE", 855, 860], ["Human", "ORGANISM", 688, 693], ["patients", "ORGANISM", 864, 872], ["Human", "SPECIES", 688, 693], ["patients", "SPECIES", 864, 872], ["simulation labs", "TEST", 195, 210]]], ["This allows patients to remain in their homes and decreases potential exposure to harmful viruses or other complications from delays in care.Promote Innovation and Telehealth\u2022 Expand the ability for health care organizations and providers to use telehealth to increase the numbers of patients they can see through virtual health and reduce potential exposure to COVID-19 patients for health care professionals and the public. session preparing us to meet with our legislators.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 284, 292], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 284, 292], ["patients", "SPECIES", 371, 379], ["harmful viruses", "PROBLEM", 82, 97], ["other complications", "PROBLEM", 101, 120], ["COVID", "TREATMENT", 362, 367]]], ["We are advocating for legislation supported by the larger nursing community-reauthorizing and funding nursing workforce development programs and increasing access to care.", [["increasing access to care", "TREATMENT", 145, 170]]], ["We attend these meetings as a group and represent many areas in our state.", [["many", "OBSERVATION_MODIFIER", 50, 54], ["areas", "OBSERVATION", 55, 60]]], ["Upon returning home, I e-mailed the staffers I met with, thanking them for their time, reiterating my \"ask,\" and offering myself as an educational resource on nursing and patient care issues.June 5, 2020Yesterday, I participated in AONL's first virtual advocacy day.", [["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 171, 178]]], ["I was disappointed when AONL canceled the Washington, DC event, but was grateful there was still an opportunity to join my colleagues in advocating for our patients and nursing teams.", [["DC", "ANATOMY", 54, 56], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164]]]], "PMC7131366": [["IntroductionIn this ultra-competitive e-commerce landscape, the ability of an e-commerce firm to form a seemingly single function is an important determinant of firm performance and business value.", [["IntroductionIn", "TREATMENT", 0, 14], ["firm", "OBSERVATION", 89, 93]]], ["This requires tight coordination among discrete business activities which ultimately enables the firm to respond to pressing competitive forces (Markus, 2000).", [["tight", "OBSERVATION_MODIFIER", 14, 19], ["coordination", "OBSERVATION_MODIFIER", 20, 32]]], ["As an industry moves toward real-time supply chains, the integration of external and internal business activities at both the front end (marketing and sales, customer services, outbound logistics) and the back end (operations, technology development, procurement) becomes critical.", [["back", "ANATOMY", 205, 209]]], ["Interdependencies between front-end and back-end offices, that is, the extent to which organisational units depend upon each other for resources due to information complexity and resource scarcity, is an important capability needed for firms to achieve business integration.", [["end", "OBSERVATION_MODIFIER", 32, 35], ["back", "ANATOMY", 40, 44]]], ["Effective organisational interdependencies ensure the appropriate configurations of firm processes and assets, and increase a firm's capacity to respond quickly and effectively to market forces (Rockart & Short, 1989).IntroductionAsia will continue to lead global e-commerce growth.", [["Effective organisational interdependencies", "PROBLEM", 0, 42], ["a firm's capacity", "PROBLEM", 124, 141], ["IntroductionAsia", "TREATMENT", 218, 234], ["firm", "OBSERVATION", 84, 88], ["firm", "OBSERVATION_MODIFIER", 126, 130]]], ["China alone will boast 269.4 million digital buyers this year (2014) according to independent market research firm, eMarketer.", [["firm", "OBSERVATION", 110, 114]]], ["Driven by the increasing popularity of e-commerce and the dramatic increase in the amount of economic activity generated through it, China's e-commerce firms are locked in severe competition.", [["the dramatic increase", "PROBLEM", 54, 75], ["economic activity", "PROBLEM", 93, 110], ["China's e-commerce firms", "TREATMENT", 133, 157], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["popularity", "OBSERVATION_MODIFIER", 25, 35], ["dramatic", "OBSERVATION_MODIFIER", 58, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["amount", "OBSERVATION_MODIFIER", 83, 89], ["economic activity", "OBSERVATION", 93, 110], ["severe", "OBSERVATION_MODIFIER", 172, 178]]], ["This places more scrutiny on the system and business integration strategies adopted by these firms.", [["business integration strategies", "TREATMENT", 44, 75]]], ["The new economy provides a unique context for research on business integration in e-commerce firms, which in turn will offer valuable feedback to firms striving to survive and thrive in such competitive environments.IntroductionGiven its crucial role, the concept of business integration in the e-commerce context has garnered research interest for many years.", [["new", "OBSERVATION_MODIFIER", 4, 7], ["economy", "OBSERVATION", 8, 15]]], ["However, extant studies often focus on the integration of front-end and back-end IT systems to support e-business activities, reflecting an assumption that business integration is automatically enabled by IT systems and that, following IT system integration, cooperation among departments would naturally ensue.", [["extant studies", "TEST", 9, 23], ["back", "ANATOMY", 72, 76]]], ["However, according to management theories, different types of organisational interdependencies across a firm will shape the structure of the firm and its internal cooperation differently (G\u00f6z\u00fcb\u00fcy\u00fck, 2013).", [["organisational interdependencies", "PROBLEM", 62, 94], ["firm", "OBSERVATION", 104, 108], ["firm", "OBSERVATION", 141, 145]]], ["In turn, the complexities of firm structure processes and cooperation are critical determinants of business integration.", [["firm", "OBSERVATION", 29, 33]]], ["Hence, business integration and organisational interdependencies are tightly coupled.", [["organisational interdependencies", "PROBLEM", 32, 64]]], ["To date, many studies have posited the important antecedents for business integration and organisational interdependencies.", [["many studies", "TEST", 9, 21]]], ["Organisational interdependencies are complex and multifaceted phenomena embedded within a firm's context.", [["Organisational interdependencies", "PROBLEM", 0, 32], ["multifaceted phenomena", "PROBLEM", 49, 71], ["complex", "OBSERVATION_MODIFIER", 37, 44], ["multifaceted", "OBSERVATION_MODIFIER", 49, 61], ["phenomena", "OBSERVATION", 62, 71], ["firm", "OBSERVATION_MODIFIER", 90, 94]]], ["Given the role of organisational interdependencies in contemporary business environments, it is imperative to investigate how to coordinate and support organisational interdependencies in order to achieve business integration.IntroductionThe objective of this case study is to examine approaches to supporting organisational interdependencies to achieve business integration.", [["this case study", "TEST", 255, 270]]], ["For example, it is likely that firms that are uncertain about the state of their environment will spend a greater amount of time and resources on environmental scanning and forecasting.", [["environmental scanning", "TEST", 146, 168], ["is likely", "UNCERTAINTY", 16, 25], ["firms", "OBSERVATION", 31, 36]]], ["The deployment of IT systems also plays an important role by, for example, reducing the risk of loss of resource control.", [["resource control", "TREATMENT", 104, 120]]], ["Our case study examines the unique composition of IT capabilities and asset orchestration required to achieve e-commerce front and back office integration.", [["Our case study", "TEST", 0, 14]]], ["In the following sections, the case firm is described.", [["sections", "ANATOMY", 17, 25], ["firm", "OBSERVATION", 36, 40]]], ["The focal processes in the case firm are then discussed.", [["The focal processes", "PROBLEM", 0, 19], ["focal", "OBSERVATION_MODIFIER", 4, 9], ["firm", "OBSERVATION", 32, 36]]], ["The lessons learned are then highlighted, followed by the conclusion.Case descriptionWe selected M.com as our case firm.", [["firm", "OBSERVATION", 115, 119]]], ["M.com is one of the largest electronic retailers in a very competitive business-to-consumer (B2C) market in China.", [["M.com", "CHEMICAL", 0, 5], ["largest", "OBSERVATION_MODIFIER", 20, 27]]], ["The foundation of M.com dates back to 1998 when the firm was operating as a retailer.", [["firm", "OBSERVATION", 52, 56]]], ["Its closest rivals are Suning and Amazon, according to an independent market research firm, Analysys International.", [["Amazon", "TREATMENT", 34, 40]]], ["Today, M.com offers approximately 31.3 million stock-keeping units across 13 categories of products including computers, mobile phones, home appliances, cosmetics, luxury goods, and childcare products.", [["home appliances", "TREATMENT", 136, 151]]], ["To fulfil its orders, M.com owns and operates seven fulfilment centres and a total of 82 warehouses across 34 cities in China as part of its extensive logistics and distribution network.Case descriptionDespite its recent achievements, the firm's management faced a myriad of challenges during the early stages of its growth.", [["the firm's management", "TREATMENT", 235, 256], ["firm", "OBSERVATION_MODIFIER", 239, 243]]], ["At the time of the Severe Acute Respiratory Syndrome epidemic in 2003, falling consumer confidence forced sales across its retail stores to plunge.", [["Acute Respiratory Syndrome", "DISEASE", 26, 52], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 15, 52], ["Severe", "OBSERVATION_MODIFIER", 19, 25], ["Acute", "OBSERVATION_MODIFIER", 26, 31], ["Respiratory Syndrome", "OBSERVATION", 32, 52]]], ["The firm was faced with the decision to close all of the retail stores and risk changing its mode of operation from physical storefront to online.", [["firm", "OBSERVATION_MODIFIER", 4, 8]]], ["Over the next three years, the business thrived; M.com began offering an extended range of products and services to an expanded customer base including raw material manufacturers, agents, distributors, retailers, stores and other online shops.", [["M.com", "CHEMICAL", 49, 54], ["an extended range of products", "TREATMENT", 70, 99]]], ["However, the growing volume of orders each year outpaced the IT capabilities, placing high demands on strategic planning and order processing and leading to large distribution channels on its infrastructure.", [["strategic planning", "TREATMENT", 102, 120], ["large distribution channels", "PROBLEM", 157, 184], ["growing", "OBSERVATION_MODIFIER", 13, 20], ["volume", "OBSERVATION_MODIFIER", 21, 27], ["large", "OBSERVATION_MODIFIER", 157, 162], ["distribution channels", "OBSERVATION", 163, 184]]], ["Scepticism towards technical development issues and the robustness of the web technology grew among the managers attempting to leverage these technologies.", [["Scepticism", "PROBLEM", 0, 10], ["technical development issues", "PROBLEM", 19, 47]]], ["In October 2009, M.com made a widely publicised announcement about the splitting of its 800-staff IS department into front and back offices, which posed another challenge to the firm's management.Case descriptionDespite the various challenges, M.com flourished, taking advantage of China's rise in personal computing usage and changing customer behaviour.", [["the firm's management", "TREATMENT", 174, 195]]], ["According to the CEO, buying goods on the internet had not been popular ten to twelve years earlier in China; but, as Taobao1and other platforms grew, people started to see the potential and promise of B2C.", [["people", "ORGANISM", 151, 157], ["B2C", "CANCER", 202, 205], ["people", "SPECIES", 151, 157], ["B2C", "TEST", 202, 205]]], ["Another factor was the continuous creation and improvement of management functions and practices, which enabled the transformation of the firm.", [["management functions", "TREATMENT", 62, 82], ["firm", "OBSERVATION", 138, 142]]], ["As well as relying on external allies and suppliers to speed up their movement to the web, M.com started rebuilding its technological infrastructure and increased efforts in internal business integration-related activities.", [["external allies", "TREATMENT", 22, 37], ["increased", "OBSERVATION_MODIFIER", 153, 162]]], ["To fulfil the 211 Program guarantee, the firm improved many processes, particularly its focal processes of strategic planning and reporting, order processing, and product design and development.", [["firm", "OBSERVATION_MODIFIER", 41, 45], ["focal", "OBSERVATION_MODIFIER", 88, 93]]], ["This required not just a fully optimised web interface, but also the support of a large-scale web content repository to enable its entire supply chain.", [["a large-scale web content repository", "TREATMENT", 80, 116]]], ["The following sections discuss the company's business integration and the role of organisational interdependencies and IT asset orchestration in the context of focal business processes.Forecasting and planning ::: Focal processes in M.comForecasting and planning enables M.com to establish a resource base from which it can adapt and extend its operations.", [["organisational interdependencies", "TREATMENT", 82, 114], ["IT asset orchestration", "TREATMENT", 119, 141], ["Focal processes", "PROBLEM", 214, 229], ["a resource base", "TREATMENT", 290, 305], ["its operations", "TREATMENT", 341, 355], ["focal", "OBSERVATION_MODIFIER", 160, 165]]], ["We need to report on total running costs, timetabling of delivery, marketing analysis reports, complaints, after-sales feedback, technical reports, external partnership information and results.", [["total running costs", "TREATMENT", 21, 40], ["delivery", "TREATMENT", 57, 65]]], ["\u2018A\u2019 goods are those that we have eyes on or we think that will do well with them [a specific customer group], so the exposure is higher than the rest, they have priority when it comes to stocking.", [["eyes", "ANATOMY", 33, 37], ["eyes", "ORGAN", 33, 37]]], ["We decided to automate the procurement process for goods that are daily essentials; the 100 things that people use every day are automatically procured by the system.\u201dThrough these practices, the business data warehouse and information control departments of M.com were able to generate a large number of extended indicators to help identify the segments of customers using the site.", [["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110]]], ["As evidenced, the pooled data develops a profile of the consumer behaviours in the online environment and this has an effect on the firm's planning operations including the procuring of stock.", [["the firm's planning operations", "TREATMENT", 128, 158]]], ["This composite profiling of customers and products enables the managers to segregate and plan their marketing and service strategies specific to the particular demographic needs.Order processing ::: Focal processes in M.comWhen an order is confirmed, the order triggers the next system in each warehouse called the warehouse management system.", [["Focal processes", "PROBLEM", 199, 214], ["the warehouse management system", "TREATMENT", 311, 342]]], ["The relevant information also goes to a distribution management system at each delivery centre for delivery.", [["a distribution management system", "TREATMENT", 38, 70], ["delivery", "TREATMENT", 99, 107]]], ["At M.com, a range of IT systems were adopted to complete this sequential order fulfilment process and facilitate collaboration between departments, from the logistics system at its back end to the customer service system (supported by its National Customer Service Centre with 150 call agents) at its front end.", [["150 call agents", "TREATMENT", 277, 292]]], ["The manager of the supply chain department explained the crucial role of IT:\u201cBesides an in-house ERP, we have a series of systems to support the order processing centre.", [["ERP", "PROTEIN", 97, 100]]], ["Systems allow us to monitor the distribution of sales orders to the warehouses for processing, and it will simultaneously report back information on [the] status of warehouse and delivery.\u201dWith a fully optimised web interface supported by a large-scale web content repository, M.com created a competitive advantage in order processing.", [["delivery", "TREATMENT", 179, 187], ["large", "OBSERVATION_MODIFIER", 241, 246]]], ["As the manager of the product management department (back-end operations) explained:\u201cCompetition has moved from front-end to back-end systems and logistics, have a look at [other e-commerce firms in China], their back-end delivery is bad so customer experience is bad, they don\u2019t have their own storage nor have their own distribution and logistics.", [["back", "ANATOMY", 213, 217]]], ["Because M.com owns and controls the supply chain end-to-end, many other popular e-commerce platforms in China are not able to compete on its scale in terms of shipping and distribution.", [["shipping", "OBSERVATION", 159, 167], ["distribution", "OBSERVATION_MODIFIER", 172, 184]]], ["As a result, M.com has developed a reputation in the industry as a technically enabled e-commerce company and an optimal logistics company.Product development and management ::: Focal processes in M.comProduct development and product management processes are vital given the myriad of product lines in M.com.", [["M.com", "CHEMICAL", 13, 18], ["product lines", "CELL_LINE", 285, 298], ["M.com", "CELL_LINE", 302, 307], ["Focal processes", "PROBLEM", 178, 193], ["product management", "TREATMENT", 226, 244], ["product lines", "OBSERVATION", 285, 298]]], ["The mutual requirement for work and resources creates a unique reciprocal and highly interdependent relationship between product development and product management.", [["product management", "TREATMENT", 145, 163]]], ["The development of customer products (including working on the source code), the development framework and error checking are the responsibilities of research developers from the product research and development department.", [["error checking", "TEST", 107, 121], ["customer products", "OBSERVATION", 19, 36]]], ["On the other hand, monitoring the sales of the products, finding innovative means to market the products and repositioning goods into new product lines where necessary are handled by product managers from the product management department.", [["product lines", "CELL_LINE", 138, 151], ["the products", "TREATMENT", 43, 55], ["the products", "TREATMENT", 92, 104], ["repositioning goods", "TREATMENT", 109, 128], ["new product lines", "TREATMENT", 134, 151]]], ["Hence, product managers create an important source of work for developers and product managers need developers in order to maintain their product lines.", [["lines", "CELL", 146, 151], ["product lines", "OBSERVATION", 138, 151]]], ["ROI, the length of [product] development process, potential conflicting resources, scheduling and discussion with our sales departments helps us determine which product line we should be focusing our efforts on.\u201dOn the other hand, as the manager of the product research and development explained:\u201cUltimately, different product managers tend to want to push for their product lines and safeguard their interests.", [["their product lines", "TREATMENT", 361, 380]]], ["There is going to be a conflict for resource when product managers claim the importance of their programs.\u201dOver the years, the rapid rise in the types of products and product lines introduced, coupled with the drop in the ratio of product managers to product developers, meant that there has been a growing scarcity of resources, particularly product developers.", [["the rapid rise", "PROBLEM", 123, 137], ["product lines", "TREATMENT", 167, 180], ["rapid", "OBSERVATION_MODIFIER", 127, 132], ["rise", "OBSERVATION_MODIFIER", 133, 137], ["product lines", "OBSERVATION", 167, 180], ["growing", "OBSERVATION_MODIFIER", 299, 306], ["scarcity", "OBSERVATION_MODIFIER", 307, 315]]], ["The role of the product manager is crucial for integrating the product development work, as the product manager determines which product line the firm should be focusing its efforts on and ultimately where to allocate resources.", [["firm", "OBSERVATION_MODIFIER", 146, 150]]]], "PMC7152053": [["DefinitionAcute gastroenteritis is an infectious disease of the alimentary tract which may be caused by one or more bacterial, viral or protozoal pathogens producing damage to the mucosa either structural or functional of variable extent and severity.DefinitionAnother definition of acute gastroenteritis is the clinical syndrome of diarrhoea and/or vomiting of acute onset, often accompanied by fever and constitutional disturbance which is of infective origin and is not secondary to some primary disease process outside the alimentary tract.Role of bacteria ::: AetiologyNo bacterial pathogen can be isolated from the stools of the majority of children with gastroenteritis who are admitted to hospital in a developed country, but in developing countries over 50% of children may have bacterial isolations.Role of bacteria ::: Aetiology", [["alimentary tract", "ANATOMY", 64, 80], ["mucosa", "ANATOMY", 180, 186], ["alimentary tract", "ANATOMY", 527, 543], ["DefinitionAcute gastroenteritis", "DISEASE", 0, 31], ["infectious disease of the alimentary tract", "DISEASE", 38, 80], ["gastroenteritis", "DISEASE", 289, 304], ["diarrhoea", "DISEASE", 333, 342], ["vomiting", "DISEASE", 350, 358], ["fever", "DISEASE", 396, 401], ["Aetiology", "DISEASE", 565, 574], ["gastroenteritis", "DISEASE", 661, 676], ["Aetiology", "DISEASE", 830, 839], ["alimentary tract", "ORGAN", 64, 80], ["mucosa", "MULTI-TISSUE_STRUCTURE", 180, 186], ["alimentary tract", "ORGANISM_SUBDIVISION", 527, 543], ["stools", "ORGANISM_SUBDIVISION", 621, 627], ["children", "ORGANISM", 647, 655], ["children", "ORGANISM", 770, 778], ["children", "SPECIES", 647, 655], ["children", "SPECIES", 770, 778], ["DefinitionAcute gastroenteritis", "PROBLEM", 0, 31], ["an infectious disease of the alimentary tract", "PROBLEM", 35, 80], ["more bacterial, viral or protozoal pathogens", "PROBLEM", 111, 155], ["damage to the mucosa", "PROBLEM", 166, 186], ["acute gastroenteritis", "PROBLEM", 283, 304], ["the clinical syndrome", "PROBLEM", 308, 329], ["diarrhoea", "PROBLEM", 333, 342], ["vomiting", "PROBLEM", 350, 358], ["acute onset", "PROBLEM", 362, 373], ["fever", "PROBLEM", 396, 401], ["constitutional disturbance", "PROBLEM", 406, 432], ["some primary disease process", "PROBLEM", 486, 514], ["bacterial pathogen", "PROBLEM", 577, 595], ["gastroenteritis", "PROBLEM", 661, 676], ["bacterial isolations", "PROBLEM", 788, 808], ["gastroenteritis", "OBSERVATION", 16, 31], ["infectious", "OBSERVATION_MODIFIER", 38, 48], ["alimentary tract", "ANATOMY", 64, 80], ["may be caused", "UNCERTAINTY", 87, 100], ["bacterial", "OBSERVATION_MODIFIER", 116, 125], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["protozoal pathogens", "OBSERVATION", 136, 155], ["mucosa", "ANATOMY", 180, 186], ["functional", "OBSERVATION_MODIFIER", 208, 218], ["variable", "OBSERVATION_MODIFIER", 222, 230], ["extent", "OBSERVATION_MODIFIER", 231, 237], ["severity", "OBSERVATION_MODIFIER", 242, 250], ["acute", "OBSERVATION_MODIFIER", 283, 288], ["gastroenteritis", "OBSERVATION", 289, 304], ["diarrhoea", "OBSERVATION", 333, 342], ["acute", "OBSERVATION_MODIFIER", 362, 367], ["fever", "OBSERVATION", 396, 401], ["infective origin", "OBSERVATION_MODIFIER", 445, 461], ["not secondary to", "UNCERTAINTY", 469, 485], ["primary", "OBSERVATION_MODIFIER", 491, 498], ["disease", "OBSERVATION", 499, 506], ["alimentary tract", "ANATOMY", 527, 543], ["bacteria", "OBSERVATION", 552, 560], ["bacterial", "OBSERVATION_MODIFIER", 577, 586], ["pathogen", "OBSERVATION", 587, 595], ["stools", "OBSERVATION", 621, 627], ["gastroenteritis", "OBSERVATION", 661, 676], ["bacterial isolations", "OBSERVATION", 788, 808], ["bacteria", "OBSERVATION", 817, 825]]]], "PMC7128170": [["The recent emergence of the Middle East Respiratory Syndrome (MERS) has brought renewed attention to the possibility of rapid international dissemination of respiratory disease from the Hajj [1].", [["respiratory", "ANATOMY", 157, 168], ["Middle East Respiratory Syndrome", "DISEASE", 28, 60], ["MERS", "DISEASE", 62, 66], ["respiratory disease", "DISEASE", 157, 176], ["the Middle East Respiratory Syndrome", "PROBLEM", 24, 60], ["respiratory disease", "PROBLEM", 157, 176], ["Middle", "ANATOMY_MODIFIER", 28, 34], ["Respiratory Syndrome", "OBSERVATION", 40, 60], ["rapid", "OBSERVATION_MODIFIER", 120, 125], ["respiratory disease", "OBSERVATION", 157, 176]]], ["The 2009 Hajj occurred during the influenza A (H1N1) pandemic, which also prompted public health officials to place an increased emphasis on mitigating the potential spread of respiratory disease [2].", [["respiratory", "ANATOMY", 176, 187], ["influenza A (H1N1) pandemic", "DISEASE", 34, 61], ["respiratory disease", "DISEASE", 176, 195], ["influenza A (H1N1", "ORGANISM", 34, 51], ["influenza A (H1N1", "SPECIES", 34, 51], ["pandemic", "PROBLEM", 53, 61], ["an increased emphasis", "PROBLEM", 116, 137], ["respiratory disease", "PROBLEM", 176, 195], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["respiratory disease", "OBSERVATION", 176, 195]]]], "77fdcdae457ca0c39561d6a8e056db86d042325d": [["Because of this simplicity, numerical solutions can be generated easily and key properties of the epidemic wave can still be obtained exactly.", [["numerical solutions", "TREATMENT", 28, 47]]], ["In particular, we present exact expressions for the herd immunity level, the final size of the epidemic, as well as for the shape of the wave and for observables that can be quantified during an epidemic.", [["size", "OBSERVATION_MODIFIER", 83, 87]]], ["We find that in strongly heterogeneous populations the epidemic reaches only a small fraction of the population.", [["heterogeneous", "OBSERVATION_MODIFIER", 25, 38], ["populations", "OBSERVATION", 39, 50], ["epidemic", "OBSERVATION_MODIFIER", 55, 63], ["small", "OBSERVATION_MODIFIER", 79, 84], ["fraction", "OBSERVATION_MODIFIER", 85, 93], ["population", "OBSERVATION_MODIFIER", 101, 111]]], ["This implies that the herd immunity level can be much lower than in commonly used models with homogeneous populations.", [["the herd immunity level", "PROBLEM", 18, 41]]], ["Using our model to analyze data for the SARS-CoV-2 epidemic in Germany shows that the reported time course is consistent with several scenarios characterized by different levels of immunity.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "SPECIES", 40, 48], ["the SARS", "TEST", 36, 44], ["CoV", "TEST", 45, 48], ["several scenarios", "PROBLEM", 126, 143], ["consistent with", "UNCERTAINTY", 110, 125], ["several", "OBSERVATION_MODIFIER", 126, 133], ["scenarios", "OBSERVATION", 134, 143]]], ["These scenarios differ in population heterogeneity and in the time course of the infection rate, for example due to mitigation efforts or seasonality.", [["infection", "DISEASE", 81, 90], ["These scenarios", "PROBLEM", 0, 15], ["the infection rate", "PROBLEM", 77, 95], ["seasonality", "PROBLEM", 138, 149], ["population", "OBSERVATION_MODIFIER", 26, 36], ["heterogeneity", "OBSERVATION", 37, 50], ["infection", "OBSERVATION", 81, 90]]], ["Our analysis reveals that quantifying the effects of mitigation requires knowledge on the degree of heterogeneity in the population.", [["Our analysis", "TEST", 0, 12], ["heterogeneity in the population", "PROBLEM", 100, 131], ["heterogeneity", "OBSERVATION", 100, 113]]], ["Our work shows that key effects of population heterogeneity can be captured without increasing the complexity of the model.", [["population heterogeneity", "PROBLEM", 35, 59]]], ["One infected person can infect several others who are susceptible to the infection, characterized by the basic reproduction number R 0 , initially typically generating an exponential growth of the number of infections.", [["infection", "DISEASE", 73, 82], ["infections", "DISEASE", 207, 217], ["person", "ORGANISM", 13, 19], ["person", "SPECIES", 13, 19], ["the infection", "PROBLEM", 69, 82], ["infections", "PROBLEM", 207, 217], ["infected", "OBSERVATION", 4, 12], ["infection", "OBSERVATION", 73, 82], ["exponential", "OBSERVATION_MODIFIER", 171, 182], ["growth", "OBSERVATION_MODIFIER", 183, 189], ["number", "OBSERVATION_MODIFIER", 197, 203], ["infections", "OBSERVATION", 207, 217]]], ["The number of infections reaches a peak and later dies down when there is a sufficient number of individuals that have gained immunity after they recovered from the infection so that further growth is hampered.", [["infections", "DISEASE", 14, 24], ["infection", "DISEASE", 165, 174], ["infections", "PROBLEM", 14, 24], ["the infection", "PROBLEM", 161, 174], ["further growth", "PROBLEM", 183, 197], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infections", "OBSERVATION", 14, 24], ["peak", "OBSERVATION_MODIFIER", 35, 39], ["infection", "OBSERVATION", 165, 174]]], ["The fraction of immune individuals reached at the point when the epidemic starts to recede is called herd immunity [1, 3, 4] .I. INTRODUCTIONThere are big uncertainties as to when and why an epidemic reaches its peak and the levels of herd immunity required [5] .", [["herd", "ORGANISM_SUBDIVISION", 235, 239], ["immune individuals", "PROBLEM", 16, 34], ["an epidemic", "PROBLEM", 188, 199], ["immune individuals", "OBSERVATION", 16, 34]]], ["Simple models of infections dynamics predict that for an initially fast growing epidemic most of the population will become infected before the epidemic dies down [1, 3, 6] .", [["infections", "DISEASE", 17, 27], ["infections dynamics", "PROBLEM", 17, 36], ["infections", "OBSERVATION", 17, 27], ["infected", "OBSERVATION", 124, 132]]], ["It was noted early by William Farr when investigating smallpox and other epidemics that epidemics appear to follow a general time course in the form of a skewed bell shaped curve [7, 8] .", [["smallpox", "DISEASE", 54, 62], ["smallpox", "PROBLEM", 54, 62]]], ["The fact that an epidemic dies down is usually attributed to the fact that there exists some degree of immunity in the population [9] .", [["an epidemic dies", "PROBLEM", 14, 30], ["some", "OBSERVATION_MODIFIER", 88, 92], ["degree", "OBSERVATION_MODIFIER", 93, 99]]], ["The uncertainty about when the peak of an epidemic is reached and why an epidemic dies out even if there remains a large number of still susceptible individuals reveals that the factors that limit an epidemic are not well understood.", [["still susceptible individuals", "PROBLEM", 131, 160], ["large", "OBSERVATION_MODIFIER", 115, 120]]], ["Furthermore, the effectiveness and impact of mitigation measures such as social distancing to counter a fast growing epidemic are not known.I. INTRODUCTIONSimplified models of infection dynamics, such as the classic Susceptible-Infected-Removed (SIR) model have been used for a long time to describe the dynamics of epidemics spreading through a population [1, 3, 6, 10] .", [["infection", "DISEASE", 176, 185], ["mitigation measures", "TREATMENT", 45, 64], ["a fast growing epidemic", "PROBLEM", 102, 125], ["infection dynamics", "PROBLEM", 176, 194], ["infection", "OBSERVATION", 176, 185], ["Infected", "OBSERVATION", 228, 236]]], ["Such models capture key features of the epidemic as a nonlinear wave with qualitative properties that match observed bell-shaped dynamics of epidemic waves.", [["shaped", "OBSERVATION_MODIFIER", 122, 128]]], ["However, more quantitatively, such models exhibit the robust feature that a quickly growing epidemic does not stop unless the majority of a susceptible population has reached immunity after going through the infection [1] .", [["infection", "DISEASE", 208, 217], ["a susceptible population", "PROBLEM", 138, 162], ["the infection", "PROBLEM", 204, 217], ["infection", "OBSERVATION", 208, 217]]], ["This raises the question whether important factors are missing in these simple and elegant models.", [["raises the question", "UNCERTAINTY", 5, 24]]], ["This aspect is also key to understand the role and effectiveness of social distancing measures to influence dynamics of an epidemic wave [10] [11] [12] .I. INTRODUCTIONSimple epidemic models treat the population as effectively consisting of identical individuals.", [["social distancing measures", "TREATMENT", 68, 94], ["an epidemic wave", "TREATMENT", 120, 136]]], ["The importance of population heterogeneity was put forward to understand smallpox epidemic which could not be captured by simple models [13] .", [["smallpox", "DISEASE", 73, 81], ["population heterogeneity", "PROBLEM", 18, 42], ["smallpox epidemic", "PROBLEM", 73, 90]]], ["Such heterogeneity has been taken into account by adding details such as introducing several compartments to a model [14] or by introducing distributions of susceptibility [13, 15] or infectiousness [15, 16] .", [["infectiousness", "PROBLEM", 184, 198]]], ["It was suggested that population heterogeneity reduces effective herd immunity levels [13, 15, 17, 18] .I. INTRODUCTIONIn this paper, we present a generalization of the SIR model that takes into account effects of population heterogeneity.", [["herd", "ORGANISM_SUBDIVISION", 65, 69], ["population heterogeneity", "PROBLEM", 22, 46], ["the SIR model", "TREATMENT", 165, 178], ["population heterogeneity", "PROBLEM", 214, 238], ["population", "OBSERVATION_MODIFIER", 214, 224], ["heterogeneity", "OBSERVATION", 225, 238]]], ["We show here that effects of heterogeneity can be added without losing the simplicity of the SIR model and keeping its mathematical structure.", [["the SIR model", "TREATMENT", 89, 102]]], ["We introduce a single new parameter, the susceptibility exponent \u03b1, which characterizes a generic powerlaw heterogeneity in the distribution of infection susceptibilities of the population.", [["infection", "DISEASE", 144, 153], ["a generic powerlaw heterogeneity", "PROBLEM", 88, 120], ["infection susceptibilities of the population", "PROBLEM", 144, 188], ["susceptibility exponent", "OBSERVATION_MODIFIER", 41, 64], ["generic", "OBSERVATION_MODIFIER", 90, 97], ["powerlaw heterogeneity", "OBSERVATION", 98, 120], ["distribution", "OBSERVATION_MODIFIER", 128, 140], ["infection", "OBSERVATION", 144, 153], ["population", "OBSERVATION_MODIFIER", 178, 188]]], ["Power laws are often found in nonlinear and complex systems [19] [20] [21] [22] .", [["[19] [20] [21] [22]", "SIMPLE_CHEMICAL", 60, 79]]], ["In the present context, power laws could be expected for example based on a variability of immune responses of different individuals which could imply a wide variability in the efficiency of the transmission of an infection [23, 24] .", [["infection", "DISEASE", 214, 223], ["different individuals", "PROBLEM", 111, 132], ["a wide variability", "PROBLEM", 151, 169], ["an infection", "PROBLEM", 211, 223], ["wide", "OBSERVATION_MODIFIER", 153, 157], ["variability", "OBSERVATION_MODIFIER", 158, 169], ["infection", "OBSERVATION", 214, 223]]], ["Furthermore, population heterogeneity could be relevant at very different scales, from the the immune response of cells to the behaviors of individuals that affect infection rates.", [["cells", "ANATOMY", 114, 119], ["infection", "DISEASE", 164, 173], ["cells", "CELL", 114, 119], ["population heterogeneity", "PROBLEM", 13, 37], ["infection rates", "PROBLEM", 164, 179], ["population", "OBSERVATION_MODIFIER", 13, 23], ["heterogeneity", "OBSERVATION", 24, 37], ["infection", "OBSERVATION", 164, 173]]], ["Such as broad range of relevant scales could give rise to approximately scale free properties or power laws.I. INTRODUCTIONIn the heterogeneous SIR model proposed here, the qualitative behaviors of the the epidemic wave are unchanged.", [["heterogeneous", "OBSERVATION_MODIFIER", 130, 143], ["unchanged", "OBSERVATION_MODIFIER", 224, 233]]], ["However, as a function of the parameter \u03b1, the wave can become self-limited at much lower levels of infected individuals as compared to the classic SIR model.I. INTRODUCTIONIn the limit of large \u03b1 we recover the classic SIR model of homogeneous populations.", [["infected individuals", "PROBLEM", 100, 120], ["infected", "OBSERVATION", 100, 108], ["large", "OBSERVATION_MODIFIER", 189, 194], ["homogeneous", "OBSERVATION_MODIFIER", 233, 244], ["populations", "OBSERVATION_MODIFIER", 245, 256]]], ["For smaller \u03b1 we find that the number of infections at the peak and the cumulative number of infections after the epidemic has passed can be strongly reduced.", [["infections", "DISEASE", 41, 51], ["infections", "DISEASE", 93, 103], ["infections", "PROBLEM", 41, 51], ["infections", "PROBLEM", 93, 103], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["infections", "OBSERVATION", 41, 51], ["peak", "OBSERVATION_MODIFIER", 59, 63], ["cumulative", "OBSERVATION_MODIFIER", 72, 82], ["number", "OBSERVATION_MODIFIER", 83, 89], ["infections", "OBSERVATION", 93, 103]]], ["Our work has implications for the concept of herd immunity and clarifies that herd immunity cannot be discussed independently of population heterogeneity.I. INTRODUCTIONWe discuss the dynamics of the SARS-CoV-2 pandemics using the heterogeneous SIR model applied to data on reported infection numbers and COVID-19 associated deaths in Germany [25] .", [["SARS", "DISEASE", 200, 204], ["infection", "DISEASE", 283, 292], ["deaths", "DISEASE", 325, 331], ["herd", "ORGANISM_SUBDIVISION", 45, 49], ["herd", "ORGANISM", 78, 82], ["CoV-2", "ORGANISM", 205, 210], ["SARS-CoV", "SPECIES", 200, 208], ["the SARS", "PROBLEM", 196, 204], ["the heterogeneous SIR model", "TREATMENT", 227, 254], ["reported infection numbers", "PROBLEM", 274, 300], ["COVID", "TEST", 305, 310], ["infection", "OBSERVATION", 283, 292]]], ["We estimate parameter values including the susceptibility exponent \u03b1 andI.", [["andI", "PROTEIN", 69, 73]]], ["INTRODUCTIONwhere the dots denote time derivatives,x is a dimensionless average susceptibility and the rate \u03b2(t) describes a probability per unit time and per person to become infected, which can in general depend on time t.", [["person", "SPECIES", 159, 165], ["infected", "PROBLEM", 176, 184], ["infected", "OBSERVATION", 176, 184]]], ["This time dependence could correspond to seasonal changes or mitigation measures [10, 12, 26] .", [["seasonal changes", "PROBLEM", 41, 57], ["mitigation measures", "TREATMENT", 61, 80]]], ["The cumulative number of infections is C = N \u2212 S. A key parameter is the basic reproduction numberI.", [["infections", "DISEASE", 25, 35], ["infections", "PROBLEM", 25, 35], ["cumulative", "OBSERVATION_MODIFIER", 4, 14], ["number", "OBSERVATION_MODIFIER", 15, 21], ["infections", "OBSERVATION", 25, 35]]], ["INTRODUCTIONwhich denotes the average number of new infections generated by an infected individual.I. INTRODUCTIONThe growth rate of infections is\u0130I.", [["infections", "DISEASE", 52, 62], ["infections", "DISEASE", 133, 143], ["new infections", "PROBLEM", 48, 62], ["an infected individual", "PROBLEM", 76, 98], ["infections is\u0130I", "PROBLEM", 133, 148], ["average", "OBSERVATION_MODIFIER", 30, 37], ["number", "OBSERVATION_MODIFIER", 38, 44], ["new", "OBSERVATION_MODIFIER", 48, 51], ["infections", "OBSERVATION", 52, 62], ["infected", "OBSERVATION", 79, 87], ["growth", "OBSERVATION_MODIFIER", 118, 124], ["infections", "OBSERVATION", 133, 143]]], ["INTRODUCTIONThe time course of an epidemic is often provided as the number of new cases per day.I. INTRODUCTIONThis corresponds to the rate of new infections per unit timeI.", [["infections", "DISEASE", 147, 157], ["new infections", "PROBLEM", 143, 157], ["new", "OBSERVATION_MODIFIER", 143, 146], ["infections", "OBSERVATION", 147, 157]]], ["INTRODUCTIONwith J =\u010a = \u2212\u1e60 and R = J/(\u03b3I).A. Infection dynamics in homogeneous populationsIn the simple case of a homogeneous population, all individuals have the same degree of susceptibility, x = 1 and the population average of x isx = 1 independent of time.", [["INTRODUCTIONwith", "TEST", 0, 16], ["J", "TEST", 17, 18], ["Infection dynamics in homogeneous populations", "PROBLEM", 45, 90], ["a homogeneous population", "PROBLEM", 112, 136], ["Infection", "OBSERVATION", 45, 54], ["homogeneous populations", "OBSERVATION", 67, 90], ["homogeneous", "OBSERVATION_MODIFIER", 114, 125], ["population", "OBSERVATION", 126, 136], ["same degree", "OBSERVATION_MODIFIER", 163, 174], ["susceptibility", "OBSERVATION_MODIFIER", 178, 192]]], ["This is the classic SIR model.", [["SIR model", "OBSERVATION", 20, 29]]], ["An example for a solution to these equations for homogeneous populationx = 1 and constant \u03b2 is given in Fig. 1 (a) ,(b).", [["a solution", "TREATMENT", 15, 25]]], ["The corresponding time dependent reproduction number is presented in Fig. 1 (c) .", [["time", "OBSERVATION_MODIFIER", 18, 22], ["dependent", "OBSERVATION_MODIFIER", 23, 32], ["reproduction", "OBSERVATION_MODIFIER", 33, 45], ["number", "OBSERVATION_MODIFIER", 46, 52]]], ["The number of infections first grows exponentially with growth rateA.", [["infections", "DISEASE", 14, 24], ["infections", "PROBLEM", 14, 24], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infections", "OBSERVATION", 14, 24]]], ["Infection dynamics in homogeneous populationsAs the number of susceptible decreases, the epidemic reaches a peak number of infectedA.", [["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["susceptible decreases", "PROBLEM", 62, 83], ["the epidemic", "PROBLEM", 85, 97], ["infectedA", "PROBLEM", 123, 132], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["susceptible", "OBSERVATION_MODIFIER", 62, 73], ["decreases", "OBSERVATION_MODIFIER", 74, 83], ["epidemic", "OBSERVATION_MODIFIER", 89, 97], ["peak", "OBSERVATION_MODIFIER", 108, 112], ["number", "OBSERVATION_MODIFIER", 113, 119], ["infectedA", "OBSERVATION_MODIFIER", 123, 132]]], ["Infection dynamics in homogeneous populationsEq.", [["Infection dynamics", "PROBLEM", 0, 18], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["Eq", "OBSERVATION_MODIFIER", 45, 47]]], ["(6) is the classic herd immunity level which is the fraction of immune individuals in the population beyond which the epidemic can no longer grow.", [["herd", "ORGANISM_SUBDIVISION", 19, 23], ["the classic herd immunity level", "PROBLEM", 7, 38], ["immune individuals", "PROBLEM", 64, 82], ["no longer", "UNCERTAINTY", 131, 140]]], ["Infection dynamics in homogeneous populationswhereA.", [["populationswhereA", "CANCER", 34, 51], ["Infection dynamics in homogeneous populationswhereA", "PROBLEM", 0, 51], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33]]], ["Infection dynamics in homogeneous populationsis the fraction of susceptible individuals that remain after long times.", [["Infection dynamics", "PROBLEM", 0, 18], ["susceptible individuals", "PROBLEM", 64, 87], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["susceptible individuals", "OBSERVATION", 64, 87]]], ["Here W (z) denotes Lambert W-function, see Appendix A. The total fraction of infections over the course of theA.", [["infections", "DISEASE", 77, 87], ["infections", "PROBLEM", 77, 87], ["Appendix", "ANATOMY", 43, 51], ["infections", "OBSERVATION", 77, 87]]], ["Infection dynamics in homogeneous populationsFor a classic SIR model with homogeneous population we have for R 0 = 2.5, a herd immunity level C I /N of 60% of the population, see Fig. 1 The fraction of the population that become infected increase for larger R 0 .", [["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["a herd immunity level", "TEST", 120, 141], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["infected", "OBSERVATION", 229, 237]]], ["The SIR model thus suggests that for R 0 > 2 the epidemic wave exceeds a majority of the population before the epidemic begins to die out.A. Infection dynamics in homogeneous populationswhich for the whole population implies Eq.", [["A. Infection dynamics", "PROBLEM", 138, 159], ["Infection", "OBSERVATION", 141, 150]]], ["Infection dynamics in homogeneous populationswhich is in general time dependent.A. Infection dynamics in homogeneous populationsThis time dependence can be discussed by introducing the variable \u03c4 that is a measure for how far the epidemic has advanced.", [["Infection dynamics", "PROBLEM", 0, 18], ["A. Infection dynamics", "PROBLEM", 80, 101], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populationswhich", "OBSERVATION", 34, 50], ["Infection", "OBSERVATION", 83, 92], ["homogeneous", "OBSERVATION_MODIFIER", 105, 116], ["populations", "OBSERVATION_MODIFIER", 117, 128]]], ["It increases monotonically with time as\u03c4 = \u03b2I/N .", [["I/N", "PROTEIN", 44, 47], ["increases", "OBSERVATION_MODIFIER", 3, 12], ["monotonically", "OBSERVATION_MODIFIER", 13, 26]]], ["Infection dynamics in homogeneous populationswhere s 0 (x) is the initial susceptibility distribution at time t = t 0 with averagex = 1, seeA.", [["Infection dynamics", "PROBLEM", 0, 18], ["the initial susceptibility distribution", "PROBLEM", 62, 101], ["averagex", "TEST", 123, 131], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33]]], ["Infection dynamics in homogeneous populationsAppendix B.A. Infection dynamics in homogeneous populationsC.", [["populationsC", "CANCER", 93, 105], ["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["Infection dynamics", "PROBLEM", 59, 77], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["Infection", "OBSERVATION", 59, 68], ["homogeneous populationsC", "OBSERVATION", 81, 105]]], ["Infection dynamics with generic power law heterogeneityA.", [["Infection dynamics", "PROBLEM", 0, 18], ["power", "OBSERVATION_MODIFIER", 32, 37], ["law heterogeneityA", "OBSERVATION", 38, 56]]], ["Infection dynamics in homogeneous populationsThe dynamics of epidemic waves depends on the shape of the initial distribution s 0 (x).A. Infection dynamics in homogeneous populationsHere, we consider distributions that have the special property of shape invariance under the dynamics of epidemics.", [["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["epidemic waves", "PROBLEM", 61, 75], ["A. Infection dynamics", "PROBLEM", 133, 154], ["epidemics", "PROBLEM", 286, 295], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["epidemic", "OBSERVATION_MODIFIER", 61, 69], ["waves", "OBSERVATION_MODIFIER", 70, 75], ["shape", "OBSERVATION_MODIFIER", 91, 96], ["Infection", "OBSERVATION", 136, 145], ["homogeneous", "OBSERVATION_MODIFIER", 158, 169], ["populations", "OBSERVATION_MODIFIER", 170, 181]]], ["This property is satisfied by a gamma distributionA.", [["gamma distributionA", "OBSERVATION", 32, 51]]], ["Infection dynamics in homogeneous populationswhich is governed by a power-law at small x, characterized by the exponent \u03b1, and a cut off at large x.", [["Infection dynamics", "PROBLEM", 0, 18], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populationswhich", "OBSERVATION", 34, 50], ["small x", "OBSERVATION_MODIFIER", 81, 88], ["exponent", "OBSERVATION_MODIFIER", 111, 119]]], ["The distribution s 0 (x) has averagex = 1 and variance 1/\u03b1.", [["averagex", "TEST", 29, 37]]], ["Infection dynamics in homogeneous populationswhere the time dependence enters viax(t), see Appendix C. This shape invariance implies that the gamma distribution is maintained at all times and is not merely an initial condition.", [["Infection dynamics", "PROBLEM", 0, 18], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["Appendix", "ANATOMY", 91, 99], ["gamma distribution", "OBSERVATION", 142, 160]]], ["Furthermore, starting with any initial distribution that exhibits a power law s 0 (x) \u223c x \u22121+\u03b1 at small x, it will converge for large \u03c4 to the shape invariant gamma distribution, which therefore is an attractor of the dynamics, see Appendix B. Note that in the limit of large \u03b1, we recover the classic SIR model for a homogeneous population.A. Infection dynamics in homogeneous populationsFor small \u03b1, the population is strongly heterogeneous.A. Infection dynamics in homogeneous populationsFor the choice (12) we haveA.", [["small \u03b1", "GENE_OR_GENE_PRODUCT", 393, 400], ["A. Infection dynamics", "PROBLEM", 341, 362], ["small \u03b1, the population", "PROBLEM", 393, 416], ["A. Infection dynamics", "PROBLEM", 443, 464], ["shape", "OBSERVATION_MODIFIER", 143, 148], ["invariant", "OBSERVATION_MODIFIER", 149, 158], ["gamma distribution", "OBSERVATION", 159, 177], ["Appendix", "ANATOMY", 232, 240], ["homogeneous", "OBSERVATION_MODIFIER", 318, 329], ["population", "OBSERVATION", 330, 340], ["Infection", "OBSERVATION", 344, 353], ["homogeneous", "OBSERVATION_MODIFIER", 366, 377], ["populations", "OBSERVATION_MODIFIER", 378, 389], ["small", "OBSERVATION_MODIFIER", 393, 398], ["population", "OBSERVATION", 406, 416], ["strongly", "OBSERVATION_MODIFIER", 420, 428], ["heterogeneous", "OBSERVATION_MODIFIER", 429, 442], ["Infection", "OBSERVATION", 446, 455], ["homogeneous", "OBSERVATION_MODIFIER", 468, 479], ["populations", "OBSERVATION_MODIFIER", 480, 491]]], ["Infection dynamics in homogeneous populationsThe average susceptibility isxA.", [["isxA", "PROTEIN", 72, 76], ["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["average", "OBSERVATION_MODIFIER", 49, 56], ["susceptibility isxA", "OBSERVATION", 57, 76]]], ["Infection dynamics in homogeneous populationswhich starts fromx = 1 for \u03c4 = 0 and decreases for increasing \u03c4 , thus dampening the epidemic.", [["Infection dynamics", "PROBLEM", 0, 18], ["dampening the epidemic", "PROBLEM", 116, 138], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["dampening", "OBSERVATION_MODIFIER", 116, 125], ["epidemic", "OBSERVATION_MODIFIER", 130, 138]]], ["The epidemic starts out with exponential growth of infected individuals at rate \u03bb 0 = \u03b3(R 0 \u2212 1),A. Infection dynamics in homogeneous populationsWhen the reproduction number drops to R = 1, the number of infected reaches a maximumA.", [["infected individuals", "PROBLEM", 51, 71], ["rate", "TEST", 75, 79], ["A. Infection dynamics in homogeneous populations", "PROBLEM", 97, 145], ["infected", "OBSERVATION", 51, 59], ["Infection", "OBSERVATION", 100, 109], ["homogeneous populations", "OBSERVATION", 122, 145], ["infected", "OBSERVATION", 204, 212]]], ["Infection dynamics in homogeneous populationsBeyond the herd immunity level given by the cumulative number of infections at the maxi-A.", [["infections", "DISEASE", 110, 120], ["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["infections", "PROBLEM", 110, 120], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["infections", "OBSERVATION", 110, 120]]], ["Infection dynamics in homogeneous populationsthe reproduction number R drops below 1 and the epidemic dies down.", [["Infection dynamics", "PROBLEM", 0, 18], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33]]], ["In Eqns.", [["Eqns", "PROTEIN", 3, 7]]], ["(17)- (19) we have considered the limit of small I 0 /N for simplicity.", [["(17)- (19)", "SIMPLE_CHEMICAL", 0, 10]]], ["In the limit of large \u03b1, these expressions converge to those obtained for the homogeneous SIR model, see Appendix A.A. Infection dynamics in homogeneous populationsThe remaining fraction of susceptible individuals at the peak and after the epidemic has passed is shown as a function of \u03b1 in Fig. 2 (a) and (b).", [["\u03b1", "GENE_OR_GENE_PRODUCT", 22, 23], ["\u03b1", "PROTEIN", 286, 287], ["susceptible individuals", "PROBLEM", 190, 213], ["large", "OBSERVATION_MODIFIER", 16, 21], ["Appendix", "ANATOMY", 105, 113], ["Infection", "OBSERVATION", 119, 128], ["homogeneous", "OBSERVATION_MODIFIER", 141, 152], ["populations", "OBSERVATION_MODIFIER", 153, 164], ["remaining", "OBSERVATION_MODIFIER", 168, 177], ["fraction", "OBSERVATION_MODIFIER", 178, 186], ["susceptible", "OBSERVATION_MODIFIER", 190, 201], ["individuals", "OBSERVATION", 202, 213], ["peak", "OBSERVATION_MODIFIER", 221, 225]]], ["This reveals that as \u03b1 is reduced, the fraction of the population reached by the epidemic decreases and can become very small for small \u03b1.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 21, 22], ["\u03b1", "PROTEIN", 21, 22], ["reduced", "OBSERVATION_MODIFIER", 26, 33], ["fraction", "OBSERVATION_MODIFIER", 39, 47], ["population", "OBSERVATION_MODIFIER", 55, 65], ["epidemic", "OBSERVATION_MODIFIER", 81, 89], ["decreases", "OBSERVATION_MODIFIER", 90, 99], ["small", "OBSERVATION_MODIFIER", 120, 125]]], ["At the same time the infections are more spread out over time and a larger fraction occurs after the peak when \u03b1 is reduced, see Fig. 2 (c).A. Infection dynamics in homogeneous populationsAn important case is a strongly heterogeneous population.", [["infections", "DISEASE", 21, 31], ["\u03b1", "PROTEIN", 111, 112], ["the infections", "PROBLEM", 17, 31], ["a larger fraction", "PROBLEM", 66, 83], ["A. Infection dynamics", "PROBLEM", 140, 161], ["infections", "OBSERVATION", 21, 31], ["more", "OBSERVATION_MODIFIER", 36, 40], ["spread", "OBSERVATION_MODIFIER", 41, 47], ["larger", "OBSERVATION_MODIFIER", 68, 74], ["fraction", "OBSERVATION", 75, 83], ["Infection", "OBSERVATION", 143, 152], ["homogeneous", "OBSERVATION_MODIFIER", 165, 176], ["populations", "OBSERVATION_MODIFIER", 177, 188], ["heterogeneous", "OBSERVATION_MODIFIER", 220, 233], ["population", "OBSERVATION", 234, 244]]], ["For small \u03b1 1, we obtain simple analytical expressions for the behavior of the system, see Appendix E. In this limit we have I max /N \u03b1(ln R 0 + 1/R 0 \u2212 1) and C I /N \u03b1 ln R 0 .", [["C I", "PROTEIN", 160, 163], ["N \u03b1 ln R 0", "CELL_LINE", 165, 175], ["small \u03b1 1", "PROBLEM", 4, 13], ["C I", "TEST", 160, 163], ["small", "OBSERVATION_MODIFIER", 4, 9], ["Appendix", "ANATOMY", 91, 99]]], ["An important quantity is the rate J of new cases per time.", [["important", "OBSERVATION_MODIFIER", 3, 12], ["quantity", "OBSERVATION_MODIFIER", 13, 21]]], ["For small \u03b1 it takes the maximal valueA.", [["small", "OBSERVATION_MODIFIER", 4, 9]]], ["Infection dynamics in homogeneous populationsThe final number of susceptible individuals is given byA.", [["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["susceptible", "OBSERVATION_MODIFIER", 65, 76], ["individuals", "OBSERVATION", 77, 88]]], ["Infection dynamics in homogeneous populationswhere for small \u03b1 the average susceptibility after the infection has passed isx \u221eA. Infection dynamics in homogeneous populationsWe finally have for small \u03b1A.", [["infection", "DISEASE", 100, 109], ["\u03b1A.", "SPECIES", 200, 203], ["Infection dynamics", "PROBLEM", 0, 18], ["small \u03b1 the average susceptibility", "PROBLEM", 55, 89], ["the infection", "PROBLEM", 96, 109], ["Infection dynamics in homogeneous populations", "PROBLEM", 129, 174], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["small", "OBSERVATION_MODIFIER", 55, 60], ["infection", "OBSERVATION", 100, 109], ["homogeneous", "OBSERVATION_MODIFIER", 151, 162], ["populations", "OBSERVATION_MODIFIER", 163, 174]]], ["Infection dynamics in homogeneous populationsA key result is that for small \u03b1 the herd immunity level can be much below the classical value suggested by the SIR model.", [["Infection dynamics in homogeneous populations", "PROBLEM", 0, 45], ["small \u03b1 the herd immunity level", "PROBLEM", 70, 101], ["homogeneous", "OBSERVATION_MODIFIER", 22, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["small", "OBSERVATION_MODIFIER", 70, 75]]], ["For example for R 0 = 2.5 and \u03b1 = 0.1, we have I max /N 2.8%, and a fraction C I /N 8% of infected individuals required for herd immunity, much lower than is usually suggested.", [["I max /N", "TEST", 47, 55], ["a fraction C I /N", "TEST", 66, 83], ["infected individuals", "PROBLEM", 90, 110], ["herd immunity", "TREATMENT", 124, 137], ["infected", "OBSERVATION", 90, 98]]], ["The total number of infected at long times is C \u221e /N 14%, see Appendix C.III. APPLICATION TO THE SARS-COV-2 EPIDEMIC IN GERMANYWe analyze the dynamics of the SARS-CoV-2 epidemic in Germany using public data provided by the Robert Koch institute [25] .", [["SARS", "DISEASE", 158, 162], ["C \u221e /N", "PROBLEM", 46, 52], ["the SARS", "PROBLEM", 154, 162], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["infected", "OBSERVATION", 20, 28], ["Appendix", "ANATOMY", 62, 70]]], ["These daily reports provide the numbers of reported positive tests for each day, but also the dates of reporting of those infections which later turn out as fatal.", [["infections", "DISEASE", 122, 132], ["positive tests", "PROBLEM", 52, 66], ["those infections", "PROBLEM", 116, 132], ["infections", "OBSERVATION", 122, 132]]], ["The total number of new reported infections per day J t rep (red symbols) are shown in Fig. 3 (a) together with the number of reported infections per day that were later fatal (blue symbols), which we denote J f rep (t).", [["infections", "DISEASE", 33, 43], ["infections", "DISEASE", 135, 145], ["J t rep", "DNA", 52, 59], ["new reported infections", "PROBLEM", 20, 43], ["J t rep (red symbols", "TREATMENT", 52, 72], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["new", "OBSERVATION_MODIFIER", 20, 23], ["infections", "OBSERVATION", 33, 43], ["infections", "OBSERVATION", 135, 145]]], ["They show qualitatively similar behavior, a rapid growth and a decline after passing a maximum.III. APPLICATION TO THE SARS-COV-2 EPIDEMIC IN GERMANYHowever there are quantitative differences, in particular the growth rates at early and late times, given by the slopes of the data in a single logarithmic plot are different, see Fig. 3 (b).", [["a rapid growth", "PROBLEM", 42, 56], ["a single logarithmic plot", "PROBLEM", 284, 309], ["rapid", "OBSERVATION_MODIFIER", 44, 49], ["growth", "OBSERVATION_MODIFIER", 50, 56], ["quantitative", "OBSERVATION_MODIFIER", 167, 179], ["differences", "OBSERVATION_MODIFIER", 180, 191], ["growth", "OBSERVATION_MODIFIER", 211, 217]]], ["The number of new cases per day that are later fatal J f rep (t) is related to the number of new infections per day as J f rep (t) = Jf , where f denotes the infection fatality rate, the fraction of infections that are fatal, which we consider to be constant for simplicity.", [["infections", "DISEASE", 97, 107], ["infection", "DISEASE", 158, 167], ["infections", "DISEASE", 199, 209], ["new infections", "PROBLEM", 93, 107], ["the infection fatality rate", "PROBLEM", 154, 181], ["infections", "PROBLEM", 199, 209], ["new", "OBSERVATION_MODIFIER", 14, 17], ["new", "OBSERVATION_MODIFIER", 93, 96], ["infections", "OBSERVATION", 97, 107], ["infection", "OBSERVATION", 158, 167], ["infections", "OBSERVATION", 199, 209]]], ["It is surprising that the model fits the data of fatal cases with just two fit parameters while yielding a reasonable infection fatality rate.", [["infection", "DISEASE", 118, 127], ["a reasonable infection fatality rate", "PROBLEM", 105, 141], ["infection", "OBSERVATION", 118, 127]]], ["This is further clarified when using the fit values of R 0 and \u03b3 to calculate \u03bb 0 0.24 day \u22121 , slightly smaller than the estimate given in In order to understand how the shape of the wave of infections constrains the possible parameter values of R 0 , \u03b3 and \u03b1, we consider in addition to the initial growth rate \u03bb 0 and the final decay rate \u03bb \u221e two coefficients describing the epidemic dynamics near its peak, using the expansionIII.", [["infections", "DISEASE", 192, 202], ["the fit values", "TEST", 37, 51], ["infections", "PROBLEM", 192, 202], ["the initial growth rate", "TEST", 289, 312], ["the expansionIII", "TREATMENT", 417, 433], ["smaller", "OBSERVATION_MODIFIER", 105, 112], ["infections", "OBSERVATION", 192, 202]]], ["APPLICATION TO THE SARS-COV-2 EPIDEMIC IN GERMANYwhere the linear term disappears by definition at the maximum J max = J(t J ) at time t J .III. APPLICATION TO THE SARS-COV-2 EPIDEMIC IN GERMANYThe coefficients A 2 =J/J| t=t J and A 3 = ... shaded regions corresponding to estimated uncertainty ranges of these values.III. APPLICATION TO THE SARS-COV-2 EPIDEMIC IN GERMANYWe find that the ratio A 2 /\u03bb 2 \u221e , which is independent of \u03b3 depends only weakly on \u03b1.", [["\u03b3", "PROTEIN", 432, 433], ["the maximum J max = J(t J )", "TREATMENT", 99, 126], ["THE SARS", "TEST", 160, 168], ["COV", "TEST", 169, 172]]], ["This reveals that \u03b1 1 must be small and that the classic SIR model with homogeneous population is not consistent with this data.", [["\u03b1 1", "GENE_OR_GENE_PRODUCT", 18, 21], ["\u03b1 1", "PROTEIN", 18, 21], ["small", "OBSERVATION_MODIFIER", 30, 35], ["homogeneous", "OBSERVATION_MODIFIER", 72, 83], ["population", "OBSERVATION", 84, 94], ["not consistent with", "UNCERTAINTY", 98, 117]]], ["We can now estimate \u03b3 using the small \u03b1 limit.", [["small", "OBSERVATION_MODIFIER", 32, 37]]], ["For R 0 2.6, we have \u03b3 2\u03bb \u221e 0.14 day \u22121 , see Fig. 5 (d).III. APPLICATION TO THE SARS-COV-2 EPIDEMIC IN GERMANYThe data does not provide information about the true total number of infections.", [["infections", "DISEASE", 180, 190], ["infections", "PROBLEM", 180, 190], ["infections", "OBSERVATION", 180, 190]]], ["Therefore the precise value of \u03b1 remains unknown.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 31, 32], ["\u03b1", "PROTEIN", 31, 32], ["the precise value", "TEST", 10, 27]]], ["We can use estimates from immunological studies estimating the number of infections [27, 29, 30] to determine \u03b1.", [["infections", "DISEASE", 73, 83], ["\u03b1.", "SPECIES", 110, 112], ["immunological studies", "TEST", 26, 47], ["infections", "PROBLEM", 73, 83]]], ["This suggests a range of about 0.01 < \u03b1 < 0.15, corresponding to 0.65% > f > 0.04%.", [["range", "OBSERVATION_MODIFIER", 16, 21]]], ["Fig. 5 also shows the estimated ranges for data on all reported cases in red.", [["red", "OBSERVATION", 73, 76]]], ["For this case the inferred values of R 0 is larger and the consistency with the data is less strong.C. Effects of mitigation and social distancing measuresDuring an epidemic conditions can change over time.", [["C.", "SPECIES", 100, 102], ["C.", "SPECIES", 100, 102], ["mitigation", "TREATMENT", 114, 124], ["social distancing measures", "TREATMENT", 129, 155], ["an epidemic conditions", "PROBLEM", 162, 184], ["larger", "OBSERVATION_MODIFIER", 44, 50]]], ["For example, mitigation by social distancing measures, quarantining or seasonal changes could affect how quickly an infection spreads on average from person to person.", [["infection", "DISEASE", 116, 125], ["person", "SPECIES", 150, 156], ["person", "SPECIES", 160, 166], ["social distancing measures", "TREATMENT", 27, 53], ["seasonal changes", "PROBLEM", 71, 87], ["an infection", "PROBLEM", 113, 125], ["infection", "OBSERVATION", 116, 125]]], ["In the following, we discuss scenarios of mitigated epidemics, starting from a reference point with an initial infection rate \u03b2 0 prior to mitigation.", [["infection", "DISEASE", 111, 120], ["mitigated epidemics", "PROBLEM", 42, 61], ["an initial infection rate", "TEST", 100, 125], ["infection", "OBSERVATION", 111, 120]]], ["For immunity levels above herd immunity, C \u2265 C I , the population is stable after mitigation measures are completely relaxed and \u03b2 is restored to its original value \u03b2 0 .C. Effects of mitigation and social distancing measuresWe examine three different scenarios with a comparable total number of infections.", [["infections", "DISEASE", 296, 306], ["immunity levels", "TEST", 4, 19], ["mitigation measures", "TREATMENT", 82, 101], ["mitigation", "TREATMENT", 184, 194], ["social distancing measures", "TREATMENT", 199, 225], ["infections", "PROBLEM", 296, 306], ["stable", "OBSERVATION_MODIFIER", 69, 75], ["infections", "OBSERVATION", 296, 306]]], ["These In the case of early mitigation, Fig. 6 (a-c) , fast reduction of \u03b2 suppresses the epidemic before any appreciable progress towards herd immunity was made.", [["herd", "ORGANISM_SUBDIVISION", 138, 142], ["\u03b2", "PROTEIN", 72, 73], ["fast reduction", "TREATMENT", 54, 68]]], ["Mitigation needs to be strong and sustained to be compatible with the data.", [["the data", "TEST", 66, 74]]], ["By July, the population reaches only about 6 \u2212 7% of herd immunity in this case.", [["herd", "ORGANISM_SUBDIVISION", 53, 57]]], ["Note that this is the only scenario of the classic SIR model with a homogeneous population (\u03b1 \u2192 \u221e) that could be compatible with the data.", [["\u03b1 \u2192 \u221e", "CELL_LINE", 92, 97]]], ["For heterogeneous populations with \u03b1 0.2, scenarios with milder mitigation and with infection levels closer to herd immunity are compatible with the data, see Fig. 6 (d) andC.", [["infection", "DISEASE", 84, 93], ["Fig. 6 (d) andC", "PROTEIN", 159, 174], ["heterogeneous populations", "PROBLEM", 4, 29], ["milder mitigation", "PROBLEM", 57, 74], ["infection levels", "PROBLEM", 84, 100], ["the data", "TEST", 145, 153], ["heterogeneous", "OBSERVATION_MODIFIER", 4, 17], ["populations", "OBSERVATION", 18, 29], ["milder", "OBSERVATION_MODIFIER", 57, 63], ["mitigation", "OBSERVATION", 64, 74], ["infection", "OBSERVATION", 84, 93]]], ["Effects of mitigation and social distancing measures(g).", [["mitigation", "TREATMENT", 11, 21], ["social distancing measures", "TREATMENT", 26, 52]]], ["A case of moderate mitigation with \u03b1 = 0.1 is shown in Fig. 6 (d-f ).", [["moderate mitigation", "PROBLEM", 10, 29], ["moderate", "OBSERVATION_MODIFIER", 10, 18]]], ["The population in this case reaches by July 1st about \u223c 45% of herd immunity.", [["herd", "ORGANISM_SUBDIVISION", 63, 67]]], ["A sustained mitigation is needed to account for the data, albeit with smaller magnitude compared to the first case.C. Effects of mitigation and social distancing measuresIf the epidemic starts slightly earlier (3 days for the case shown in Fig. 6 (g-i) as compared to (d-f)), the population reaches \u223c 95% of herd immunity by July 1st.", [["C.", "SPECIES", 115, 117], ["C.", "SPECIES", 115, 117], ["A sustained mitigation", "TREATMENT", 0, 22], ["the data", "TEST", 48, 56], ["mitigation", "TREATMENT", 129, 139], ["social distancing measures", "TREATMENT", 144, 170]]], ["Here, mitigation has the effect to reduce the cumulative number of infections as compared to a non-mitigated case (C/N = 5.8% compared to 11% by July 1st).", [["infections", "DISEASE", 67, 77], ["infections", "PROBLEM", 67, 77], ["C/N", "TEST", 115, 118], ["cumulative", "OBSERVATION_MODIFIER", 46, 56], ["number", "OBSERVATION_MODIFIER", 57, 63], ["infections", "OBSERVATION", 67, 77]]], ["This reduction of cumulative infections C results from a reduction of the number of infectious individuals I at the point when herd immunity is reached.", [["infections", "DISEASE", 29, 39], ["herd", "ORGANISM_SUBDIVISION", 127, 131], ["cumulative infections C", "PROBLEM", 18, 41], ["cumulative", "OBSERVATION_MODIFIER", 18, 28], ["infections", "OBSERVATION", 29, 39], ["reduction", "OBSERVATION_MODIFIER", 57, 66], ["infectious", "OBSERVATION", 84, 94]]], ["In the absence of mitigation, I reaches its maximum when C = C I , whereas mitigation can reduce I to small numbers as herd immunity is reached, preventing further infections.", [["infections", "DISEASE", 164, 174], ["further infections", "PROBLEM", 156, 174], ["mitigation", "OBSERVATION", 18, 28], ["small", "OBSERVATION_MODIFIER", 102, 107], ["infections", "OBSERVATION", 164, 174]]], ["The minimal number of infections that can be achieved by temporary mitigation is C I , which is up to 50% smaller than the long lime limit C \u221e in an unmitigated epidemic (see Fig. 2c ). for comparison, see Appendix H. This mobility data shows a sharp decline and a slow but steady return to the initial state roughly in line with inferred changes of \u03b2(t).C. Effects of mitigation and social distancing measuresThe three scenarios differ in the fraction of herd immunity they reach by July 1 and therefore in their future trajectories.", [["infections", "DISEASE", 22, 32], ["herd", "ORGANISM_SUBDIVISION", 456, 460], ["\u03b2(t)", "PROTEIN", 350, 354], ["infections", "PROBLEM", 22, 32], ["a sharp decline", "PROBLEM", 243, 258], ["mitigation", "TREATMENT", 369, 379], ["social distancing measures", "TREATMENT", 384, 410], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["infections", "OBSERVATION", 22, 32], ["long lime limit", "OBSERVATION_MODIFIER", 123, 138], ["sharp", "OBSERVATION_MODIFIER", 245, 250], ["decline", "OBSERVATION", 251, 258]]], ["However, \u03b2(t) was adjusted by a fitting procedure such that all scenarios are consistent with the data on reported infections.", [["infections", "DISEASE", 115, 125], ["\u03b2(t)", "PROTEIN", 9, 13], ["a fitting procedure", "TREATMENT", 30, 49], ["reported infections", "PROBLEM", 106, 125], ["infections", "OBSERVATION", 115, 125]]], ["This reveals that it can be difficult to distinguish effects of heterogeneity leading to a time dependent average susceptibilityx from mitigation effects corresponding to time-dependent \u03b2.", [["heterogeneity", "PROBLEM", 64, 77], ["a time dependent average susceptibilityx", "PROBLEM", 89, 129], ["heterogeneity", "OBSERVATION", 64, 77]]], ["Indeed our analysis shows that changes in mitigation strength can be compensated to some degree by changes of heterogeneity described by \u03b1.IV. DISCUSSIONWe have presented a generalization of the classic Susceptible-Infected-Removed model for epidemic waves, which adds one new parameter to the model that captures population heterogeneity by a power-law exponent \u03b1.", [["our analysis", "TEST", 7, 19], ["changes in mitigation strength", "PROBLEM", 31, 61], ["epidemic waves", "PROBLEM", 242, 256], ["Infected", "OBSERVATION", 215, 223]]], ["This exponent describes the power law that characterizes the distribution of susceptibility in the population s(x) \u223c x \u22121+\u03b1 for small x.IV. DISCUSSIONA special case for such distributions is the gamma distribution.", [["distribution", "OBSERVATION_MODIFIER", 61, 73], ["susceptibility", "OBSERVATION_MODIFIER", 77, 91], ["gamma distribution", "OBSERVATION", 195, 213]]], ["Gamma distributions have been used before to describe heterogeneous populations [13, 15, 16] . that only a minority of the population exhibits antibodies [27, 29, 30] .", [["antibodies", "PROTEIN", 143, 153], ["Gamma distributions", "PROBLEM", 0, 19], ["antibodies", "TEST", 143, 153], ["heterogeneous", "OBSERVATION_MODIFIER", 54, 67]]], ["This is consistent with a fit of our model to the data using a small value of \u03b1.", [["consistent with", "UNCERTAINTY", 8, 23], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["Clearly the fatal cases represent a different sampling as these cases correspond to predominantly old individuals and therefore measure a different quantity.", [["the fatal cases", "PROBLEM", 8, 23], ["fatal", "OBSERVATION_MODIFIER", 12, 17], ["predominantly", "OBSERVATION_MODIFIER", 84, 97], ["different", "OBSERVATION_MODIFIER", 138, 147], ["quantity", "OBSERVATION_MODIFIER", 148, 156]]], ["However, starting from all reported cases and then using the fatal outcome as a second criterion could reduce biases due to changes in testing rates, testing strategies as well as testing errors.IV. DISCUSSIONAn epidemic wave does not progress under constant conditions but is subject to changes such as mitigation measures and seasonal effects.", [["testing rates", "TEST", 135, 148], ["testing strategies", "TEST", 150, 168], ["testing errors", "TEST", 180, 194], ["IV", "TREATMENT", 195, 197], ["mitigation measures", "TREATMENT", 304, 323]]], ["This scenario further requires mitigation to be sustained and it leads to a fragile and unstable state when mitigation measures are relaxed.IV. DISCUSSIONIn the case of heterogeneous populations, intermediate scenarios are possible which stay below herd immunity or just reach herd immunity, see Fig. 6 (d)-(i).", [["mitigation", "TREATMENT", 31, 41], ["a fragile and unstable state", "PROBLEM", 74, 102], ["mitigation measures", "TREATMENT", 108, 127], ["IV", "TREATMENT", 140, 142], ["heterogeneous populations", "PROBLEM", 169, 194], ["fragile", "OBSERVATION", 76, 83], ["unstable", "OBSERVATION_MODIFIER", 88, 96], ["heterogeneous", "OBSERVATION_MODIFIER", 169, 182], ["populations", "OBSERVATION", 183, 194]]], ["In the latter example shown in Fig. 6 (g)-(i), mitigation effectively reduces the total number of infections by keeping immunity just at herd immunity level, leading to a stable state where mitigation can be safely relaxed.", [["infections", "DISEASE", 98, 108], ["infections", "PROBLEM", 98, 108], ["total number", "OBSERVATION_MODIFIER", 82, 94], ["infections", "OBSERVATION", 98, 108]]], ["This is a desirable outcome because the number of infections could be reduced by mitigation by up to 40% without the need of sustaining mitigation, see Fig. 2 (c).IV. DISCUSSIONWhen discussing rapidly evolving epidemics such as SARS-CoV-2, herd immunity is often not considered to be reachable as it is predicted to require an unacceptably high fraction of cumulative infections [32] .", [["infections", "DISEASE", 50, 60], ["SARS", "DISEASE", 228, 232], ["infections", "DISEASE", 368, 378], ["SARS-CoV-2", "ORGANISM", 228, 238], ["herd", "ORGANISM", 240, 244], ["SARS-CoV", "SPECIES", 228, 236], ["infections", "PROBLEM", 50, 60], ["sustaining mitigation", "TREATMENT", 125, 146], ["IV", "TREATMENT", 163, 165], ["rapidly evolving epidemics", "PROBLEM", 193, 219], ["SARS", "PROBLEM", 228, 232], ["cumulative infections", "PROBLEM", 357, 378], ["infections", "OBSERVATION", 50, 60], ["reduced", "OBSERVATION_MODIFIER", 70, 77]]], ["Interestingly, the picture changes dramatically if a strongly heterogeneous population is considered.", [["a strongly heterogeneous population", "PROBLEM", 51, 86], ["heterogeneous", "OBSERVATION_MODIFIER", 62, 75], ["population", "OBSERVATION", 76, 86]]], ["In this case herd immunity can be reached rather quickly while a large majority of the population is still susceptible.", [["large", "OBSERVATION_MODIFIER", 65, 70]]], ["This raises the question of what are the features that are variable and that give rise to heterogeneity and how widely they are expected to vary in the population.", [["raises the question of", "UNCERTAINTY", 5, 27]]], ["One possibility is that differences of susceptibility stem from differences in the abilities of immune systems of susceptible individuals to react to a new pathogen.", [["susceptibility stem", "PROBLEM", 39, 58], ["susceptible individuals", "PROBLEM", 114, 137], ["a new pathogen", "PROBLEM", 150, 164], ["susceptibility stem", "OBSERVATION", 39, 58], ["new", "OBSERVATION_MODIFIER", 152, 155], ["pathogen", "OBSERVATION", 156, 164]]], ["In addition to adaptive immunity related to the presence of specific antibodies, many individuals show a T-cell response to SARS-CoV-2 [24] .", [["T-cell", "ANATOMY", 105, 111], ["T-cell", "CELL", 105, 111], ["specific antibodies", "PROTEIN", 60, 79], ["SARS-CoV", "SPECIES", 124, 132], ["adaptive immunity", "TREATMENT", 15, 32], ["specific antibodies", "TEST", 60, 79], ["SARS", "TEST", 124, 128], ["CoV", "TEST", 129, 132]]], ["This response could for example be due to less specific cross reactions related to earlier encounters with related viruses [23] .IV. DISCUSSIONHere we have focused on data from Germany until July 2020 because it provides detailed information that is not available in most countries.", [["less specific cross reactions", "PROBLEM", 42, 71], ["related viruses", "PROBLEM", 107, 122], ["IV", "TREATMENT", 129, 131]]], ["Furthermore, Germany has relatively few reported infections and deaths per capita.", [["infections", "DISEASE", 49, 59], ["deaths", "DISEASE", 64, 70], ["relatively", "OBSERVATION_MODIFIER", 25, 35], ["few", "OBSERVATION_MODIFIER", 36, 39], ["infections", "OBSERVATION", 49, 59]]], ["Our work shows that even this rather mild manifestation of the epidemic can be captured by a heterogeneous SIR model with mild mitigation.", [["mild mitigation", "PROBLEM", 122, 137], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["heterogeneous", "OBSERVATION_MODIFIER", 93, 106], ["mild", "OBSERVATION_MODIFIER", 122, 126], ["mitigation", "OBSERVATION", 127, 137]]], ["The data of newly infected cases with fatal outcome can even be explained in a strongly heterogeneous population without considering any mitigation effects at all.IV. DISCUSSIONThis implies that in order to quantify the effects of mitigation, population heterogeneity has to be taken into account.", [["mitigation", "TREATMENT", 231, 241], ["population heterogeneity", "PROBLEM", 243, 267], ["heterogeneous", "OBSERVATION_MODIFIER", 88, 101], ["population", "OBSERVATION", 102, 112]]], ["In order to disentangle effects from heterogeneity and from mitigation the combination of different types of information is important.", [["heterogeneity", "PROBLEM", 37, 50], ["mitigation", "TREATMENT", 60, 70], ["heterogeneity", "OBSERVATION", 37, 50]]], ["For example, analyzing in different countries the circumstances under which different sero-prevalence levels or multiple epidemic waves are observed could be key to understand the roles of mitigation and heterogeneity.Appendix A: Properties of the homogeneous SIR modelFor a homogeneous population withx = 1, the SIR model given in Eqns.", [["different sero-prevalence levels", "PROBLEM", 76, 108], ["multiple epidemic waves", "PROBLEM", 112, 135], ["the SIR model", "TREATMENT", 309, 322], ["multiple", "OBSERVATION_MODIFIER", 112, 120], ["epidemic", "OBSERVATION_MODIFIER", 121, 129], ["homogeneous", "OBSERVATION_MODIFIER", 275, 286]]], ["(1-2) can be written as\u0130Appendix A: Properties of the homogeneous SIR modelWe can eliminate \u03c4 and findAppendix A: Properties of the homogeneous SIR modelThe maximum I max = I(\u03c4 I ) with I (\u03c4 I ) = 0, where the prime denotes a \u03c4 -derivative, occurs forAppendix A: Properties of the homogeneous SIR modelTherefore we the maximal number of infected individuals readsAppendix A: Properties of the homogeneous SIR modelAt the maximum I max , we have dI/dS = 0, which impliesAppendix A: Properties of the homogeneous SIR modelAt long times, the infection dies out when I(\u03c4 \u221e ) = 0 withAppendix A: Properties of the homogeneous SIR modelwhere W (z) denotes the 0-branch of Lambert W-function.", [["infection", "DISEASE", 539, 548], ["\u03c4", "PROTEIN", 92, 93], ["dI", "PROTEIN", 445, 447], ["dI/dS", "TEST", 445, 450], ["the infection dies", "PROBLEM", 535, 553], ["Appendix", "ANATOMY", 102, 110], ["infected", "OBSERVATION", 337, 345], ["Appendix", "ANATOMY", 469, 477], ["infection", "OBSERVATION", 539, 548], ["branch", "ANATOMY_MODIFIER", 656, 662], ["Lambert W-function", "OBSERVATION", 666, 684]]], ["The time dependent solution \u03c4 (t) can be obtained from N d\u03c4 /I(\u03c4 ) = \u03b2dt viaAppendix A: Properties of the homogeneous SIR modelTo discuss empirical data, we consider the time-course of the rate of new cases J = \u03b2IS/N .", [["The time dependent solution", "TREATMENT", 0, 27], ["empirical data", "TEST", 138, 152]]], ["We haveJ/J = \u03b2K withAppendix A: Properties of the homogeneous SIR modelThe maximum J max = J(\u03c4 J ) is reached for K(\u03c4 J ) = 0 which impliesAppendix A: Properties of the homogeneous SIR modelwhere W \u22121 (z) denotes the \u22121 branch of the Lambert W -function with W (z)e W (z) = z.", [["haveJ", "TEST", 3, 8], ["The maximum J max = J(\u03c4 J )", "TREATMENT", 71, 98], ["K", "TEST", 114, 115], ["W (z)e W (z)", "TREATMENT", 259, 271], ["homogeneous SIR model", "OBSERVATION", 50, 71], ["branch", "ANATOMY_MODIFIER", 220, 226]]], ["At the maximum J max of J we have\u1e60I +\u0130S = 0 and thereforeAppendix A: Properties of the homogeneous SIR modeland thereforeAppendix A: Properties of the homogeneous SIR modelNear the maximum of the rate J max withJ = 0 we have A 2 =J/J| t=t J and A 3 = ...Appendix A: Properties of the homogeneous SIR modelFor the homogeneous SIR model, we haveAppendix B: Distributions of infection susceptibility in the populationFor an initial distribution s 0 (x) of susceptible individuals with susceptibility x, we defineAppendix B: Distributions of infection susceptibility in the populationWe can then write the dynamics of the epidemic spreading given in Eqns (1) and (2) as two equations for I(t) and \u03c4 (t)Appendix B: Distributions of infection susceptibility in the populationwhich is the gamma distribution.Appendix B: Distributions of infection susceptibility in the populationAppendix C: The generalized SIR model with population heterogeneityAppendix B: Distributions of infection susceptibility in the populationWe have shown in Appendix B that for susceptibility distribution with a power law at small x the gamma distribution is an attractor of the dynamics.", [["infection", "DISEASE", 372, 381], ["infection", "DISEASE", 538, 547], ["infection", "DISEASE", 727, 736], ["infection", "DISEASE", 830, 839], ["infection", "DISEASE", 968, 977], ["\u1e60I", "TEST", 33, 35], ["\u0130S", "TEST", 37, 39], ["withJ", "TEST", 207, 212], ["J", "TEST", 239, 240], ["infection susceptibility", "PROBLEM", 372, 396], ["susceptible individuals", "PROBLEM", 453, 476], ["susceptibility x", "PROBLEM", 482, 498], ["infection susceptibility", "PROBLEM", 538, 562], ["infection susceptibility", "PROBLEM", 727, 751], ["infection susceptibility", "PROBLEM", 830, 854], ["The generalized SIR model", "PROBLEM", 884, 909], ["population heterogeneity", "PROBLEM", 915, 939], ["infection susceptibility", "PROBLEM", 968, 992], ["susceptibility distribution", "PROBLEM", 1047, 1074], ["Appendix", "ANATOMY", 254, 262], ["infection", "OBSERVATION", 372, 381], ["infection", "OBSERVATION", 538, 547], ["Appendix", "ANATOMY", 698, 706], ["infection", "OBSERVATION", 727, 736], ["gamma distribution", "OBSERVATION", 782, 800], ["infection", "OBSERVATION", 830, 839], ["Appendix", "ANATOMY", 872, 880], ["population", "OBSERVATION_MODIFIER", 915, 925], ["heterogeneity", "OBSERVATION", 926, 939], ["Distributions", "OBSERVATION_MODIFIER", 951, 964], ["infection", "OBSERVATION", 968, 977], ["Appendix", "ANATOMY", 1027, 1035], ["susceptibility", "OBSERVATION_MODIFIER", 1047, 1061], ["distribution", "OBSERVATION_MODIFIER", 1062, 1074], ["power", "OBSERVATION_MODIFIER", 1082, 1087], ["law", "OBSERVATION_MODIFIER", 1088, 1091], ["small", "OBSERVATION_MODIFIER", 1095, 1100], ["gamma distribution", "OBSERVATION_MODIFIER", 1107, 1125]]], ["It is given byAppendix B: Distributions of infection susceptibility in the populationHere (\u03b1 \u2212 1)! denotes Euler's gamma function.", [["infection", "DISEASE", 43, 52], ["\u03b1 \u2212 1", "GENE_OR_GENE_PRODUCT", 91, 96], ["Euler's gamma", "GENE_OR_GENE_PRODUCT", 107, 120], ["infection susceptibility", "PROBLEM", 43, 67], ["infection", "OBSERVATION", 43, 52], ["gamma function", "OBSERVATION", 115, 129]]], ["We then have S(\u03c4 ) = (N \u2212 I 0 )(1 + \u03c4 /\u03b1) \u2212\u03b1 and S = \u2212(N \u2212 I 0 )(1 + \u03c4 /\u03b1) \u2212(1+\u03b1) , where the prime denotes a derivative with respect to \u03c4 .", [["1+\u03b1", "SIMPLE_CHEMICAL", 77, 80], ["\u03c4", "PROTEIN", 137, 138], ["S", "TEST", 13, 14], ["\u2212\u03b1", "TEST", 42, 44], ["S", "TEST", 49, 50], ["\u03c4", "TEST", 69, 70], ["\u03b1", "TEST", 72, 73], ["\u2212", "TEST", 75, 76]]], ["As time evolves, the shape of the distribution s(x, t) is time independent.Appendix B: Distributions of infection susceptibility in the populationIndeed, with \u2202 \u03c4 s = \u2212xs we have s(x, \u03c4 ) = s 0 (x)e \u2212\u03c4 x and thusAppendix B: Distributions of infection susceptibility in the populationwithx(\u03c4 ) = (1 + \u03c4 /\u03b1) \u22121 .", [["infection", "DISEASE", 104, 113], ["infection", "DISEASE", 241, 250], ["infection susceptibility", "PROBLEM", 104, 128], ["s", "TEST", 179, 180], ["e \u2212\u03c4 x", "TEST", 197, 203], ["Appendix", "TEST", 212, 220], ["infection susceptibility", "PROBLEM", 241, 265], ["the populationwithx", "TEST", 269, 288], ["shape", "OBSERVATION_MODIFIER", 21, 26], ["distribution", "OBSERVATION_MODIFIER", 34, 46], ["infection", "OBSERVATION", 104, 113], ["Appendix", "ANATOMY", 212, 220], ["infection", "OBSERVATION", 241, 250]]], ["The time-invariant distribution is then given byAppendix B: Distributions of infection susceptibility in the populationThe dynamic equation of the heterogeneous SIR model rea\u1e0bAppendix B: Distributions of infection susceptibility in the populationDefining I =\u0130/\u03c4 , we haveAppendix B: Distributions of infection susceptibility in the populationFor constant \u03b2, we then have by integrating over \u03c4Appendix B: Distributions of infection susceptibility in the populationThe maximum of I is reached for \u03c4 = \u03c4 I with I = 0 and thusAppendix B: Distributions of infection susceptibility in the populationWe thus obtainAppendix B: Distributions of infection susceptibility in the populationThe epidemic ends at long times for I(\u03c4 \u221e ) = 0, for whichAppendix B: Distributions of infection susceptibility in the populationwith S \u221e individuals that remain susceptible.", [["infection", "DISEASE", 77, 86], ["infection", "DISEASE", 204, 213], ["infection", "DISEASE", 300, 309], ["infection", "DISEASE", 421, 430], ["infection", "DISEASE", 551, 560], ["infection", "DISEASE", 636, 645], ["infection", "DISEASE", 765, 774], ["infection susceptibility", "PROBLEM", 77, 101], ["infection susceptibility", "PROBLEM", 204, 228], ["infection susceptibility", "PROBLEM", 300, 324], ["infection susceptibility", "PROBLEM", 421, 445], ["infection susceptibility", "PROBLEM", 551, 575], ["infection susceptibility", "PROBLEM", 636, 660], ["The epidemic ends", "PROBLEM", 678, 695], ["infection susceptibility", "PROBLEM", 765, 789], ["infection", "OBSERVATION", 77, 86], ["heterogeneous", "OBSERVATION_MODIFIER", 147, 160], ["SIR model", "OBSERVATION", 161, 170], ["infection", "OBSERVATION", 204, 213], ["infection", "OBSERVATION", 300, 309], ["Appendix", "ANATOMY", 392, 400], ["infection", "OBSERVATION", 421, 430], ["maximum", "OBSERVATION_MODIFIER", 467, 474], ["Appendix", "ANATOMY", 522, 530], ["infection", "OBSERVATION", 551, 560], ["infection", "OBSERVATION", 636, 645], ["infection", "OBSERVATION", 765, 774]]], ["This quantity obeysAppendix B: Distributions of infection susceptibility in the populationWe then findAppendix B: Distributions of infection susceptibility in the populationWhere the function F (z, \u03bd) is defined as the inverse of the function x \u03bd (1\u2212x) via the conditionAppendix B: Distributions of infection susceptibility in the populationWe then writeJAppendix B: Distributions of infection susceptibility in the populationWe then haveAppendix B: Distributions of infection susceptibility in the populationThe maximum of J occurs at \u03c4 = \u03c4 J with K(\u03c4 J ) = 0.", [["infection", "DISEASE", 48, 57], ["infection", "DISEASE", 131, 140], ["infection", "DISEASE", 299, 308], ["infection", "DISEASE", 384, 393], ["infection", "DISEASE", 467, 476], ["infection susceptibility", "PROBLEM", 48, 72], ["infection susceptibility", "PROBLEM", 131, 155], ["infection susceptibility", "PROBLEM", 299, 323], ["infection susceptibility", "PROBLEM", 384, 408], ["infection susceptibility", "PROBLEM", 467, 491], ["infection", "OBSERVATION", 48, 57], ["infection", "OBSERVATION", 131, 140], ["infection", "OBSERVATION", 299, 308], ["infection", "OBSERVATION", 384, 393], ["Appendix", "ANATOMY", 438, 446], ["infection", "OBSERVATION", 467, 476]]], ["We thus have A 2 = (J/J)| t=t j = \u03b2KAppendix B: Distributions of infection susceptibility in the populationPlugging in S(\u03c4 ) = N (1 + \u03c4 /\u03b1) \u03b1 for the heterogeneous SIR model with I 0 << N , yieldsAppendix B: Distributions of infection susceptibility in the populationAt the maximum in J, we have K = 0, yielding 2\u03b1 + 1Appendix B: Distributions of infection susceptibility in the populationUsing the function F (z, \u03bd) defined by F \u03bd (1 \u2212 F ) = z, we can solve this for \u03c4 J : This allows us to compute A 2 and A 3Appendix B: Distributions of infection susceptibility in the populationThe parameters \u03bb 0 , \u03bb \u221e , A 2 and A 3 can be obtained from linear and cubic fits to the logarithm the number of daily reported cases J rep .", [["infection", "DISEASE", 65, 74], ["infection", "DISEASE", 225, 234], ["infection", "DISEASE", 347, 356], ["infection", "DISEASE", 540, 549], ["1Appendix B", "CHEMICAL", 317, 328], ["1Appendix B", "PROTEIN", 317, 328], ["J rep", "DNA", 716, 721], ["t j", "TEST", 28, 31], ["infection susceptibility", "PROBLEM", 65, 89], ["the populationPlugging in S", "TEST", 93, 120], ["the heterogeneous SIR model", "TEST", 146, 173], ["I", "TEST", 179, 180], ["infection susceptibility", "PROBLEM", 225, 249], ["K", "TEST", 296, 297], ["infection susceptibility", "PROBLEM", 347, 371], ["infection susceptibility", "PROBLEM", 540, 564], ["The parameters", "TEST", 582, 596], ["infection", "OBSERVATION", 65, 74], ["infection", "OBSERVATION", 225, 234], ["infection", "OBSERVATION", 347, 356], ["infection", "OBSERVATION", 540, 549]]], ["For these fits, time intervals corresponding to initial exponential growth (T i ), peak T p and final decay T f need to be defined.", [["T f", "GENE_OR_GENE_PRODUCT", 108, 111], ["initial exponential growth", "PROBLEM", 48, 74], ["peak T p", "TEST", 83, 91]]], ["We use the time point t rep m , where J rep reaches its maximum as a reference point relative to which the intervals are given by:Appendix B: Distributions of infection susceptibility in the populationThese time intervals are further reduced depending on the used data and \u2206t such that all time points before the last day with J rep = 0 prior to t rep m and after the first day J rep = 0 after t rep m are excluded.", [["infection", "DISEASE", 159, 168], ["t rep m", "DNA", 22, 29], ["J rep", "DNA", 38, 43], ["t rep m", "DNA", 346, 353], ["J rep", "TREATMENT", 38, 43], ["infection susceptibility", "PROBLEM", 159, 183], ["J rep", "TREATMENT", 327, 332], ["Appendix", "ANATOMY", 130, 138], ["infection", "OBSERVATION", 159, 168], ["reduced", "OBSERVATION_MODIFIER", 234, 241]]], ["The fits in Fig. 3 and the dashed horizontal lines in Fig. 5 and 7 correspond to fits with \u2206t = 19days.", [["horizontal lines", "CELL", 34, 50], ["dashed horizontal lines", "CELL_LINE", 27, 50], ["the dashed horizontal lines", "TREATMENT", 23, 50], ["horizontal lines", "OBSERVATION", 34, 50]]], ["The shaded areas in Fig. 5 and 7 depict the range of parameter values one obtains for fits with 10days \u2264 \u2206t \u2264 20days.", [["fits", "DISEASE", 86, 90], ["shaded", "OBSERVATION_MODIFIER", 4, 10], ["areas", "OBSERVATION_MODIFIER", 11, 16]]], ["Appendix E: Small \u03b1 limit for heterogeneous populations For small \u03b1 the system reaches a well defined limiting dynamics that can be expressed analytically.", [["heterogeneous populations", "PROBLEM", 30, 55], ["small \u03b1 the system", "PROBLEM", 60, 78], ["Small \u03b1 limit", "OBSERVATION_MODIFIER", 12, 25], ["heterogeneous", "OBSERVATION_MODIFIER", 30, 43], ["populations", "OBSERVATION", 44, 55], ["small", "OBSERVATION_MODIFIER", 60, 65]]], ["We start from I(\u03c4 ) for small I 0 /NAppendix B: Distributions of infection susceptibility in the populationThe maximum of I occurs at \u03c4 = \u03c4 I when I = 0 or \u03c4 I /\u03b1 R 0 \u2212 1.", [["infection", "DISEASE", 65, 74], ["NAppendix B", "PROTEIN", 35, 46], ["I", "PROTEIN", 158, 159], ["infection susceptibility", "PROBLEM", 65, 89], ["I", "TEST", 147, 148], ["infection", "OBSERVATION", 65, 74], ["maximum", "OBSERVATION_MODIFIER", 111, 118]]], ["We thus haveAppendix B: Distributions of infection susceptibility in the populationSimilarly, using C I /N = 1 \u2212 (1 + \u03c4 I /\u03b1) \u2212\u03b1 , we find for small \u03b1Appendix B: Distributions of infection susceptibility in the populationAt long times, we haveAppendix B: Distributions of infection susceptibility in the populationIn the limit of small \u03b1, u = \u03c4 /\u03b1 is finite.", [["infection", "DISEASE", 41, 50], ["infection", "DISEASE", 179, 188], ["infection", "DISEASE", 272, 281], ["\u03b1", "PROTEIN", 123, 124], ["\u03b1", "PROTEIN", 346, 347], ["infection susceptibility", "PROBLEM", 41, 65], ["the populationSimilarly", "TEST", 69, 92], ["infection susceptibility", "PROBLEM", 179, 203], ["infection susceptibility", "PROBLEM", 272, 296], ["infection", "OBSERVATION", 41, 50], ["infection", "OBSERVATION", 179, 188], ["Appendix", "ANATOMY", 243, 251], ["infection", "OBSERVATION", 272, 281], ["small", "OBSERVATION_MODIFIER", 330, 335]]], ["The limiting function u(t) for small \u03b1 can be expressed asAppendix B: Distributions of infection susceptibility in the populationwhere i 0 = I/(\u03b1N ) in the limit \u03b1 = 0.", [["infection", "DISEASE", 87, 96], ["asAppendix B", "GENE_OR_GENE_PRODUCT", 56, 68], ["\u03b1", "PROTEIN", 37, 38], ["asAppendix B", "PROTEIN", 56, 68], ["small \u03b1", "PROBLEM", 31, 38], ["infection susceptibility", "PROBLEM", 87, 111], ["infection", "OBSERVATION", 87, 96]]], ["The number of susceptible then becomes S N 1 \u2212 \u03b1 ln(1 + u) .Appendix B: Distributions of infection susceptibility in the populationFinally we discuss the maximum of the rate of new cases J = J max .", [["infection", "DISEASE", 89, 98], ["infection susceptibility", "PROBLEM", 89, 113], ["susceptible", "OBSERVATION_MODIFIER", 14, 25], ["infection", "OBSERVATION", 89, 98]]], ["We haveJ/J = \u03b2K,Appendix B: Distributions of infection susceptibility in the populationAt the maximum of J, \u03c4 = \u03c4 J withAppendix B: Distributions of infection susceptibility in the populationDefiningx J = (1 + \u03c4 J /\u03b1) \u22121 we have in the limit of small \u1fb1Appendix B: Distributions of infection susceptibility in the populationThe value of J at the maximum isAppendix B: Distributions of infection susceptibility in the populationWe determine A 2 =J/J = \u03b2 2K and A 3 = ...", [["infection", "DISEASE", 45, 54], ["infection", "DISEASE", 149, 158], ["infection", "DISEASE", 281, 290], ["infection", "DISEASE", 384, 393], ["haveJ", "TEST", 3, 8], ["infection susceptibility", "PROBLEM", 45, 69], ["infection susceptibility", "PROBLEM", 149, 173], ["the population", "TEST", 177, 191], ["J", "TEST", 201, 202], ["infection susceptibility", "PROBLEM", 281, 305], ["infection susceptibility", "PROBLEM", 384, 408], ["A", "TEST", 439, 440], ["J/J", "TEST", 444, 447], ["K", "TEST", 453, 454], ["Appendix", "ANATOMY", 16, 24], ["infection", "OBSERVATION", 45, 54], ["infection", "OBSERVATION", 149, 158], ["small", "OBSERVATION_MODIFIER", 245, 250], ["Appendix", "ANATOMY", 252, 260], ["infection", "OBSERVATION", 281, 290], ["Appendix", "ANATOMY", 355, 363], ["infection", "OBSERVATION", 384, 393]]], ["J /J = \u03b2 3K , withK/\u03b2 = K I/N andK/\u03b2 2 = K I 2 /N 2 .", [["N", "CHEMICAL", 28, 29], ["withK", "PROTEIN", 14, 19], ["I", "PROTEIN", 26, 27], ["andK", "PROTEIN", 30, 34], ["I 2", "PROTEIN", 43, 46], ["N 2", "PROTEIN", 48, 51], ["J", "TEST", 0, 1], ["K", "TEST", 10, 11], ["withK", "TEST", 14, 19], ["\u03b2", "TEST", 20, 21], ["K I", "TEST", 24, 27], ["andK", "TEST", 30, 34], ["\u03b2", "TEST", 35, 36], ["K I", "TEST", 41, 44]]], ["We then findAppendix B: Distributions of infection susceptibility in the populationWe also have A 2 2 A 3 = \u03b3R 0xJ 2 (E14) andAppendix B: Distributions of infection susceptibility in the populationAppendix F: Mitigation in the heterogeneous SIR modelAppendix B: Distributions of infection susceptibility in the populationWe now consider the case where the rate of infections \u03b2(t) becomes time dependent because of overall changes of conditions such as seasonal effects or measures of social distancing.Appendix B: Distributions of infection susceptibility in the populationUsing I = \u2212S + N/R 0 , we have \u03bb =\u0130/I = \u2212\u03b2S /N \u2212 \u03b3 and the reproduction numberAppendix B: Distributions of infection susceptibility in the populationwhere \u03b2 0 = \u03b2(t = 0) and R 0 = \u03b2 0 /\u03b3.", [["infection", "DISEASE", 41, 50], ["infection", "DISEASE", 155, 164], ["infection", "DISEASE", 279, 288], ["infections", "DISEASE", 364, 374], ["infection", "DISEASE", 531, 540], ["infection", "DISEASE", 680, 689], ["\u2212\u03b2S", "PROTEIN", 613, 616], ["N", "PROTEIN", 618, 619], ["\u03b3", "PROTEIN", 622, 623], ["infection susceptibility", "PROBLEM", 41, 65], ["infection susceptibility", "PROBLEM", 155, 179], ["infection susceptibility", "PROBLEM", 279, 303], ["infections", "PROBLEM", 364, 374], ["overall changes of conditions", "PROBLEM", 414, 443], ["infection susceptibility", "PROBLEM", 531, 555], ["the populationUsing I", "TEST", 559, 580], ["\u03bb", "TEST", 604, 605], ["\u0130", "TEST", 607, 608], ["\u2212\u03b2S", "TEST", 613, 616], ["\u03b3", "TEST", 622, 623], ["the reproduction", "TEST", 628, 644], ["infection susceptibility", "PROBLEM", 680, 704], ["the populationwhere", "TEST", 708, 727], ["t", "TEST", 736, 737], ["infection", "OBSERVATION", 41, 50], ["Appendix", "ANATOMY", 126, 134], ["infection", "OBSERVATION", 155, 164], ["Distributions", "OBSERVATION_MODIFIER", 262, 275], ["infection", "OBSERVATION", 279, 288], ["infections", "OBSERVATION", 364, 374], ["infection", "OBSERVATION", 531, 540], ["infection", "OBSERVATION", 680, 689]]], ["The epidemic can be mitigated by a reduction of \u03b2 over time.", [["reduction", "OBSERVATION_MODIFIER", 35, 44]]], ["As the epidemic advances, \u03c4 increases as\u03c4 = \u03b2I/N .", [["I/N", "PROTEIN", 45, 48]]], ["Growth of infection number is no longer possible for \u03c4 > \u03c4 I with \u2212 S (\u03c4 I ) = 1 R 0 (F2)Appendix B: Distributions of infection susceptibility in the populationThus the condition \u03c4 > \u03c4 I defines herd immunity conditions where the epidemic can no longer grow.", [["infection", "DISEASE", 10, 19], ["infection", "DISEASE", 118, 127], ["infection", "PROBLEM", 10, 19], ["infection susceptibility", "PROBLEM", 118, 142], ["herd immunity conditions", "PROBLEM", 195, 219], ["infection", "OBSERVATION", 10, 19], ["no longer possible", "UNCERTAINTY", 30, 48], ["Appendix", "ANATOMY", 89, 97], ["infection", "OBSERVATION", 118, 127]]], ["If mitigation sets in early, before \u03c4 = \u03c4 I , the epidemic is slowed and it takes more time to reach herd immunity. in this case a new wave starts after mitigation is relaxed.Appendix B: Distributions of infection susceptibility in the populationIf mitigation occurs for \u03c4 > \u03c4 I , mitigation facilitates the decay of infections by reducing This provides a differential equation for ln \u03b2 if ln J(t) is given, which does not require knowledge of the amplitude of J. We infer \u03b2(t) for each day, using the initial value \u03b2(0) = 0.48 days \u22121 at March 15.", [["infection", "DISEASE", 204, 213], ["infections", "DISEASE", 317, 327], ["herd", "ORGANISM_SUBDIVISION", 101, 105], ["\u03b2(t)", "PROTEIN", 473, 477], ["infection susceptibility", "PROBLEM", 204, 228], ["infections", "PROBLEM", 317, 327], ["slowed", "OBSERVATION_MODIFIER", 62, 68], ["new", "OBSERVATION_MODIFIER", 131, 134], ["wave", "OBSERVATION_MODIFIER", 135, 139], ["infection", "OBSERVATION", 204, 213], ["infections", "OBSERVATION", 317, 327]]], ["We use an iterative scheme to calculate the rate for the next day as ln \u03b2(i + 1) = ln \u03b2(i) + ln J obs (i + 1) \u2212 ln J obs (i) \u2212 \u03b2(i) + \u03b3,Appendix B: Distributions of infection susceptibility in the populationwhere ln J obs (i) = (1/7) 3 \u2206t=\u22123 J rep (i + \u2206t) is a running average over seven days of the number of reported cases.Appendix B: Distributions of infection susceptibility in the populationFor the two scenarios of a later mitigation, the heterogeneous SIR model was consideredAppendix B: Distributions of infection susceptibility in the populationln I(i + 1) = ln I(i)+ \u03b2(i)(1 \u2212Appendix B: Distributions of infection susceptibility in the populationln \u03b2(i + 1) = ln \u03b2(i)+ ln J obs (i + 1) J obs (i) \u2212 ln I(i + 1) I(i)Appendix B: Distributions of infection susceptibility in the populationThe starting value of \u03c4 (0), can be derived by inverting Eq.", [["infection", "DISEASE", 165, 174], ["infection", "DISEASE", 355, 364], ["infection", "DISEASE", 513, 522], ["infection", "DISEASE", 615, 624], ["infection", "DISEASE", 754, 763], ["an iterative scheme", "TREATMENT", 7, 26], ["the rate", "TEST", 40, 48], ["ln J obs", "TEST", 112, 120], ["\u03b2", "TEST", 127, 128], ["\u03b3", "TEST", 134, 135], ["Appendix B", "TEST", 136, 146], ["infection susceptibility", "PROBLEM", 165, 189], ["\u2206t", "TEST", 236, 238], ["J rep", "TEST", 242, 247], ["infection susceptibility", "PROBLEM", 355, 379], ["a later mitigation", "TREATMENT", 422, 440], ["the heterogeneous SIR model", "PROBLEM", 442, 469], ["infection susceptibility", "PROBLEM", 513, 537], ["infection", "PROBLEM", 615, 624], ["susceptibility", "TEST", 625, 639], ["J obs", "TEST", 697, 702], ["ln I", "TEST", 709, 713], ["Appendix B", "TEST", 725, 735], ["infection susceptibility", "PROBLEM", 754, 778], ["Appendix", "ANATOMY", 136, 144], ["infection", "OBSERVATION", 165, 174], ["Distributions", "OBSERVATION_MODIFIER", 338, 351], ["infection", "OBSERVATION", 355, 364], ["infection", "OBSERVATION", 513, 522], ["infection", "OBSERVATION", 615, 624], ["J obs", "ANATOMY", 683, 688], ["ln", "ANATOMY", 709, 711], ["Appendix", "ANATOMY", 725, 733], ["infection susceptibility", "OBSERVATION", 754, 778]]], ["(C7) for I(\u03c4 (0)) = I(0).Appendix H: Mobility DataData concerning the changes in mobility of the population has been provided by Google [31] .", [["the changes", "PROBLEM", 66, 77]]]]}